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PREFACE 
“El proceso de encuentro con la verdad requiere ante todo el asombro, seguido por un esfuerzo 
riguroso, sistemático, de profundizar ante las interrogantes que la realidad nos presenta: ¿qué 
es?; ¿para qué es?; ¿por qué es?; ¿cómo es?; ¿cuánto es?; ¿quién es?...”  
“The process of meeting with the truth requires above all the wonder, followed by rigorous and 
systematic effort to deepen the questions brought by reality: what is? What is it for? Why is? 
How is? And who is it?” (Translated from the original text in Spanish) 
Enrique Pérez Olivares  
Una Visión de la Universidad – Palabras de Apertura del primer año lectivo 1999-2000 de 
la Universidad Monteávila. 
This quote has been taken from my Alma Mater’s opening lection, which has inspired 
me the most within my professional development, and quite frankly this was probably 
the moment where my drive to challenge myself further in order to find the “truth” 
began. Throughout my studies in law I learned that besides receiving valuable academic 
education in law, this was not the sole purpose. Law is a path that takes you to look 
further into the evidence and cases that are presented before you. Being a lawyer equals 
to have the enormous privilege of making a difference into the matters and challenges 
one decides to take upon, and for me this research became that path. Always intrigued, 
always curious and always ambitious to keep on learning while knowing that my work 
could actually someday make a difference, be a contribution to something I believed 
could be achieved.  
Researching about pharmaceutical patents and access to medicines taught me beyond 
my expectations. Finding a balance between patent protection and access to medicines 
seemed at the time as probably impossible and I feared that no feasible middle could be 
found, but little did I know since narrowing the dilemma to three countries and by 
allowing myself to look into public health policies would precisely allow me to find a 
possible answer –truth- that I was looking for. Having said this, I could have not done 
it without the guidance and support of many to whom I am very grateful with to have 
encountered along my journey to complete this doctoral project.  
 I would especially like to thank my supervisor Professor Marcus Norrgård and 
Professor Niklas Bruun for having guided me throughout the process, for taking with 
me the opportunity to learn more about pressing topics (Patents and IP) in faraway 
lands (Brazil, Chile and Venezuela). Your patience, encouragement, commitment, 
dedication, valuable comments and experience have not only help me shaping my 
research but have also inspired me. A heartfelt thank you goes to Professor Denis 
Borges Barbosa and Taina Pihjalarinne for having pre-examined my work and having 
provided me with the pointers necessary to improve this manuscript. Your various 
articles and books have also been an inspiration for my research, I would have not been 
able to carry out some of the most interesting discussions without your literature. I am 
also grateful with Professor Thomas Riis for accepting to be my opponent; it has been a 
real honour.  
Another special thank goes to Professor Faustino Flamarique for your guidance and 
shared expertise to structure the Venezuelan Chapter of my research; and also to 
Monteávila University’s Rector Professor Joaquín Rodriguez Alonso for your 
encouragement to pursue postgraduate studies abroad. Thank you both for celebrating 
with me every step forward within my professional development. 
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Hanken School of Economics, the Department of Commercial Law and Accounting, and 
Hanken Foundation for Young Doctoral Students provided me with the infrastructure 
and financial means to successfully conclude my Doctoral Degree, and for this I am 
thankful. The Max-Planck Institute for Intellectual Property and Bayreuth Universitat 
in Germany also welcomed me as a fellow researcher. I was fortunate to have had the 
privilege to research at these three great institutions where I was also enriched by 
working with professors and colleagues. Special thanks goes to Rosa Maria Ballardini 
and Pia Björkwall for your friendship and example throughout this journey. I would 
also like to take on the opportunity to thank my colleagues from the INNOCENT 
graduate school with whom I have the pleasure of sharing throughout significant part 
of the degree: Wim Helwegen, Liguo Zhang, Tanja Liljeström, Anu Pitkänen, Anette 
Alén, and Amina Agovic.  
Within this journey I have required guidance from different parts of the world, 
therefore I would like to extend a heartfelt thank you to José Manuel Cousiño, Graeme 
Dinwoodie, Ansgar Ohly, Manuel Lovato, Francisco Allende, Ana María Pacon, Pedro 
Jedlika, José Ignacio Hernández, Andres Melossi, Marino Porzio, Holger Hestermeyer, 
Taniana Tobar, and Yovana Reyes Tagle. 
On a more personal note, I cannot finish these acknowledgements without giving an 
earnest THANK YOU to my family (Venezuela and Finland) and friends’ whom without 
their support, cheering and understanding I would not have been able to transit this 
path. Two phrases have particularly kept me going throughout the journey: “impossible 
nothing, the one who persevere wins and the sky is the limit;” and “everyone is entitled 
to succeed and to hear the applause, however one most earn these since success and 
applause are not for free.” And by quoting these I can only thank my Mom for being my 
rock, one of my biggest fans and toughest critic because without your example, 
strength, love and guidance I would not be where I am, and because your teachings 
have helped in shaping me into who I am today. The second phrase is in memoriam of 
my father, who in a very short time taught valuable lessons that I will treasure forever 
since they have contributed to make me who I am today. I also need to extend a 
heartfelt thank you to my brother and Padrino for being there for me all the steps of the 
way. I look up to the two of you as examples as well of achievement and perseverance; 
and to my Grandmother for reminding me the value of faith and to continue believing 
in its greatness. I have been definitely blessed with excellent examples and an even 
greater family, thank you Lord for giving me the opportunity and presenting me with 
the means to achieve this degree.  
Another earnest thanks goes to you Antti for being also my rock. Your support, love and 
endless patience kept me going, kept me grounded, but also kept me believing in 
myself. Whenever I felt like fainting you were there to cheer me, to read my manuscript 
and to point out the Spanglish that sometimes I missed. At last but not the least, special 
thanks to Rolando and Alex for bringing to me a piece of home into Finland; Begoña for 
the great discussions about Venezuelan IP law and your friendship; and to my German 
friends who have also been part of this journey. 
Since the beginning of the research the premises in Venezuela have considerably 
changed, thus, I do not loose my hope in seeing a better future where my research could 
be taken into consideration to provide further understanding about IP law and public 
health care policy issued in my home country. 
Dhanay M. Cadillo Chandler 
  
iii 
CONTENTS 
1 INTRODUCTION....................................................................................... 1 
1.1. Purpose and Research Questions ........................................................................ 4 
1.2. Structure of the Thesis ........................................................................................ 5 
1.3. Research Methodology ........................................................................................ 6 
1.3.1. Comparative Law Method and Legal Dogmatic .................................... 8 
1.3.2. Legal Research and Legal Dogmatic ..................................................... 10 
2 BACKGROUND OF THE STUDY: INTELLECTUAL PROPERTY AND 
PUBLIC HEALTH ................................................................................... 12 
2.1. Defining Intellectual Property Right Through History ..................................... 12 
2.2. What is Public Health? ...................................................................................... 15 
2.2.1. Access to Medicines as part of the Human Right to Health ................. 18 
2.3. The Relationship between Intellectual Property Rights and Public Health 
(access to medicines) ......................................................................................... 22 
2.3.1. WTO and TRIPS Agreement ................................................................. 22 
2.3.2. Doha Declaration on the TRIPS Agreement and Public Health ........... 27 
2.3.3. From the Decision on the Implementation of Paragraph 6 of the Doha 
Declaration on TRIPS and Public Health to the TRIPS Agreement 
Amendment...........................................................................................29 
3 INTELLECTUAL PROPERTY AND ACCESS TO MEDICINES IN 
BRAZIL ................................................................................................... 33 
3.1. National Intellectual Property and Public Health Policies Evolution in Brief.. 34 
3.2. Constitutional Approach towards Intellectual Property Rights and Public 
Health ................................................................................................................ 37 
3.2.1. Public Health and Access to Medicines ................................................ 39 
3.2.2. Implementing Policiesto Ensure Access To Medicines ........................ 45 
3.3. Intellectual Property Rights in Brazil – a Focus on the Pharmaceutical Patents 
System .............................................................................................................. 48 
3.3.1. Current Intellectual Property Framework: Lei n° 9.279 ..................... 49 
3.4. ANVISA: Prior Consent Challenge, and Marketing Approvals ......................... 56 
3.4.1. Prior Consent and Second Medical Uses ..............................................62 
3.5. Intellectual Property Rights and its Social Function ........................................ 65 
3.6. Competition and Compulsory Licences in Brazil ............................................. 66 
3.6.1. Exhaustion of Rights (First Sale Doctrine) and Parallel Imports ......... 70 
3.7. Summarising the Brazilan context .................................................................... 73 
  
iv 
4 INTELLECTUAL PROPERTY AND ACCESS TO MEDICINES IN 
CHILE ..................................................................................................... 75 
4.1. Chilean Patent System and Grant Procedure .................................................... 78 
4.2. U.S. – Chile Free Trade Agreement: Implementing Higher Standards of 
Protection .......................................................................................................... 81 
4.2.1. Linkage and Sanitary Permits ...............................................................85 
4.2.2. Relevant case law: ................................................................................ 89 
4.2.3. Linkage overall assessment ................................................................... 93 
4.3. Test Data Protection of Non-Disclosed Information ....................................... 94 
4.3.1. Bolar Exemption .................................................................................. 96 
4.4. Chilean Health Care System ............................................................................. 96 
4.4.1. Chilean Health Care System before Plan AUGE ................................... 97 
4.4.2. Health Care Reform: 1973-1989 .......................................................... 98 
4.4.3. Health Care Reform: 1990-2002 (two democratic governments)....... 99 
4.4.4. Plan AUGE - GES 2002-2008 ............................................................ 101 
4.4.5. Importance and Social Impact ............................................................ 104 
4.5. Chilean Health Care and Pharmaceuticals...................................................... 107 
4.5.1. National Drug Policy and the Chart of Essential Medicines ............... 109 
4.5.2. Should Essential Drugs be Patented? ................................................. 112 
4.6. Summarising the Chilean context ................................................................... 113 
5 INTELLECTUAL PROPERTY RIGHTS AND ACCESS TO MEDICINES 
IN VENEZUELA .................................................................................... 115 
5.1. Intellectual Property Rights in Venezuela....................................................... 116 
5.2. Constitutional Approach to Intellectual Property Rights: In Accordance with 
1999’s Constitutional Reform.......................................................................... 118 
5.3. Current Intellectual Property Legal Framework ............................................. 120 
5.3.1. The Patent Office (SAPI) Competences .............................................. 121 
5.3.2. Types of Patents .................................................................................. 123 
5.3.3. Inventions and Discoveries ................................................................. 125 
5.3.4. Public Interest and Patents ................................................................. 127 
5.4. Venezuelan Expropriation Procedure and Patent Rights ............................... 130 
5.4.1. Grounds for Patent Extinction ............................................................ 135 
5.4.2. Grant Procedure and Registration ...................................................... 137 
5.5. Intellectual Property Regime in Venezuela Prior to the Withdrawal from the 
Andean Community ........................................................................................ 143 
5.5.1. Bodies, Institutions and Jurisdiction .................................................. 144 
  
v
5.5.2. Principles of the Andean Community ................................................. 144 
5.5.3. Challenges and Implications for Venezuela as an Andean Community 
Member  .............................................................................................. 146 
5.6. Andean Intellectual Property Regime ............................................................. 148 
5.6.1. Andean Community Decisions 313 ..................................................... 149 
5.6.2. Andean Community Decision 344 ...................................................... 152 
5.6.3. Andean Community Decision 486 and the TRIPS Agreement ........... 154 
5.6.4. Venezuela’s withdrawal from the Andean Community: Legal 
Consequences ...................................................................................... 157 
5.7. Can MERCOSUR improve Venezuela’s current Intellectual Property system?161 
5.8. Public health and Patents ................................................................................ 165 
5.8.1. Public Health in Venezuela: Moving towards universal coverage ...... 166 
5.8.2. General Structure ................................................................................ 167 
5.8.3. Main Characteristics ........................................................................... 169 
5.8.4. Health Services and Coverage ............................................................. 169 
5.8.5. Access to Medicines ............................................................................ 173 
5.8.6. The Essential List of Medicines in Venezuela ..................................... 175 
5.9. Access to Affordable Medicines in Venezuela: Price Control Policy ............... 177 
5.9.1. Medicine Policy for the Andean Sub region: Further Efforts to Achieve 
Access to Medicines regardless of Patents .......................................... 178 
5.9.2. Venezuela and the Doha Declaration on Public Health ...................... 180 
5.9.3. Marketing approvals ........................................................................... 182 
5.10. Competition Law and Pharmaceutical Patents in Venezuela ......................... 185 
5.11. Summarising the Venezuelan context ............................................................. 189 
6 IDENTIFYING STRATEGIES .............................................................. 190 
6.1. Identifying strategies or models of protection on a case-by-case basis .......... 194 
6.1.1. Brazilian Strategy or model of protection ........................................... 195 
6.1.2. Chilean Strategy .................................................................................. 199 
6.1.3. Venezuelan Strategy ............................................................................ 201 
7 CONCLUSIONS AND SUGGESTIONS: WHERE DO WE GO FROM 
HERE ONWARDS? .............................................................................. 206 
7.1.1. Lessons from Brazil and Chile in Terms of Patent Protections ......... 207 
7.1.2. Lessons from Brazil and Chile in Terms of Access to Medicines and 
other Public Health Issues .................................................................. 211 
7.1.3. Could Venezuela Learn from either Brazil and/or Chile: How Could 
these Lessons be Implemented? ......................................................... 214 
  
vi 
7.1.4. Other General Suggestions: Developing a Side System to Create 
Incentives for R&D on Neglected Diseases ......................................... 219 
7.1.5. Suggestions for a Side or Parallel System .......................................... 220 
 
APPENDICES 
Appendix 1 List of references ................................................................................. 227 
 
  
1 
1 INTRODUCTION 
Access to medicines, pharmaceutical patents, and public health are often in the 
news. The need to tackle pressing health needs, while providing adequate 
incentives to carry out research and development are also important aspects to 
take into consideration when addressing this challenge. Neither health concerns 
nor the strategies to balance intellectual property rights and access to medicines 
are determined by the geographical context. Thus, Latin American countries i.e. 
Brazil, Chile and Venezuela, even though geographically located in the same 
continent, deal with the challenges in a different and unique manner. 
This book reviews the strategies or models of protection used in Brazil, Chile and 
Venezuela to balance both intellectual property rights (pharmaceutical patents) 
and access to medicines. Each country seems to have shaped their policies in 
accordance with their national priorities, whether these are motivated by health, 
political or commercial issues. This study portrays the different approaches 
followed in different national contexts despite all three having to implement the 
minimum standards of intellectual property protection according to the 
Agreement on Trade Related Aspects of Intellectual Property Rights (TRIPS 
Agreement). The outcome of the comparison of the policy implementations and 
the patterns followed by each of the analysed countries is without a doubt the 
main contribution of this academic study. 
Before the TRIPS Agreement countries had the freedom to decide on whether or 
not to grant patent protection for medicines. Thus, most of the developing and 
least developed countries, now WTO member countries, did not provide patent 
protection for pharmaceuticals because they feared that patent protection would 
increase the price of pharmaceuticals, and hence, become an obstacle for the 
access to medicines.1 
TRIPS did not only settle minimum standards of protection, but it also contains 
certain flexibilities and/or exceptions such as parallel imports, compulsory 
licences and the bolar exception that could be used in determined cases to 
address national concerns. Further clarification on these flexibilities was sought 
in the DOHA Declaration, as will be analysed later on, since the declaration 
brought into the spotlight the newly created link and clash between public health 
concerns (e.g. access to medicines) and patent protection.2 
On the one hand, patent protection represents an incentive for the 
pharmaceutical industry to carry out R&D for new and needed drugs.3 But on the 
other hand, patents, as the system of financing R&D, has been regarded as a 
                                                        
1 See Hestermeyer, H., Human Rights and the WTO: The Case of Patents and Access to Medicines 
(Oxford University Press, 2007) xxxiii-xxxiv. 
2 See DOHA Declaration See Declaration on the TRIPS Agreement and Public Health, World Trade 
Organization, WTO/MIN(01)/DEC/2 (20 November 2001) (Hereinafter Doha Declaracion) 
3 Lemley, M., ‘Ex Ante versus Ex Post Justifications for Intellectual Property’ (2004) 71 University 
of Chicago Law Review 129, 1-67, at 2 <papers.ssrn.com/sol3/papers.cfm?abstract_id=494424> 
accessed 6 June 2013 
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flawed system due to the high costs transferred to the finalised product 
(medicine) thus deterring access to medicines.4 
Patent protection allows the inventor to prevent others from making use, selling, 
producing or distributing the invention without his consent for a period of no less 
than 20 years.5 Moreover, these rights conferred by the patent grant seem to 
constitute the pharmaceutical industry’s incentive to recoup the high costs 
associated with the R&D of a new drug.6 It is estimated that in recent years the 
costs derived from R&D of a new medicine up to the moment that it reaches the 
market are $1.2 billion.7 
During 2011 the pharmaceutical industry reported a 25% increase in costs to 
develop medicines, a fact that has made the industry review its practices in order 
to avoid costly trial failures.8 The cost for developing a new drug in 2002 was 
estimated at $802 million according to the worth of the dollar in the year 
2000,9however, more recent studies have suggested a staggering cost of nearly 
$1.5 billion dollars in 2011 for R&D costs per new molecule entities that actually 
reach the market.10 Even though the costs embedded in R&D are important 
within the discourse and aim at ensuring access to medicines, this doctoral 
research will not use either valuation or more sophisticated costs analysis than 
the ones provided within the aforementioned reports since depicting on these 
issues will require a separate study to address them in a proper manner. Thus, the 
focus of this research is of a more legal and social nature in the hope of reaching a 
conclusion that portrays possible solutions for achieving a balance between 
legislative reforms within patent law and health care and implementation issues 
securing access to essential medicines. 
The cost of patented medicines has been considered to be one of the reasons 
limiting access to affordable medicines, and so to counteract these costs, scholars 
have come up with a number of propositions to help the pharmaceutical industry 
to cover for R&D costs so as to avoid transferring them to the finalised product. 
Among the proposed suggestions is the creation of a pool to fund R&D as a 
reward system instead of allowing the pharmaceutical companies to profit from 
                                                        
4 Love, J., and Hubbard, T., ‘The Big Idea: Prizes to Stimulate R&D for New Medicines’ (2007) 82 
Chicago Kent Law Review 3, at 1520 
5 Article 28.1(a) from the TRIPS Agreement Article 28.1(a) from the TRIPS Agreement Article 
28.1(a) from the TRIPS Agreement Marrakesh Agreement Establishing the the World Trade 
Organization, Gevena, 15 April 1994, entered into force 1 January 1995, 1867 United Nations Treaty 
Series 3, annex 1C – Agreement on Trade-Related Aspects of Intellectual Property Rights (1994), 
Article 27 (1) (Hereinafter TRIPS Agreement) See Article 28.1(a) 
6 Mishra, V.,  ‘TRIPS, Patent Products and Pharmaceuticals’ (2001) 36 Economic and Political 
Weekly 48, at 4464- 4467 
7 Kowelle, J., ‘Pharmaceuticals struggle to find next blockbuster drugs as R&D costs soar’ The 
Guardian (London, 21 November 2011) 
<www.guardian.co.uk/business/2011/nov/21/pharmaceuticals-drug-research-costs-rise> accessed 
5 May 2013 
8 Ibid 
9 Di Masi, et al. ‘The Price of innovation: new estimates of drug develpment costs’ (2003) 22 
Journal of Health Economics 2, 151-185, at 181 
10Mestre-Ferrandiz, et al. ‘The R&D Cost of a New Medicine’, Office of Health Economics  (London, 
December 2012) <www.ohe.org/publications/article/the-rd-cost-of-a-new-medicine-124.cfm> 
accessed 20 February 2014 
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new medicines by setting high prices11. In addition, a prize system incentivising 
innovation within the pharmaceutical industry has been envisaged,12, but these 
possible solutions will be discussed in the concluding remarks. Given that 
pharmaceutical advancements are necessary to address health needs, some more 
pressing than others, as is the case with illnesses like HIV/AIDS, cancer, tropical 
diseases and even neglected illnesses all afflicting both the rich and the poor. The 
research assesses national health policies in its aim to identify those factors both 
deterring or enhancing access to medicines in each of the analysed countries.  
The World Health Organization in its Medicines Strategy Reports, the UN 
Millennium Project 2005 and reports of several other scholars13 have identified 
external challenges influencing access to medicines, which are non-patent 
related. Among these, legislative delays, poor infrastructure, medical resources 
and governmental funding are to be noted.14 
This study analysed and micro-compared the patent system, public health policy 
implementations and the political traditions prevalent in Brazil, Chile and 
Venezuela and allowed the identification of different approaches towards patent 
protection in each country. In brief, Brazil is at the moment the eighth largest 
world economy, among the first to implement TRIPS into their national law and a 
key player in protecting public health (HIV/AIDS). Chile, which is becoming part 
of the BRIC economies, has strong commercial relations with several trading 
partners, among them the United States of America, and currently possesses one 
of the best universal health care programmes in Latin America. Venezuela is 
politically active in a transitional period that is affecting both national and 
international legal commitments (legislative uncertainty). In addition, Venezuela 
is undergoing constant legislative health care reforms and even when large 
investments have been made within the health sector the country is still one of 
the countries in the region with the highest out of pocket expenditure on 
medicines.  
Comparative law has been largely used in Latin America to shape its national laws 
and doctrines. Therefore, the results from the individual analysis of each country 
will be compared as to determine whether or not Venezuela could benefit from 
                                                        
11 Suggestions made by Love, J., in the context of the World Health Assembly. Ngo, B., and New, W., 
“World Health Assembly: Groups Seek To Return Focus To ‘Broken’ Medical R&D System” 
(Intellectual Property Watch, 24 May 2013) <www.ip-watch.org/2013/05/24/world-health-
assembly-groups-seek-to-return-focus-to-broken-medical-rd-system> accessed 25 May 2013 
12 See, Monteiro Veira, V. ‘O prêmio como incentivo à criação de bens intelectuais na indústria 
farmacêutica’ (2012) 6 Revista Electrônica Do IBPI – 
REVEL<ibpibrasil.org/ojs/index.php/Revel/article/view/14>accessed 20 February 2014 
13 At least within the Venezuelan context, Jaén was able to identify several factors deterring access 
to medicines even when her paper did not look at patent issues. See, Jaén, M., ‘¿Por qué un estudio 
sobre el costo del sistema de sauld en Venezuela?’ in Jaén, M., Salvato, S., Daza, A., and Rivas, J., 
Costo de la Salud en Venezuela: Gasto y Sostenibilidad Financiera del Sistema de Salud (IEASA eds. 
Caracas, 2006) 30-31 
14 UN Millennium Project, Prescription for Healthy Development: Increasing Access to Medicines, 
Report of the Task Force on HIV/AIDS, Malaria, TB, and Access to Essential Medicines, Work- ing 
Group on Access to Essential Medicines. (Sterling, Va.: Earthcscan, 2005) 29-30. WHO Strategy 
(DRAFT) WHO Medicines Strategy 2008-2013, Draft 8 (13 June 2008) 13 
<www.who.int/medicines/publications/Medicines_Strategy_draft08-13.pdf> accessed 1st April 
2014) 
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implementing a system similar to the ones used in either of the other two 
assessed countries. The overall result provided in this book will contribute to the 
Venezuelan doctrine as few books have been written about the national situation, 
and the suggestions within the conclusion could assist policy makers in both 
shaping and warranting the continuity necessary to achieve the balance between 
intellectual property protection and public health.  
1.1. Purpose and Research Questions 
The main purpose of this dissertation is to determine, through a comparative 
study, whether or not Venezuela could benefit from implementing a system 
similar to the ones used in either Brazil or Chile so as to balance intellectual 
property protection and access to medicines. Given that the minimum standards 
of intellectual property protection settled by the TRIPS Agreement are considered 
to be, by the current Administration, as a determining factor deterring access to 
medicines in Venezuela, this study also aims to demystify the aforementioned 
premise by identifying the real factors hampering access to medicines in 
Venezuela. Together with the main purpose, it is intended that the dissertation 
makes a literary contribution to Venezuela by analysing the current patent system 
from the perspectives of human rights and public health concerns. In doing so, 
the study becomes a multidisciplinary research integrating comparative law, 
legal, social and economical approaches. 
Besides shedding light on current legal challenges in Venezuela related to 
pharmaceutical patents and access to medicines, this study intends to understand 
the impact derived from implementing the TRIPS Agreement in each of the 
countries in this study, and whether or not access to medicines was hampered by 
the implementation of the Agreement.  
The core of the comparison aims at identifying the different ways to balance IP 
and access to medicines, if at all, and which model would work best in Venezuela. 
Furthermore, it is important to analyse the public health context in each country 
to determine, on the one hand, if pharmaceutical patents challenge access to 
medicines, and on the other if patented medicines are taken into consideration 
when implementing public health policy addressed to provide access to 
medicines. Given that the high costs of medicines has been pointed out to be one 
of the main factors jeopardising access to affordable medicines, it is also relevant 
to analyse if and how Brazil, Chile and Venezuela have made use of the 
flexibilities enshrined within the Agreement to address health concerns. 
Subsequently, within the analysis, it is important to look at the particular issues 
prevalent in each country in order to gather a further understanding about the 
use and interpretation of TRIPS flexibilities at a national level. For instance, in 
Brazil both the compulsory licence regime and the prior consent mechanism were 
implemented to address public health concerns. The intellectual property law in 
Brazil rapidly became compliant with the TRIPS Agreement, and 
notwithstanding, the legislation also foresees that the controversial local working 
requirement, if unfulfilled, could be corrected by issuing a compulsory licence. 
Brazil’s position towards protecting and ensuring access to essential medicines 
has been highly contested. Therefore it is required to analyse in more detail the 
challenges brought by each of the aforementioned mechanisms, while at the same 
time depicting on the evolution and content of the public health care framework 
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to determine if, at least in Brazil, TRIPS implementation has deterred access to 
medicines. 
Chile seems to have embraced even higher levels of intellectual property 
protection by ratifying a free trade agreement with the United States of America, 
which admittedly brought an array of challenges in terms of compliance. Namely, 
the pharmaceutical linkage between the patent office and the national health 
institute, the extension of the term of patent protection and the provision on test 
data protection seem to be particularly controversial since these are deemed to 
jeopardise access to medicines in Chile. Therefore, it will be also necessary to 
analyse the public health framework to understand the level of governmental 
commitment in ensuring access to medicines in Chile, and also how patent 
protection can co-exist with public health policies guaranteeing universal 
coverage. 
Lastly, Venezuela has been struggling to cope with the TRIPS Agreement since 
the withdrawal from the Andean Community. The Venezuelan context is by far 
among the most controversial in comparison with the other two countries 
analysed. In this respect, it will be indispensable to review the intellectual 
property framework according to both the Andean Community and the current 
system dating from 1955. The challenges derived from the implementation and 
withdrawal from the Andean Community, and the consequences from re-
implementing the IP law from 1955 will be also analysed. Subsequently, analysing 
the public health policy will provide the necessary context to determine if either 
of the aforementioned IP laws challenge access to medicines in Venezuela. 
Comparing the contexts and providing a solution will only be possible after 
having identified each of the strategies. This will then allow answering the main 
research questions of if and how could Venezuela benefit from implementing a 
similar strategy used in either Brazil or Chile to balance intellectual property 
rights and access to medicines.  
1.2. Structure of the Thesis 
This thesis is divided into seven chapters, and each chapter into several parts. The 
first chapter is comprised by an introduction to the study that is also divided into 
two parts. The first part presents the reader with an introduction to the study 
where the foundations for the research are laid down, such as purpose, rationale, 
research questions, structure and methodology. The second part provides the 
background for the research, specifically addressing basic concepts needed for the 
understanding of the discussion within the thesis. Specifically: what are 
intellectual property rights, their functions and development? What is public 
health? What is universal coverage? How are IP rights linked to public health and 
the relation of human rights with access to medicines? 
The third, fourth and fifth chapters are the analytical chapters and are each 
divided into several parts. In these chapters the analysis on a country-by-country 
basis begins. Although each part presents different challenges, the structure of 
the analysis is similar in all of them. In this respect, each of the contextual 
investigations focuses on the patent system, rationale and evolution, challenges 
related to national and international commitments, impact on access to 
medicines and a brief overview on the public health system. Each part describes a 
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different context: the first part the Brazilian context, the second part the Chilean 
context and the third part the Venezuelan context. 
The sixth and seventh chapters summarise the findings within the Brazilian, 
Chilean and Venezuelan contexts and also aim at identifying the strategies. The 
seventh chapter is divided into two parts, the first one discusses and compares 
the analysed contexts when its applicable, and the second one addresses the 
possibility of creating a side system of incentives for R&D to increase access to 
medicines where there is presently no sufficient supply. This last chapter presents 
the academic contribution that is the overall conclusion. In other words, whether 
and how Venezuela benefits from implementing or learning from one or the other 
contexts, and certain aspects that may constitute an advantage in tailoring TRIPS 
implementation in Venezuela. 
Given the broadness and complexity within the IP vs. Public Health debate, this 
dissertation exclusively focuses on the debate existing in Brazil, Chile and 
Venezuela over pharmaceutical patents and access to medicines. Therefore, a 
reader who is familiar with the debate, the stakeholders’ involved, the 
international framework and the agencies could skip part two of the introductory 
chapter and focus on the chapters dedicated to analysis and discussion. 
1.3. Research Methodology 
Comparative law has always the academic value of making us acquainted with other 
systems of law as a means of arriving at a better understanding of our legal institutions15 
This is a micro-comparative16study that analyses how different legal systems have 
solved a similar challenge. Specifically, it looks at which strategies for patent 
protection have been used in Brazil and Chile, aiming to obtain a better 
understanding of Venezuela’s strategy. In this respect the study is conducted on 
the basis of two-stage approach17 using mainly comparative law as the research 
method, but also the legal dogmatic method is used to carry out the study. This is 
mainly a legal research, but also theoretical, empirical and social approaches 
towards pharmaceutical patents and public health are taken into consideration. 
Vast literature has been written regarding TRIPS minimum standards. And yet 
there are countries such as Venezuela struggling to fully implement this 
Agreement. Developing countries have in common the fear that with a strong 
patent protection their chances of accessing affordable medicines will be 
diminished.  
Therefore, the methodology used in the research aims to shed light on 
implementation issues related to pharmaceutical patents and access to medicines 
in Venezuela. Each country poses unique features embedded in its system due to 
                                                        
15 Landheer, B., ‘Comparative Law in Latin-America’ (1941) 27 American Bar Association Journal 
75, at 77 
16 “Micro-comparison generally refers to the study of topics or aspects of two or more legal systems” 
See de Cruz, P., Comparative Law in a Changing World (London: Cavendish Publishing, 1995) 
7.2.4 at 224.  
17 Ibid 7.3 at 231. 
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cultural, political traditions and history. Hence, health needs, public health, 
health care policies and services also vary in each country.  
The two-stage approach comprises of description, identification and explanation 
or explanatory phase.18 Within the descriptive phase each country’s legal 
frameworks,, institutions and concepts related to pharmaceutical patents and 
access to medicines will be described at a national level. At the international level 
the main Treaties and Conventions relevant to pharmaceutical patents and access 
to medicines ratified by each of the countries will be taken into consideration. 
The identification and explanatory phase aims to identify each country’s strategy 
to balance IP rights and access to medicines, to thereafter discuss the findings 
among the systems. 
As this research intends to analyse the internal legislation, health care policies, IP 
structure and history and the role of patents in economic development, it has 
been suggested that no understanding can be achieved of the need for 
pharmaceutical patents when only the social approach that looks to justify public 
health by all means is considered.19 
Accordingly, comparisons can be useful if the legal institutions under 
investigation are natural and functionally comparable.20 However, in the case of 
Latin America, and despite the countries being compared belonging to the same 
legal systems’ family, civil law, it has been suggested how comparative law not 
only contributed to their development but also to moving “towards eclecticism for 
justifying the solutions proposed the basis for a new approach to comparative law 
in Latin America.”21 This could contribute to creating legal irritants or 
transplants.22However, it has been suggested that the idea of legal transplants is 
simply impossible because when a terminology or a rule is taken from a foreign 
jurisdiction this will change it’s meaning as soon as it is undertaken by the new 
jurisdiction.23 
Although there is a risk for transplanting foreign solutions into a foreign legal 
system, this study aims to shed light on implementation and tackling a balance 
between patent rights and access to medicines in Venezuela by looking at how 
other countries have done it and to analyse “if” there is something to learn from 
either or both of the foreign solutions. 
                                                        
18 de Cruz, P., Comparative Law in a Changing World, at 231 
19 Ramírez, J., ‘Patentes y Famacoeconomía’ (2005) 32 Revista Chilena de Derecho 32, at 463-
474<www.puc.cl/derecho/html/publicaciones/busquedas.html>accessed 15 January 2013 
20 Zweigert, K., and Kötz,  H., An Introduction to Comparative Law, 3rd Edicion, (1998). And Also 
see Örücu, E., ‘Developing Comparative Law’, in Örücü, E., and Nelken, E. (eds.) Comparative Law 
Hankdbook, (1st edn. Oxford: Hart Publishing, 2007) at 46. “What the comparative lawyer looks at 
as tertiu comparationis could be the common functions between institutions and rules, the common 
goal they set out to achieve the problem, the factual situations they are created to solve or the 
solutions offered.”  
21 Kleinheisterkamp, J., ‘Development od Comparative Law in Latin America’, in Reiman, M., and 
Zimmermann, R. (eds.), The Oxford Handbook of Comparative Law, (1st edn, Clarendon Press: 
Oxford, New York, 2006) at 285. 
22 Tuebner, G., ‘Legal Irritants: How Unifying Law Ends up in New Divergences’ (2001) Varieties of 
Capitalism, at 418 
23 Legrand, P., ‘The Impossibility of Legal Transplants’ (1997) 4 Maastricht Journal of European 
and Competition Law, 111-124 at 120 
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1.3.1. Comparative Law Method and Legal Dogmatic 
Generally, comparative lawyers use comparative law to pursue legal reforms, but 
“academic comparative lawyers will use it to provide access to legal knowledge 
not only to promote a legal reform, or as a research tool, but to fulfil its essential 
task of furthering the universal knowledge and understanding of the 
phenomenon of law”24 
To make use of the comparative law method, it is necessary to identify similarities 
and differences among the systems analysed.25 Thereafter, it is important to 
determine the main similarity among the Brazilian and Chilean systems in terms 
of TRIPS Agreement implementation and public health policies. 
Scholarly research differs from practitioners or legislators’ research; the answer 
regarding the purpose of comparative law research varies with the activity carried 
out. In other words, even though “comparative law research is undertaken to 
improve knowledge of the law and understanding of the law in context”26 the 
main goal or the ultimate goal is to discover which of the solutions given to a 
problem is the best one, possibly assessing the solution to that problem as a 
general principle of law.27 
On the one hand, the study looks at the similarity between Chile and Brazil as 
‘successful’ in implementing the TRIPS Agreement and effective public health 
policies addressing access to medicines. On the other hand, it identifies the 
differences in “how” the Agreement was implemented and “how or if” either of 
the countries has made use of the flexibilities to tackle any particular health issue. 
Comparative law can be seen as a method, a tool or a science in itself. As a 
method it is important to define “what to compare? And how to compare?”28 It is 
also known that comparative law has worked giving a new direction to national 
legislations, therefore it is plausible to see the legislator’s task of investigating and 
finding a better solution, but this shall not be carried out in a simple manner. 
Scholars suggest that before adopting a foreign solution the question must be 
asked whether it has proven satisfactory in its country of origin, and whether it 
will work in the country where is proposed to be adopted.29 
Moreover, the comparison can also be carried out from the legal institutions point 
of view. This means that the comparison between similar or alike legal 
institutions can also take place within the framework of a piece of comparative 
law research besides solely taking into consideration the legal rules with the aim 
of harmonisation. Before identifying similar or alike legal institutions, the nature 
of these institutions needs to be re- assessed.  
                                                        
24 Örücu, E., ‘Developing Comparative Law’, in Örücü, E., and Nelken, E. (eds.) The Comparative 
Law Hankdbook, (1st edn. Oxford: Hart Publishing, 2007) at 46 
25 Hoffman, M. B. and Berring, R.C. International Legal Research: in a Nutshell (Thomson/West: 
St. Paul, 2008) at 5-6 
26 Örücu, E., Developing Comparative Law, at 53 
27 Zweigert, K. and Kötz, H., An Introduction to Comparative Law, at 17. Within the idea of using 
the solution as a general principle of law the author intends to highlight how certain solutions can 
be found within the material compared 
28 Örücu,E., Developing Comparative Law, at 62 
29 Zweigert, K. and Kötz, H., An Introduction to Comparative Law, at 17 
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Whether or not comparative law works as a tool for legal reform, its main 
objectives are: 1. legal harmonisation to provide one’s country with adequate 
social change through the use of a foreign system that shares the same challenge 
and 2. to promote social change through a foreign law that was designed to 
produce such an effect in that foreign country.30 
In the past, comparative law was ‘praised for not being infected with the 
methodological disease.’31 However, it has been suggested that currently 
comparative research has become infected with the disease, since it is no longer 
about comparing rules and outcomes as functional solutions to universal 
challenges. Instead, the task goes beyond suggesting alternatives for the principal 
and even addresses what constitutes a better solution to a given challenge by 
discussing the limits of functionality.32 
Comparative law as a method presents limitations, since a comparison that is to 
be carried out between different legal systems should be described and 
understood as if they were one’s own system. Hence, implying that one shall be 
fluent enough in the foreign language as translations can mean something 
completely different to what it really means within its original context, therefore 
translations should be avoided. Nevertheless, someone attempting to compare 
may only have the illusion of understanding and yet make the best of it by using 
adequate methodology.33 
According to the principle of functionality convergence is described as a stem for 
all other rules that determine a choice of law to compare, and only those that 
fulfil the same function are comparable.34 Contrary to this, the thesis of 
convergence principle asserts that this principle allows law harmonisation and 
unification due to similar socio-economic structures.35 
Whereas functional equivalence seeks to solve similar structural problems even 
though the national legal order could be founded on diverse doctrinal traditions, 
what matters is to find which legal institution within the foreign system performs 
an equivalent function to the institution originally analysed.36 
In practice, lawyers constantly have to juxtapose; that is, compare different rules 
within their legal systems before reaching any practical or theoretical 
                                                        
30 Kahn – Freund, O., ‘On Uses and Misuses of Comparative Law’ (1974) 37 Modern Law Review 1, 
at 2 
31 Comparative law has worked successfully in the past, giving no methodological worries. However, 
trial and error seems to be a practice that aligns with the comparative law method success, as 
knowing which solution works best for a given problem heavily relies on the practical evidence and 
sence of appropriateness. See Zweigert, K., and Kötz, H., Introduction to comparative Law, at 33-
34 
32 Jansen, N., ‘Comparative Law and Comparative Knowledge’, in Reiman, M., and Zimmermann, 
R.(eds.) The Oxford Handbook of Comparative Law, (1st edn, Oxford University Press, New York, 
2006) 308 
33 Legrand, P., ‘How to Compare Now’ (1996) 16 Legal Studies2, 232-242 at 236 
34 Id ut Supra Zweigert and Kötz, at 34 
35 Tuebner, G., ‘Legal Irritants: How Unifying Law Ends up in New Divergences’ (2001)Varieties of 
Capitalism, 417-442 at 419 
36 Örücü, E., ‘Developing comparative Law’, in Comparative Law Handbook, at 51 
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conclusions.37 Hence, this investigation juxtaposes or uses the Brazilian system as 
the point of comparison given its tradition of making use of TRIPS flexibilities 
and leeway to protect and balance both IP rights and access to medicines. Thus, 
Brazil has actively taken part in most of the preparatory work before the Doha 
Declaration, and also became one of the first WTO Members in implementing the 
TRIPS Agreement into its own national system. 
1.3.2. Legal Research and Legal Dogmatic 
Legal-dogmatic research concerns researching current positive law as laid down in 
written and unwritten European or (inter)national rules, principles, concepts, doctrines, 
case law and annotations in the literature....38 
The legal dogmatic research method also encompasses legal research. On the, one 
hand, both methods are concerned with the sources of law used in legal 
processes.39 But on the other hand, they are concerned with the use of a theory to 
analyse determined rules.40 
The legal dogmatic research will present the analysis of the international, 
national and regional legal instruments related to pharmaceutical patents, public 
health and access to medicines in a systematic way, as well as the arguments 
embedded within the debate in both the national and the international context. 
This research intends to shed light on balancing strategies when implementing 
and protecting patent rights while at the same time ensuring peoples’ access to 
affordable medicines.  
Therefore, it is important not only to select the sources of law,41 but also to take 
into consideration the human rights approach when discussing and making 
relevant suggestions at the end of the study. Reviewing the relevant legislation, 
history and case law related to national health care policies and services within 
the countries is an attempt to address pharmaceutical patents and access to 
medicine from the point of view of the internal participants within the contexts 
analysed.42 
                                                        
37 Ibid at 2. “juxtapose,” means “ to put people or things together, specifically in order to show a 
contrast or a new relationship between them.” See Oxford Advanced Learner’s Dictionary, 7th edn, 
(Clarendon Press: Oxford) at 840 
38 Vraken, J., ‘Exciting Times for Legal Scholarship’ (2012) Recht en Methode in onderzoek en 
onderwijs, Aflevering 2 2012<www.bjutijdschriften.nl/tijdschrift/rem/2012/2/ReM_2212-
2508_2012_002_002_004/fullscreen> accessed 7 April 2014 
39 Idem. Also see, Vogenauer, S., ‘Sources of Law and Legal Method in Comparative Law’ in Reiman, 
M., and Zimmermann, R. (eds.), The Oxford Handbook of Comparative Law, (1st edn, Oxford 
University Press, New York, 2006) at 885 
40 Sadgren, C., ‘On Empirical Legal Science’, Stockhol Institute for Scandinavian Law, Edited by 
Peter Wahlgren, 445<www.scandinavianlaw.se/pdf/40-17.pdf>accessed 15 February 2013 
41 In many cases the legislator gives directions on how to rank and which are the sources of law 
within a system. For this purpose it is important to consult the constitutional text in each country 
part of the comparison. See Vogenauer, S., ‘Sources of Law and Legal Method in Comparative Law’ 
at 886-889. And also See de Cruz, P.,Comparative Law in a Changing World, at 232-235. 
42 Tuori, K., ‘Self-Description and External Description of the Law’ (November 2006) 2 No 
Foundations: An Interdisciplinary Journal Of Law And Justice, 27-43, 28 
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Throughout the analysis of the sources of law within the aforementioned context, 
it is expected to also take into consideration the facts as to delimit and survey the 
legal discourse when addressing i.e. the controversy around the prior consent 
mechanism in Brazil. Case law or court proceedings –when available will provide 
an insight in order to reach a better understanding of each context. 
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2 BACKGROUND OF THE STUDY: INTELLECTUAL 
PROPERTY AND PUBLIC HEALTH 
This chapter intends to analyse the nature of both intellectual property rights and 
public health, primarily focusing on the intellectual property –pharmaceutical 
patents- vs. access to medicines debate in a general fashion before exploring the 
current situation in Brazil, Chile and Venezuela. 
Within the access to medicines context, is it necessary to review not only basic 
concepts, but also the international framework behind this as a human right 
together with the most relevant organisations involved. In this respect, besides 
establishing what is to be understood for public health, its scope and its relation 
to the human right to health, the relationship and link will also be analysed 
between intellectual property rights and public health –access to medicines. 
2.1. Defining Intellectual Property Right Through History 
Intellectual property (IP) refers to creations of the mind: inventions, literary and artistic 
works, and symbols, names, images, and designs used in commerce. (WIPO) 
A patent is a document, issued, upon application, by a government office (or a regional 
office acting for several countries), which describes an invention and creates a legal 
situation in which the patented invention can normally only be exploited (manufactured, 
used, sold, imported) with the authorization of the owner of the patent. (WIPO, 
Intellectual Property Handbook) 
Intellectual property and patents have been around for a long time. History 
points to the existence of patents since 1421 when the first patent was granted in 
Florence to Filippo Brunelleschi for his innovative solution to transporting by 
ship the carrara marble used to build Florence’s Duomo.43 The patent was 
granted to the ship that Brunelleschi had built to transport the marble through 
the Arno River. It has been said that the Florentine patent system sank with the 
ship due to conflicts between the major guilds, a decree enacted that limited the 
State-governed incentives for new crafts and technological innovations to tax 
exemptions alone among other reasons.44 
Later on in 1474, the Venetian Republic began granting patent protection in the 
form of import licences and private issuance to encourage guilds dominating 
commerce and arts to come up with technological innovations.45 Guild rules are 
said to have led to the creation of the Statute of Venice in 1474. Letters of patent 
were also granted in the United Kingdom, in this respect, the Statutes of 
                                                        
43 Nard, C. A., and P. Morriss, A., ‘Constitutionalizing Patents: From Venice to Philadelphia’ (2006) 
2Review of Law and Economics2, 223-320, at 233 
44 Idem Nard, C. A., et al in ‘Constitutionalizing Patents’ quoting Bugbee, B. Genesis of American 
Patent and Copyright(Washington, D.C.: PublicAffairs Press – 1964) 
45 Moser, P., ‘Patents and Innovation: Evidence from Economic History’ (winter 2013) 27Journal of 
Economic Perspectives1, 23-44, at 25 
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Monopolies was created in 1624 to encourage manufacturing growth and to lure 
skilled workers to live in England.46  
One of the most interesting patent monopolies granted in the form of patent was 
the Darcy patent; given as an import licence to bring playing cards into the 
British market.  Patents granted for vinegar, starch and playing cards were the 
most well known letters of patent.47 The enactment of the Statute of Monopolies 
in England was an indication of the growing importance of trade within the 
country’s economy, and the willingness to foster innovation, which eventually 
allowed a step forward into industrial production.48 Initially, patents in England 
were considered a “matter of condescension” from the Crown and not a matter of 
private rights. However, there was a shift in this position allowing the country to 
gain from the export of technology as competitors used letters of patent as a 
source of information since judges often required adequate description or 
sufficient statement of the conception as justification for the monopoly granted.49 
The “disclosure” or full description of the invention became a formal requirement 
under the 1852 Patent Law Amendment Act, thus settling the foundation and 
importance of dissemination of knowledge via the patents disclosure.50 
While some countries moved forward by providing patent protection – during the 
nineteenth century- others had not even considered adopting patent law or 
simple abolished the systems. For instance, the Netherlands abolished in 1869 its 
patent system, Switzerland had no formal patent system until 1907, Germany also 
revoked its patents system from 1817 and in Denmark patent protection was only 
granted for a period of five years.51 Amid a lack of legislative consensus or 
protection among nations, the need to harmonise to a certain extent led countries 
to agree about patent protection under the framework of the Paris Convention in 
1883. Globalisation and the move towards an industrialised world are said to 
have preceded the Paris Convention. In particular history seems to recall an 
international exhibition of inventions held in 1873 in Vienna, the success of which 
was jeopardised by the fact that neither the Austria-Hungary Empire offered 
adequate legal protection, nor were many of the visiting countries willing to put 
on display their inventions due to the lack of protection.52 
Between 1873 and 1883, three important developments took place prior to 
signing and approving the Paris Convention for the Protection of Industrial 
Property. Following the close failure of 1873’s innovation exhibition fair, the 
government via special law granted temporary protection to all foreigners taking 
part in the exhibition including trademarks and industrial design. Then, the 
Congress of Vienna during the same year agreed upon a Patent Reform, where a 
                                                        
46 Craig Nard (ed.) ‘History and Architecture of the Patent System’ in The Laws of Patent ( 2nd. 
Edition, Aspen Publishers: 2010) 1-55, at 9-11. 
47 Idem. 
48  Cornish, W., and Llewelyn, Intellectual Property: Patents, Copyright, Trad Marks and Allied 
Rights (Sweet & Maxwell- London: 2010) 124-125 
49 Idem Cornish, W., et al. ‘Intellectual Property’ 125-126 
50 Nard, C., ‘History and Architecture of the Patent System’, 14-15 
51 Moser, P., ‘Patents and Innovation’, 25-26. Also See Gontíjo, C., ‘Changing The Patent 
SystemFrom The Paris Convention To The TripsAgreementThe Position Of Brazil’, (Dec. 2005) 26 
Global Issue Papers, 1-32, 5. <www.fdcl-berlin.de/fileadmin/fdcl/Publikationen/GIP_Gontijo-
Patente.pdf> accessed 20 March 2014 
52 WIPO, Intellectual Property Handbook (2nd. Edition, 2008) 1-488, 241 
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series of principles were elaborated that aimed to portray what an efficient and 
useful patent system should be like. And finally, the International Congress on 
Industrial property was held in Paris during 1878 where the attending countries 
were compelled to agree upon a harmonised system for the protection of 
industrial property under the frame of a union.53 Eventually in 1883, eleven 
States –initially- signed the Paris Convention for the Protection of Industrial 
Property.  This is said to be one of the most successful Conventions that 
harmonised intellectual property legislation, and its success is attributed mainly 
to the fact that only general principles were settled yet countries had enough 
freedom to decide on the terms of protection.54 
The Paris Convention is the basis for the Patent system as we know it today. Even 
when the principle of national treatment,55 the right of priority,56 importation, 
local working requirement and compulsory licences57 are among the most 
important provisions, nothing within the convention defines patents or invention 
or refers to patentability requirements. In terms of patent protection, the 
provision in Article 4 bis foresees the independence of patents that needs to be 
interpreted in the broadest sense possible: 
This principle is to be understood in its broadest sense. It means that the grant of a patent 
for invention in one country for a given invention does not oblige any other member 
country to grant a patent for invention for the same invention. Furthermore, the principle 
means that a patent for invention cannot be refused, invalidated or otherwise terminated 
in any member country on the ground that a patent for invention for the same invention 
has been refused or invalidated, or that it is no longer maintained or has terminated, in 
any other country. In this respect, the fate of a particular patent for invention in any given 
country has no influence whatsoever on the fate of a patent for the same invention in any 
of the other countries.58 
In the context of patent protection, several treaties, conventions and agreements 
have been ratified. Namely, the Community Patent Convention, the Patent 
Cooperation Treaty, the European Patent Convention and the Agreement on 
Trade-Related Aspects of Intellectual Property Rights are among the important 
international frameworks. However, for the purpose of giving context to the 
discussion on pharmaceutical patents and access to medicines only those 
                                                        
53Idem.  
54See Gontíjo, C., ‘Changing The Patent System’, 6-7 
55 Article 2, and 3 from the Paris Convention for the Protection of Industrial Property, as last revised 
at Stockholm. 21 UST 1583, 828 UNTS 305 
56 Article 4 from the Paris Convention 
57 Article 5 from the Paris Convention 
58 WIPO, ‘Intellectual Property Handbook’, 245. Also seeArticle 4 bis from the Paris Convention:  
“(1) Patents applied for in the various countries of the Union by nationals of countries of the Union 
shall be independent of patents obtained for the same invention in other countries, whether 
members of the Union or not. 
(2) The foregoing provision is to be understood in an unrestricted sense, in particular, in the sense 
that patents applied for during the period of priority are independent, both as regards the grounds 
for nullity and forfeiture, and as regards their normal duration. 
(3) The provision shall apply to all patents existing at the time when it comes into effect. 
(4) Similarly, it shall apply, in the case of the accession of new countries, to patents in existence on 
either side at the time of accession. 
(5) Patents obtained with the benefit of priority shall, in the various countries of the Union, have a 
duration equal to that which they would have, had they been applied for or granted without the 
benefit of priority.” 
  
15 
agreements and conventions will be referenced that are relevant to the 
discussion.59 
Modern patent law grants protection for inventions that meet with the 
patentability requirements. This protection allows the right holder to prevent 
others from using, distributing, selling or producing the patented product without 
the owners consent.60 In general terms, patent rights grant a monopoly, since 
they allocate exclusive rights to the right holder. Nevertheless, this exclusivity is 
limited in time and territory. Patent protection shall be granted without 
discrimination of the field of technology for a period of 20 years from the date it 
was applied for. Limitation to the territory where the patent has been granted 
requires a patent holder to pursue patent protection in at least each of the 
countries where the patented product or process intended to be commercialised, 
unless the countries have ratified the relevant international Treaties and 
Conventions.61 
Accordingly, patents can be assessed from the utilitarian approach perspective. 
This approach facilitates the understanding of reproducibility and enforceability 
as part of elements defining patents. The inventor would not feel compelled to 
disclose an invention if patent protection were not available, as within the 
utilitarian fruits approach patents are a reward for the inventor for the fruits of 
his work that is translated into public disclosure as the price for protection.62 
2.2. What is Public Health? 
Besides intellectual property rights, certain aspects of public health such as its 
definition, scope, classification and terminology require addressing before 
identifying or making the connection between pharmaceutical patents and access 
to medicines.  
In 1948, after the Second World War, the United Nations committed to 
promoting international cooperation not only in the economic, social, cultural 
and educational fields but also in the field of health. In this respect, Article 57 
from the United Nations Charter foresaw the creation of specialised agencies to 
                                                        
59 For more detailed information on the evolution of intellectual property right and historical facts, 
seeNard, C. A., and P. Morriss, A., ‘Constitutionalizing Patents: From Venice to Philadelphia’ 
(2006) 2 Review of Law and Economics2, 223-320; Moser, P., ‘Patents and Innovation: Evidence 
from Economic History’ (winter 2013) 27 Journal of Economic Perspectives1, 23-44; Craigand see 
Nard, C.  (ed.) ‘History and Architecture of the Patent System’ in The Laws of Patent ( 2nd. Edition, 
Aspen Publishers: 2010) 1-55 
60 Cornish, W., ‘Intellectual Property’, 7-8, and 144-148 
61 WIPO, Intellectual Property Handbook (2nd. Edition, 2008) at 17-22  
62 Aly Crowne, E., ‘The Utilitarian Fruits Approach to Justifying Patentable Subject Matter’, (2011) 
10 Johnl Marshall Review of Intellectual Property Law 753, 754-763 
63 Article 13(1)b, Charter of the United Nations, 24 October 1945, 1 UNTS XVI 
<www.refworld.org/docid/3ae6b3930.html> accessed 24 September 2013. “…promoting 
international co-operation in the economic, social, cultural, educational, and health fields, and 
assisting in the realization of human rights and fundamental freedoms for all without distinction as 
to race, sex, language, or religion.” 
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assist Member Countries in solving or assessing challenges related to the 
realisation of human rights.64 
The World Health Organization (hereinafter WHO) is a specialised agency of the 
United Nations system65 that has become the leading organisation in the 
discussion about health related topics, and provides Member Countries with 
guidelines on global health, as well.66In a general fashion, the WHO defines 
“health systems” according to what citizens should be provided with. In this 
respect, the World Health Report from 2000 foresees that “all the activities 
whose primary purpose is to promote, restore or maintain health” 67are to be 
included within the health system definition. The aforementioned report also 
establishes that a health care system has many variables determining the extent 
to what should or should not be covered. Nevertheless, this implies 
responsibilities beyond improving people’s health. Preventing people from 
enduring financial hardship or avoiding self-impoverishment due to high costs 
derived from illness, is also considered to be essential for an adequate 
performance or coverage.68 
Despite several studies having shown differences between health systems in Latin 
America, the financial aspect embedded in these systems seems to be one of the 
determining factors influencing this classification. For instance, the WHO takes 
into consideration countries’ level of income, whereas other scholars have 
provided broader classifications based on the governmental role; in other words, 
from more statutory to less statutory. 
Thus far, the National Health Services Systems (NHS), National Social Insurance 
Systems (NHIS) and Mixed National Health Systems (MNSH) are the three 
categories that most commonly describe the health care frame available in Latin 
America. The National Health Services Systems (NHS) can be understood as the 
systems where central government institutions play an important part in the 
provision of health care services, and at the same time social health insurance 
institutions are non-existent or only represent a small part in the financing of the 
system.69 National Social Insurance Systems (NHIS) are those systems where one 
or more social insurance institutions play an important role in the provision of 
health care services that cover only 50% or more of the total population. And 
Mixed National Health Systems (MNSH) are characterised by the fact that public 
sector institutions play a small part in the provision of health care services, the 
coverage of the mandatory social health-insurance covers less than one-third of 
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the total population and the out of pocket expenditure on health services is very 
high.70 
Having said this, it has been also highlighted that the WHO classifies most of 
Latin American countries’ national health systems as Mixed National Health 
Systems given that none of them provide real universal coverage as offered by i.e. 
European health care services.71 Within the systems’ definition and scope, 
independent of their level in the classification, universal coverage seems to be the 
ideal scenario for health care. Thus, it means that everyone should have access to 
appropriate promotive, preventive, curative and rehabilitative health care when 
they need it and at an affordable cost.72 
The WHO in the World Health Assembly from 1975 through Resolution WHA 
28.66 encouraged countries to implement drug policies aligned with their needs. 
Defining each country’s essential medicines together with the formulation of 
strategies for appropriate procurement of quality drugs according to health needs 
and providing both education and training in various elements of pharmaceutical 
programmes were addressed within the Resolution as well.73 According to the 
WHO, deterring or improving access to medicines within the public health 
discourse is commonly challenged by the price of medicines, but these do not 
solely influence access to medicines as several other aspects interfere in the cycle 
as is addressed below. 
The UN Millennium Project in its report from 2005 pointed out six of the most 
important barriers to access of medicines. By describing challenges to both 
existing medicines and to the development of affordable new ones, these barriers 
have been divided into two categories.74 First, inadequate national commitment 
and human resources, lack of finance on behalf of the international community 
and persistent lack of coordination of international aid have been identified as the 
barriers deterring access to existing medicines.75And secondly, the report pointed 
out that the barriers related to the development of affordable drugs the facts that 
the Agreement on Trade Related Aspects of Intellectual Property Rights 
(hereinafter TRIPS Agreement) may block access to affordable medicines and the 
inadequacy of the current incentive structure to promote R&D of medicines. 
Defining certain terminologies to delimit the scope of the discussion may provide 
guidance to both the reader and stakeholders. Therefore, the WHO defines 
Essential medicines as those needed to fulfil the population’s health care 
priorities and those that also are intended to be available within the context of 
functioning health systems at all times, in the required dosage forms, with 
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assured quality and at affordable prices for individuals to purchase them.76At the 
same time, ‘access’ has been defined by the United Nations Development Group  
‘as having drugs continuously available and affordable at public or private health 
facilities or drug outlets that are within one hour’s walk of the population.’77 Both 
‘access’ and ‘essential medicines’ are important terms used within the public 
health general discourse, therefore the definition provided aims at facilitating the 
reader with an understanding of the scope of both terminologies. 
2.2.1. Access to Medicines as part of the Human Right to Health 
The race towards achieving universal coverage so as to ensure people’s access to 
essential medicines brought to the spotlight the discussion on access as part of 
the human right to health.78 Pharmaceutical patents among other things have 
been identified as a barrier to adequate public health79 that just a few countries 
within the developing world can provide. Thus far, access to essential medicines 
seems to be considered as a derivate right within the broader sense of the human 
right to health.80 Human Rights Law has made a significant contribution to the 
codification of the human right to health and its scope.81 
Since 1945, the Charter for the United Nations in various articles has overseen 
health and the creation of specialised agencies to achieve or promote solutions to 
challenges related to it.82 Later, in 1966, the International Covenant on 
Economic, Social and Cultural Rights (hereinafter ICESCR) specified or codified 
the right to health. In this respect, Article 12.1 from the ICESCR establishes that 
State Parties recognised the right of everyone to the enjoyment of the highest 
attainable standard of physical and mental health including treatment, 
prevention and control of epidemic, endemic, occupational and other diseases.83 
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However, the aforementioned convention was unclear regarding the meaning of 
the highest attainable standard of health.84 In 2000, the Committee on 
Economic, Social and Cultural Rights (CESCR) in its twenty-second session 
settled the parameters for understanding the right to health in the document ‘The 
right to the highest attainable standard of health: 11/08/2000. E/C.12/2000/4. 
(General Comment 14).’ In this regard, not only are access to essential medicines, 
primary health care attention and minimum health services among others to be 
provided to country nationals,85 but also Member Countries’ duty to fully comply 
with the ICESCR is to be upheld unless they lack the necessary resources to 
accomplish the minimum health goals.86 
The UN - Commission on Human Rights in Resolution 2001/33 recognised that 
‘access to medication is a key element for achieving full realization of the right of 
everyone to the enjoyment of the highest attainable standard of physical and 
mental health.’87 Consequently, the right to health seems to have a particular 
importance in the context of pandemics such as HIV/AIDS, malaria and 
tuberculosis. Therefore, governments need to be encouraged to provide essential 
medicines while at the same time ensuring citizens minimum standards of health 
care. Scholars have highlighted the importance that non-state actors have in the 
sector of public health, since their role in finding donors to finance health 
programmes has perhaps given better results than in any other field.88 
Diverse initiatives have been developed towards achieving a wider understanding 
of the challenges faced by the developing world in regards to health needs and 
also at finding solutions to these challenges. The Global Strategy and Plan of 
Action on Intellectual Property Rights, Innovation, and Public Health, the 
Millennium Goals, the Belinda Gates Foundation HIV/AIDS Program and The 
World Bank-WHO initiatives are among the few projects based on the importance 
of the human right to health. 
For instance, in 1997 the World Bank published the ‘Health, Nutrition and 
Population Strategy’ that focused on health outcomes and emphasised support 
for improved health system performance.89 Later, in 2007, this strategy was 
updated, but the ultimate objective of the World Bank is to ‘is to improve health 
conditions of the people in client countries, in the context of its overall strategy 
for poverty alleviation.’90
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Another international convention to take into consideration when analysing the 
Human Right to Health is the International Covenant on Civil and Political Rights 
(hereinafter ICCPR).  This is a multilateral treaty adopted under the United 
Nations umbrella during its General Assembly on 16 December 1966, which came 
into force in March 1976. This treaty is particularly relevant not only because it 
has been ratified by 152 nations, but also because it complements the human 
right to health by protecting the right to life.91 
A broad interpretation of the ‘right to life’ extends to the basic conditions of life,92 
which includes access to life-saving drugs or essential medicines since States 
must protect by law, fulfil and prevent violations of people’s right to life.93 It has 
been argued that by denying access to life-saving drugs, this right could be in 
jeopardy given that the right to life evolved beyond ‘the right to be free from 
arbitrary killing’.94 
Human rights, in general, are intended to be applicable to every human being 
without any kind of discrimination.95 However, the human right to health does 
not only seem to be affected by globalisation,96 but it is also dependent on the 
realisation of other human rights i.e. education, privacy and non-
discrimination.97 
On the one hand, globalisation is reported to bring development into nations’ 
economies, but on the other hand it has been suggested that this also creates a 
‘new global order where corporate and financial interests prevail over the 
interests of the population.’98 Therefore, it is advisable to implement legislative 
reforms on the basis of the human rights- approach so as to ensure a lesser 
negative impact on peoples’ rights, given that, human rights intertwine with the 
relationship between individuals and the state by creating rights for one and 
obligations for the state to fulfil.99 
Alleged national policies based on human rights ensure a governmental 
commitment towards the realisation of the right to health in a way that is 
internationally recognised, which at the same time creates legal responsibilities 
for the State.100 
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The rights-based approach to development describes situations not simply in terms of 
human needs, or of developmental requirements, but in terms of society's obligation to 
respond to the inalienable rights of individuals. It empowers people to demand justice as 
a right, not as charity, and gives communities a moral basis from which to claim 
international assistance where needed.101 (Kofi Annan, Secretary-General of the United 
Nations) 
 
In terms of the right-based approach, specifically in medicines programmes, the 
need to follow basic principles of non-discrimination and equality has been 
highlighted since these can feature health care conditions for all groups of the 
population, thus making it easier to determine different health needs within 
various groups.102 To determine the needs and the implementation of this 
approach, recognition of everyone’s right to the enjoyment of the highest 
attainable standard of health within national Constitutions’103 seems to be an 
important question that needs asking when assessing governmental commitment 
to the right to health. 
Accepting access to medicines as part of the human right to health does not seem 
to be troublesome for nations, since reportedly several national constitutions 
already acknowledge these rights within the internal framework. However, this 
recognition is neither a guarantee nor an essential step taken by many 
countries.104 
The human right-based approach has an impact on national legislation, since the 
State is the main guarantor for the fulfilment of this right. For instance, basic 
health needs are deemed health rights, and priorities need to be settled within the 
health sector for government to allocate sufficient financial resources to comply 
with their commitments.105 
Despite increasing the governments’ accountability due to the human right 
approach to health, it has been suggested that given the nature of their business 
that the pharmaceutical industry should also take into consideration this 
approach.106 The industry’s role towards the realisation of the right to health will 
be examined in the conclusion. 
Thus far, access to medicines seems to be recognised as part of the human right to 
health as defined by several international agreements. Moreover, implementing 
measures to ensure access to medicines according to scholars derives from the 
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state’s legal obligation to do so. In addition, there is the suggestion that ‘access’ 
needs to be reflected as a priority within budget planning and health care 
organisation since access cannot be guarantied independently from a functioning 
health care system.107 Another important aspect embedded within the 
implementation of a human right approach to health is its enforceability within 
national courts. Accordingly, with the report on the World Medicine Situation 
from 2011, in several countries national health policies have been challenged as a 
direct consequence of not fulfilling the legal obligation of providing access to 
essential medicines.108 
Health as a human right has been recognised fundamentally as the responsibility 
of the state. However, globalisation as already highlighted seems to have 
redressed the burden into the international community and other non-state 
actors due to countries receiving influence from trade regimes, loans and 
development assistance.109 
2.3. The Relationship between Intellectual Property Rights and 
Public Health (access to medicines) 
With the creation of the World Trade Organization (hereinafter WTO) in 1994 its 
member countries also ratified a series of Agreements, among these, the 
Agreement on Trade Related Aspects of Intellectual Property (hereinafter 
TRIPS), which linked public health to intellectual property rights by extending 
protection to all fields of technology.  This part aims at providing the reader with 
some general information necessary to understand the context, relevance and 
impact on public health issues and access to medicines presented in the 
discussion. Therefore it is important to address the creation of the WTO, the 
importance of the TRIPS Agreement and Doha Declaration in the context of 
patents. 
2.3.1. WTO and TRIPS Agreement 
The WTO was created in 1994 through the Marrakesh Agreement during the well-
known Uruguay Round. The Organisation became operational in 1995 and does 
not only deal with trade rules between nations, but is also responsible for setting 
international trade rules.110 
Annexed to the Marrakesh Agreement Establishing the World Trade 
Organization, a total of 12 Agreements were to be mandatorily ratified by nations 
becoming Members of the WTO. Among these, the Agreement on Trade-Related 
Aspects of Intellectual Property Rights Agreement (hereinafter TRIPS 
Agreement), that was ratified by 158 Members on 2 February 2013, re-
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conceptualised intellectual property rights as trade issues111 when minimum 
standards of protection were not only established but also extended to all fields of 
technology, including the pharmaceutical field.112 
This part of the analysis will assess both the content of the TRIPS Agreement 
relating to patents and public health and its impact on WTO Member Countries. 
Nations, by acceding to the WTO, also agreed upon extending the term of 
protection for a period of 20 years113 both to products and processes, as they now 
were contracting parties.114 This new provision was also binding for developing 
and least-developed nations that did not provide patent protection for the length 
settled for all fields of technology, since the Paris Convention allowed Member 
Countries to legislate over the fields of technology that should be subject to patent 
protection.115 
To a certain extent some scholars perceive the TRIPS Agreement as an “agent of 
change in the health sector”116 since patents for pharmaceutical products and 
processes were now to be granted. Allegedly in the past, this sector was excluded 
from patentability due to public or social concerns in terms of countries’ need to 
ensure access to medicines at a low price and also to protect the national 
pharmaceutical industry.117 
The Agreement, besides extending patent protection to all fields of technology 
and stating patentability requirements, does not define what an invention is. In 
this respect, the lack of consensus on a universal definition has been highlighted, 
which is not indicative of an omission or a loophole in the TRIPS Agreement.118 
Allegedly, this is not the only definition that is not provided by the Agreement: 
the same Article 27(1) aims at defining inventions by giving their patentability 
requirements –new, inventive step and capable of industrial application- but 
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none of these are defined, except for the ‘inventive step’ that can be taken as ‘non-
obvious’.119 
Article 27(2) and (3) also foresee patentability exceptions, namely those “contrary to 
public order or morality, including to protect human, animal or, plant life or health” 
animals, and members may also exclude from patentability diagnostic and/or therapeutic 
and surgical methods.120 
Articles 7 and 8 give the first link to public health within the Agreement, since the 
need to balance rights and obligations and the importance to promote social and 
economic welfare as well as to protect public health are acknowledged.121 
 Although, the Agreement intends to provide a harmonised intellectual property 
regime with minimum standards of protection, it also allows Member Countries 
to tailor their national systems to implement the Agreement.122 Some developing 
countries seemed to have implemented stronger IP protection, reportedly as a 
strategy to attract the pharmaceutical industry to innovate, transfer and 
disseminate its technology.123 Nevertheless, exceptions are also foreseen by the 
Agreement to protect public health, correct anticompetitive practices and to 
address national emergencies. 
Besides allowing Members to take the necessary measures to protect both public 
health and public interests, the Agreement in Articles 30 and 31 settles the 
exceptions for patent protection. Namely, Article 30 entails limited exceptions to 
these exclusive rights as long as the measures taken do not unreasonably conflict 
with the normal exploitation of the patent or with the legitimate interests of the 
patent owner, taking into account the legitimate interests of third parties as 
well.124 
The other exception foreseen within the Agreement is the compulsory licences 
regime, also known within the Agreement’s Article 31 as ‘Other use without 
Authorization of the Right Holder.’ Accordingly, country members are entitled to 
enact compulsory licences to predominantly supply the internal market125 and 
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after adequately remunerating the right holder.126 In general terms, even when a 
compulsory licence has been enacted, “the right holder shall be paid adequate 
remuneration taking into account the economic value of the authorization” as 
pointed out by Article 31 (h) from the TRIPS Agreements. However, the 
Agreement also foresees an exception to this rule settled within the same Article 
part (k) from where it could be inferred that the aforementioned compensation 
does not necessarily take place under the terms initially foreseen within Article 
31(h) since the amount of the compensation may need to be taken into 
consideration when correcting anti-competitive practices.127 The original 
Agreement –draft- brought along a gap in members’ ability to take measures to 
address public health or national emergencies given to Article’s 31 (b) 
requirement to pursue voluntary licence from patent holders before actually 
enacting compulsory licences.128 
Following the TRIPS Agreement, countries began lobbying for further 
clarification in terms of the flexibilities.  Two particular cases seemed to have 
played an important role in the move towards recognising public health concerns 
in the years to come. During 1997 the South African Government modified its 
National Drug Policy in a manner favourable to compulsory licences and parallel 
imports in their aim to tackle the HIV/AIDS crisis, but both the U.S. government 
and the U.S. pharmaceutical industry strongly opposed such implementation by 
arguing that it was an abrogation to patent rights and subsequently a breach of 
TRIPS.129 The USTR placed South Africa on the Special 301 reports watch list for 
two years in a row (1998-1999) and later on also withheld trade benefits for a 
selection of products that were already approved within the Generalized System 
of Preferences (GSP) as a method of pressure on South Africa to back down from 
implementing the revised National Drug Policy.130 Given the media attention, and 
the work of activists, the U.S. Government shifted its policy towards South Africa 
in a manner consistent with South Africa’s need to achieve greater access to 
essential medicines.131 
In 2000the U.S. Government called for consultations with Brazil due to the 
implementation of the working requirement within its IP legislation, which, if 
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130 Idem at 7. During 1998 the South African Pharmaceutical Association brought their complaint 
about the revised National Drug Policy before the High Court of South Africa. The industry 
challenged the constitutionality of the legislation, allegetions that were later on dismissed by the 
High Court. (Fischer, W. et al) 
131 Idem at 8-9. Also See Dicey, V., ‘AIDS drug imperialism’ (1999) 42 The Monthly Journal of the 
Socialist Party<www.socialismtoday.org/42/aids.html> accessed 15 January 2013 
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unfulfilled, would suffice for the government to enact compulsory licences and/or 
parallel trade to satisfy the internal market.132 These two cases portrayed the 
conflict of interests, sometimes still prevalent, between the interests of the 
pharmaceutical industry on the one hand and on the other with the duty to 
implement the TRIPS Agreement in a manner consistent with each country’s 
national needs (i.e. to supply the internal market to grant access to essential 
medicines). The local working requirement in Brazil is not strictly to address 
public health issues, as will be assessed later on within the Brazilian chapter, and 
instead the aforementioned provision is settled within the frame of compulsory 
licences. 
Thus far it has been established that the TRIPS Agreement does not only settle 
minimum standards of protection, but also foresees exceptions to patent rights.  
More attention shall be given to both the Doha Declaration and other flexibilities 
conceived to address public health concerns among other national interests. Thus 
far, TRIPS flexibilities can be summarised as compulsory licences, parallel 
imports and early working exceptions or Bolar exception. These have been 
defined as: 
 Compulsory Licences can be understood as “the authorization given by 
the State to a third party to exploit a patented invention, generally 
against a remuneration to the patent holder, and these may be granted 
according to national laws on several grounds, such as emergency, 
public interests, non-working of the invention, anticompetitive practices 
and dependency of patents.”133 
 Parallel imports refer to the situation “when a product made legally (i.e. 
not pirated) abroad is imported without the permission of the 
intellectual property right-holder (e.g. the trademark or patent 
owner).”134 
 Regulatory exception or ‘Bolar exception’ “allows manufacturers of 
generic drugs to use the patented invention, without the patent owner's 
permission and before the patent protection expires, for the purpose of 
obtaining marketing approval from public health authorities. Generic 
producers are thus able to market their versions almost as soon as the 
patent expires.”135 
It has been suggested that developing and the least-developed countries have 
taken advantage of TRIPS’ options and safeguards, for instance, in determining 
when intellectual property rights have been exhausted either at a national or an 
                                                        
132 Roffe, P.. et al. ‘From Paris to Doha’, at 17, Also See WTO Dispute DS199 
<www.wto.org/english/tratop_e/dispu_e/cases_e/ds199_e.htm> accessed 14 March 2014 
133 Correa, C., ‘Public Health and Intellectual Property Rights’ (2002) 2Global Social Policy3, 261-
278, at 268 
134 WTO Glossary<www.wto.org/english/thewto_e/glossary_e/parallel_imports_e.htm> accessed 
14 March 2014 
135 WTO Agreement and Public Health: a joint study by the WHO and the WTO Secretariat (WTO 
Secretariat, 2002) 44. <www.wto.org/english/res_e/booksp_e/who_wto_e.pdf> accessed 14 
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international level depending on each Members’ preference.136 TRIPS- Agreement 
flexibilities, as these set of exceptions became known, were object to further 
negotiations and clarifications in the Doha Round since these link intellectual 
property rights with public health concerns. The flexibilities were deemed 
necessary given that IP protection was now available for medicines as well. 
2.3.2. Doha Declaration on the TRIPS Agreement and Public Health 
Following the TRIPS Agreement WTO Members began pushing for further 
clarification in terms of the use of TRIPS flexibilities and also for international 
recognition of public health concerns. As part of the analysis, it is important to 
address the structure, content and importance of the Doha Declaration on the 
TRIPS Agreement and Public Health and the Decision implementing paragraph 6 
from the Doha Declaration and its following amendment. 
In 2001 during the Fourth Ministerial Conference in Doha, public health 
concerns were recognised by WTO Member States in the ‘Declaration on the 
TRIPS Agreement and Public Health’ (hereinafter Doha Declaration or 
Declaration) and also in the Doha Ministerial Declaration.137 The Doha 
Declaration is structured in seven paragraphs that assess the Agreement’s 
provision relevant to public health concerns, bringing also to the spotlight the 
need to modify the compulsory licence regime as first established. In this respect, 
HIV/AIDS, tuberculosis and malaria are recognised as some of the epidemics that 
afflict the most; hence further R&D is needed.138 
The Doha Declaration is considered as a milestone in the debate between TRIPS 
and access to medicines, since it makes the agreement both development and 
public health-friendly in terms of interpretation.139 The Declaration is said to 
include similar language as to the one found in the Submission by the African 
group140 before the Ministerial Conference, together with other developing and 
least developed countries, which have been perceived as a relevant issue to 
facilitate both the interpretation and the implementation of the Agreement since 
protecting public health is still a major concern.141 
Paragraph 5 of the Declaration does not only honour the commitments within the 
Agreement, but also recognises and clarifies to a certain extent the use of 
                                                        
136 Deere, C., The Implementation Game: The TRIPS Agreement and the Global Politics of 
Intellectual Property Reform in Developing Countries (Clarendon Press: Oxford, 2008) at 75 
137 Doha Declaration on the TRIPS Agreement and Public Health, World Trade Organization, WTO 
Doc. WT/MIN(01)/DEC/2, (1 November 2001) ,  and Also see, Doha Ministerial Declaration, 
World Trade Organization, WTO Doc. WT/MIN(01)/DEC/1, (14 November 2001) 
138 Paragraph 1, Doha Declaration WT/MIN(01)/DEC/2 
139 Nagah, A., ‘TRIPS and Public Health: What should African Countries Do?’ African Trade Policy 
Centre, Working Paper Nº 49 (January 2007) at 3 
140 Submission by the African Group, Barbados, Bolivia, Brazil, Cuba, Dominican Republic, 
Ecuador, Honduras, India, Indonesia, Jamaica, Pakistan, Paraguay, Philippines, Peru, Sri Lanka, 
Thailand, and Venezuela, Council for Trade-Related Aspects of Intellectual Property Rights, 
IP/C/W/296 (June 2001) at 22 <commerce.nic.in/wto_sub/trips/sub_Trips-
ipcw296.htm>accessed 10 February 2013 
141 Yu, P. K., ‘The Objectives and Principles of the TRIPS Agreement’ (2009) 46Houston Law 
Review979 <www.peteryu.com/correa.pdf> accessed 10 January 2013 
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compulsory licences, parallel imports and the leeway given to Member Countries 
to determinate what constitutes a national emergency.142 However, Doha 
Declaration as it was adopted, is said to contain stronger language than the one 
originally used within the drafts prior to the final version. Working groups had 
reported to have had disagreed on two key issues, namely the use of “access to 
medicines” instead of “public health” and with regard to paragraph 4’s choice of 
words in allowing member countries to take measures to protect public health 
without breaching the Agreement.143 Developing nations requested the phrase, 
“Nothing in the TRIPS Agreement shall prevent Members from taking measures 
to protect public health”144 to be included within the final document, but instead 
during the negotiations the phrase “…the TRIPS Agreement does not and should 
not prevent Members from taking measures to protect public health” was 
approved for the final draft.145 
Another important issue addressed within the Doha Declaration referred to the 
difficulties in making effective use of compulsory licences by Members with no or 
insufficient manufacturing capability. In this regard, in paragraph 6 the Council 
for TRIPS was instructed to find a solution to the problem and report back to the 
General Council by 2002.146 
The least developed countries had the prerogative to fully implement the 
Agreement, specifically patent protection for pharmaceutical products, by 
2016.147 This provision within the Doha Declaration is consistent with Article 65 
(4) from the TRIPS Agreement.148 However, scholars have highlighted that both 
the ambiguity embedded within paragraph 7 in terms of the so-called ‘mailbox 
provision’ and whether or not countries had to either grant ‘exclusive marketing 
rights’ or implement the mailbox provision before the end of the transitional 
period are important issues to clarify.149 
In light of the TRIPS Agreement’s Article 70 (9), Member Countries that did not 
provide patent protection for pharmaceutical products, but granted marketing 
approvals for a new product through its national health agency, had to grant 
                                                        
142 Paragraph 5 (a)-(d) Ministerial Conference, Forth Session, Declaration on the TRIPS Agreement 
and Public Health, WT/MIN(01)/DEC/2, 20 November 2001 (Herein after Doha Declaration) 
143 Watal, J., ‘From Punta del Este to Doha and beyond: Lessons from the TRIPS negotiation 
process’ (2011) 3 TheWIPO Journal1, 24-35, at 30 
144 Proposal by the African Group, Bangladesh, Barbados, Bolivia, Brazil, Cuba, Dominican 
Republic, Ecuador, Haiti, Honduras, India, Indonesia, Jamaica, Pakistan, Paraguay, Philippines, 
Peru, Sri Lanka, Thailand and Venezuela, General Councilfor Trade-Related Aspects of Intellectual 
Property Rights IP/C/W/312, WT/GC/W/450 (4 October 2001) at 1  
<www.wto.org/english/tratop_e/trips_e/mindecdraft_w312_e.htm> accessed 10 January 2013  
145 Paragraph 4 from Doha Declaration 
146 Paragraph 6 from Doha Declaration 
147 Paragraph 7 from Doha Declaration 
148 Article 65(4) from TRIPS Agreement, “To the extent that a developing country Member is 
obliged by this Agreement to extend product patent protection to areas of technology not so 
protectable in its territory on the general date of application of this Agreement for that Member, as 
defined in paragraph 2, it may delay the application of the provisions on product patents of Section 
5 of Part II to such areas of technology for an additional period of five years.” 
149 Frederick, A., ‘WTO TRIPS Agreement and its Implications for Access to Medicines in 
Developing Countries’ Study Paper 2a, United Kingdom Commission on Intellectual Property 
Rights, (February 14, 2002) 1-69, at 11<ssrn.com/abstract=1924420>accessed 15 January 2013 
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exclusivity for a period of 5 years.150 However, on the 8 July 2002 the General 
Council decided to waive exclusive marketing rights for the Least Developed 
Country members.151 
Allegedly, the terminology ‘exclusive marketing rights’ was unusual in the legal 
jargon and became introduced with the TRIPS Agreement, presenting Member 
Countries with a new challenge. Exclusive marketing rights, after following the 
Oxford dictionary’s definition, strictly mean that a product that obtained a 
marketing approval in a country making use of the transitional period can only be 
commercialised in that country by the applicant. However, this is not to prevent 
third parties from producing, exporting and commercialising the product in 
foreign markets.152 
2.3.3. From the Decision on the Implementation of Paragraph 6 of 
the Doha Declaration on TRIPS and Public Health to the TRIPS 
Agreement Amendment 
Despite WTO Members having received the Declaration as a positive step towards 
ensuring adequate use of TRIPS flexibilities, the interpretation of paragraph 6 
became worrisome as little information about its procedure was provided.153 
Hence, different positions and interests preceded long negotiations before 
reaching consensus over the implementation of Paragraph 6 of the Doha 
Declaration. 
Furthermore, on the 30 August 2003 in the General Council, WTO Member 
States adopted Decision WT/L/540 that settled rules to issue compulsory licences 
to export patented medicines to countries with no manufacturing capacity.154 This 
Decision is considered to have broken new ground in clarifying the relationship 
                                                        
150Article 70(9) from TRIPS Agreement, “Where a product is the subject of a patent application in a 
Member in accordance with paragraph 8(a), exclusive marketing rights shall be granted, 
notwithstanding the provisions of Part VI, for a period of five years after obtaining marketing 
approval in that Member or until a product patent is granted or rejected in that Member, whichever 
period is shorter, provided that, subsequent to the entry into force of the WTO Agreement, a patent 
application has been filed and a patent granted for that product in another Member and marketing 
approval obtained in such other Member.” 
151 General Council, Decision of 8 July 2002, Least-Developed Country Members – Obligations 
Under Article 70.9 of the TRIPS Agreement with Respect to Pharmaceutical Products, World Trade 
Organization, WTO Doc. WT/L/478, 12 July 2002 
152 UNCTAD-ICTSD, ‘Resource Book on TRIPS and Development: An Authorative and practical 
guide to the TRIPS Agreement’ (Cambridge University Press, July 2005) at 
774<www.iprsonline.org/unctadictsd/ResourceBookIndex.htm>accessed 20 January 2013 
153 Lalitha, N., ‘Doha Declaration and Public Health issues’ (September 2008) 13Journal of 
Intellectual Property Rights401-413, at 405 
154 General Council, ‘Implementation of Paragraph 6 of the Doha Declaration on the TRIPS 
Agreement and Public Health Decision 30 August 2003’, World Trade Organization, WTO Doc. 
WT/l/540 (1 September 2003). (hereinafter Decision WT/1/540) 
<www.wto.org/english/tratop_e/trips_e/implem_para6_e.htm> accessed 20 January 2013. Note 
that the TRIPS Agreement in Article 31(f) did not foresee compulsory licences for export purpoces, 
therefore countries with no manufacturing capacity were not able to obtain pharmaceutical 
products produced under the compulsory licence’s scheme in a foreing country. 
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between TRIPS and public health and also because it ratified country members’ 
‘freedom’ to issue compulsory licences to address public health emergencies.155 
The aforementioned Decision contains three waivers besides establishing the 
notification system and settling the conditions to benefit or to be fulfilled before 
intending to make use of compulsory licences under Paragraph 6 of the Doha 
Declaration.  This Decision basically waives ‘the obligation in 31(f) that 
compulsory licences shall be used predominantly to supply the internal market, 
and the obligation in 31(h) for the Importing Country to pay adequate 
remuneration to the right holder, and the obligation in 31(f) allowing re-export of 
important pharmaceuticals among members or a regional trade agreement if half 
of its members are least developed countries.’156 
Thus far, it has been established that the scope of Decision WT/L/540 is 
pharmaceutical products as defined in paragraph 1 (a). The same text defines 
both eligible Importing Members157 and Exporting Members.158 However, it is not 
enough to become either an Importing or an Exporting Member by notifying the 
TRIPS Council if the conditions settled in the Decision are not met.  
In this respect, the notification submitted by an eligible importing Member shall 
(i) specify the means and expected quantities of the products(s) needed,159 (ii) 
confirmation that the eligible importing Member-other than least-developed 
country Member- has established that it has insufficient or no manufacturing 
capacities in the pharmaceutical sector for the products in question,160 and (iii) 
the confirmation that the country intends to grant a compulsory licence or that 
the country has already been granted one given that the product is patented 
within the territory.161 
On the other hand, the compulsory licence issued by the Exporting Member shall 
contain (i) only the amount necessary to meet the needs of the eligible Importing 
Member, therefore it can only manufacture the highlighted amount under this 
                                                        
155 Vandoren, P., and Van Eeckhaute, J., ‘The WTO Decision on Paragraph 6 of the Doha 
Declaration on the TRIPS Agreement and Public Health’  (2003) 6The Journal of World 
Intellectual Property6, at 779-793 
156 Kommerskollegium National Board of Trade, The WTO Decision on Compulsory Licensing: Does 
it enable import of medicines for developing countries with grave public health problems (2008) 1-
100, at 23 
157 Paragraph 1(b) from Decision WT/L/540 defines elegible importing Member as “any least-
developed country Member, and any other Member that has made a notification to the Council for 
TRIPS of its intention to use the system as an importer, it being understood that a Member may 
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159 Paragraph 2(a)(i) from the Decision WT/L/540 
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licence which also needs to be exported in its totality;162 (ii) products produced 
under the licence shall be clearly identified as being produced under the system, 
taking into consideration that labelling, packaging, and shaping needs to be 
different from the products commercialised outside the system, prices cannot 
increase due to strict labelling and marking rules;163 and (iii) the licensee shall 
post on a website164 both the quantities being supplied to each destination and 
the distinguishing features of the products before the shipment begins.165 
As of today, Canada and Rwanda are the only countries making use of the system 
set out by paragraph 6 of the Doha Declaration.166 Accordingly, 33 countries have 
opted out to use the system as importers, and 11 agreed to use it exclusively in 
cases of extreme urgency.167 
To effectively make use of the mechanism set out in Paragraph 6, exporting 
Members need to adapt their patent legislations so as to grant compulsory 
licences for exporting purposes, since it is not enough to have the WTO Decision 
allowing Members to grant these kind of licences. Allegedly, one of the reasons 
behind developing and least-developed Members’ impossibilities in making use of 
the system relates to the implementation of the aforementioned system within its 
national laws.168 Despite the mechanism representing an effective flexibility to 
tackle access to medicines, scholars have identified its complexities as a drawback 
in itself for the system. For instance, potential eligible importing Members are 
able to purchase generics from India at reasonable prices without having to enact 
a compulsory licence to carry out such an import and also due to both 
implementation issues and confusing rules in terms of the adequate 
remuneration that needs to be paid.169 
This notification system was intended to be temporary until the amendment to 
the agreement became permanent in 2005.170 On 6 December 2005 the General 
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Council passed the Amendment of the TRIPS Agreement, so as to integrate 
Article 31bis into the Agreement that comprised the notification system and the 
terms for compulsory licences to work.171 
For the amendment to come into force, it is necessary for two-thirds of the 
Members to ratify it. Thus far only 71 countries have ratified it from a total of 120 
Country Members.172 Nevertheless, the waivers of the Decision have been in use 
since 30 August 2003.173 
                                                                                                                                                        
its provisions takes effect for that Member. The TRIPS Council shall initiate by the end of 2003 
work on the preparation of such an amendment with a view to its adoption within six months, on 
the understanding that the amendment will be based, where appropriate, on this Decision and on 
the further understanding that it will not be part of the negotiations referred to in paragraph 45 of 
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171 General Council, ‘Amendment of the TRIPS Agreement- Decision of 6 December 2005’, World 
Trade organization, WT Doc. WT/L/641 (8 July 2005) 
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3 INTELLECTUAL PROPERTY AND ACCESS TO 
MEDICINES IN BRAZIL 
Even though Brazil, Chile and Venezuela are found within South-America, each of 
these countries portrays a very different economical, socio-political and 
legislative context. On the one hand, Brazil and Chile are commonly recognised 
because of their level of development, and on the other, Venezuela seems to be 
constantly acknowledged for its political instability. The following chapter will 
describe and analyse in brief each of the country’s political contexts to allow the 
reader to understand the challenges embedded in both intellectual property and 
public health contexts. 
It is widely known that Brazil is an emerging and leading economy among many 
other developing countries. After twenty years of military dictatorship, Brazil has 
moved towards an open economy. Accordingly, political and neo-liberal 
economical reforms were carried out during the years of repression. This allowed 
society to reach considerable governmental representation that at the same time, 
forced the State to have higher levels of social participation.174 
The military rule in Brazil began in April 1964 when the armed forces ousted Joao 
Goulart from the presidency. In 1975, after several years of military dictatorship, 
social and political repression, the new constitutional reform allowed limited, 
political and social activity.175 At this time, Brazilian politicians began drafting 
the 1988 political constitution, which guided the country towards progress by 
ending the previous abusive period where human rights violations had taken 
place.176 This constitutional reform was seen as an important factor in achieving 
the new democracy. Social needs were acknowledged, and therefore the system 
sought to include peoples health concerns by aiming to build a comprehensive 
public health care system based on universal coverage as a social benefit as given 
by Brazil’s constitution.177 
Brazil has a large geographic extension with a population that extends to over 190 
million inhabitants, according to the data collected in the official census by the 
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Instituto Brasileiro de Geografia e Estatística –IBGE in 2010.178 Recent data 
shows a population increase of nearly four million up to 2012.179 
This chapter, besides presenting the reader with a brief historical overview, seeks 
to analyse the origins of intellectual property protection, the constitutional 
approach of these rights, the social function embedded within the constitutional 
framework and to later on assess the public health tradition and current 
developments related to pharmaceutical patents in Brazil. In other words, despite 
having established the relationship between patents and access to medicines in 
the previous chapter, it is important to understand the level of governmental 
commitment towards the fight against HIV/AIDS. Public health concerns seemed 
to have played an important role in Brazil’s decision to enact a compulsory licence 
and to create the mechanism known as Anuência Previa or Prior Consent. 
3.1. National Intellectual Property and Public Health Policies 
Evolution in Brief 
In respect to intellectual property rights, Brazil was one of the first countries to 
provide IP protection via internal legislations. Patent law was first foreseen in the 
Alvará de D. João VI (The charter of D. João VI) that was enacted on the 28 April 
1809. Later, Brazil joined the Paris Convention in 1883.   
Brazil, as a founding member of the Paris Convention granted patents with 
Constitutional acceptance and protection within the first Imperial Charter of 
1824.180  Nowadays, IP rights find constitutional protection in Article 5 (XXIX) 
from the Constituição do República Federativa do Brasil, as reformed in 1988 
(hereinafter the constitution).181 On 1 January 1995 Brazil became a WTO 
member state and thereafter enacted the IP law N° 9279 (hereinafter IP Code) 
where rights and obligations relating to industrial property were regulated, 
including compulsory licences.182 This legislative reform has allowed the country 
to comply with the minimum standards of protection settled by the Agreement on 
Trade-Related Aspects of Intellectual Property Rights – TRIPS Agreement. 
Patents for chemical products, foods, pharmaceutical products and processes are 
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to be granted as long as the patent claim meets the patentability requirements 
also settled by law.183 
The Brazilian government made use of the compulsory licence provision within 
the IP Code on 4 May 2007 to address a national public health challenge. With 
Decreto 6.108, published at the DOU on 7.5.2007, the patents to produce and for 
the product Efavirenz were considered to be of public interest. The Government 
sanctioned the compulsory licence for the antiretroviral ‘Efavirenz’ for a period of 
five years.184 Once the term expired in 2012, it was deemed necessary to extend 
the use of the patent via compulsory licence for an additional five years.185 
Scholars have pointed out that the Brazilian patent system should not have been 
structured in a manner simply to please or fulfil trading partners’ or foreign 
interests, but instead, the Brazilian patent system should be restructured 
accordingly with Brazilian societal needs.186 Protecting public health in Brazil 
seems to be a priority given by the amendment to the IP Code and the creation of 
the prior consent mechanism to specifically address public health concerns 
related to patents. In Lei N° 10196/01 (hereinafter the new IP Code) the Agência 
Nacional de Vigilância Sanitária-ANVISA was enabled to assess the impact on 
public health derived from granting a pharmaceutical patent.187 This mechanism 
will be further analysed below. 
Other scholars have argued in favour of Brazil’s consciousness over public health 
challenges, asserting that the new IP Code aims to protect and promote the 
development of new technologies that will allow the national industry to develop 
as well, thus benefiting Brazil’s social needs.188 The rationale behind prompting 
developing countries to improve their internal legislation with the minimum 
standards of intellectual property protection is due to the system’s contribution to 
national development. By encouraging the creation of new companies, in theory, 
these will also benefit from technology transfer while the patent system is also 
intended to boost the economical development of the given country.  
Brazil is currently a Member country of both the World Trade Organization and 
the Mercado Común del Sur-MERCOSUR. It has ratified several free trade 
agreements in the context of MERCOSUR, but none of these with major 
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economies.189 In terms of intellectual property rights, there is no FTA ratified by 
Brazil that thus far regulates these rights in the same manner as it has been 
regulated within the TRIPS Agreement; for instance, the Asunción Treaty 
provides the framework to MERCOSUR, but does not regulate intellectual 
property rights in a similar manner to other FTAs that settle higher standards of 
protection.190 Nevertheless, it is important to highlight that even when patents 
are not governed within MERCOSUR’s frame or subsequent FTAs, it does not 
mean that IPRs are excluded from the interests of this integration organisation. 
In terms of intellectual property, MERCOSUR has the following framework 
Protocolo de Harmonização de Normas Sobre Propriedade Intelectual no 
Mercosul em Matéria de Marcas, Indicações de Procedência e Denominações de 
Origem- also known as Protocol of the Harmonization of Intellectual Property 
Norms; the Protocolo De Armonización De Normas En Materia De Diseños 
Industriales Mercosur/Cmc/Dec Nº16/98; and the Protocolo do Solução de 
Controvérsias, de obtenções vegetais MERCOSUR/CMC/DEC N°1/99.191 
Some have asserted that the commitment to public health and the local industry 
on behalf of the Government goes beyond commercial relations. Recent 
negotiations with the Peoples Republic of China, which have led to rumours on a 
FTA between the nations, backs up the argument in favour of Brazil. Such 
commercial exchange or negotiations only reached a “global strategic 
partnership” given their influence on the global economy, but allegedly the 
Brazilian government is reluctant to raise IP standards of protection via TRIPS 
plus agreements since this will be detrimental to its local auto industry, among 
other industries.192 
Despite efforts towards development, there are social challenges to overcome in 
Brazil. These are namely prevalent poverty rates, social discomfort in terms of 
national expenditure due to what is seen as unnecessary expenditure (World Cup 
2014), rampant corruption and poor public services that have all caused social 
turmoil prompting the Government to take action and to take care of the pressing 
issues.193 
In terms of public health, public health care in Brazil has not always been what it 
is today. Before its democratisation, as labelled by scholars, at least 70% of the 
population was excluded from public health services and access to medicines 
since the military government at that time “only provided medical curative 
services for civil servants and urban middle class”.194 
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After the military dictatorship Brazil began to re-structure the public health care 
system. Community pressure played an important role in achieving the health 
reform as foreseen within the Constitutional amendment of 1988.195 From the 
early 1980s, when the first HIV/AIDS cases were reported, 210,254 accumulative 
HIV/AIDS cases have been counted in the country until 2001.196 Scholars have 
suggested that a ‘first generation’ of Brazilian activists approached the 
government to bring their attention to the illness making use of a human rights 
based strategy to raise awareness towards creating a health care system equal for 
all.197 
This social pressure later on translated into the constitutional amendments of 
1988, which integrated access to medicines as part of the right to health. The 
constitutional approach towards public health will be analysed within the heading 
below. From the evolution of the public health perspective, after the military 
government was overthrown, to tackle illnesses such as HIV/AIDS, high blood 
pressure, asthma and diabetes became among the top priorities for the Brazilian 
government.198 For the purpose of this research, when making reference to and 
analysing the health care system, policies and developments the focus will be on 
access to medicines and the most important developments in terms of the 
HIV/AIDS crises. 
3.2. Constitutional Approach towards Intellectual Property Rights 
and Public Health 
Intellectual property rights in Brazil were protected long before the Constitution 
of 1988, as stated above, but this constitutional reform conditioned IP rights to a 
social function criteria. They received constitutional protection even before the 
independence of Brazil from Portugal. Thus, expropriating patent rights due to 
public interest was possible from as early as 1891 by virtue of Articles 72, § 17 to 
25ofthe Constitution.199 
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The Brazilian political constitution – Constituição Federativa da República do 
Brasil, even within the latest amendment in 2010 named ‘Emenda Constitucional 
N° 64’ from the 4 February of that year, maintains in Article 6that the right to 
health is to be considered as a part of the other social rights to be enjoyed by 
Brazilians.200 
Intellectual property rights are found under the umbrella of fundamental rights, 
specifically in Titulo II (I) from the Constitution where Dos Direitos e Garantia 
Fundamentais (Fundamental Rights and Guaranties) are settled. Health rights 
are also foreseen within the same Title, but after intellectual property rights. This 
has given grounds for a debate to arise among scholars on whether or not patents 
should have been drafted in the section for economical rights within the 
constitution: 
 Article 5, … everyone are equal before the law, without distinction whatsoever, 
guaranteeing to Brazilians and foreigners residing in the country the inviolable right to 
life, liberty, equality, safety and property, as follows: 
XXIX – The law shall ensure temporary privileges for the use of industrial inventions by 
their authors, as well as the protection of industrial creations, ownership of trademarks, 
company names and other distinctive signs, taking into consideration the social and 
technological interests and the country’s economic development.201 
Together with the debate on IPRs being natural rights, the ‘priority’ given to these 
over health in the political Constitution became highly contested. Some scholars 
have argued that intellectual rights are economic rights; also arguing that as 
immaterial property rights these should have been enclosed within either the 
property or the economic rights chapter.202 Some other scholars assert that even 
when IP rights are within the scope of fundamental rights, the difference with 
fundamental rights per se relies on the fact that the first have a direct and 
immediate application, whereas the second ones need to be regulated by a 
legislative tool. The Constitution highlights that “the law shall ensure temporary 
rights…”, hence, only foreseeing the property right of the invention as a 
fundamental right entails the creator to obtain protection for their invention, but 
in any case a legal instrument is necessary to safeguard temporary protection.203 
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Whether or not intellectual property rights are given the status of fundamental 
rights or as safeguards within the constitutional text, the fact is that these rights 
are “constitutionally protected”, and the country shall ensure adequate legislative 
mechanisms to enforce their protection.  
By arguing about the priority given in Brazil to IPRs, the debate on balancing 
rights has emerged. In order to balance rights or to establish real priority it seems 
necessary to question which institution is entitled to balance them. If there is a 
range of possibilities in giving a solution, then in general terms the parliament 
should be the body to solve such issues. Balancing means a range of possible 
solutions, but if there is only a single possible outcome then the institution 
providing the solution should be a constitutional court; a constitutional court is 
the only one that can examine and rule over constitutional interpretation issues.  
According to some foreign scholars, balancing the right to property and the right 
to health is very important as to delimitate the scope of intellectual property 
rights for this matter.204  The trend followed by judges does not seem to be 
unanimous, however, the Segunda Seção do Superior Tribunal de Justiça from 
the Superior Tribunal de Justiça in June 2010 ruled over the time of protection 
for a pipeline patent held by Pfizer for the production and commercialization of 
Viagra in the country. This case brought certain concerns to the spotlight, mostly 
due to the interpretation used by the judge who ruled in favour of the nation 
clarifying the expiration day for the patent within the national territory arguing 
that this expired at the end of 2010 instead of at the end of 2011 as it would 
happen in the rest of the world.205 Even when the ruling does not specifically 
addresses the issue of Constitutional balancing it does portray to a certain extent 
the position of Brazilian judges when taking into consideration Brazilian health 
concerns. 
Given that the Brazilian Constitution requires a specific legislative tool to provide 
protection to that temporary right, then attention must be drawn to the 
intellectual property legislation in Brazil. An analysis of this will follow later in 
the chapter. 
3.2.1. Public Health and Access to Medicines 
The right to health rights finds constitutional protection within Articles 6, 196 -
200 of the Constitution, where not only are the rights settled but also terms, 
scope and the States’ duties to ensure access to public health. In this regard, 
Article 6 defines health as a social right safeguarded within the scope of 
fundamental rights. 
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According with this Constitution, social rights are education, health, nutrition, work, 
housing, leisure, welfare, motherhood and child protection, assistance for the 
homeless…206 
Health is a right of all and a duty of the State and shall be guaranteed by means of social 
and economic policies aimed at reducing the risk of illness and other hazards and at the 
universal and equal access to actions and services for its promotion, protection and 
recovery.207 
To implement the right to health the Brazilian government enacted Lei n° 
8.080/90 and Lei n° 8.142/90208 structuring the universal health care system 
named Sistema Único de Saúde (hereinafter SUS) based on the principles of 
universality, equality and full health care coverage.209 The right of access to 
medicines can be also inferred, as suggested by some scholars, from Lei n° 
8.080/90, Article 6.I (d) where pharmaceutical assistance and integral medical 
care are described as part of SUS duties.210 In views of consolidating SUS, thus to 
ensure access to medicines as part of the fundamental right to health, the 
Ministry of Health committed to providing AIDS treatment to tackle the 
HIV/AIDS crisis in response to society’s demands, while at the same time it 
began producing generic ARV drugs in 1993 as well.211 
One of the challenges to controlling HIV/AIDS from spreading in Brazil was 
related to blood transfusions. Allegedly, 70% of haemophiliacs were infected with 
the illness. Therefore, controlling quality and safety was paramount in the success 
in the fight against HIV/AIDS.212 Before the Constitutional amendmentof1988, 
no law or nothing within the existent legislation neither forbade nor controlled 
the selling of blood.213  Constitutional Article 199, paragraph 4 expressly restricts 
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blood sale mandating to regulate by law these kinds of transactions within a strict 
framework.214 The legislation came later on in 2001 as part of the reforms that re-
shaped the current health care system.215 
The first Brazilian drug policy dates from 1964 when the Relação Básica e 
Prioritária de Produtos Biológicos e Materais para uso Farmacêutica Humano e 
Veterinario (Basic and Priority List of Biological Products and Material for 
Human Pharmaceutical and Veterinarian use) was enacted by Decree n° 53.612 
on the 26 February 1964. Promoting access to medicines or essential medicines 
was deemed challenging, as some scholars have pointed out. Strong political 
influence in selecting and purchasing the medicines contained on the “List” did 
not correspond to any specific strategy, since the concept of solidarity among 
politicians was not that relevant when tackling illnesses afflicting Brazilians.216 
Moreover, the new drug policy in Brazil is the result of massive campaigning 
towards prioritising public health at the National and Federative level. 
Allegedly, access to HIV/AIDS medicines became firmly established in 1996 when 
free distribution of these medicines was guaranteed by the government via Lei n° 
9.313.217  This legislation was also known as ‘Sarney’s Law’ due to the sponsorship 
by the former president José Sarney. In light of the universal and equality 
principles, free access to HIV/AIDS drugs to treat people living in Brazil with the 
illness was now provided.218 
Later on in 1998, the National Drug Policy (Portaria n° 3.916/98 - Política 
Nacional de Medicamentos) was enacted to complement the National Health 
Policy. Ensuring safety, quality and efficiency, together with promoting rational 
use of medicines and access to essential medicines are now the principles settled 
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within the National Drug Policy.219 This drug policy was aimed at creating and 
approving the Relação Nacional de Medicamentos Essenciais – National List of 
Essential Medicines (hereinafter RENAME or the list). The first paragraph of this 
Misnisterial regulation recognises the need to provide the country with a proper 
and well-structured National Drug Policy, as well as to define essential medicines 
and the role of the institutions involved.220 
RENAME did not seem to have been created without counter arguments; some 
scholars have suggested that this list of essential medicines is not completely legal 
given to its restrictive character. Since the list is limited to only those common or 
most popular diseases affecting the Brazilian population, access to medicines 
should be granted in general and it should not be restrictive.221 Both the National 
Drug Policy and a National List of Essential Medicines are key pieces of 
legislation for each country to settle priorities within the health care system, i.e. 
access to determined medicines and also treatment.222 
The evolution of public health in Brazil is closely related to the national 
programmes developed to treat HIV/AIDS and STDs, and thus far, it has been 
estimated that by 1998 some 540,000 people were living with AIDS.223 The 
rationale behind addressing access to health towards solving the aforementioned 
crisis seems to rely on significant expenditure savings for the government. 
Scholars have highlighted two key arguments in favour of the distribution and 
continuation of HIV/AIDS treatment. On the one hand, there seems to be a clear 
effect of antiretroviral treatment in terms of reducing deaths; and on the other, a 
significant decrease in hospital admissions and treatment costs have reflected up 
to $ 1.1 billion in savings for the Ministry of Health.224 
Besides the HIV/AIDS programme, in general the national health care system 
also provides attention and access to other needed essential medicines. In the 
light of Chapter III of the Law regulating terms and conditions to promote and 
protect health, therapeutic assistance and medicines are to be provided in 
accordance with medical protocols.225 If there are no protocols available, then 
medicines and treatment are to be provided according to the guidelines 
instructed by an official agent from SUS.226The duties of the Brazilian health care 
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system extend to the distribution of medicines to patients, as long as assistance is 
sought in public hospitals.227 Health care services can also be provided by the 
private health care sector although it is not obliged to grant either free medication 
or medical care.228 
According to the legislation, Brazilians should have access to essential medicines 
for free, and if not, at affordable prices. Thus, scholars have brought to the 
spotlight that access to medicines is correlated not only with affordability but also 
with availability of medicines.229  Availability seems to be a topic of great concern 
in Brazil given that from a total of 71% of essential medicines in the market, the 
availability of generics during 2009 was below 10%.230 Nevertheless, these rates 
grew by 2013, and it is estimated that at least 23,5% of the medicines are 
available in their generic form.231When discussing affordability, it has been 
suggested that prices of medicines within the retail sector are influenced by 
procurement practices. This indicates that pharmacies that purchase smaller 
quantities from those purchased by wholesalers are not able to provide cheaper 
prices due to all the costs involved.232 
One of the goals of the Brazilian health care model is to provide universal 
coverage and also to protect people from economical hazards. Therefore the 
government launched the ‘popular pharmacy programme’ in 2004 that was to 
ensure affordability and availability of medicines.233 In light of the provisions in 
the programme, the government subsidised medicines to ensure lower prices also 
at private pharmacies. According to the legislation, priority must be given to 
generic versions both for treatment and prescriptions.234 Regardless of legislative 
efforts, the popular pharmacies managed by the public sector portray lower 
availability of medicines than the ones privately managed.235 
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Despite scholars arguing against the availability of generic medicines in Brazil,236 
recent studies have shown that both delays and difficulties to access health care 
provided within the public health care system are by far the more pressing things 
to solve when seeking access than the availability of medicines in one or the other 
sector.237 Accordingly, 61% of the population gave negative remarks when asked 
about access to public health care providers. Of those interviewed, some 55% 
regarded delays and difficulties in receiving health care attention as among the 
main issues challenging the public health care providers, and just 4% regarded 
the lack of medicines as an issue.238 In this respect, the role of judges in 
improving health care policies has been acknowledged, on the one hand, since 
they have often ruled in favour of Brazilians by addressing access to health as a 
mandate from the Constitution;239 but on the other hand, the challenge in 
obtaining such decisions has been pointed out given that only those with a certain 
level of understanding about their rights and legislation are able to seek legal 
advise in claiming their right to health before a judge.240 
In order to improve health care services, scholars also argue for the need to assess 
the issue from two different perspectives. From the Constitution’s point of view, 
health challenges can be solved from an idealistic standpoint; whereas when 
foreseeing a solution from the illness point of view, social, economical and 
cultural implications will be taken into consideration. Therefore, it is said that the 
ideal health care system is one that provides scheduled and preventive medicine, 
and in its higher level this shall integrate preventive and incidental, physical and 
psychological health care.241  Some have even argued in favour of health care 
development as a consequence of technical and scientific developments at a 
national level.  
Another important player to take into consideration is the National Health 
Institute (Agência Nacional de Vigilância Sanitária (hereinafter ANVISA) created 
in the National Drug Policy.  This is an independent regulatory agency under the 
Health Ministry created in 1999 to protect public health by ensuring quality, 
efficiency and safety of those products and processes subject to sanitary 
control.242 Among ANVISA’s competences, is to determine whether or not a 
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pharmaceutical product meets with the necessary requirements to obtain a 
marketing approval.243 It must be highlighted that marketing approvals are –a 
regulatory requirement - needed before any pharmaceutical product can be 
commercialised within the market since these ensure the safety of the product. 
In 2001 Brazil implemented a mechanism known as Anuência Previa or Prior 
Consent aiming to protect public health –this mechanism has nothing to do with 
marketing approvals even when it is ANVISA the institution granting both. This 
mechanism has created a dilemma since it grants, or initially granted, a veto 
power over patents to a different institution than the patent office per se. Prior 
consent will be analysed in detail in the heading below.  
3.2.2. Implementing Policies to Ensure Access To Medicines 
Brazil has been praised for its efforts in tackling HIV/AIDS –among other 
illnesses- through the implementation of the National Drug Policy; this policy 
foresees the use of generics and public procurement as two key elements that 
address both availability and affordability.244 The José Serra law (as is also known 
the health reform of1998 in Portaria n° 3.916/98) in principle decentralised the 
procurement and distribution of the essential medicines in RENAME. However, 
the same legislation reserves the right to centralise procurement and distribution 
of certain medicines for illnesses whose magnitude has severe repercussions for 
the country’s public health context.245 In this respect, the legislation establishes 
the need to survey, assist and guide i.e. procurement processes to achieve the 
legislation’s mandate to obtain lower medicine prices to increase the population’s 
access to affordable medicines.246 This legislation has been suggested to be the 
most important health reform implemented addressing the National AIDS 
Programme, since its objective involved scaling up generic production in Brasil by 
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244 Nunn, A. ‘The Politics and History of AIDS’ at 108 
245 Brasília, Ministerio da Saúde – Secretaria de Políticas de Saúde, Departamento de Formulação 
de Políticas de Saúde, Portaria n° 3.916/GM em 30 de outubro de 1998, Política Nacional de 
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246 Idem Artigo 3.3 (d) ”no desenvolvimento de iniciativas que possibilitem a reduc a o nos prec os 
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means of a centralised public strategy to supply generic antiretrovirals both under 
and without patent protection.247 
The ambition and race to scale up production of generics and to achieve lower 
prices for antiretroviral seems to be motivated by Lei n° 9.313/96 that made it 
mandatory for SUS to provide all HIV/AIDS patients with free access to 
medicines necessary for their treatment.248 Given that patent protection was 
being implemented in Brazil, thus some of the antiretroviral previously 
manufactured would now fall under patent protection, the country had to find a 
way to compel the pharmaceutical industry to keep supplying the medicines 
needed at low prices, and one way to achieve it was via compulsory licences.249 
Even when the legislation favoured generics, the Brazilian government became 
concerned over the quality of generics given amid manufacturing restrictions 
deriving from TRIPS.250 In 1999 Lei n° 9.787 was enacted that mandated that all 
generics purchased through public procurement had to be registered by ANVISA 
after providing quality tests, and satisfying bioequivalence and disponibility 
criterion as well.251 
Although SUS provides access to free medication, it has been pointed out that in 
some cases and given the decentralisation of the public procurement there are 
actual limitations or medicine shortages impeding patients from receiving free 
medicines, even when medical attention has been sought at public health care 
providers. Therefore, patients need to pay full price out of their pocket in the 
private market unless the medicines are purchased in popular pharmacies where 
the Government subsidises 90% of the full price while the remaining 10% is 
covered by the patient.252 Nonetheless, studies have shown that patients have 
actually managed to continue their treatment thanks to the availability of the 
medicines within the popular pharmacies programme despite citizens having to 
pay for treatment themselves.253 
Brazil has been particularly successful in battling HIV/AIDS.H. Hence, to ensure 
the programme’s sustainability and continued improvement, the Brazilian 
Government has implemented a strategy focusing on three elements: (a) 
“building on the capacity of social movements to strengthen prevention (early 
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248 Brasília, Presidência da República, Lei n° 9.313 de 13 de Novembro de 1996, Dispõe sobre a 
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Working Paper No. 18/2010, 1-24, 6 
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detection of HIV-positive) and to enhance patients compliance with protocols; (b) 
promoting the use of multi-source/generics and the public production of 
antiretroviral; and (c) including good surveillance and well-coordinated system of 
care that ensures access to appropriate diagnostic and treatment.”254 
The first element of the strategy seems to emphasise the need to prevent the 
disease via education programmes. Although the surveillance, treatment of 
opportunistic infections and the development of partnerships between the 
government and the civil society are also part of this element of the strategy, the 
mobilisation of the civil society and the work of activists has been key in achieving 
a wider reach of people in terms of the illness.255 The second element of the 
strategy entails the development of the Brazilian pharmaceutical industry as to 
ensure the sustainability of the programme. In previous years all purchases where 
centralised by the Central Medicine Agency (CEME;); however, after 
implementing the Drug Policy this was decommissioned and all public 
procurement was to be carried out by the Ministry of Health256 whom invited 
those interested for a competitive tender to according to the procedures 
established within Federal Procurement Law.257And the third element has to do 
with surveillance and coordinating health care practices that ensure access to 
both diagnostic and treatment services.258 
The Câmara de Regulação do Mercado de Medicamentos (CMED) was created by 
Decreto n° 4.766 on26 June 2003 to promote the availability of medicines and to 
regulate to a certain extent the prices of medicines by allowing manufacturers to 
adjust prices according to an index fixed in three bands, which at the same time 
relates to the level of competition based on the market share of generics.259 The 
idea behind mass scale purchases is to increase the availability and affordability 
of medicines by promoting competition among the local pharmaceutical sector as 
well, thus, the use or threat to use compulsory licences is said to have increased 
the government’s bargaining power to reduce medicines’ prices.260Allegedly, the 
Brazilian government was able to drop the yearly cost of antiretroviral treatment 
from $4860 per person in 1997 to $1000 (US dollars) per person in 2001.261 With 
these price reductions the government managed to save approximately $1.2 
billion (US dollars) on AIDS treatment costs.262 
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Public procurement can … be a powerful driver of sustainability, by providing incentives 
for investment, innovation, and scaling of sustainable enterprises, goods, services, and 
infrastructure across the public and private sectors.263 
By 2004, 7 of the 18-comercially available antiretroviral were produced by local 
manufacturers, which represent approximately 50% of the ARVs used to treat the 
illness.264Due to the price reductions of nearly 78% on average, the Ministry of 
Health highlighted that by 2001 HIV/AIDS deaths had reduced to between 48-
49%.265 The Brazilian government, in order to fulfil the goal of providing 
universal health coverage for the treatment of HIV/AIDS, had to indebt itself to 
several donors and had to allocate local resources to finance the aforementioned 
programme. For instance, Brazil’s determination in battling the disease has been 
pointed out, given that despite the World Bank’s restrictions on using borrowed 
money on drugs to treat the disease, Brazil moved forward in implementing the 
programme, including investing in infrastructure and human recourses 
development.266 All of these actions are said to have inspired or contributed to the 
development of similar programmes in developing countries.  
Regardless of the improvements, certain challenges remain to be solved; for 
instance, the periodic revision and expansion of the list of essential medicines are 
key for Brazil to ensure the realisation of the universal coverage of all medicines 
provided by SUS.267 Given Brazil’s commitment to protecting both public health 
and international trading partners, it is necessary to analyse the intellectual 
property regime to understand how it works and how Brazil has benefited from 
TRIPS. 
3.3. Intellectual Property Rights in Brazil – a Focus on the 
Pharmaceutical Patents System 
The Brazilian doctrine provides several different theories to justify intellectual 
property rights. One theory focuses on natural rights, arguing that everyone is 
entitled to his or her own ideas, whilst another theory focuses on the need to 
compensate the innovator and the inventors for their contribution to society.268 
Regarding natural rights, Thomas Jefferson discussed the issue in a letter 
addressed to Isaac McPherson during 1813, highlighting that there is no such 
thing as intellectual property rights being natural rights. He strongly argued the 
fact that fundamental rights are natural rights embedded in the human being, 
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and the constitutional framework is there to protect human dignity.269 Thus, 
temporary property rights given to an inventor are nothing else but a gift from 
social law.270 
Despite justifying intellectual property rights according to one or the other 
theory, these are regulated by a specific legal framework. Therefore, it is 
important to analyse the constitutional approach toward IPRs in Brazil as 
reflected within the national law, and other relevant international treaties ratified 
by the country, especially since the constitution requires IPRs to fulfil with the 
social function requirement, as will be analysed below. 
3.3.1. Current Intellectual Property Framework: Lei n° 9.279 
The Instituto Nacional da Propiedade Industrial – National Institute for 
Intellectual Property (hereinafter INPI or patent office) is a federal agency 
attached to the Ministério do Desenvolvimento, Indústria e Comércio Exterior –
Ministry of Development, Industry and Foreign Trade, and was created on 11 
December 1970 by Lei n° 5.648.271 INPI is responsible for processing, 
disseminating and managing intellectual property rights in Brazil.272 
Trade marks registration, patent grants, evaluation of technology transfer 
contracts and franchising businesses’, and also registering computer software,273 
industrial design and geographical indications are among the competences given 
by law to the patent office.274 
Without prejudice of other attributions that could be assigned to INPI, it can also 
implement measures aiming to accelerate and regulate technology transfer, and 
to establish mechanisms to improve negotiating conditions, patent grants as well 
as advising on the need or desirability in ratifying or denouncing conventions, 
treaties and agreements related to intellectual property rights. The patent office is 
also to promote extra judicial measures to enforce intellectual property rights in 
case of infringements.275 
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The national framework governing intellectual property rights in Brazil comprises 
the Brazilian Constitution, the Lei nº 9.279 (IP Code), the Lei nº 10.196 (new IP 
Code) and other internal Resolutions. The international framework shaping the 
system consists of the Patent Cooperation Treaty, TRIPS Agreement and Paris 
Convention.  
Both the IP Code and the new IP Code brought a series of challenges, namely the 
working requirement, the pipeline provision and the anuência prévia (prior 
consent) that in some cases may constitute steps to comply with or to take into 
consideration before patent protection can be granted e.g. pharmaceutical 
patents. However, before addressing the aforementioned challenges, it is 
important to analyse further the formalities required to comply with patent 
procedures in Brazil. 
The standards of protection settled by the Agreement on Trade Related Aspects 
on Intellectual Property Rights were integrated into the domestic law in 1996 and 
enforced in 1997, however, this was done without making full use of the 
provisional time given to developing and least-developed nations to make 
adequate their internal legislation, hence to comply with the minimum standards 
of protection. 
By raising the standards of protection, the term of protection in itself also 
lengthened. The 1971 IP law (old IP Code) granted 15 years of protection to 
patents and the IP Code extended the term of protection to 20 years as mandated 
in Article 33- TRIPS. Since Brazil had no, or a very short transitional period, 
between the IP and its reform, the aforementioned five years became challenging 
given that there were patent applications left in the pipeline. Hence, settling the 
time of protection for a patent claim caught within the transition seemed to be 
more complicated than originally envisaged.  
Scholars suggested that the issue beyond extending the term of protection related 
to the retroactivity applied in many cases, and sought by right holders whom had 
filed patent claims TRIPS and the statutory reform, which was less favourable 
than the new one. Article 33 TRIPS and note 8,276 highlight that the term of 
protection shall be for 20 years from the filing date and note 8 establishes that in 
cases where 20 years of protection were not granted then the new term shall be 
computed from the filing date in the previous system. Depending on the 
interpretation given to the norm meant that a period of five extra years as a 
period of grace was given to right holders to keep exploiting the patent. Precisely 
this point is deemed controversial and unconstitutional according to Article 5° 
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part XXIX of the 1988 constitution. It has been pointed out that, in theory, an 
already granted patent could not be extended.277 
In general terms the patent system sought to promote constant technology 
innovation by promoting free competition and inviting companies to invest in 
obtaining new products as an attempt to accelerate the country’s development.278 
Therefore, an invention that meets with the patentability requirements settled 
within Article 8 - Lei nº 9.279 should obtain patent protection.279 The Brazilian 
IP code does not define what inventions means or is by profiting a definition per 
se, but on the other hand, and in the case of utility model, these have been 
delimited as “practical objects, or part of it, susceptible to industrial application 
that also presents a new form or disposition implied within the innovation, and 
that results in either functional or production improvement.”280 
Patentability prohibitions within the IP Code are found in Article 10, which at the 
same time provides a frame or defines what an invention is by enunciating the 
things that cannot be considered inventions or utility models; thus restrictions 
related to methods are settled in part (VIII). Techniques, surgical methods or 
therapeutic methods to treat either humans or animals are excluded from 
obtaining patent protection despite meeting with the patentability 
requirements.281 
The legislation is structured in a manner that instead of establishing prohibitions 
on a field-by-field basis does it in a more general or vague manner to avoid 
branching the prohibition of discrimination settled within Article 27 from the 
TRIPS Agreement. Nevertheless, scholars have contested the recent protection 
granted to inventions that originally could not be awarded with patent protection 
or that were expressly excluded from patent protection. However, since these 
inventions comprise of products and processes related to the chemical sector, the 
pharmaceutical industry and also biotechnology caught within the transition then 
patent protection was granted accordingly with the new standards of 
protection.282 
In accordance with the IP Code inventions, contrary to moral, public order or 
public health reasons, substances, materials and compositions resulting from 
modifications of their atomic nucleus and all or part of living organisms (except 
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those trans-generic microorganisms) despite meeting with patentability 
requirements, shall remain excluded by law from patent protection.283 
Patent ownership in case of several applicants is determined according with the 
principle ‘first to file’. On the one hand, Article 6º from the IP Code foresees the 
rules to claiming ownership over an invention, but on the other hand it is in 
Article 7º where the principle is formally settled. The legislator addresses the 
possibility of several inventors working separately on the same invention and 
later on claiming patent rights in different periods of time. To solve this possible 
scenario, the legislator decided to grant patent rights to the inventor who filed the 
application first or the one with the oldest application in chronological terms.284 
The aforementioned principle leads to examining the priority rights per se, in 
case of foreign inventors looking forwards to protecting their inventions within 
the Brazilian territory. Brazil as a signatory of the Paris Convention, 
acknowledges within Article 16ofits IP Code that patent claims vindicating foreign 
patent rights produce a ‘national deposit’ effect.285 The practical implication of 
such applications could translate to receiving preferential treatment, once the 
patent office receives the application; these have priority even over national 
claims that might have been presented before the international one.286 
However, some preconditions apply so as to recognise priority rights. Firstly, the 
application has to be made before another member according with the provisions 
dealing with priority issues within the member countries involved in such an 
application, for instance the Paris Convention; and secondly, this claim can only 
be applied for within a period of twelve (12) months from the filing date in the 
originating country.287 
Other scholars have highlighted that the priority right is not a right to a national 
patent, but it only indicates the value of the application before the Brazilian 
Government in terms of patentability. Nevertheless, despite having priority 
rights, these could be challenged either because of specific Brazilian procedural 
law issues, or because the novelty requirement is not fulfilled.288 Once a patent 
application has been submitted, the patent office (INPI) will postpone its 
publication for a period of 18months so as to prevent it from falling within the 
public domain,289 unless the applicant requests for an early publication.290 
According with one part of the doctrine, when a patent application is published 
the inventor satisfies the social function requirement, since the information will 
now be accessible to everyone.291 Therefore, it is the administration’s duty to 
protect the application from public display in this ‘period of silence’ or otherwise 
                                                        
283Lei nº 9.279. “Art. 18. Não são patenteáveis…” 
284 See Article 7º Lei nº 9.279 
285 Article 16º Lei nº 9.279 
286 Rocha Furtado, L., ‘Sistema de Propiedade Industrial no Dereito Brasileiro’ at 48 
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compensation for damages incurred due to disclosure can be claimed.292 
Nevertheless, in certain circumstances INPI will not make public patent 
applications even after the period of silence passes; that is applications 
originating in Brazil, the object of which are of interest to national defence.293 
The Brazilian patent procedure is with preliminary examination, and after having 
verified formal requirements the applicant or interested third party needs to 
petition within thirty-six (36) months for INPI to perform the substantive 
examination.294 If there is no petition to examine the content of the patent claim 
within that timeframe, counted from the filing date, the patent claim will be 
dismissed and archived. 
With the effective start of the examination procedure both the applicant and the 
interested third party have sixty- (60) days from the publication of the 
examination request to present the authorities with the documents settled within 
Article 34ofLei n° 9.279.295  After this period, if the application has not been 
shelved, then the administration will publish the decision denying or granting 
patent rights.296 
Beyond the formalities in the Brazilian IP Code, compulsory licences are foreseen 
within Article 68 §1° (I) for cases where the local working requirement has not 
been fulfilled. Therefore, if it has taken more than 3 years from the day it was 
granted,297 then a compulsory licence could be sanctioned to satisfy the internal 
                                                        
292 Article 44 §1 from Lei n° 9.279 
293 Article 75 from Lei n° 9.279 “A patent application originated in Brazil the object of which is of 
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296 See Article 37 from Lei n° 9.279 “Once examination is concluded, a decision will be issued, 
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297 Article 68 §5 from Lei n° 9.279 provides that a compulsory licence due unfulfillment of the local 
working requirement can be only requested after a period of three (3) years elapses from the date 
the patent was granted. For other cases different rules apply, and no specific timeframe seems 
necessary. 
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market, unless the right holder is able to justify the rationale for not working the 
patent within the given timeframe. 
Article 68 § 1 the following cases shall be also object to compulsory licensing: 
I - not to exploit the object of the patent in Brazilian territory or failure to manufacture or 
incomplete manufacture of the product, or even non-use of a patented process, except in 
cases not economically feasible, when importation will be admitted, or 
II - the marketing that does not meet the needs of the market. 
§5° the compulsory licence in § 1º shall be only requested after a period of 3 (three) years 
from the day the patent was granted”298 
Since the legislation gives a three-year timeframe to work the patent, some 
scholars have argued against it and even suggested its illegality. But both Article 
27 of TRIPS299  and  Article 5 of the Paris Convention foresee compulsory licences 
to correct abusive practices. The Convention itself establishes that, “Each country 
of the Union shall have the right to take legislative measures providing for the 
grant of compulsory licenses to prevent the abuses which might result from the 
exercise of the exclusive rights conferred by the patent, for example, failure to 
work.”300 
Article 68 “§ 1 - The following may also result in a compulsory licence: 
I - the non-exploitation of the subject matter of the patent on the territory of Brazil, by 
lack of manufacture or incomplete manufacture of the product or, furthermore, by lack of 
complete use of a patented process, except in the case of non-exploitation due to 
economic in viability, when importation will be admitted… 
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299 Scholze, S., ‘Política de Patentes em Face da Pesquisa em Saúde Humana: Desafios e 
Perspectivas no Brasil’ in Política de Patentes em Saúde Humana (Jurídica Atlas, 2001) at 45 -47 
300 Article 5 (A)II. Paris Convention for the Protection of Industrial Property, as last revised at 
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Some scholars have interpreted this provision as a way to benefit the local 
pharmaceutical industry, and also as a kind of limit to unfair competition. This 
mechanism would also avoid parallel imports since the provision seems to be 
targeting “the lack of manufacture or incomplete manufacture of the product” 
which seems to allow or give advantage to local manufacturers to exploit the 
patent locally on the grounds of national emergency, public interest and abuse of 
economic power by the right holder. The provision also seems to already 
acknowledge “importation” or admitting importation of the goods that initially 
were to be manufactured in the country when economic inability prevented the 
patentee from producing locally. 
In this respect, it has been highlighted that compulsory licences can be granted 
only to a person or institution technically and economically capable of ensuring 
efficient exploitation of the patent. Such a case can occur only after proving that 
the initial right holder it incapable of producing or manufacturing the product to 
supply in emergency crises or in cases of public interest need.301  Compulsory 
licensing in Brazil is regulated in Decreto n° 3.201/99 (hereinafter Compulsory 
License Law) later on amended by Decree n° 483/03.T. These Executive Decrees 
only envisage the compulsory licence regime to address national emergencies and 
public interest cases, thus compulsory licences for other purposes are to be solved 
according with the provisions settled within the IP Code. 
The other controversial issue brought by the IP Code is the so-called pipeline 
provision, as it was briefly assessed above, that was initially designed to address 
patent applications caught up within the transition between the IP legislation 
prior to TRIPS and current IP Code. Patents for pharmaceutical products and 
processes were not granted in Brazil before 1996, therefore a mechanism 
providing patent protection or allowing patent applications to be submitted 
accordingly with the new standards of protection was not in force before the IP 
Code. Mainly, the applications were for pharmaceutical products and processes 
that were still in the clinical trial phase and for which application was not legal in 
Brazil prior to the TRIPS Agreement. 302 This “mailbox provision” as it also 
became known was supposed to be a temporary provision within the Brazilian IP 
Code, in accordance with Articles 70(8) and 70(9)– TRIPS.303However, this 
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provision as, will be shown later on, was made permanent in the Brazilian 
legislation with the amendment of the IP Code in 2001.  
Another important challenge is given by the anuência prévia or prior consent 
requirement also created within the amendment of the IP Code. Allegedly, it is 
aimed at protecting public health interests in Brazil, but its creation brought on 
another set of challenges. Namely, discrepancies among the criterion used by 
ANVISA, its delimitations and difference from the examination carried by INPI.  
Some scholars have even suggested that ANVISA has a veto power over the patent 
office since patents for both pharmaceutical products or processes depended on 
the prior consent given by ANVISA.304 
3.4. ANVISA: Prior Consent Challenge, and Marketing Approvals 
Anuência Prévia or Prior Consent dates from 1999 when a Medida Provisória 
(Provisional Measure) n° 2,006 of14 December1999 amended Article 229 from 
Lei n° 9,279/96 (IP Code). The reform added three new parts to the article in 
question, turning it into Article 229-C. Before the reform, Article 229of the IP 
Code only referred to certain procedures to be followed for those pending 
applications that were related to the patentability of processes and procedures for 
chemical substances,305 but the new reform created the prior consent mechanism 
for which only ANVISA had the legal competence to verify it.306 This provisional 
measure became permanent law in 2001 through Lei n° 10196/01.Brazilian 
scholars have highlighted that the word “anuência” within the Brazilian 
administrative law implies exercising a judgment of both convenience and 
opportunity, which means manifestation of the administration’s discretionary 
will.307 Furthermore, the legislation implies that ANVISA in effect expresses a 
                                                                                                                                                        
VI, for a period of five years after obtaining marketing approval in that Member or until a product 
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304 See Medida Provisória n° 2.105 – 14 from the 27 of December 2000, reformulates Article 229 
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307 Borges Barbosa, D., A Inconstitucionalidade da anuência da ANVISA no procedimento de 
concessão de patentes como manifestação discricionária da Administração Federal. Unpublished 
(Julho -2004) <denisbarbosa.addr.com/anuencia.doc> accessed 1 December 2012 
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judgment of both convenience and opportunity when it denies or grants prior 
consent to the pharmaceutical patent applications examined by this institution.308 
No direito administrativo brasileiro, a expressão “anuência” implica exercício de juízo de 
conveniência e oportunidade, ou seja, de manifestação discricionária da vontade 
administrativa. (Barbosa-2004) 
It has also been pointed out that since the terminology “anuência previa” was not 
defined either by the law or within the legislation creating it, brought uncertainty 
as to which is the role of ANVISA in examining pharmaceutical patent claims.309 
Also part of the discussion deriving from the legislative reform introducing Prior 
Consent in Brazil as a patent requirement has to do with the difference in criteria 
used when examining patents for pharmaceutical products and for second 
medical uses by the both the Patent Office –INPI, and ANVISA. One is to allow 
patents for second medical uses, and the other one is said not to grant marketing 
approvals for these kinds of products. Until a recent decision from the A Primeira 
Seção Especializada do Tribunal Regional Federal da 2ª Região, no Rio de 
Janeiro allowed patent protection for second medical uses if these met with the 
patentability requirements.310 Even then, it seems to be a single court ruling and 
it cannot be said to represent the general understanding about the issue within 
the whole judiciary system, but it does reflect to a certain extent a better 
understanding about patent issues on behalf of judges, at least those judges. 
Brazil is one of the leading countries in granting and protecting access to 
medicines. Therefore, patents have to also meet with social requirements.  Before 
amending the IP Code, INPI was the only authority evaluating and examining 
whether or not patent applications for a pharmaceutical product or process 
complied with the patentability requirements.311 After the legislative reform, and 
with the creation of the prior consent mechanism, the legislator aimed to 
safeguard access to medicines. Thus, ANVISA became the designated authority 
assessing the impact of that patent on social needs relating to public interest, 
issues that in the agency’s opinion are not taken care of by the patent examiners 
at INPI.312 Scholars have shown to be particularly concerned about the 
complexity hidden behind Article’s 229-C drafting; both delimitation and 
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parameters of this surveillance mechanism are deemed scarce and possibly create 
a conflict of attributions between INPI and ANVISA.313 
At the beginning, there was no clear knowledge about the criteria used by 
ANVISA when addressing public health at the time an application for a 
pharmaceutical patent was being reviewed. After pressing for the agency to 
publish the guidelines, in 2005 the Agency announced on their website a 
clarification about Prior Consent for patent applications for pharmaceutical 
products – Esclarecimentos: anuência Prévia a pedidos de patentes de produtos e 
processos farmacêuticos, that did not shed any more light than the existent one at 
that time.314 Nevertheless, ANVISA had a veto power according to some 
scholars315over patent grants by INPI. 
If ANVISA assesses the social impact of a patent and also has veto power,316 then 
the question in the mind of scholars was how do these two authorities solve 
controversies over criteria. Accordingly, a technical meeting shall be carried out 
to take into consideration all relevant factors to grant or deny the patent.317 
Another interesting fact regarding the prior consent requirement is that it was not 
only conceived to assess the impact on public health concerns, but it was also to 
be used for traditional knowledge protection as denoted by Medida Provisória n° 
2,186-16.  
In the past, scholars have stressed the need for the Brazilian patent system to be 
structured in a manner that emphasises the country’s social needs, so patent 
rights also contribute to the economical and technological development; however, 
prior consent does not receive endorsement from everyone.318 However, other 
parts of the doctrine did find grounds to implement this mechanism; after all, the 
TRIPS Agreement allows countries to take measurements as to ensure public 
health protection. 319 The fact that a “fourth patent requirement” was created by 
law,, and that this had to be analysed by ANVISA, was deemed incompatible with 
the Constitution’s Article 5 XXIX. The right to claim a patent is given by the 
constitutional text, and that right shall not be modified by any other norm that 
conditions the right to comply with the will of others; in this case ANVISA.320 
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It is still not clear how INPI and ANVISA communicated, and what guideline for 
criteria was used when assessing societal impact on a patent for a pharmaceutical 
product. INPI and ANVISA do not only seem to be colliding when it comes to the 
criteria used to grant a patent, but also it has been found that INPI actually grants 
patent protection for second medical uses; ANVISA clearly stated in 2004321 that 
that institution will not grant prior consent for second medical uses. In other 
words, by ANVISA denying prior consent, INPI has to deny the patent since this 
agency cannot grant a patent if there is no prior consent. 
It has been highlighted that ANVISA was examining patent applications under 
higher and stricter standards than those carried out by INPI.322 The fact is that 
ANVISA’s guidelines were kept secret as assured by scholars, and given the 
agency’s ambiguity in the resolutions enacted by it.323The Prior consent 
mechanism raised the question of compliance with the TRIPS Agreement, despite 
being envisaged to protect and address public health concerns that were also 
recognised within the DOHA declaration. In this regard, Article 63 (1)of TRIPS 
states that all regulations should be publically displayed as to enable both right 
holders and users to become acquainted with the legislation in force.324 
Allegedly, in 2008 after several years of pressure both at the national and 
international level,325 ANVISA published a formal resolution “clarifying” the 
extent of its attributions when examining patent application submitted to it by 
INPI. This administrative Resolution 45 – Resolução N° 45 – in Article 4° ratified 
to a certain extent prior consent as a fourth requirement when stating that “after 
receiving patents application submitted by INPI, ANVISA will perform the prior 
consent analysis in light of patentability requirements and other criteria given by 
law.”326 This Resolution N° 45 also gave evidence on ANVISA’s discretionary 
power when examining patent applications by envisaging the request of further 
requirements from the applicants so as to keep with the analysis.327 Beyond 
providing the public with the aforementioned Resolution, it seemed to have failed 
in disclosing the real criteria used to actually determine the public health aspect 
embedded within prior consent.   
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Another argument against Prior Consent is that this mechanism is deemed 
discriminatory, since it only affects pharmaceutical products and processes. In 
light of the TRIPS Agreement, it has been suggested that under Article 27- TRIPS 
patent applications shall not be examined under different grounds than those of 
novelty, inventive step and usefulness, since prior consent could be used in a 
sensitive fashion to cope with the goals settled within Articles 7 and 8ofthe 
agreement.328Article TRIPS 27.2329 may allow countries to deny pharmaceutical 
patents on grounds related to public health concerns, however, the issue at stake 
is the legality of Prior Consent and the right in including a second agency to take 
part in the examination procedure of determined patent applications. 330 
In this respect, attributing discretionary powers to a national agency to deny or 
grant patent rights on the basis of judgment of both convenience and opportunity 
according to the agency’s will seems to be incompatible with the constitution, 
since this is the one that creates substantive rights by examining the legal 
requirements in determined procedures.331 Part of the illegitimacy of ANVISA 
seemed to initially rely on the secrecy held related to both the guidelines used to 
protect or approach the societal impact of a patent and the veto power itself. 
Eight years later the Agency published a Resolution actually addressing the 
criterion defining the social aspect332 analysed by them. This issue will be address 
within the concluding remarks. 
INPI published its guidelines in 2002, but nothing within these redirect 
applications to the other agency, or make a difference among inventions.333 The 
Patent Office has shown reluctance in acknowledging both ANVISA’s rulings or 
attributions, and accordingly the national health institute has denied 119 patents. 
Thus far, INPI has never disclosed the reports, and generic industry was not 
allowed to make use of the knowledge embedded in the applications to produce 
needed medicines.334 
Given the confusion within the roles of each agency, INPI, in 2007, sought from 
the Advocacia Geral da União – Brazilian Attorney-General (hereinafter AGU) to 
intervene by clarifying or delimiting ANVISA’s role.335 Later on in 2009, AGU 
issued Parecer N° 210/PGF/AE/2009 settling the conflict of competences in 
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favour of INPI.336 In this respect, the ruling established that INPI is the only 
authority with legal competence to examine patent applications on the basis of 
novelty, inventive step and industrial applicability.337 Therefore, this limited 
ANVISA to performing public health assessments over patent applications for 
pharmaceuticals. To complicate things further, during the same year the 
Ministério Público Federal (MPF) sought the nullity of Parecer N° 
210/PGF/AE/2009 in a public civil action with a request for preliminary 
injunction before the 7ma Vara Da Seção Judiciária Do Distrito Federal. In this 
process the MPF requested 7maVFDF to ratify ANVISAS competence to examine 
pharmaceutical patent claims in light of the patentability requirements foreseen 
within the IP Code since ANVISA under Article 18(I) of the IP Code also allowed 
the agency to deny patents contrary to public health needs.338This Processo nº 
46656-49.2011.4.01.3400, 7ª VFDF339 denoted the misinterpretation of Article 
18(I) of the IP Code on behalf of ANVISA, who allegedly misunderstood its role in 
addressing the public health concern, but the 7ma VFDF instead ratified AGU’s 
ruling where ANVISAS competences are delimited to assessing the public health 
aspect in patent claims. 
Scholars suggest that ANVISA is now restricted from examining patent 
applications,, and therefore is it no longer possible for applicants to request 
information about novelty and inventive steps as Resolution N° 45 allowed it to 
do in the past.340 Before AGU’s ruling, ANVISA in fact rejected 119 applications 
from a total of 1346 applications submitted to the agency. The ruling also 
acknowledged the need to enact a regulation establishing the terms of the 
collaboration between the Patent Office and the National Health Institute and to 
also make clear the distinction between their roles and duties in light of the 
requirements settled in the new IP Code.341 In this respect, and amid growing 
confusion about ANVISA’s role, the Federal Government created via Portaria 
MS/MDIC/AGU no 1.956, dated 16 August 2011 an Interministerial Working 
Group (Grupo de Trabalho Interministerial-GTI) with the purpose of analysing 
and to suggest both criteria and procedures to carry out the prior consent analysis 
by ANVISA in light of the Article 229-C.342 Within their report, the GTI delimits 
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the scope of action of each of the institutions, addresses the terms of cooperation 
between both INPI and ANVISA and also provides a 5-step flowchart that 
illustrates the procedure when carrying out the prior consent process.343 
To prevent medicines from reaching the market, when patents for these would 
have a negative effect on public health related matters, according to ANVISA’s 
assessment, it has been suggested to do so at the moment when marketing 
approvals are applied for.344Thus, ANVISA in RDC n° 21 has finally made public 
the guidelines used to assess the public health aspect within the patent claims 
channelled via INPI. This Resolution goes further than Resolution n° 45 in terms 
of defining the scope of prior consent mechanism,, in this respect Article 2(1) 
reads “anuência previa is a deliberative act from ANVISA carried out in light of 
Article 229-C of Lei n° 9.279 from 1996, in which the Agency examines the object 
of the claim in terms of the public health context.”345 Furthermore, the 
aforementioned resolution initially delimits the analysis to the contexts of 
medicines containing substances forbidden by law,346 patent claims for products 
or processes that represent an interest to drug policies and pharmaceutical 
services under the SUS context and does not meet the patentability requirements 
and other criteria established by the Lei n° 9.279.347 The following articles from 
the Resolution seem to clarify the context of its analysis established previously in 
Article 4§1(I-II), however it does not seem to clarify the context of the wording 
used when addressing that such analysis will also examine the patentability 
requirements. Since this last issue seems to allow certain interpretation, it will be 
analysed within the conclusions of the research. 
3.4.1. Prior Consent and Second Medical Uses 
Given that INPI and ANVISA collide when examining patents for second medical 
uses, it is only fair to assess the main difference between the points of view of the 
agencies. On the one hand, INPI considers that once the application for a second 
medical use meets the novelty and the inventive step then a patent shall be 
granted; and on the other hand, ANVISA considers that a patent for second 
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medical uses does not fulfil the patentability criteria and that it would also 
hamper access to public health. 348 
The discussion on whether granting or denying patents for second medical uses 
not only concerns the fulfilment of patentability requirements;; it goes beyond 
this, extending to the constitutionality of the norm and the practice carried out by 
the agency. Interestingly enough, both the Brazilian Federal Constitution and the 
TRIPS Agreement stand for and against ANVISA’s criteria and overprotective 
approach. 
Both intellectual property rights and health rights are foreseen and protected 
within the Constitutional. Article 5 XXIX protects intellectual property rights and 
at the same time the same article takes into consideration social needs: 
Article 5: everyone is equal before the law, without distinction whatsoever, guaranteeing 
Brazilians and foreigners residing in the country the inviolable right to life, liberty, 
equality, safety and property, as follows: 
XXIX – the law shall ensure to the authors of industrial inventions a temporary privilege 
for its utilization, taking into consideration the social interest, and the technological and 
economical development of the Country.349 
By interpreting the abovementioned constitutional Article, it becomes possible to 
consider excluding second medical uses from patentability if such uses would 
interfere with the country’s development or their social interests. By denying 
prior consent to patents for second medical uses, if the law so excluded, the 
agency seeks to prevent ever greening within the patent system with me-too 
drugs that could be needed to address national health issues.350 
The issue with access to medicines is that as a fundamental right it is also 
constitutionally protected. Therefore, the challenge is to determine which right 
weighs more, and to do is this, scholars will most likely need to engage in 
discussion of a more philosophical and theoretical nature. The human right to 
health is of great importance, and private rights cannot be considered over the 
needs of thee vast majority. But, the discussion on a general level was assessed 
within the background of the study. 
The rationale arguing against considering that patent rights are a fundamental 
right goes beyond the scope of pharmaceutical patents per se. A part of the 
Brazilian doctrine has pointed out that intellectual property rights should have 
never been foreseen as fundamental rights within the Constitution, since these 
are economic rights; and given the nature of IP rights this should have been 
enshrined within economic rights, instead of within the respective constitutional 
chapter, as this would be by far more suitable.351 
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ANVISA’s decision in not granting patents for second medical uses is deemed 
illegal despite aligning with the agency’s criteria, since patent rights are a sort of 
property protected or guaranteed within the Federal Constitution. Scholars bring 
to the spotlight the fact that no uniformity regarding second medical uses is 
found in Brazil, since several court rulings have settled the issue differently, 
evidencing lack of understanding within the whole framework. These court 
rulings draw attention to the concept of bad patents since granting them would 
hamper society’s access to medicines. 
Scholars have addressed the need for a legal reform shedding light not only on 
the definition of Prior Consent, but also to the function delimitation for ANVISA’s 
performance or accurate role when examining patents. Due to the ambiguity 
within the legislation creating the mechanism and the lack of understanding 
between the two agencies, it is practically impossible to reach an agreement on 
how neither to examine patent nor to assess the societal impact for the first or a 
second medical use. 352 
On 24 August 2004 the agency released a report on its web page, on the basis of 
The Collegiate Board’s meeting held on 26 November 2003, in which it suggested 
that examination of patent applications seeking protection for a new use for a 
chemical substance have shown that those new uses are harmful for public health 
and for the country’s scientific and technological development, with a particular 
impact on access to medicines. Thereafter, it decided not to grant prior consent 
for patent applications for second medical uses.353This report was categorised as 
extremely generic, and it also appears to offer a more political answer than a legal 
one, given that patents for second medical uses are legal within the Brazilian 
legislative framework.354 
In this respect, AGU’s ruling shed light on the roles of each agency, but no 
immediate legislative reform or resolution followed clarifying the rules on how to 
proceed or assess the public health impact given by a determined pharmaceutical 
patent. ANVISA has failed to provide the public with a proper explanation on 
why patents for second uses are harmful, but instead the agency has suggested 
that second medical uses do not meet with the novelty requirement. Anvisa 
recently published a resolution shedding light on, and perhaps for the first time 
making public, the criteria used to assess the public health aspect embedded in 
determined patent applications This issue will be addressed within the 
conclusions of the research.  
Interestingly enough, patents for second medical uses promote research and 
innovation since the prohibiting costs of R&D and clinical trials will also reduce 
considerably. Given that patents protect the investments and the intellectual 
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efforts carried out, it is highly advisable that countries provide a well-structured 
patent system.355 
The aspirin case becomes relevant when assessing the discussion on whether 
patents for further medical uses should be allowed.  It is a well-known fact that 
this chemical compound (Acetylsalicylic Acid) was initially used as an antipyretic 
–medicine to prevent or control fever- and to prevent swelling. Later it was found 
that the same active ingredient could be used to prevent myocardium heart 
attacks and brain vascular diseases. Hence, patent protection granted for those 
uses demonstrated how second uses are necessary and that these have been 
granted in the past despite the assertions about extending patent protection for 
Aspirin in a fictitious manner. 
One thing to take into consideration when analysing second medical uses is the 
fact that nothing within the Brazilian legislation regarding intellectual property 
rights excludes or forbids them. Instead, what it is regulated and excluded are 
techniques and surgical methods applied to humans or animals, methods 
destined to diagnose and therapeutic methods.356 The Brazilian legislation 
distinguishes between therapeutic methods, surgical methods and techniques 
applicable to humans and animals and diagnoses methods. INPI also forbids 
patent applications for the protection of therapeutic methods.357 
3.5. Intellectual Property Rights and its Social Function 
Within the public health and access to medicines discussion in Brazil, scholars 
constantly bring up another factor, that is, the social function “requirement” 
established by the political constitution. 
The debate seems to be divided between those who argue on whether or not 
intellectual property rights are conditioned to the social and economical 
development of the country; and others point put that the impact of patent 
protection on society is that of fulfilling social and economical needs according 
with the economical and technological development within the country.358 
These arguments about the pre-condition to grant or guarantee a temporary 
property right rely on the need to limit a right to become superior to other rights. 
It has been highlighted that as efficient as the patent system might be, it will 
always have its limits when these rights turn into a threat to public health and 
public order. Acknowledging the existence of the patent system also implies 
recognition or acknowledgement of the social benefits brought by this system to 
the Brazilian society. The patent system is not an absolute guarantee, but on the 
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contrary it is conditioned to the legal principles conceived by the legal system 
itself (public interest).359 
The social function principle in Brazil is a Constitutional right and a limitation to 
the right of property, as assessed in Article 5 (XXIII) and Article 170360 of the 
Constitution. Even though the aforementioned article refers to the economic 
order, this article highlights the principles contained within the Constitution. 
Therefore, private property is also conditioned to the social principle function. 
The rationale behind this conditioning seems to rely on possible disparities 
among the owner’s interest (private) and the general one.  Scholars have 
suggested that the right to property in Brazil, beyond being an individual 
institution for ownership, protection and enjoyment is a privilege granted by 
public will. And this is why the social function finds its supremacy in the public 
interest over private interest in Brazil. Attention has also been drawn to the fact 
that the Brazilian legislator primarily looked forward by protecting the productive 
and technological activities in the country, since the Constitution also emphasises 
these issues.361 
The paradox of the legal monopoly given by patents to the right holder is also 
addressed within the aforementioned social function rationale.  On the one hand, 
the patent system is conceived of as an incentive or a way to promote 
technological innovation, but on the other hand the reward given to the owner for 
a determined period of time might be seen as contrary to fair competition.  
3.6. Competition and Compulsory Licences in Brazil 
The monopoly given to a right holder has been widely debated in many countries. 
The challenge for the Pharmaceutical industry is to demonstrate that patents do 
promote innovation, that these rights do not severely hamper access to essential 
medicines and that the patent system accomplishes its goal of promoting 
innovation in various fields i.e. for neglected diseases.   
The benefits of the patent system may seem difficult to prove, given that many 
reports showcase it as detrimental for access to medicines. In 2001 Médicines 
Sans Frontiéres (hereinafter MSF) released a report where the humanitarian aid 
organisation asserted that up to 1999 from 1,393 new drugs approved for 
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commercialisation only 13 were of relevance for tropical diseases.362 This report 
also suggested the failure of the patent system in terms of innovation within the 
field of neglected diseases. Certainly there are opposing views on the system’s 
efficiency, nevertheless the balance between both private and public interests 
remain unachieved.  
Pharmaceutical patents, as it is widely suggested, may contribute with elevated 
drug prices363, and therefore countries must find measures to counterbalance 
such an effect. In Brazil, compulsory licences are not only a counter measure for 
those who abuse economic power and market position, but also a way to ensure 
access to essential medicines. The TRIPS Agreement and several multilateral and 
bilateral agreements envisage compulsory licences as a method to limit 
monopoly. Prior to providing protection for pharmaceutical inventions in Brazil, 
one way to create competition in the local market was to allow the national 
industry to copy the products from multinational companies dominating the 
international market. 
It has been argued that inventors unfold in a context of imperfect competition 
since IP protection “creates” barriers to competition, thus it is necessary to limit 
the creation of these barriers while guaranteeing both economic and social 
rights.364 Within the monopoly discourse, it has been asserted that right holders 
see their rights limited due fair competition intervention in an attempt to reduce 
production costs to ensure consumers access to the new product.365 This 
limitation to individual rights is given by the Constitution. Accordingly, right 
holders receive a monetary reward as long as society finds their invention useful, 
and as long as it does not collide with social interest.  
Compulsory licences in Brazil may be granted if the right holder “exercises IP 
rights in an abusive manner or by means of it practices abuse of economic power 
that is proven under the terms of the law by an administrative or court 
decision.”366  Among these abusive behaviours, failing to work the patent, unless 
justifiable, seems to fall within the grounds to grant such licence. In this respect, 
Article 68 § 1(I) from the IP Code establishes that failure to exploit or the non-
exploitation of a patent in a period of three years from the date the patent was 
granted could result in the enactment of a compulsory licence.  
Allegedly, compulsory licences are normally used as a countermeasure to 
monopolies or anti-competitive practices. But these can also be granted in cases 
of a national emergency or public interest as regulated in Decreto n° 3.201 
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regarding ex oficio compulsory licences.367 Other methods to correct anti-
competitive practices seem to be price control policies that could also be achieved 
by promoting production of generic medicines. Controlling pharmaceutical prices 
seems to be complicated, as it also requires finding out prices of the same 
medicines in neighbouring countries, which is done to settle adequate prices 
without either severely putting in jeopardy the profits of the right holder in the 
country where the price control policy exists, or restraining affordability.368 
Even when compulsory licences may be enacted the right holder will be 
compensated accordingly, but precisely determining the amount or “adequate 
remuneration” may be challenging. Several suggestions have been drawn to 
address the issue, for instance the WHO issued the “Remuneration Guideline for 
Non-Voluntary Use of a Patent on Medical Technologies” where royalty setting is 
portrayed as a not very complicated method to compensate the right 
holder.369Another option to calculate the remuneration could be “by basing it on 
the economic value of the patent, which is then discounted by certain factors, by 
taking the economic value into account but not using it as a basis, or on the value 
that the patent generates to the licensee”370. Ultimately though, the final decision 
on setting the remuneration relays on the Government enacting the compulsory 
licence. 
Abuse of either dominant position or relevant market are considered punishable 
behaviours within Article 36 from Lei n° 12.529/11.371 Determining unfair 
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competition is not part of the National Patent Office’s attributions, and therefore 
it is the Conselho Administrativo de Defensa Econômica – Administrative 
Council doe Economic Defence (hereinafter CADE) that is the Governmental 
body in charge of providing the interested party with either an administrative or 
judicial decision to sanction the misconduct. In general terms, a third party 
interested in obtaining a compulsory licence to exploit a patent that is currently 
not being exploited or for which the right holder is overusing its right, must 
request CADE to initiate an investigation in order to find on whether or not anti-
competitive practices actually exist. If restrictive practices are proven, CADE’s 
decision needs to be taken to INPI for the compulsory licence to be obtained to 
manufacture the said product.372 
It has been suggested that a compulsory licence may be also used as a legal 
mechanism to limit or suppress the rights of a patent holder when they have been 
involved in abusive practices when making use of their exclusive right. The 
mechanism aims to correct anti competitive behaviours. Compulsory licences are 
of great importance for the patent system, as highlighted by several authors, since 
its acceptance and establishment by law allows governments to balance public 
and private interests when they are against the legal framework.373 
According to some authors, the pharmaceutical industry finds compulsory 
licences to be a threatening mechanism for future research and development 
since revenues will be limited to the production costs, which will probably not 
cover the full R&D expenses.374 This happens due to the price reduction suffered 
by the product marketed under compulsory licensing. Thus far, the only country 
making use of the import system through compulsory licence according to the 
World Trade Organization (WTO) is Canada. Moreover, Brazil made use of 
TRIP's flexibility in 2007 when it issued a compulsory licence to supply the 
internal market with the anti-retroviral Efavirenz after failed negotiations with 
MERCK.375 This compulsory licence was prolonged in 2012 for a period of five 
years.376 
Some benefits are embedded in enacting compulsory licences. Part of the doctrine 
highlights that two of the benefits for licensees derived from the use of this 
mechanism are the possibility to promote the national industry’s development 
through production of the product licensed, and it may considerably reduce both 
risks and costs in producing the medicine.377 Other scholars deem compulsory 
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licences as a discouraging mechanism for the pharmaceutical industry, arguing 
that pharmaceutical companies will tend to spend less on R&D for essential 
medicines if there is no real certainty in recouping their investment due to loosing 
monopoly powers to the government’s compulsory licensing policies.378 
3.6.1. Exhaustion of Rights (First Sale Doctrine) and Parallel Imports 
Exhaustion of rights may play a role within the access to medicines discourse. 
Therefore, scholars suggest that patent rights may be limited by having a clear 
national exhaustion of rights regime, given that in theory once the right is 
exercised by either selling the product (the first sale doctrine) or obtaining 
economic exclusivity granted to its owner, the rights will cease to exist.379 
The exhaustion principle is settled in Article 43 (IV) of the IP Code.380 This 
provision envisages a limit to the patent holder’s rights by disregarding them 
from preventing others to make use, produce or distribute the patented product 
or the process when the product per se has already been manufactured in 
accordance with a process or product patent that has been introduced onto the 
domestic market directly by the patent holder or with his consent.381Admittedly, 
patent rights grant exclusivity, but this is not an absolute and unlimited right. 
An important aspect to take into consideration is that even though the patent 
holder may not be able to exercise in full his exclusive rights, given that this has 
been fulfilled with the first sale doctrine, if a third party as an exception makes 
use of patent rights, this use cannot interfere with or jeopardise the patent 
holder’s legitimate interests.382Exhaustion of rights or the first sale doctrine, as 
commonly referred to, also relates to parallel imports and compulsory licences 
within the IP Code. On the one hand the principle is settled, but on the other 
scholars have pointed out certain issues in terms of the consent given by the 
patent holder in cases of parallel imports.383 Scholars have argued that Brazil 
follows the rules for national exhaustion of rights since the legislator includes the 
words national market in the legislation.384 However, the fact that Brazil belongs 
to MERCOSUR, which is an economic union, might pose another set of 
challenges in relation to parallel imports.  
In principle, as soon as the patented product has been sold in the country where 
the patent has been obtained, the right holder cannot interfere with the product’s 
free circulation within that market. With this, the patent holder’s right should be 
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in theory exhausted. However, the Brazilian IP Code brings to the spotlight the 
fact that patented products or products manufactured according with the process 
patented can be imported or commercialised by third parties as long as the 
original right holder has either placed them himself first or he has consented to 
such an import.385 Precisely, the aforementioned consent is considered to be an 
implied consent, since the Government takes it from the patent holder to supply 
the internal market when the right holder i.e. has neglected his duty or denied to 
work the patent within the time frame given by law, since this behaviour is 
considered to be an abusive practice.386 
Compulsory licences can also be considered as a way to exhaust rights. Article 68 
§4 from the IP Code foresees international exhaustion by allowing a third party to 
import a product manufactured according to a process or product patent,387 since 
according with the legislation the right holder cannot prevent free circulation of 
the product within the local market when such a situation falls within the context 
of Article 68 §3 and §4 from the IP Code.388 On the other hand, parallel imports 
are envisaged with the aim of supplying the national market in determined cases, 
namely as an exception to the rule settled by law. Thus, allowing parallel imports 
on a general basis is believed to be detrimental to the patent system, since 
companies would decrease productivity and efficiency when no regard to their 
efforts is given.389 
Some scholars have asserted that compulsory licences granted to correct abusive 
practices such as failure to comply with the local working requirement, or 
insufficient local supply are the most important provisions foreseen within 
Brazil’s IP code.390 It is said to express the national concern over insufficient 
national supply and also provides determined requirements that must be fulfilled 
by the third party seeking to obtain a compulsory this licence. This requirement is 
not generally established within the international framework, since, as previously 
established, economic unfeasibility needs to be proven before the compulsory 
licence to import the product can actually take place. In this respect, Article 68 
from the IP Code does not necessarily aim at demanding the local working 
requirement, but instead aims to prevent an import monopoly on behalf of the 
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patent owner since this would not fulfil the goal of promoting national 
development and technology transfer.391 
The United Stated of America contested the aforementioned provision, regarding 
it as a breach of TRIPS and an infringement of Articles 27 -28 from the 
Agreement. On the other hand, Brazil argued that both Article 27 from TRIPS and 
Articles 5 and 8 from the Paris Convention entitled the Government to take 
necessary measures to protect public health concerns and also to avoid or correct 
anti-competitive behaviours on behalf of the right holder.392 After a lengthy 
process, the case that was only brought to consultations concluded with the 
United States withdrawing the complaint before the Dispute Settlement Body. 
Allegedly, the measure had to do with major commercial interests that were at 
stake for the complaining country.393 
Generally, parallel imports could be considered as a restriction to patent rights. 
However, the TRIPS Agreement also allows member countries to choose either 
the regime for national or international exhaustion of rights; whichever complies 
with the principles of national or regional treatment and the most favoured 
nation.394In this respect, scholars assert that parallel imports, although “illegal” 
at first if the country in question implements an international exhaustion regime, 
are  “legalizing” parallel imports395, since to a certain extent in the context of a 
regional market it is acceptable and justified to favour reciprocity among 
neighbouring nations while also using this as an element to incentivise 
competition among the national industries of the countries belonging to the 
regional market.396 This alleged “reciprocity” does not seem to be a widely 
accepted argument since the pharmaceutical industry opposes parallel imports on 
the basis of price discrimination given that prices will not be settled by the 
company, thus loosing revenues that could be allocated for R&D. So price control 
policies are somewhat imposed on the products imported via this mechanism, 
and according to the industry parallel imports may represent a threat to public 
safety since wholesalers and distributors may not be as reliable as the 
originator.397 
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From an economical perspective, it has been suggested that parallel imports 
could promote fair competition preventing the pharmaceutical industry from 
settling medicines’ prices, which is also said to represent an advantage from the 
public health perspective since it will enable consumers to have greater access to 
affordable medicines.398 Whether Brazil moved forward in implementing the 
Agreement or engaging in further commercial relations, some scholars consider 
that the amendments to the IP Code transformed it into one of the most advanced 
IP legislations within the South American continent.399 Nonetheless, Brazil seems 
to keep on tailoring their IP system, since a proposal to reform the IP law was 
disclosed during October 2013. This reform will be addressed within the 
conclusions of the research. 
3.7. Summarising the Brazilian context 
Thus far, Brazilian scholars continue to disagree on the overall benefits of the 
patent system. Some argue in favour and some against the theory suggesting that 
patents would boost national development.400  Regardless of the doctrinal 
debate, Brazil was one of the first countries to implement the TRIPS Agreement 
into their national IP regime among the countries analysed in this research. Given 
that pharmaceutical products would now receive patent protection, and that a 
health crisis needed to be tackled, the Brazilian legislator seemed to have also 
created certain mechanisms to ensure access to public health and medicines. 
Admittedly, the IP law contains provisions targeting the national industry 
development and also to increase transfer of technology by ‘foreseeing’ the 
pharmaceutical industry to actually produce patented products in Brazil. 
Pharmaceutical patents are of great importance and a challenge for Brazil, since 
public health and access to medicines as part of the right to health are both 
fundamental rights.  
So far, the Brazilian government has received pressure from international trading 
partners due to their internal policies and main objectives in guaranteeing access 
to medicines based on the flexibilities given by the TRIPS Agreement.  
Intellectual property rights are not only about economic rights in Brazil, they are 
also about complying with a social function that shall prevail over private 
interests that are contrary to the majority’s interest. 
Protecting public health care has required the country to withstand the heat from 
the pharmaceutical industry lobbying against the mechanisms envisaged within 
the system to serve this purpose, namely prior consent, local working 
requirement and compulsory licences. The Brazilian Government has undertaken 
serious pressures to forgo its Anuência Prévia requirement. In June 2011, Luis 
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Carlos Wanderley Lima,401 the senior officer responsible for the prior consent 
policy, resigned from his post at ANVISA as a form of protest given that the 
Advocacia Geral da União-AGU ratified or clarified both INPI’s and AVISA’s 
competences. Hence, ANVISA since January 2011 could not keep on examining 
patentability requirements examined also by INPI, thereafter, voiding to a certain 
extent the whole prior consent concept. In this respect the Portaria n° 21 from 
2013 came to play an important role in clarifying and delimitating ANVISA’s 
competences in terms of examining the patentability requirements. However, as 
it will be analysed later on, the aforementioned regulation does not entirely seem 
to forego its intention of examining patentability requirements since it is also 
established that a patent claim for a pharmaceutical product is contrary to the 
public health when the product or processes are of interest for the national drug 
policy and SUS or when patentability requirements are not met. Even when the 
decision will justify the rationale, due to its binding character, it will be 
interesting to follow the interpretation given to Article 4 §1 (II) by ANVISA in the 
years to come.  
Pharmaceutical products –especially ARV’s– are part of a strategic sector for the 
country, and therefore, one of the ways to ensure availability and affordability is 
to produce them locally.402 However, discouraging the pharmaceutical industry 
would pose a problem since finding a cure for certain illnesses is still an issue 
according to scholars, but perhaps at this point where protection is granted 
through a patent system the government may have to either put more pressure on 
the pharmaceutical companies to innovate in the required field or create new 
incentives to satisfy public health needs. 
By creating incentives to encourage innovation within the neglected diseases 
field, it maybe necessary to develop a parallel system to the patent system itself. 
Hence, within the conclusions’ chapter the hypothesis of granting out-licencing 
agreements for the generic industry is considered to be a viable solution to 
partially solve the problem of expensive medication. But whether this solution 
would incentive innovation it is still to be addressed.  
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4 INTELLECTUAL PROPERTY AND ACCESS TO 
MEDICINES IN CHILE 
Chile has been praised for its economical stability and growth after going through 
an era of turmoil and change. In 1973 former president Salvador Allende was 
ousted by Augusto Pinochet, whose governmental dictatorship lasted for 17years 
in what has been catalogued as a defining moment for the country’s history.403 
Pinochet’s regime was not only characterised by its brutality and human rights 
violations, but also by paradoxical economic experiments with neoliberals that 
lead the country into its highest level of economic growth in 1989.404The group of 
economists known as the Chicago Boys had much to do with Chile’s economic 
success regardless of the highly controversial era. Implementing tariff reductions 
from 70% to 33%, cutting governmental spending by 27% and reducing fiscal 
deficit from 8.9% GDP to 2.9%, were among the economic measures taken to 
boost the national economy.405 Privatising health care, the pension system and 
education also played an important role in Chile’s growth. Accordingly, Pinochet’s 
regime had four stages, in which a constitutional reform took place in 1980 that 
allowed later on the casting of ballots that brought the era of democracy. Hence, 
new elected president, Patricio Aylwin, eventually ousted Pinochet in 1990.406 
Nowadays, Chile is an export-based economy with an average economic growth of 
5,5%, and it is also considered to be the most stable economy within the region.407 
Chile managed to reduce its poverty rates from 40% to 14% between 1990 and 
2006.408 Some scholars suggest that the government aggressively engaged in, and 
is constantly looking ahead to, concerting preferential trade agreements with not 
only the developed, but also neighbouring countries, that will ensure growth.409 
Thus far50trade agreements have been negotiated by Chile,410 including those 
with the United States of America, the European Union and Asian countries.  
This chapter intends to briefly assess the origins of intellectual property 
protection and its constitutional approach in Chile, the challenges brought by the 
US-Chile Agreement related to pharmaceutical patents and the public health 
tradition and current developments related to pharmaceutical patents. It is 
important to understand the level of governmental commitment towards health 
care and access to medicines in a country with strong market oriented policies, 
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namely, identifying the strategy used to ensure protection and balance of both 
intellectual property right and access to medicines. 
In respect to intellectual property rights, Chile has engaged in a long tradition of 
protection. Initially, in 1833 the Chilean Political Constitution (hereinafter the 
Constitution) granted protection for authors and scientists regarding productions 
and inventions for a period of time determined by the law in the field.411 
Currently, IP rights receive protection in the Chilean Political Constitution’s 
Article 19 (25) and (26) as Reformed in Ley Nº 20.644 of 15 December 
2012412and also in Law No. 19.996 (hereinafter Patent Law).  
On 1 December 2005 Chile issued the Patent Law that modified the previous law 
(Ley No. 19.039) after the Free Trade Agreement with the United States of 
America was signed in 2003 (hereinafter US-Chile FTA). This Agreement is 
known as a TRIPS plus agreement since it settles conditions far beyond the 
minimum standards of protection foreseen within TRIPS.413After this legislative 
reform, major concerns came along in relation to a possible conflict of 
competence between the Public Health Institute and national courts trying to 
solve controversies originating from previous products that had obtained 
marketing approvals authorising their commercialisation within the country. 
Marketing approvals per se became controversial as well due to the linkage 
between the National Health Institute and the Patent Office.  
The Chilean Senate in the Bulletin No. 4180-03414 highlighted the need to 
carefully review the aforementioned reform since neither protection for non-
disclosed information in the terms established by the US-Chile FTA, namely 
protection of test data used in producing pharmaceuticals from being released to 
the public for a period of 5 years, or the above-mentioned issues were sufficiently 
developed within the legislation. Allegedly, Chile prior to implementing the US-
Chile FTA was reluctant to execute TRIPS because these policies were deemed 
detrimental to the citizens’ well-being415 and also inconsistencies within the 
Patent Law available at the time challenged the compliance with TRIPS. Despite 
not all of these being related to patents, or the pharmaceutical industry, it is 
worth noting that IP enforcement in general, and effective search mechanisms to 
identify counterfeited goods,416 in the field of copyright are challenging Chile’s 
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performance.  Hence, piracy is one major concern when it comes to intellectual 
property rights infringements in Chile. 
It must be pointed out that the Office of the United States Trade 
Representatives417  (hereinafter USTR) has included Chile within the “watch list” 
and the “priority watch list” as a result of an “Out-of-Cycle Review”418 done to 
verify this trading partner’s commitment and compliance with the Agreement in 
terms of intellectual property rights.  
Initially, Chile has been compelled by the United States negotiators to protect 
undisclosed test data from unfair commercial use, as well as unauthorised 
disclosure when processing marketing approvals for pharmaceutical products, to 
seek punishment for end-user piracy, to give a proper correlation between the 
patent granted and the authorisation to commercialise the product (linkage)419 
and to extend the time of protection due to unnecessary curtailments of time 
when granting patents. 
According to a press release in 2007 by the USTR, Chile was highlighted as not 
giving priority to IPR issues since intellectual property rights were not sufficiently 
protected, specifically within the pharmaceutical industry. In this respect, patent 
owners alleged that Chile “had authorized the marketing of patent-infringing 
pharmaceutical products and had also failed in providing appropriate and 
effective mechanisms for patent holders to prevent or oppose marketing 
approvals for similar products.”420 
So, Chile modified its Patent law in 2007 under Ley de Propiedad Industrial N 
20.154 (hereinafter New Patent Law) and also created the Instituto Nacional de la 
Propiedad Industrial- Industrial Property National Institute. This is the 
competent body that has dealt with intellectual property rights since 1 January 
2009.421 
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Although improving IPR enforcement is among Chile’s priorities, public health 
and access to medicines are priorities as well.  Hence, promoting competition and 
the issue of affordable medicines will also be analyses within the chapter. On the 
one hand, price competition seems to be an adequate solution to lower medicine 
prices. However, it has been suggested that generic producers are also making 
significant profits out of highly pricing their products, which contradicts the 
principle of “affordable medicines.” 
4.1. Chilean Patent System and Grant Procedure 
Chile has offered protection for intellectual property rights since 1833, but in the 
past the protection was not as well defined as later on in 1980 when the new 
Chilean Political Constitution was reformed. Chile also ratified the Paris 
Convention for the Protection of Industrial Property on 14 November 1991.423 
However, protection for pharmaceutical products was not available until after 
Chile joined the World Trade Organization (WTO) and had to comply with the 
new standards of protection settled in light of the TRIPS agreements.   
Before analysing the patent system and the implementation of TRIPS in Chile it is 
important to highlight that the Treaties, Agreements and Conventions negotiated 
by the President require parliamentary approval before they can be effectively 
executed.424 
The Intellectual Property Law Nº 19.039 modernised the Chilean intellectual 
property system, providing adequate protection for inventions and scientists. 
Furthermore, the law provides precise definitions for the concepts of inventions 
and patents,425 patentability requirements426 and terms and conditions related to 
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effects, obligations and limitations embodied in the patent shall be determined by this Law.” 
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compulsory licences427 and marketing approvals (or sanitary registrations as 
defined by the legislation).428 
The Instituto Nacional de Propiedad Industrial – National Institute for Industrial 
Property (hereinafter INAPI) is the competent body to grant patent rights and to 
deal with intellectual property rights in Chile.429 Even though this is an 
independent agency, INAPI observance is under the Ministerio de Economía, 
Fomento y Reconstrucción – Ministry of Economics, Development and 
Reconstruction.  Previously, the Departamento de Propiedad Industrial – 
Department for Industrial Property had as its main attributions processing 
applications for industrial property protection, solving cases related to acceptance 
or rejection of IPR’s’ and managing other general aspects. Whereas the new 
patent office is not limited to manage IPRs, since their attributions extend to 
analysing possible international treaties or agreements that Chile could become 
part from.430 
This part of the chapter intends to analyse the patent grant procedures within the 
legislation in light of the amendments to comply with both TRIPS and the US-
Chile FTA. The Chilean Patent law begins by establishing its competence to 
review and registered IP rights. Accordingly, patent applications, before being 
accepted for registration shall pass a formal or preliminary exam that is designed 
to verify if the application fulfils the requirements given by law.431 
Article 4º from the Patent Law Nº 19.996 mandates the publication of an extract 
of the patent application within the Official Journal once the application has been 
accepted for processing by INAPI, which only occurs after the preliminary 
examination. This provision is complemented by Article 5 from the Ley Nº 19.039 
that grants 60 days from the filing date for INAPI to comply with mandatory 
publication. 
Following the publication, the interested parties may present opposition before 
INAPI in a period of forty-five (45) days from the time of the publication.432 After 
this initial verification phase expires, the patent office will perform the 
substantial examination as requested by the parties,433giving INAPI 60 days to 
return the report to the experts. 434 
An interesting issue within the Chilean IP Law is the fact that the chapter related 
to patents is named “De las Invenciones” (Inventions) instead of “Patents” as 
                                                                                                                                                        
Translation by WIPO. Highlight and modifications made by the author 
<www.wipo.int/edocs/lexdocs/laws/en/cl/cl046en.pdf>accessed 10 March 2013 
426 See Articles 33, 35 and 36 from Patent Law Nº 19.996 
427 See Article 51 from Patent Law Nº 19.996 
428 See Título VIII, Párrafo 2º, Articles 89 -91 from Patent Law Nº 19.996 
429INAPI was created by Ley Nº 20.254 published within Diario Oficial de la República de Chile Nº 
39.036 dated 14 April 2008. 
430 See Article 3 from Ley Nº 20.254, published in Gaceta Oficial Nº 39.036 
431 Article 45 from Patent Law Nº 19.996 “The patent application shall be accompanied by the 
following documents: an abstract of the invention;a description of the invention; a claims sheet; 
drawings of the invention where appropriate.” 
432 Article 5 from Ley Nº 19.996 
433 Article 6 from Ley Nº 19.996 
434 Article 7 from Ley Nº 19.996 
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generally found in other legislations. Inventions are defined by the law, “as any 
solution to technical problem arising from an industrial concern, which can be 
related to a product or process.”435 
Articles 33, 35 and 36 from the Patent Law Nº 19.996 provide definitions as to 
what is to be understood as novelty, innovation and industrial applicability within 
the Chilean context. In between these definitions, the legislation approaches the 
priority right given to foreign applications. Without elaborating too much on the 
case, the legislator limits it to granting twelve (12) months from the date of 
application abroad to submit the claim in Chile.436 
Both prohibitions and non-patentable subject matters are settled within Article 
37 of the IP Law. Among these are second medical uses, discoveries, scientific 
theories and mathematical methods.437Any patents that go against public order or 
public health are prohibited. In terms of prohibitions the legislation is specific in 
highlighting the possibility of preventing certain inventions in being 
commercialised within the country due to public health or national security 
reasons or to preserve the environment.438 
Only three scenarios are foreseen by the legislation to void patents in Chile, 
namely when the claimant of the patent rights is not the real inventor, when the 
patent grant was based on misleading or deficient examination of content (or 
expert reports as assessed by the Law) and when the patent was granted contrary 
to patentability requirements which constitute a cause for invalidating the 
patent.439 
Compulsory licences are also envisaged within the legislation. Despite Chile being 
a Paris Convention Member, no provision expressly settling the local working 
requirement is found within the legislation. Thus, compulsory licences are mainly 
to correct anti-competitive practices and to solve public health emergencies.440 
                                                        
435 Article 13 from Ley Nº 19.996 English version provided by WIPO. Law No. 19.039 on Industrial 
Property (Consolidated Law approved by Decree-Law No. 3) 
436 Article 34 from Ley Nº 19.996 
437 Second uses are initially forbidden. However, the same article highlights that if a second use 
fulfills patentability requirements established by Law then it could obtain patent protection. Article 
37 from Patent Law Nº 19.996 
438 See Article 37 from Patent Law Nº 19.996 
439 Article 50 from Patent Law Nº 19.996 “A patent may be invalidated on any of the following 
grounds: where the person who obtained the patent is neither the inventor nor his licensee;  
where the patent has been granted on the basis of erroneous or manifestly deficient examiners’ 
reports; where the title has been granted in contravention of the rules of patentability and 
related requirements, as provided for in this Law. A patent for an invention may be the subject of an 
invalidation action during a period of five years, beginning from the date of registration.” 
440 Article 51 from Patent Law Nº 19.996 “Nonvoluntary licenses may be granted in the following 
cases: (1) where the holder of a patent has engaged in conduct or practices declared contrary to free 
competition, directly related to the use or exploitation of the patent in question, according to a final 
decision by the Antitrust Tribunal; (2) where the granting of such licenses may be justified for 
reasons of public health, national security, noncommercial public use or on other extremely urgent 
grounds declared by the competent authority; (3) where the purpose of the nonvoluntary license is 
the exploitation of a subsequent patent that could not be worked without infringing a previous 
patent.” 
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One particular point brought by this IP Law is the protection of undisclosed 
information, as Article 89 specifically delimits the need to safeguard these kinds 
of data from third parties when applying for a marketing approval to 
commercialise known products. This Article also forbids the National Health 
institute from using the information available in the files related to that product, 
as a basis to approve marketing approvals.441 Certain exceptions to this rule also 
apply, mainly related to public health needs. 
An interesting fact denoting Chile’s evolution on industrial property matters is 
the creation of an Industrial Property Court where issues related to these kinds of 
rights must be heard before passing over to a higher judicial and civil instance. 
The Chilean law is very clear in delimiting functions, jurisdiction and the 
competence for this Court.  
4.2. U.S. – Chile Free Trade Agreement: Implementing Higher 
Standards of Protection* 
Thus far Chile has signed three free trade agreements and one association 
agreement where intellectual property right issues are discussed and negotiated. 
Among the most important ones are the Chile- Korea, Chile – USA, Chile - 
Mexico442 and Chile-E.U443 
                                                        
441 Article 89 from Patent Law Nº 19.996 “Where the  !"  # "(ISP – Public Health 
Agency)… requires the submission of proof or other undisclosed information concerning the safety 
and effectiveness of a pharmaceutical product or agricultural chemical that utilizes a new chemical 
entity that has not been previously approved by the competent authority, such information shall be 
considered confidential pursuant to the regulations in force.  
The nature of nondisclosure shall be deemed satisfied if the data have been subject to reasonable 
measures to keep it undisclosed and they are not generally known to or easily accessed by persons 
within the circles in which the type of information in question is normally used.  
The competent authority may not disclose or utilize such data to grant a health registration or 
authorization to someone who does not have the permission of the holder thereof, for a period of 
five years for pharmaceutical products and 10 years for agricultural chemicals, beginning from the 
first health registration or authorization granted by ISP or SAG, as the case may be.  
In order to enjoy protection under this Article, the nature of non-disclosure of such data shall be 
expressly stipulated in the health registration or authorization application.” 
* Substantive parts from the analysis of the pharmaceutical linkage carried out within this heading 
were already published by the Doctoral student in Cadillo Chandler, D.M., ‘Pharmacuetical Patents 
and Marketing Approvals within the U.S. –Chile Free Trade Agreement Context: A brief Analysis’ in 
In Search of New IPR regimes (IPR University Center, Helsinki - 2010) 201-218 
442 Palma Oyedo, P., ‘Los Tratados de Libre Comercio y los Medicamentos’ (2004) Medicamentos y 
Tratados de Libre Comercio, at 25 
443 Association Agreement between the European Union and Chile. “Article 2. 1 This Agreement 
establishes a Political and Economic Association between the Parties, based on reciprocity, common 
interest and on the deepening of the relationship in all areas of application. 2. The Association is a 
process that will lead to a growing relationship and cooperation between the Parties structured 
around the bodies created in this Agreement. 3. This Agreement covers in particular the political, 
commercial, economic and financial, scientific, technological, social, cultural and cooperation fields. 
It may be extended to other areas to be agreed upon by the 
Parties”<www.sice.oas.org/Trade/chieu_e/Chieu1_e.asp> accessed 10 April 2013 
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The Free Trade Agreement between Chile and the United States (hereinafter U.S.- 
Chile FTA) received the Congress’s approval on Decree Nº 312 in 2003 by the 
Ministry of Foreign Relations.444 
It has been highlighted that Chile’s major challenge is the full implementation of 
the FTA. Therefore, preventing patent infringements and solving the alleged 
linkage unconstitutionality are of great importance so as to comply with the 
signed agreement.445 The problem with the linkage regards to possible patent 
infringements by third parties due to a legislative reform post U.S.-Chile FTA that 
does not legitimate the linkage. 
Allegedly there is an increasing trend in qualifying bilateral agreements signed 
with industrialised countries like the U.S., as TRIPS plus agreements are 
generally a consequence from a bargain for market access.446 Professor José 
Manuel Cousiño from the Chilean Chamber for the Pharmaceutical Industry does 
not find the agreement to be very different from the TRIPS Agreement previously 
ratified by Chile when becoming a World Trade Organization Member State, and 
the fact that a country implements higher standards of protection within a free 
trade agreement does not make it a TRIP plus agreement. Moreover, attention 
has also been drawn to the fact that Chile will be a different country in 10 years 
due to a greater access into international markets.447 The fact that these 
agreements involve higher intellectual property standards is causing great 
concern and has led to a part of the doctrine to suggest that the agreement 
ratified by Chile with the U.S. was a bad deal.448 
Within the U.S.-Chile FTA context there are some other relevant provisions 
regarding intellectual property rights but for the purpose and clarity of this study 
mainly those related to regulated products or pharmaceutical products will be 
analysed. In the light of the U.S.-Chile FTA not only pharmaceutical products are 
regulated but also agricultural products, identifying these within the agreement 
as regulated products. It must be highlighted and, as mentioned before, that this 
is not the first time that Chile negotiated higher standards of protection through a 
free trade agreement with another trading partner. In 1999 Chile signed an 
Economic Complementation Agreement with Mexico449, where among many 
                                                        
444 Govierno de la República de Chile, Decreto Nº 312 del 01 de Diciembre de 2003, Publicado en 
Diario Oficial el 31 de Diciembre de 2003 
<www.bcn.cl/lc/tinterna/tratados_pdf/tratado_vally072.pdf> English 
version<www.ustr.gov/sites/default/files/uploads/agreements/fta/chile/asset_upload_file941_40
19.pdf> accessed 10 April 2013 
445 Palma Oyedo, J., ‘Los Tratados de Libre Comercio y los Medicamentos’ at 25 
446 Ho, C., ‘A New World for Addressing Patenting Rights and Public Health’ (2007)82 Chicago 
Kent Law Review 3 <www.cklawreview.com/wp-content/uploads/vol82no3/Ho.pdf> 
447 Cousiño,J.M., ‘Tratados de Libre Comercio y sus Efectos Sobre el Mercado Farmacéutico 
Chileno’ (2004) Medicamentos y Tratados de Libre Comercio, at 41 - 49. Original text in Spanish, 
part of the reference is also corroborated in an interview held in May 2009 with Professor Cousiño. 
448 Correa, C.,  ‘Mal Negocio de Chile con Estados Unidos’ in Le monde Diplomatique, March 2004. 
<www.insumisos.com/diplo/NODE/156.HTM> Original text in Spanish. English translation 
available at <www.qiap.ca> 
449Levis, M., ‘Role, Perspectives and Challenges of the Generic Pharmacautical Industry in Latin 
America, ICTSD – UNCTAD’ in Dialogue on Ensuring Policy Options for Affordable Access to 
Essential Medicines,  Bellagio,12-16 Oct. 04, at 1-9. Free Trade Agreements between the United 
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other things, intellectual property rights were negotiated450 particularly in the 
field of trademarks. 
Another important issue is regards whether or not Chile resigned the use of the 
flexibilities available in the TRIPs Agreement by virtue of the bilateral agreement 
signed with the United States. It has been suggested that this FTA will be a 
barrier for Chiles’ public health due to the impossibility of legally introducing 
generics onto the market based on patent availability; hence Chile would be 
giving up many of the flexibilities previously granted by the TRIPS. 
Article 17.1.5 clause on applicability, expressly points out that “nothing in the 
Chapter concerning intellectual property rights shall derogate ... the obligations 
and rights of one party in respect to the other by virtue of the TRIPS 
Agreement”451 and also the Chilean legislation provides the conditions and terms 
for enacting a compulsory licence. Reading both the Spanish and the English 
versions of the Agreement brings to forefront the rationale over the impossibility 
in making use of the flexibilities by Chile. Initially these flexibilities were granted 
by the TRIPS Agreement and the DOHA declaration on the TRIPS Agreement 
and Public Health,452 but nevertheless within the context of the English version of 
the clause related to the exception it suggests the existence of certain 
discrepancies, giving perhaps some space for confusion, while the Spanish 
version is crystal clear.  
The US-Chile FTA covers a great variety of topics related to trade between the two 
contracting parties, and this is deemed beneficial for the Chilean economy due to 
its international exposure.453 Some have even described the FTA as a bad deal by 
mainly emphasising the higher levels of protection for pharmaceutical products, 
highlighting the negative impact on the access to medicines as mentioned 
previously. In this respect, access to medicines was seen as endangered due to a 
possible extension on the length for patent protection, delaying the entry of 
generics into the market.454 Moreover, a special concern exists over the clauses 
regarding data protection, linkage, extension of protection and TRIP Flexibilities.  
Attention must be drawn to the fact that most of the doctrine against the FTA was 
written in 2004, and Chile managed to reform the intellectual property legislation 
according with the TRIPS almost 5 years after the FTA was ratified.  
                                                                                                                                                        
States and Developing countries. Negotiating further intellectual property protection templates 
which most likely go beyond the general TRIPS Agreement 
450 Roffe, P., ‘Bilateral agreements and a TRIPS-plus world: the Chile-USA Free Trade Agreement’ 
(October 2004) Quaker International Affairs Programme - TRIPS Issue Paper 4 
451 Free Trade Agreement between Chile and USA. Article 17.1.5. “ Nothing in this Chapter 
concerning intellectual property rights shall derogate from the obligations and rights of one Party 
with respect to the other by virtue of the TRIPS Agreement or multilateral intellectual property 
agreements concluded or administered under the auspices of the World Intellectual Property 
Organization (WIPO)...” 
452 WT/MIN(01)/DEC/2, 20th November 2001 “Declaration on the TRIPS Agreement and Public 
Health”. The Doha Declaration recognises the need of least developed and developing countries 
with no manufacturing capability and the need to protect public health beyond the previous 
negotiated within the TRIPS Agreement, therefore granting certain flexibilities and freedom for 
countries to supply internal market needs. 
453 Cousiño, J.M., ‘Tratados de Libre Comercio y sus Efectos Sobre el Mercado Farmacéutico 
Chileno’  ( 2004) Medicamentos y Tratados de Libre Comercio, at 41 - 49. Original text in Spanish 
454 Idem 
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Another relevant argument stressed during 2004 was that nothing within the 
Chilean legislation at that time stated anything related to compulsory licences 
and parallel imports, but by 2006 when the Patent Law Nº19.039 came into force 
posterior to the FTA, Articles 51(2), 51 bis A, and Article 70 from the patent law’s 
Regulation, the Chilean government clearly foresaw a compulsory licence 
regime.455 As with to parallel imports, the only way for an exemption to be 
available may be through Sanitary Code Articles 100 and 102, where the first 
Article points out the creation of a National Chart of Indispensable Medicines 
(Formulario Nacional de Medicamentos), and the second Article establishes 
within the second paragraph that no marketing approval or sanitary permit is 
needed in cases of medical urgency.456 With the creation of a National Chart of 
Indispensable Medicines, the Chilean Government makes sure to determine 
which pharmaceutical products are not patentable subjects and those that could 
be required with no further notice to patent owners due to a national emergency 
or medical urgency.457 
                                                        
455 Ley Nº 19.039, Article 51 “the decision on a compulsory licence will proceed within the following 
cases: ... 3) due to public health reasons, national security, non-commercial public use or national 
emergency or other extreme emergency declared by the competent authority, justifies the granting 
of those licenses...” Article 51 bis A “the compulsory licence applicant will have to provide 
documentation enought to justify his previous request to the patent owner for the use of a patent 
licence and that this one was not possible to be achieved within reasonable terms, conditions and 
time. This requirement will not proceed due to the previously established by this law Articles’ 51.2. 
Nor will be required in cases where the compulsory licences’ object is to sanction anti competitive 
practices”  
<www.leychile.cl/Navegar?idNorma=250708&idVersion=2007-01-26> 
456 Sanitary Code (Código Sanitario) Decree Nº 725/67 later on modifie by Ley Nº 20.308 published 
by Oficial Diary 27.12.2008. Article 100 “The Ministry of Health, previous technical report from its 
Technical Regulation Units, will approve a Nationla Chart of Indispensable Medicines to supply the 
country’s needs. This Chart will specify the pharmaceutical form and dosage of the pharmaceutical 
product and it will also describe the use, limitations and side effects of those products...” Article 102 
“... no pharmaceutical product shall be commercialised or distributed in the country without 
previous registration at the National Health Institute... Although the sanitary authority is able to 
authorise the provisional distribution and commercialisation of such a product for medical urgency 
reasons” Original text in Spanish translations by the author. Para concretar una Reforma de salud 
global, en el ámbito del acceso a medicamentos seguros, efectivos y de calidad se espera la 
participación y el compromiso de los fabricantes/importadores de medicamentos en la 
producción/importación de éstos bajo denominación genérica. Que el país cuente con 
medicamentos bajo denominación genérica implica la factibilidad de ampliar el acceso a las terapias 
farmacológicas incluidas en el AUGE. 
457 Decreto 194 enacted on 26.08.2005, published on Diario Oficial 10.03.2006. This Official Decree  
settles the existence of the National Chart of  Indispensable Medicines (Fomulario Nacional de  
Medicamentos). Decreto 264 enacted on 10.12.2003 and published on Diario Oficial on 16.03.2004. 
This Official Decree is the Complementary Regulation to the Decree 194 and the Regulation settles 
the parameters to the National Chart of Indispensable Medicines 
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4.2.1. Linkage and Sanitary Permits458 
The existing link between the patent and the sanitary permit established in 
Article 17.10.2 has created controversy among the Chilean legislative community.  
“Article 17.10.2. With respect to pharmaceutical products that are subject to a 
patent, each Party shall: 
(a) make available an extension of the patent term to compensate the patent 
owner for unreasonable curtailment of the patent term as a result of the 
marketing approval process; 
(b) make available to the patent owner the identity of any third party requesting 
marketing approval effective during the term of the patent; and 
(c) not grant marketing approval to any third party prior to the expiration of the 
patent term, unless by consent or acquiescence of the patent owner”459 
This Article expressly foresees the contracting parties’ duty in preventing third 
parties commercialising an already patented product by a third party different 
than the owner without its consent. Although Article 17.9.4 points out the duties 
of the parties when importing or exporting, this procedure or linkage is developed 
through Article 17.9 and 17.10, where not only the duty to provide information to 
patent owners is settled but also the duty to deny sanitary permits on basis of the 
existence of an available patent for that pharmaceutical product. 
A report from the United Nations Development Program in 2005 highlighted that 
in most countries pharmaceutical patents and their registrations to 
commercialise e status are two separate issues, thus also assessed by two different 
bodies or institutions.460 In Chile the Instituto Nacional de la Propiedad 
Industrial – INAPI (Patent Office) is the body responsible for evaluating if the 
pharmaceutical product or process complies with the patent requisites, and the 
Instituto Nacional de Salud Pública – ISP (National Health Institute) is the one 
responsible for assessing on whether or not the pharmaceutical is of sufficient 
quality, safe and effective to be granted a marketing approval.461 
The challenge with the linkage regards the functions originally given to the ISP by 
the Ministry of Health, which according to its own regulation’s Article 4(b) is 
                                                        
458 The term “sanitary permit” is a direct translation from the Spanish “permisos sanitarios”. As the 
discussion will later highlight, this concept is used as a marketing approval, commercial 
authorisatio and formal registration synonyms, which are a formality required prior to the 
commercialisation of a pharmaceutical product. This sanitary permit is to be granted by the Chilean 
National Health Institute 
459Article 17.10.2 Free Trade Agreement US-Chile. This Article brings to the spotlight three different 
situations that are seen as higher standards than the ones already established by the TRIPS 
Agreement. 
460 Ruth Mayne; “Regionalism, Bilateralism, and “TRIPS Plus” Agreements: The Threat to 
Developing Countries” in Human Development Report Office Occasional Paper, Human 
Development Report 2005, UNDOP 2005/18. 
461 Reglamento del Instituto de Salud Pública. Article 4. “The National Health Institute functions 
will be: b.) To perform the activities related to drug quality control, medical food use and other 
products subject to health controls, which include the following functions:”“3: control the 
conditions, exports, manufacturing process, distribution and commercialisation ... of those product 
according with the regulations” Original text in Spanish, translation by the author. 
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entitled to control quality and effectiveness of those products462 regulated under 
the National Control System for Pharmaceutical Products Regulation.463 
Allegedly, the FTA could be creating a new function for the ISP through Article 
17.10.2.c when stressing the duty to deny a sanitary permit. 
Article 17.10.2. Each party shall: (c) not grant marketing approval to any third party prior 
to the expiration of the patent term, unless by consent or acquiescence of the patent 
owner464 
Accordingly, as a new procedure in the Chilean legislation to protect 
pharmaceutical products, the fact that the legislation per se does not define what 
linkage means and the ISP’s refusal in recognising their duty to provide 
marketing approvals even when its own legislation and regulation provided so 
has divided scholars in Chile. Thus far, linkage could be understood as the 
available connection within the sanitary permit and the patent before a 
pharmaceutical product could be commercialised in a specific market. And this is 
produced by the connection that exists between the authorities granting 
marketing approvals and the one granting patents. Secondly, within the context 
of the FTA as pointed out above, the authority granting the sanitary permit shall 
“not grant marketing approval to any third party prior to the $%& '%
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462 See Decreto 194 enacted on 26.08.2005 
463 National Control System for Pharmaceuticals, Food and Medical Use Cosmetics Regulation 
(Reglamento del Sistema Nacional De control de Productos Farmacéuticos, alimentos de Uso 
Médico y Cosmeticos, D.S 1876/1995)  
464 Correa, C., ‘Mal Negocio de Chile con Estados Unidos’ 
465 Mayne,R., ‘Regionalism, Bilateralism, and ’TRIPS plus‘ Agreements’ 
466 30 Juzgado Civil de Santiago, Rol C-6613-2003, Porzio Bozzolo (Pfizer Chile S.A.) Vs. 
Ministerio/ Instituto de Salud Pública (2006). This case took around three years in court before 
been decided, but so far this is one of the few ruling where a Chilean court has really analysed in 
depth the intellectual property and pharmaceutical legislation with regard to a sanitary permit 
(marketing approval) 
467 Postinal is the pharmaceutical product manufactured on basis of Levonorgestrel. This is a drug 
according to the Chilean Supreme Court’s ruling of30 August 2001, Rol Nº2186-2001 which is 
deemed unconstitutional due to its abortive effects. As will be discussed below, this Court ruling 
voided the sanitary permits granted to commercialiseand distribute the product in the country. 
Original text in Spanish. 
468 National Control System for Pharmaceuticals, Food and Medical Use Cosmetics Regulation 
(Reglamento del Sistema Nacional De control de Productos Farmacéuticos, alimentos de Uso 
Médico y Cosmeticos, D.S 1876/1995) Article 37: “the application for marketing registration to 
commercialize (marketing approval) or to distribute a pharmaceutical product imported or 
manufactured in the country, the applicant shall present before the ISP, in pre approved forms the 
ones that will be registered by the person or its legal representative” Translation by the author, 
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to the patent owner the identity of any third party requesting marketing approval 
effective during the term of the patent...”.469 This became controversial, but it did 
not seem to be different from what was already stated by the Resolution Nº14 in 
relation to the sanitary permits and patents from the ISP. Within the Resolution 
parts 7 and 8, patent holders were to be informed about third parties requesting 
marketing approvals for similar products to the ones already patented.470 
In the light of the aforementioned Article’s part (b), Chile should not only provide 
the information to patent holders, but the ISP should also have access to the 
information on whether or not there is a patent pending or expired. Currently this 
institution stated its lack of competence to access that kind of information 
through Resolution No. 005572, where the ISP delimitates its attributions in not 
interfering with patent rights.471 Besides their incompetence over intellectual 
property matters, the ISP on several occasions has made obvious their 
incapability to grant marketing approvals, since only sanitary registrations are to 
be granted which under any circumstances can be acknowledged as an 
authorisation to commercialise in according with the Republic of Chile 
Comptroller’s Office472 (Contraloría General de la República de Chile) in 2002. 
                                                                                                                                                        
bolded and in cursive to highlight a point by the author. The D.S 1876/1995 was modified by Dto. 
245/03, and this reform made reference in Article 37 to a plain registration and not a marketing 
approval as will later on be discussed. 
469 Ibid 
470 Instituto de Salud Pública de la Repulica de Chile, Circular No. 14, Santiago 28 de Noviembre de 
2001. Part 7: “in order to provide transparency to the rights and expectations of the diverse right 
holders, the institute shall provide information regarding patent certificates of products with 
similar composition, of those applications to integrate patent certificates into the registry system, by 
providing all the relevant documents". Part 8: “In the same respect this Institution will provide 
information to right holders which are also patent owners about posterior applications to register a 
product with similar composition as the one previously registered by them” Original text in Spanish, 
translations by the author. This Circular No. 14 (Resolution No.14 was modified later on by 
Resolution  No.005572 in July 12th 2004) 
471 Instituto de Salud Pública de la República de Chile, Resolución No. 005572, Santiago 12 de Julio 
de 2004. Taking into consideration: “First: considering that the ISP due to its juridical nature, 
attributions and functions lacks competence to solve conflicts derived from rights and privileges 
granted by the Law No. 19.039 in relation to patents” “Second: nevertheless it is necessary to 
provide guarantees enough to every counterpart, as in regards of patents related to pharmaceutical 
products sanitary permits, as to enable them in taking the matter to competent judicial and 
administrative instances to solve those conflicts they may be part of…” “Third: the previous 
objective is granted by allowing the interested parties to have access to the information related to 
applications or requests for sanitary permits for pharmaceutical products, so as the resolutions 
granting the permits…” Decides to: “1st: …publishi a list with the information related to sanitary 
permits applications for pharmaceutical products, providing the relevant information about the 
applicants and product...”This Resolution leaves in the right holder’s hands the duty to look after 
their own interests by periodically checking for similar products as theirs, because the ISP will not 
inform them about any application or deny a similar marketing approval for the same product. 
Original text in Spanish, translations by the author. 
472The General Comptroller Office of the Republic of Chile (CGR)is in charge of controlling the 
State’s Administration; a task assigned it in the Political Constitution.  It is independent from the 
Executive Branch and other government entities and essentially ensures that the acts of the State 
Administration are legal.  It is not subordinate or overseen by the Executive Branch or Congress. 
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By 2 September2002 the Quinta Sala from the I Corte de Apelaciones (I Court of 
Appeals, Fifth Chamber) acknowledged Pfizer Chile S.A a motion to prevent the 
marketing approvals or sanitary permits for second uses to Laboratorios 
Recalcine S.A by the ISP for the same pharmaceutical product (Ziprasidona) and 
the procedure to obtain Ziprasidona.473 Pfizer Chile S.A sought to prevent the 
granting of those sanitary permits on basis of a patent infringement, but the 
Court of Appeals sentenced Pfizer to cover the cost of the trial while at the same 
time legitimised Recalcines’ sanitary permits on the basis of the ISP’s lack of 
competence to rule over conflicts related to patent rights. Interestingly, the Court 
of Appeals dealt with the issue, and regardless of what was established in the 
legislation and the ISP’s Resolution Nº14, the Court ruled that the ISP had no 
competence what-so-ever to either deny a marketing approval or to acknowledge 
any right derived from a patent.  
Beyond pointing out the fact that the ISP has been under the microscope for a 
while, these lines intend to draw attention to the fact that some of the challenges 
attributed to the FTA already existed even before its ratification. Therefore, the 
necessity to analyse the most relevant cases available were not only 
contradictions between the Court rulings over the matter, but also the ISP itself 
and the legislation. The fact that the ISP grants a sanitary permit albeit 
authorisation to commercialise, lies on Article 102 from the Sanitary Code and 
Article 11 from the Reglamento Nacional de Control Sanitario (National 
Regulation on Sanitary Control), where both Articles correlate with each other by 
stating that no pharmaceutical product shall be sold in the country if a sanitary 
permit has not been previously granted.474 So if a pharmaceutical product cannot 
be sold without this sanitary permit, is it not then possible to assume that this 
sanitary permit is actually a marketing approval or an authorisation to 
commercialise? 
                                                                                                                                                        
The task of the CGR is by far oversight. It is charged with protecting the principle of legality, i.e. 
confirming that the organs of the State’s Administration act according to their attributions 
following the procedures contemplated in the law. 
<www.contraloria.cl/NewPortal2/portal2/appmanager/portalCGR/eng?_nfpb=true&_pageLabel=
ENG_WhoWeAreCGR_v2> 
Contraloría General de la República de Chile. Dictamen 051760N02 from 17.12.2002. Cámara de la 
Industria Famaceutica vs. ASILFA and ISP 
473 Ziprasidona (Ziprasidone) is a neuropharmacologic used for schizophrenia and to prevent 
psychotic relapses commercialised and manufactured in Chile by Pfizer Chile S.A. The procedure is 
protected by the patent No. 36.533, and the product is protected by the patent No. 41.031. I Corte 
de Apelaciones de Santiago, Rol. 3747-2002, Pfizer Chile S.A. Vs. Laboratorios Recalcine S.A. and 
the ISP (2002) 
474 Sanitary Code (Código Sanitario) Decree Nº 725/67 later on modifie by Ley Nº 20.308 published 
by Oficial Diary 27.12.2008; Article 102: “No pharmaceutical product …shall be commercialized or 
distributed in the country without previous registration at the National Health Institute...”; 
National Control System for Pharmaceuticals, Food and Medical Use Cosmetics Regulation 
(Reglamento del Sistema Nacional De control de Productos Farmacéuticos, alimentos de Uso 
Médico y Cosmeticos, D.S 1876/1995) Article 11: “Every product imported or manufactured in the 
country, before been distributed or sold in the country, shall have a sanitary permit granted 
according the terms and conditions established by this regulation...” 
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4.2.2. Relevant case law: 
I Court of appeals, Republic of Chile, Rol 3747-2002475 
 
In this case, Pfizer sought an injunction to prevent the ISP in granting the 
sanitary permits in favour of Laboratorio Recalcine, which would have had 
allowed them to commercialise the generic version of Pfizer’s product without 
their consent (original owner). In doing so, the plaintiff also sought to delimit the 
ISP’s competences and also the National Health Institute sought, at the same 
time, to clarify its position in terms of marketing approvals. 
The Court of Appeals ruled within the Rol. 3747-2002, that the National Health 
Institute lacks competence to solve any controversy derived from a patent and 
therefore this institution attribution only allows pharmaceutical product 
registrations to thereafter grant a sanitary permit. The original motion for an 
injunction to prevent the granting of a sanitary permit deviated into a conflict of 
pure intellectual property between the parties in question.  
During the proceedings the Court understood the matter as a conflict derived 
from an intellectual property privilege granted to the owner by the Law Nº 19.039 
and therefore this conflict accordingly should have been presented before the 
INAPI Chief of Department whom would have had to decide. Otherwise, a Civil 
Court should have solved the case. Moreover, the court stated that this institution 
has nothing to do with a patent right or the ability to determine the scope of 
patent protection granted and thereafter if a sanitary permit was requested by a 
third party the ISP had to limit itself in only verifying exclusively that the 
requirements were fulfilled. Another relevant argument used by Pfizer, and later 
on used against the company, was the fact that the company alleges to have 
accidentally learned about Laboratorio’s Recalcine request before the ISP for the 
approval of the permits in question. Later on the court, due to the ISP’s 
allegation, dismissed the previous argument over the matter, which basically 
suggested their good diligence in making the plaintiff aware of the situation when 
the institution submitted a letter of notification that was not accepted.476The last 
argument draws attention to the duty of the ISP in making available to patent 
owners the identity of third parties requesting marketing approvals during the 
term of the patent, as the U.S.-Chile FTA Article 17(10) b suggested a year after 
this ruling.     
General Comptroller Office, Republic of Chile Dict. 
051760N02477 
 
Perhaps the previous case was reinforced by the comptroller’s office ruling over 
the Chilean Pharmaceutical Chamber’s claim to clarify the National Health 
Institute’s real attributions, as this was granting sanitary permits for copies of 
pharmaceutical products with a valid patent. In this case the Asociación 
                                                        
475 Quinta Sala, I Corte de Apelaciones de Santiago, Rol No.3747-2002, Pfizer Chile S.A. Vs. 
Laboratorio Recalcine S.A./ Instituto Nacional de Salud  (Ziprasidona case) 
476 Id. Ut Supra 38 
477 Contraloría General de la República de Chile, Dictamen No. 51760 de fecha 17.12.2002, Cámara 
de la Industria Farmacéutica Vs. ASILFA/ISP 
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Industrial de Laboratorios Farmacéuticos Chilenos A.G. (hereinafter ASILFA)478 
sought for the Comptroller to clarify the ISP and to acknowledge that its main 
responsibility did not regard granting the sanitary permits to those products that 
fulfil the legal requirements, but also to verify the existence of patent rights. 
After an extensive analysis, the Comptroller’s Office dismissed the 
Pharmaceutical Chambers petition dictating that the ISP was not legally 
attributed to deny a sanitary permit neither on the basis of a valid patent nor to 
analyse the privileges deriving from the Law No. 19.030 (patent law). And 
therefore the parties shall present in court when fears over the vulnerability of 
their rights where plausible. 
It is important to highlight that Resolution No.14 was still valid and therefore the 
ISP had the duty to inform patent owners about third parties’ applications to 
obtain marketing approvals or sanitary permits to commercialise similar 
products without their consent.  
20° Civil Court of Santiago, Rol No. 5.839-2004479 
 
Even when during the two previous cases the National Health Institute had no 
attributions or competences to validate any right derived from patents, and 
therefore their only duty was to grant sanitary permits within the present case, 
this theory seemed to bend as the Court started recognising the practical 
consequence of such permits. 
In this case, Centro Juvenil Ages sought to void the sanitary permit granted by 
the ISP to Laboratorios Grünenthal Chilena Ltda, to commercialise Postinor-2 
(with the same abortive effects as Postinol)480 also known as the ‘after day pill.’ 
This court ruling in 2004 contradicts a similar case solved by the Court of 
Appeals and the Supreme Court in 2001. In this respect, the 20th Civil Court 
reinforced the Court of Appeals ruling in relation to the “after day pill”481 by 
revoking the sanitary permit granted for this pharmaceutical product upon 
Centro Juvenil Ages’s motion. The Court decided to safeguard the rights of the 
unborn since the pill had the same abortive effects as the aforementioned 
Postinol. Despite the fact that neither of these cases alleges a breach in the 
intellectual property legislation, it is important to draw attention to the fact that 
the sanitary permits began to be addressed as marketing approvals. The 
distribution of the Levonorgestrel pill, brought to the spotlight the ‘real’ 
implications of such a sanitary permit given that it allowed the commercialisation 
                                                        
478 Asociación Industrial de Laboratorios Farmacéuticos (ASILFA – Industrial Assotiacion of 
Pharmaceutical Laboratories) is an associationdedicated to ensure the maintenance and 
implementation of conditions that favour the development of the National Pharmaceutical 
Industry. This Association works with national and foreign laboratories. Original Text in Spanish. 
Asilfa web, Mission<www.asilfa.cl/mision.asp> 
479 20 Juzgado Civil de Santiago, Rol No. 5839-2004, Centro Juvenil Ages Vs. Laboratorios 
Grünenthal Chilena Ltda./ISP. 
480 Article 17.10.2 Free Trade Agreement US-Chile 
481 Noriga Alcala, A., ‘Análisis de la Sentencia del Tribunal Constitucional Chileno sobre el Decreto 
Supremo que Regula la Distribución de la Pildora del Día Después (Levonorgestrel 
0.75MG)’Estudios Contitucionales, Año 6, No.1, 2008 
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of a pill that in principle was contrary to the Chilean Constitution, due to its 
abortive effects.482 
 
On 28 May 2001 the Court of Appeals in Rol No. 850-2001 denied the injunction 
petitioned by five nongovernmental organisations, among them Centro Juvenil 
Ages483, against the National Health Institute and Laboratorio Médico Silesia S.A. 
for the commercialisation of the pill in question.  By this time one of the 
arguments used against the ISP was the fact that by limiting itself to verify if a 
pharmaceutical product fulfilled the sanitary legislation, at the same time they 
granted a sanitary permit to commercialise a product with unconstitutional 
effects. The argument was dismissed and the petitions did not proceed on the 
basis that no one was actually threatened since they were intending to protect the 
right of unborn children. Later on that the same year in August the Supreme 
Court acknowledged the cause and granted in Rol No. 2.186-2001 an injunction 
against the Lab and voided the Resolution No. 2.141 from the National Health 
Institute where the Postinal was authorised.  
Even after the ISP had to withdraw the approval granted for the Postinal on 24 
August2001, the same institute granted a sanitary permit for a product named 
Postinor-2, which is manufactured on the basis of Levonorgestrel and causes the 
same abortive effects.  
30th Civil Court, República de Chile, Rol No. C-6613-
2003484 
 
Within the previous cases it seems like the perception over the marketing 
approvals or sanitary permits started to shift in Chile, as they are now considered 
to actually have the power to allow the commercialisation of unwanted products 
such as the Postinal. 
This case brings to the spotlight the attributions of the ISP in light of the FTA. In 
other words, whether or not a linkage existed between the patent office and the 
ISP. Accordingly, Pfizer obtained a patent for the process to produce Postinal and 
a patent for the product per se; these were to expire in 2003 and 2016 
respectively, and consequently a marketing approval was also granted to 
commercialise the product in 2003. The conflict began in 2003 after Laboratorios 
Recalcine requested the marketing approval for “known products” before the ISP 
to commercialise a similar product to the ones already registered by Pfizer.  
The Court concluded that by granting a sanitary permit, the validity to 
commercialise a pharmaceutical product as stated within the Sanitary Code 
Article number 102485 was also granted. Thereafter the Court reached the 
conclusion that a sanitary permit is an authorisation to commercialise, and that is 
                                                        
482 Constitución Política de La República de Chile, Senado de la República de Chile, Available at: 
<www.senado.cl/prontus_senado/antialone.html?page=http://www.senado.cl/prontus_senado/sit
e/artic/20050516/pags/20050516221649.html> 
483 Corte Suprema de Chile, Rol No. 2.186-2001, ONGs’ Vs. ISP 
484 30º Juzgado Civil de Santiago, Rol No. C-6613-2003, Porzio Bozzolo Vs. M/Instituto de Salud 
(2006)  
485 Sanitary Code (Código Sanitario) Decree Nº 725/67 later on modifie by Ley Nº 20.308 
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very obvious from the fact that no distribution of pharmaceutical products can be 
carried out without the mentioned permit. 
For the first time in 2006 a Chilean Court actually recognised the existence of a 
linkage between the ISP and the INAPI. Within the present case, Pfizer Chile S.A. 
introduced before the court a motion to annul the administrative act through 
which the ISP accepted and began the process to grant a secondary sanitary 
permit for Laboratorio Recalcine to commercialise Ziprasidona.486 
Pfizer is the right holder for the patent for procedures No. 36.533 valid until 
November 2003 and the patent for products No.41.031 valid until May 2016.  
Both patents protect the procedure to obtain the Ziprasidone and the product as 
such and therefore no generics could be commercialised without Pfizer’s consent. 
In 2003 the ISP granted the sanitary permits to the company, so it seems obvious 
that the Institution had knowledge about the existence of both valid patents and 
sanitary permits by the time that Laboratorio Recalcines had requested a 
secondary sanitary permit for the same product and procedure as Pfizer. 
One of the issues to be highlighted about this ruling is the fact that the court 
never denied which were the National Health Institute’s attributions and 
competences, but also did not limit those attributions to a simple requirement 
fulfilment verification as the previous cases did. In this case the court actually 
gave a proper interpretation about the linkage and the real duties derived from 
the sanitary regulation. The question of whether or not the acts executed by this 
Service are excluded from the applicability of other norms related to patents and 
property right as such can be raised, enabling them to infringe the rights of others 
when for example they are analysing similar products. 
Data protection and the Chilean Government duties and obligations within the 
U.S.-CHILEFTA context were also taken into consideration for the ruling that 
voided Laboratorio Recalcine’s sanitary permits request. 
3° Court of Criminal Trial, República de Chile, R.U.C 
0510012831-6487 
 
Following the trend settled with the previous case, this case was one of the most 
expected cases among the Chilean legal society due to the fact that it was one of 
the few times when a pharmaceutical company sought criminal enforcement of 
intellectual property right in Chile. As with the Ziprasidona case, this case seeks 
to clarify the duties of ISP in regard to the linkage.488 
Laboratorio Sanofi Aventis sought a court patent infringement in the criminal 
court for the import, commercialisation and distribution of a pharmaceutical 
                                                        
486 I Corte de Apelaciones de Santiago, Rol. 3747-2002, Pfizer Chile S.A. Vs. Laboratorios Recalcine 
S.A. and the ISP (2002) 
487 3° Tribunal de Juicio Oral en lo Penal de Santiago, R.U.C. No. 0510012831-6, Laboratorios 
Sanofi Aventis Chile Vs. Jaime Kattan (Laboratorios Royal Pharma) 
488 Read further in “LABORATORIOS NACIONALES VS. INTERNACIONALES / Presunta copia de 
medicamento reabre la discusión. Propiedad intelectual: farmacéuticas a la espera de fallo que 
sentará precedente” press Article in El Mercurio Journal from 3 September 2007. 
<diario.elmercurio.cl/detalle/index.asp?id={bc1e145d-5f5d-4d4c-a535-88773b61d14c}>accessed 
01 September 2009 
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product name “ISKIMIL” from Laboratorios Royal Pharma, which is a generic 
version of the original product manufactured by the plaintiff.  
The Chilean court condemns the patent infringement for the production of the 
generic version without the patent owners consent. This was a challenging case 
that also caused great expectations as Sanofi Aventis’s legal representatives sued 
Royal Pharma’s legal representatives and general manager. Petitioning to fine 
Jaime Ramirez Kattan for a sum of 100 monthly tax units (UTM) which if 
calculated in Chilean pesos is worth around 33 million pesos or 50,000 Euros. 
The court reached their decision after finding the defendant guilty of a charge 
according to the Chilean Penal Code Article 15 and Law No.19.039 Article 52.489 
The reason for suing Royal Pharma’s representative was the fact that he was 
considered to be carrying out the imports and commercialisation in bad faith,490 
since Sanofi Aventis is the patent holder for the product PLAVIX491 which is the 
original version. Although the court recognised ISP certain liability on the 
sanitary permit issue it did not go into the matter very deeply, declaring more or 
less like an issue out of its competences. The trial was full of technicalities 
regarding the procedure to manufacture the PLAVIX, and several experts within 
the field were called to the stand to help the court in solving the issue.  
4.2.3. Linkage overall assessment 
Since Chile ratified the Free Trade Agreement with the United States several 
challenges regarding intellectual property rights have risen; especially those 
related to pharmaceutical patents due to the importance to provide fair access to 
medicines. But the Chilean Administration began working on promoting better 
access to health care and medicines through Plan AUGE, that will be analysed 
below, prior the U.S.-Chile FTA. Plan AUGE in brief, is a dynamic system that 
grants access to opportune and effective health care and according to some 
studies only one of the pharmaceutical product used is protected by a patent. 
Therefore, asserting that patents restrain access to medicines in developing 
countries in the case of Chile could be proven wrong, since Chile is also one of the 
countries in Latin America with the lowest average price of medicines. 
Thus far, the “Linkage” and the marketing approvals seem to challenge for 
nations, especially those obliged to these kinds of procedures, due to their duties 
as signatories of “TRIPS Plus Agreements”, but in the case of Chile the challenge 
                                                        
489 Law Nº 19.039,  “Article 52:  will be sentenced to pay a fine of twenty five thousand mounthly 
tax units all those: a) who maliciously manufacture, use, offers or introduce into the market a 
patented invention, or those who import or withhold the patented element with commercial 
purposes” original text in Spanish, translation by the author 
490 Código Penal de la República de Chile, “Article 15: The authors of a crime are: 1 those who take 
part in the execution of an act, whether is through a direct and immediate involvement, or by 
impeding efforts to prevent or avoid the act” Original text in Spanish, translation by the author. In 
this case the court found that the general manager was directly responsible for the import, 
distributions and commercialisation of the product since he was the person authorising such 
activities 
491 Quinta Sala, I Corte de Apelaciones de Santiago, Rol No.3747-2002, Pfizer Chile S.A. Vs. 
Laboratorio Recalcine S.A./ Instituto Nacional de Salud (Ziprasidona case). Plavix is the trade name 
under which Sanofi commercialises Clopidogrel, which is an antiplatelet agent to inhibit blood clots 
in coronary artery disease, peripheral vascular disease and cerebrovascular disease 
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or misconceptions about the marketing approval dates from a time even before 
the agreement was signed as the analysed cases pointed out.492 
Moreover, the Chilean sanitary legislation, as reviewed, seems to be using the 
terms of sanitary permits as synonyms of marketing approvals, and despite the 
courts contradictions and refusal to acknowledge those permits as marketing 
approvals, in practice there is no other possible way to assess them differently 
than being “marketing approvals”. 
The issue of the linkage is still to be solved by the Chilean legislators, but 
nevertheless the feasible truth about the sanitary permits nowadays seems to be 
more plausible than a few years ago.  What still raises questions is why the ISP 
reformed the legislation on the sanitary permits proceeding and concept after the 
FTA came in force. And even when the valid regulation refers to sanitary permits, 
the undeniable fact is that no pharmaceutical product shall be sold without this 
permit.  
4.3. Test Data Protection of Non-Disclosed Information 
 
It is not uncommon to find that data protection restrains access to medicines 
since the competition will be restricted and generic products will not make it into 
the market before a period of five years from the registration, in the case of a FTA. 
Scholars have pointed out that these provisions are designed to require generic 
producers to render their own clinical trial data instead of relying on the already 
provided data by the brand name producer.493 Thereafter, market competition 
will not only be delayed due data protection but also because of the exclusivity 
granted to the originator product, and because the costs of repeating clinical trials 
to verify safety and quality to satisfy the regulatory requirements would be very 
costly and most likely prohibitive enough so as to deter generic competition.494 
Before discussing further the relevant arguments and the implications of data 
protection Article 39 TRIPS and Article 17.10.2 U.S.-Chile FTA shall be assessed 
to understand the main difference between both regulations and the challenges 
derived from them. 
“TRIPS, Article 39.3: Members, when requiring, as a condition of approving the 
marketing of pharmaceutical … products which utilize new chemical entities, the 
submission of undisclosed test or other data, the origination of which involves a 
considerable effort, shall protect such data against unfair commercial use. In 
addition, Members shall protect such data against disclosure, except where 
                                                        
492 Chile, Instituto de Salud Pública de la Repúlica de Chile, Circular No. 14, Santiago 28 de 
Noviembre de 2001. 
493 Sell, S.K., ‘TRIPS-PLUS Free Trade Agreements and Access to Medicines’ (2007) 28 Liverpool 
Law Review, at 45-75. 
494 Clift, C., ‘Data Protection and Data Exclusivity in Pharmaceuticals and Agrochemicals’ in 
Douglass, P., et al. (eds.) Intellectual Property Management in Health and Agricultural 
Innovation: A Handbook of Best Practices (
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necessary to protect the public, or unless steps are taken to ensure that the data 
are protected against unfair commercial use.”495 
U.S. – Chile FTA, Article 17.10.1: If a Party requires the submission of undisclosed 
information concerning the safety and efficacy of a pharmaceutical … product which 
utilizes a new chemical entity, which product has not been previously approved, to grant a 
marketing approval or sanitary permit for such product, the Party shall not permit third 
parties not having the consent of the person providing the information to market a 
product based on this new chemical entity, on the basis of the approval granted to the 
party submitting such information. A Party shall maintain this prohibition for a period of 
at least five years from the date of approval for a pharmaceutical product ...Each Party 
shall protect such information against disclosure except where necessary to protect the 
public.496 
Article 39.3 TRIPS already foresees Member states’ duty to protect undisclosed 
test or other data, as the wording denoted within the article, when needed to fulfil 
regulatory requirements at the moment of a marketing approval registration. The 
duty to protect this kind of data against unfair commercial use or competition is 
assessed by the TRIPS in the first place and then by the FTA. The U.S. – Chile 
FTA among other clauses incorporates the need to protect this data for a period of 
5 years, but it must also be highlighted that as denoted from the article itself the 
wording and duties for the party are much more defined than in the TRIPS 
Agreement.   
Both articles take into consideration the protection of data for those products that 
utilise a new chemical entity, and the exception for protecting such data are those 
cases when it is necessary to protect the public. A question arises though about 
the mention of ‘protection of the public’: If this brief and unelaborated mention 
enough to address public health emergencies, to enact a compulsory licence even 
if breaching the data protection clause or to allow parallel imports within the 
country to satisfy the local market needs?497 
Some scholars point out that the data exclusivity right is a much stronger right 
than the intellectual property right because this regime does not possess 
flexibilities that allow governments to adapt their legislation accordingly with 
their needs.498 Adding to the discussion, data exclusivity may act as a barrier for 
compulsory licences since this could prevent a compulsory licence on an 
equivalent product to the one patented or with data exclusivity. A part of the 
doctrine disputes the differences between data protection and data exclusivity, 
pointing out the first one as the protection of trade secrets and the second one as 
the right granted to the originator of a product which uses a new chemical entity 
that is not necessarily protected by a patent. 
The problem posed by data protection, either by TRIPS or the FTA, has also to do 
with the implementation of such a regulation. In the Chilean case, it is known 
                                                        
495 Article 39 (3) from TRIPS Agreement 
496 Govierno de la República de Chile, Decreto Nº 312 del 01 de Diciembre de 2003, Publicado en 
Diario Oficial el 31 de Diciembre de 2003 
<www.bcn.cl/lc/tinterna/tratados_pdf/tratado_vally072.pdf> English version 
<www.ustr.gov/sites/default/files/uploads/agreements/fta/chile/asset_upload_file941_4019.pdf> 
accessed 14 September 2013 
497 Parallel imports under the TRIPS Agreement are allowed as long as they are to satisfy local 
market needs, as highlighted by Article 31 (f). 
498 Clift, C., ‘Data Protection and Data Exclusivity’ at 434. 
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that PhRMA has been lobbying to enforce a data protection regime that portrays 
an efficient system against unfair competition.  
Data exclusivity seems to be an issue in Chile:: during the same Special Senate 
Session where an analysis about the pharmaceutical industry in Chile was carried 
out in 2009, the illegality of Article 8 from the Decreto Supremo Nº 153 A 
circulated during 2007. The aforementioned Decree is nowhere to be found and 
on the Library of Congress database Decree 153/2005 remains in force.  
4.3.1. Bolar Exemption 
The Bolar exemption is dealt with in Article 17.9.4 of the FTAA. This provision, as 
some authors suggest, looks forward by preparing the entrance of generic 
pharmaceuticals as soon as the patent expires.  
This issue must be linked to the fact that, allegedly, in Chile the manufacture of 
copied medicines from patented pharmaceuticals represents a 45% share of 
sales499 in the market. The Chilean President at the moment of signing the treaty 
ratified the administration’s position on this issue, highlighting that within the 
context of the treaty there are mechanisms available to allow third parties the use 
of protected data with the purpose to further commercialise those products once 
the patent has expired.500 Thereafter, even when the President settled the 
government’s position on the matter, the fact that the internal legislation allows 
the use by third parties of protected data before the patent has expired might be 
seen by their trading party as an alarming situation leading to a breach in the 
treaty.  
Within the context of the agreement there are two articles dealing with the extra 
time given to patent owners due to unreasonable delays when granting a patent. 
These articles are 17.9.6 and 17.10.2, whereas the first one establishes the general 
grounds when making available the option of the term extension, the second only 
regards pharmaceutical products.  
4.4. Chilean Health Care System 
The right to health care in Chile is given by Article 19 part 9° where the State gives 
citizens the opportunity to access health care through private or public means.501 
                                                        
499 Hartwig, G., Chilean Pharmaceutical & Medical Devices Market Overview 2009 (OSEC + 
Business Network Switzerland: 2009) 1-128<www.s-
ge.com/sites/default/files/bbf_chile_pharmaceutical_market_2009.pdf> accessed 14 September 
2013 
500 Cousiño, J.M., ‘Tratados de Libre Comercio.’  Also, ‘Bachelet dijo que TLC con Estados Unidos 
no le quitó soberanía a Chile’ El País Digital, 6 November 2006 
<historico.elpais.com.uy/06/11/06/pnacio_246032.asp>accessed 10 March 2013. 
See Carey, G., ‘La Protección de Exclusividad de Datos’ in La Propierdad Intelectual en Chile y 
Tratado de Libre Comercio EE.UU, Serie de Estudios Técnicos AmCham, Documento Nro. 
2<www.amchamchile.cl/sites/default/files/SET%20documento%202%20actualizado.pdf> 
accessed 10 March 2013 
501 Constitution of Chile, Article 19 part 9º: “- The right to protection of health. The State protects 
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This part of the chapter focuses on public health policy in Chile, assessing the 
main health programmes and provisions related to both access to medicines and 
health services in Chile.  
 
The current health care system is constituted by compulsory social health care 
insurance that is granted by both public and/or private health care providers in 
accord with the Chilean public health legislation. The Plan de Salud con Garantías 
Explícitas – GES (Health Plan with Explicit Benefits) is the one defining the 
guaranties that are to be granted within the social insurance scheme. GES is the 
reformed version from Plan AUGE- Acceso Universal de Garantía Explícitas 
(Universal Access with Explicit Benefits Plan), that was nothing more than a 
universal social health care system, as will be explained below.502 
History reveals the different stages the Chilean health care system has undergone 
that were required for it to evolve to the point where it is nowadays. Furthermore, 
to understand the relation within the pharmaceutical patents and the access to 
medicines in Chile, an analysis will be carried out to understand the public health 
care system. 
4.4.1. Chilean Health Care System before Plan AUGE 
Before President Lagos implemented the Plan AUGE in 2004, the Chilean health 
care system had a different structure. The previous system was based on a 
separation between blue and white-collar workers. At the end of 1952 the Servicio 
Nacional de Salud - SNSS (National Health care Service) was created in Chile 
through the Ministerio de Salud (Ministry of Health). This new institution would 
follow the philosophy, objectives and organisation used by Great Britain when it 
created the British National Health Service to provide medical attention four 
years earlier.503 At a first glance the health care system in Chile separated blue-
collar workers and indigents received medical attention through the National 
Health Service while the white-collar workers and civil servants received medical 
attention through the Employees Medical Services, also known as SEMERNA. 
While the State bared the entire weight of the health care system during the 
                                                                                                                                                        
and rehabilitation of the individual. The coordination and control of activities related to health shall 
likewise rest with the State. It is the prime duty of the State to guarantee health assistance, whether 
undertaken by public or private institutions, in accordance with the form and conditions set forth in 
the law, which may establish compulsory health quotations. Each person shall have the right to 
choose, the health system he wishes to join, either State or private- controlled.” Original text in 
Spanish, translation in English <confinder.richmond.edu/admin/docs/Chile.pdf>accessed 10 
March 2013 
502 Bastías, G.. and Valdivia, G., ‘Reforma de Salud en Chile; El Plan AUGE ó Régimen de Garantías 
Explícitas en Salud (GES). Su Origen y Evolución’ (2007) 32 Boletín Escuela de Medicina U.C. 
Pontificia Universidad Católica de Chile 2,51-58 
503 Cerededa T., L.. and Hoffmeister, L., ‘La Reforma de Salud en Chile: Cambios Constitucionales, 
Logros y Dificultades en su Implementación’ in The Center for Migration and Development, 
Working Paper Series #08-05e, (Princeton University, December 2008) 
<www.princeton.edu/cmd/working-papers/idlac08/wp0805e.pdf> accessed 10 March 2013 
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Allende period, the Pinochet regime adopted a more market-oriented strategy 
where the health care would be framed under the idea of the subsidiary state.504 
The need to expand the health care system to every citizen during the 1960s led 
Presidents Eduardo Frei and Salvador Allende to carry out massive expansion of 
the health care system to forgotten sectors such as the rural and the self-
employed urban workers. By late 1960 the health care system covered 71.9% of 
the population, and by the end of 1970 the system granted health care protection 
to 80% of the population.505 
4.4.2. Health Care Reform: 1973-1989 
The Pinochet regime (1973-1989) was characterised among many other things -as 
highlighted at the beginning of the chapter- for introducing the idea of a 
subsidiary state, which aimed to amend the State provisions of social services and 
regulatory activities, transferring those to individuals and private health care 
providers.506 These private health care providers were to be regrouped in 1981 
under the Instituto de Salud Previsional – ISAPREs507 (Private Health Insurance 
Funds) and offered medical insurances and workman’s compensation packages. 
Usually these entities required a 7% payroll contribution plus the 2 or 3% of 
additional premium, which was agreed between the ISAPRE and the beneficiary 
depending on the size of the package offered by the ISAPREs.508 
As far as public health care policies go, these have never been separated from the 
political situation governing a country. It is a well-known fact that the Pinochet 
regime in Chile was authoritarian. During the Pinochet regime and the regime’s 
market oriented mechanisms, the privatisation era began within the health care 
sector, as the regime believed that the country should have less involvement in 
that area. None the less, the past leaders of Chile all have seen the necessity in 
developing a strong health system and to a certain extent during the past 50 years 
health became a public matter and therefore both dictatorial and democratic 
governments have sought health improvements for Chilean citizens.509 
Moreover, the privatisation of the Chilean health care system in 1981 meant that 
the solidarity concept used when defining the system changed from using three 
financing sources (state, employees and workers) to a private and mixed model. 
In this new model, those who would prefer the private health care system would 
                                                        
504 Borzutzky Yozmot, S., ‘Health in Chile: is the Government Doing Everything it can to Achieve 
Social Justice?’ (September 2008) 27 Medicine and Law, at 645-659 
505 Borzutzky, S., ‘Social Security and Health Policies in Latin America: The Changing role of the 
State and the Private Sector’(1993)28 Latin American Research Review 2,at 246-256 
506 Borzutzky, S., ‘Health in Chile’ at 646 
507 ISAPRESS are private health services providers created in 1981 with the Healthcare reform. This 
Institution receives the mandatory health fee paid by workers from those who choose to use the 
private healthcare services. Information available in Spanish at: <www.ISAPRESs.cl> 
508 Cartin, B., ‘The Effectiveness of the Reform’ in Cruz-Saco, M.A., andMesa-Lago, C., (Eds.)Do 
Options Exist? The Reform of Pentions and Healthcare systems in Latin America,(Pittsbourg 
University Press, 1999) at 210 quoted by Silvia Borzutzky in “Health in Chile: is the Government 
Doing Everything it Can to Achieve Social Justice?” in 27 Med. & L. 645, September 2008 
509 Román A, O., et. Al. ‘Una mirada crítica en torno al plan AUGE. Algunos aspectos generales y 
valóricos’ (2008) 136 Revista Médica de Chile, 1599- 1603 
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pay the mandatory health fee directly to ISAPREs, and those who would not earn 
that much would make use of the public health care system. This public health 
care system was regrouped under the Fondo Nacional de Sauld – National Health 
Fund (FONASA).  Apparently, by then there was a mix between who were the 
FONASA beneficiaries as there also was a small differentiation among workers 
and employees. This last fact lead to a legal reform where workers and employees 
would benefit from the use of the public health care system as long as they would 
contribute to the system according to their salary level;; the new law allowing 
both workers and employees to enjoy the public system was Ley Nº 18.469.510 
The health care reform did not only restructure the way the health care system 
was to work in Chile, in the sense of service providers and who would have access 
to which kind of health care. The reform also implied changes within the 
administrative and efficiency functions. The administrative part had to do with 
the decentralisation of the 26 autonomous services provided by the Sistema 
Nacional de Servicios de Salud (SNSS) created in 1952. The control and legislative 
responsibility would remain as part of the Ministry of Health’s duties, the 
hospitals’ administration would now be the responsibility of those Servicios de 
Salud and the primary health care establishments would go under the 
municipalities’ administrations.511 
Regarding the impact on efficiency due to the administrative structure explained 
above, it is important to highlight that the budgeting structure was also handled 
in a different manner. Previous to the decentralisation of the health care system, 
the budget was assigned according to the historic or past year’s expenditure 
records. The new system was deemed to be more direct, canalising hospitals’ 
budgets according to invoices for used services, and health care provided at a 
municipality level was calculated on the basis of the invoices for used services 
within the municipal level to pay for doctors’ offices.512 
4.4.3. Health Care Reform: 1990-2002 (two democratic 
governments) 
While the previous health care reform focused on the private health care sector, 
the new health care reform proposed by President Allan Aylwin, during a period 
also known as Primer Gobierno de Concertación (The First Consultation 
Government), focused on rescuing the public health care system, which at the 
time was considered to be neglected by the previous government. Among the 
problems found within the system, was the lack of financial sources to cover costs 
of treatment and to provide the services as such. Therefore, during this period a 
tax reform was also necessary to increase the public health care budget. After 
raising general taxes the health care budget increased 33% between 1991-1992, 
thus allowing salaries, operational recourses and pharmaceutical expenditures to 
be improved.513 
                                                        
510 Oyarzo, C., ‘La Mezcla Público – Privada: una Reforma Pendiente en el Sector Salud’ (Invierno 
1994) Estudios Económicos 55,143 – 170 
511 Cerededa , L., et al. ‘La Reforma de Salud en Chile’ at 3 
512Idem at 11 
513 Oyarzo, C., ‘La Mezcla Público – Privada’ at 12 
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Accordingly, the gross domestic product increased from 0, 7% to 1, 3% during the 
year 1989 and between 1996 and 2003 it was up 6,1%. This was perceived as a 
beneficial fact, as in those years the state’s health expenditure increased by 140%, 
and this was also financed by the tax reform.514 
Even though the first democratic period emphasised rescuing the public health 
care sector, during the second period in 1994 the ISAPREs continued subscribing 
more affiliates due to dissatisfaction with the performance of the public sector.515 
Initially, those who could afford private health care insurance chose to pay the 
’ISAPRE’s mandatory contribution and its co-payments, but those who were not 
financially capable had to receive medical attention from the public sector. The 
new democratic era denoted efforts and interest in balancing the health care 
system and therefore worked towards providing better access to primary health 
care within the public system. Moreover, in 1994 Chile introduced an innovative 
Family Health Plan (Plan de Salud Familiar), which was intended to provide a 
basic package of health interventions in accord with the demographic and 
epidemiological variations. 
During the previous political regime, the health care sector was decentralised and 
provided a different structure, and therefore a new funding and payment 
structure needed to be redesigned. Even when the primary health care was the 
focus of this new period, the government implemented a “diagnosis related 
payment” (PAD) aiming to define a set of standard interventions associated with 
a determined diagnosis and the cost would be estimated as an average, making 
the services less expensive for secondary and tertiary health care. Another 
important step within the period was to eliminate the mixed subsidiaries for the 
health care sector that had existed in the past.516 
Both democratic terms aimed at restructuring the health care sector, but the 
second term worked towards regaining the trust of health care beneficiaries 
within the public sector. Hence, an important legal reform in 1999 was needed to 
redefine FONASA’s mission by transforming it into a public health insurer, 
providing that this institution would be responsible for raising its own funds by 
collecting fiscal contributions, co-payments and national insurance contributions 
from its beneficiaries to pay for health care service providers.517 
Chilean history denotes that there were three important health care reforms 
leading to the new Plan AUGE - GES health care system. Their main 
characteristics were: (a) the 1952 health care reform nationalised the Chilean 
health care system, defining financial matters and designating the service 
providers; (b) the Neoliberal or Pinochet reform in 1981 was based on market 
freedom and health care privatisation; and c) the 1990-2003 period was 
characterised by rescuing the public sector and turning it into a public health care 
insurance by granting access to health care to every Chilean citizen. 
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4.4.4. Plan AUGE - GES 2002-2008 
The right to health and the principles of equal access to health, efficiency and 
social participation inspired the new health care reform in 2002. These principles 
were also taken into consideration by past rules, but the implementation of the 
new health care system that was being drawn required the development of an 
innovative legal base.  
As mentioned above, defining issues such as funding, structure, regulatory 
entities, rights and duties and the health care system itself were of great 
importance to the success of implementing this new reform. Moreover, five 
relevant legal projects within the reform have been identified, namely, the laws 
defining patient’s rights and duties, funding sources and methods, the health and 
management authority, the ISAPRE’s law and the regime for health guaranties, 
also know as GES. 
Each of these projects had a specific purpose: (a) Patient rights and duties: this 
law defined and regulated legal remedies and measures taken against health 
providers, either public or private; (b) Funding sources: this law estimated to 
increase value added taxes (VAT) by 1% to support the health care system and the 
creation of new health care tax destined to finance the Régimen con Garantías 
Explícitas en Salud – GES (Regime with explicit guaranties in Heal) for all of 
those FONASA beneficiaries; (c) Health management authority: intended to 
strengthen the health care authority by delimitating functions and duties. Leaving 
regulatory and fiscal matters to the Ministry of Health, and the management and 
administrative matters were left for the Red Asistencial (assistance network; (d) 
ISAPRE’s Law: foresaw the creation of a surveillance and control entity for those 
health care service providers, taking care of health care plans prices, service 
catalogues and information; and (e) GES: establishes a mandatory health care 
plan for FONASA and ISAPRES.518 
After introducing the main legal projects supporting the health care reforms, Plan 
AUGE requires further explanation and why it is considered to be one of the most 
innovative plans implemented in Chile and perhaps in Latin America regarding 
health care. AUGE stands for Acceso Universal con Garantías Explícitas 
(Universal Access with Explicit Guaranties) and the Explicit Guaranties in Health 
are known as GES. Within the lines above, GES was referred to the regime for 
health guaranties as well as for the explicit guaranties in health, which given by 
Law No. 19.966, Article 1 are the same. This Law defines GES as the legal 
instrument designed to regulate the Health care services regime, which at the 
same time is constituted by a sum of explicit guaranties destined to foresee 
access, quality, financial protection and opportunity. 519 
Accordingly, in 2005 Plan AUGE started providing treatment for 25 basic 
diseases, which included the different diagnoses and a strict use of protocols for 
practitioners when treating those diseases520. In all, 16 diseases were added to the 
                                                        
518 Bastías, G., and Valdivia, G., ‘Reforma de Salud en Chile; El Plan AUGE’ at 52 
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disease list in 2006, another 16 in 2007521 and seven more were added as a pilot 
plan during 2008,522meaning there were 64 diseases covered by GES. The goal of 
Chile is to provide proper care for 80 diseases that afflict the Chilean population. 
Integral maternity care, including pre and postnatal subsidy, hypertension, 
diabetes, cancer and HIV/AIDS are among the conditions treated within the Plan 
AUGE.  
The Chilean Government committed to providing its nationals with four explicit 
guaranties when protecting the 64 current treated diseases in Chile since the early 
democracy days. These explicit guaranties are defined as: (a) Explicit guarantee 
of access: is the obligation given by law to FONASA and ISAPREs to ensure the 
benefits are granted to all the beneficiaries; (b) Explicit guarantee of quality: 
understood as the duty to provide guaranteed health care by a registered or 
accredited provider; (c) Explicit guarantee of opportunity: defined as the need to 
comply with a deadline to provide care for the health benefits granted by law; and 
(d) Explicit guarantee of financial protection: regarding the members or 
beneficiaries’ duty to fulfil their contribution, payment or co-payment due health 
care fees and or group of benefits ensured.523 
Plan AUGE –GES, covers at this point 56 diseases and seven more are being 
implemented in a pilot plan. Patients and beneficiaries will pay a deductible of 
20% from the total attention cost and patients with no means of support will have 
access free of charge. If patients would like to receive full coverage for the 
treatment of those highly costly diseases then they can subscribe to a 
complementary insurance from either ISAPRE or FONASA. The private health 
care insurance requires further co-payments whilst the public one does not. 
It should be mentioned that Ley Nº 18.469524 classified Chilean beneficiaries 
within the Article 160, ante 29, in four groups according to their income 
level.525The main idea with this structure was to define fair deductibles and co-
                                                        
521 Decreto N° 44, Publicado en Diario Oficial de 31.01.2007, Minsterio de Salud, Garantía 
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dependants do not exceed from two. In case of having more than two dependants the beneficiary 
will be classified within the Group C.”  The minimum wage at the moment in Chile is $165.000,00 
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payments to health care providers due health care attention. The groups in 
question are A, B, C and D. Whereas group A and B receive total free health care 
attention, groups C and D generally will have to cover 20% of the total price for 
the medical care provided to them. The exception to this rule is when it comes to 
dental health care attention, in which case Group B will pay 30% of the total 
value, Group C 50% and Group D 80%.526 
The basic and mandatory premium for health care is 7%, thus this entitles citizens 
to either make use of the system through the Modalidad de Atención Institucional 
–MAI (Institutional Attention Pattern) or the Modalidad de Libre Elección – 
MLE (Free Choosing Pattern).  These two patterns are differentiated by the fact 
that the MLE is only accessible to those within groups B, C and D as previously 
mentioned; and because if someone needs medical attention under the MAI he or 
she will receive medical attention only during the available times designated by 
the hospital, whereas the MLE allows patients to be treated by a chosen attendant 
at the time that suits the patient instead of having to wait until there is an 
available time.527 Of course, in case of medical emergency the Chileans are treated 
immediately.   
Accordingly, after the primary health care attention there are complementary 
benefits within the system to ensure higher coverage and less money expenditure 
on the behalf of the Chileans. These plans existed before Plan AUGE’s 
implementation, namely the FONASA Catastrophic insurance (Seguro 
Catastrófico de FONASA), the Elderly Programme (Programa Adulto Mayor), and 
the Opportunity Attention Programme (Programa Oportunidad en la atención). 
These programmes should fasten up response times and coverage for the 
treatment of certain diseases.  
Both FONASA and ISAPRES offer extra coverage for what are called catastrophic 
diseases, which are generally considered as those forcing individuals to pay an 
equivalent to 40% or more from the family income to overcome a health care 
treatment thereafter obstructing the treatment finalisation due to medical and 
pharmaceuticals costs.528 The difference between the insurance offered by 
ISAPREs and FONASA is that the ISAPRES one is not only called Cobertura 
Adicional para Enfermedades Castastróficas – CAEC (Additional Coverage for 
Catastrophic Diseases), but also requires extra payment on the beneficiary’s 
behalf whilst the FONASA insurance seems to be free of charge; and the groups 
allowed to take the extra coverage are B, C and D as they also initially chose to be 
served under the MLE pattern. 
One important remark about the MLE is that it allows affiliates to choose from 
those clinics affiliated to FONASA or those with collaboration agreements with 
FONASA, otherwise the system would work as normal private health care 
insurance.  
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4.4.5. Importance and Social Impact 
Plan AUGE - GES was a great improvement for Chile’s health care system, but it 
also seemed to have some critique on behalf of opposing governmental parties as 
in practice financing the system did not seem possible and therefore new 
measurements were also to be considered for the success of the programme.  The 
new financial means were to be guaranteed by new taxes on alcohol, tobacco, 
gasoline as well as raising the VAT and the creation of a solidarity fund to finance 
the health care system. This solidarity fund was to take a 0.6% off from the 7% 
health tax paid to ISAPREs to finance the new maternity fund, which was to pay 
pre and post natal subsidies.529 
Nowadays, and according with a FONASA report, the health care sector in Chile is 
financed primarily by fiscal contributions equivalent to 32,1% in 2004, social 
security compulsory contributions equivalent to 37,5% and the so-called fair 
pocket expenditure530 equivalent to 30,4%.531 
Besides finding out which are the funding sources for Plan AUGE – GES, what 
matters is to demonstrate that countries such as Chile have been able to achieve 
an extensive health care protection plan that includes detection and treatment for 
cancer, asthma and HIV among many other diseases at a very low cost or at no 
cost whatsoever for patients.  The Decreto Nº 44 of 2007 in its Article 2º defines 
what stands for benefits among some other relevant definitions:  benefits stands 
for health actions, technology or medicine units, exams, procedures and most 
importantly entails the distribution of medicines to beneficiaries as long as they 
belong to those 56 or 62 pathologies covered by GES.532 
Reducing the pocket expenditure of medicines is another important achievement 
of the health care reform in Chile. This kind of expenditure is due to purchases of 
pharmaceuticals by individuals at their own expense when the AGES-GES does 
not cover those medicines.    
The Chilean government with the Plan AUGE looked forward to granting 
adequate access to health care independently of its citizens’ payment 
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capabilities.533 Moreover, due to the financial protection guarantee foreseen in 
GES a Chilean can rely on the fact that he or she will not pay more than the 20% 
deductible due to medical services or medicines; this is with the exception of 
those citizens who agreed upon an extra coverage with an ISAPRE or those 
FONASA citizens with coverage provided by any of the plans offered by that 
institution. The health care plans are measured or estimated in pesos or UF – 
unidad de fomento (unit of account), and the unit of account is used to express 
prices and is adjusted according to inflation.534 According with the data provided 
by the Chilean Central Back, the unit of account is equivalent to $20, 974.19 
Chilean pesos and there is a minimum wage of $165,000 Chilean pesos as 
denoted in footnote 27. 
Within the financial guarantee, not only the deductibles but also the fact that a 
worker is protected 100% when they need to take days off from employment due 
to illness could also be taken into consideration. Meaning, that a worker will be 
subsidised or continue to be compensated as if he will be attending his job 
regularly. The Chilean health care system or its providers will write a Licencia 
Medica Curativa – LMN (sick leave) to the ill worker, and this will also be 
registered in a National Formulary of LMC. This LMN is used as well to prevent 
frauds in the health care system in the sense of workers taking leave of absence 
with no real cause and been compensated by their job; the permit also allows 
authorities to keep the relevant data, such as medicines subscribed, days of sick 
leave and treatment to follow.535 
Another point against AUGE – GES is that since both the private and public 
health care system are bound to cover the diseases or health care problems, the 
state might be assuming higher costs due to aging beneficiaries changing from 
ISAPRES to FONASA when they are not able to pay for the higher premiums and 
co-payments imposed by the “private insurer” to cover catastrophic illnesses536. 
FONASA seems to be registering 40% of poor or unable to contribute 
beneficiaries, which eventually may compromise health care quality and 
efficiency. 
Despite the observations on GES and the Chilean health care system, up to 2010 
the perception over the reform seems to be positive. According to WHS statistics, 
by 2006 the Chilean Government was spending 5,2% of its GDP on health care, 
about 360$ on every citizen and even though the average health expenditure is 
8,7%, Chile managed to increase life expectancy to 77 years old and reduce infant 
mortality significantly after AUGE GES was implemented.537 The data offered by 
                                                        
533 Arrau C., F., ‘Conceptualizacion del Plan de Acceso Universal con Garantías Explísitas (AUGE), 
eje de la Actual Reforma a la Salud’ in Serie de Estudios de Anticipación/CEA/BCN, Año I N 1, Abril 
2002 
534 Shiller, R., ‘Indexed Units of Account: theory and Assessment of Historical Experience’ in 
Documento de Trabajo del Banco Central de Chile, Nº 28, April 1998 
535 Mesa, F., et al, ‘Fraudes a los sistemas de Salud en Chile: un modelo para su detección’ (2009)1 
Revista Panamericana de Salud Pública 25, at 56 – 61 
536 Bes, M., ‘Public tensions, private woes in Chile’ (2008) 86 Bulletin of the World 
HealthOrganization11, < www.who.int/bulletin/volumes/86/11/en/index.html> accessed 14 
September 2013 
537 Organización Mundial de la Salud, Estadísticas Mundiales 2009, in Catálogo de la Biblioteca de 
la OMS. <www.who.int/whosis/whostat/ES_WHS09_Full.pdf> accessed 14 September 2013 
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the report highlights that Chile’s GDP expenditure in health care is around 15 
times lower than the health care expenditure of the United States of America. 
Chilean society counts with a dual system that aims to complement both the 
private and public health care systems through an elaborate insurance system. 
Some would argue that the State is forcing ISAPRES to compete against FONASA 
so as to offer better incentives and therefore gain more affiliates. Apparently the 
public health care insurance system seems by far more appealing to those with a 
higher risk and those with less resources; and the private due to better quality 
and efficiency turns out to be more appealing for those with better income. A 
consumer behaviour study highlighted how some would make use of both the 
private and the public health care system: people would purchase the ambulatory 
insurance from the ISAPRE while at the same time signing in for the catastrophic 
insurance offered by FONASA, which is free of charge.538 
Having mentioned the health care system structure, it must also be mentioned 
that the ISAPRES has its own duality, as it can either be an open or a closed 
system. This means that the open ISAPRES receives the mandatory contribution 
of every worker who chooses to do so, but only eight539 ISAPRES providers are 
registered to receive the mandatory contribution and provide the “private” health 
care insurance. Whereas, the closed ISAPRES will only provide health care 
attention to employees of companies affiliated to that specific ISAPRE. These 
employees generally have better incomes and they can afford the regular private 
health care insurance system. 
The ISAPRE is understood as the bodies relieving the State from those functions 
that can be carried out by private parties and that at the same time operate on a 
competition system within the private health care insurance sector.540 The fact 
that the ISAPRE needs to offer competitive health care plans according to some 
studies has become a very challenging task, as competing against the public 
health care system where a beneficiary or affiliate is able to receive total coverage 
for those catastrophic diseases free of charge (FONASA) turns out to be by far 
more attractive than having to pay an extra fee due health care plans. 
Accordingly, the product offered by ISAPRE is structured in two parts: the first 
one covers the GES guaranties, and the second is the Plan de Salud 
Complementario (Complementary Health care Plan) of which the benefits to the 
user cannot be lesser than those provided by FONASA within the MLE pattern 
highlighted above and the price of which shall be determined by depending on the 
beneficiary’s age, gender and quotation group.541 
                                                        
538 Sapelli, C., et al., ‘The Mandatory Insurance System in Chile: Explaining the Choice between 
Public and Private Insurance’ (2001) 1 International Journal of Healthcare Finance and 
Economics2, at 97- 110 
539 An interesting fact is that isapreschile.cl registers only eight accredited ISAPRES ant the Chilean 
Superintendence registers 14 ISAPRES providers. By 2009, further agreements with healthcare 
providers or insurers were reached 
540 Superintendencia de ISAPRE, ¿Cuáles son los beneficios del Sistema Isapre?, in Guía del 
Usuario, 2001. <alegislativo.bcn.cl/alegislativo/pdf/cat/docs/2981-11/200.pdf> accessed 14 
September 2013 
541 Sanchéz, M., et al., Producto y Precios en el Sistema ISAPRE (Septiembre 2001) Documento de 
Trabajo – Departamento de Estudios y Desarrollo, Superintendencia de Salud 
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If the statistics from the World Health Report in 2000 on Health Systems and 
WHO statistics on performances, which were provided previously, are compared 
it is possible to find how the life expectancy has changed in Chile from 1997 to 
2006. In 1997 the life expectancy was 66 years and by 2006 it had increased to 77 
years. The GPD expenditure on health decreased from 6.1% in 1997 to 5,2% in 
2006.542 This WHO report from 2000 put Chile in 33rd place worldwide when 
assessing the health system attainment and performance; interestingly enough, 
even though at that time AUGE-GES was not implemented, Chile managed to 
move up the rankings for improving its health care. 
4.5.  Chilean Health Care and Pharmaceuticals 
One of the social positive remarks as mentioned above is the fact that Plan AUGE 
– GES provides free medication for the treatment of those diseases covered 
within the plan, as long as the protocols foresee it. The Chilean effort in 
improving access to medicines becomes visible when dealing with the HIV/AIDS 
pandemic. In September 2006, the Mercurio Journal highlighted how the 
governmental policy and efforts in treating such a disease were seen by the 
international community, which qualified Chile as an example to follow jointly 
with Argentina, Brazil, Costa Rica and Mexico among the countries providing by 
2006, 100% therapy coverage for HIV treatment. 543 
As highlighted above, each disease has a protocol to follow when preventing-
treating-following a disease covered within Plan AUGE. These extensive and 
detailed protocols are also been objected to by part of the Chilean society, as it is 
believed that the health care sector will be object of legal intervention and 
schematisation on behalf of the health care providers and beneficiaries. When 
reading the protocol and clinic guide for the HIV/AIDS treatment in Chile,544 it is 
possible to find the antiretroviral used for this disease and the majority of them 
are generic versions, possibly only one of them is a patented product. HIV/AIDS 
is one of the critical topics dealt with in the context of health care within 
developing, least developed and developed nations since providing access to 
affordable medication has been highlighted to be crucial in the fight against the 
illness. India, Brazil, Chile and many African countries are among the 
acknowledged nations which due to innovation not only provide suitable 
treatment, but which also ensure affordable treatment for citizens. In this respect, 
Chilean public health care policies seem to have been reformed with the aim of 
striking a balance between their international duties and social needs. 
Within the context of the present chapter it has been mentioned several times 
that AUGE – GES covers 56 diseases and that 7 were being implemented in a 
                                                                                                                                                        
Quotation group shall be understand as the groups used by the Chilean healthcare system to classify 
its users or beneficiaries. e.g Group A,B,C or D as explained above. 
542 The World Health Report 2000 – Health systems: Improving Performance, World Health 
Organization, Geneva (2000) 1-206<www.who.int/whr/2000/en/whr00_en.pdf> accessed 10 
September 2013 
543 Editorial, E. M. Medicamentos y AUGE. El Mercurio . (1st-September, 2006). 
544 See further, Guía Clínica – Síndrome de Inmunodeficiencia Adquirida VIH/SIDA, in Series de 
Guías Clínicas (MINSAL – 2009) at 74 
<www.redsalud.gov.cl/portal/url/item/7220fdc4340c44a9e04001011f0113b9.pdf> accessed 14 
September 2013 
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pilot programme, but what are these diseases and what do the protocols and 
clinical guides cover. The table in (Annex 1) highlights the type of attention 
provided and if medicines are given to the beneficiaries to treat the disease.  
In 2008 eight more diseases were being treated in a pilot form, and then in 2009 
eight additional diseases were added. The curious thing is that by 2008 the 
Ministry of Health on its web page only showed the clinic guides for 7 diseases, 
and with respect to the 2009 one, only two guides are available. Although, in both 
cases, the site states that these are the 8 guides for the Pilot AUGE – GES 2008 
and the same thing happened for those in the 2009.545 
Moreover, the medicines suggested to treat the diseases within the guides are 
generics, and most are to be found within the Formulario Nacional de 
Medicamentos Escenciales (National Chart of Essential Medicines).546This chart 
was created by the Código Sanitario (Sanitary Code) in its Article 100, stating that 
“… The Ministry of Health, previous technical report from its Technical 
Regulation Units, will approve a National Chart of Essential Medicines to supply 
the country’s needs. This Chart will specify the pharmaceutical form and 
dosage of the pharmaceutical product and it will also describe the use, limitations 
and side effects of those products...”547 Generally, the medicines contained on the 
countries’ national lists of essential medicines are listed by the name of their 
active ingredient, and in their generic versions, since for most of these patent 
protections have already expired. 
Accordingly, the Central de Abastecimiento – The Central Procurement Office 
(hereinafter CENABAST) acts as a government body channelling the public 
health sector’s demands and standardises acquisition processes to ensure the 
availability and affordability of those essential medicines within the National 
Chart. Furthermore, this is a functionally decentralised public service, provided 
with legal independence and own equity and falls within the Ministry of Health 
mandate.548  Due to AUGE – GES requirements, the country needs to ensure 
either access to generic pharmaceuticals or negotiate low prices via bulk 
procurement in order to fulfil its obligation to provides access to medicines and 
those pharmaceutical therapies included in the Plan.  
CENABAST within its various roles obtains medicines at accessible prices using 
an effective and efficient business model; a scale acquisition programme has 
become the preferred model since 2004. To ensure affordable prices the 
governmental body prompts competition by public bids, calling providers to 
make offers and therefore the one that makes the best one, translated in a better 
                                                        
545 See further, MINSAL site at: 
<www.redsalud.gov.cl/portal/url/page/minsalcl/g_gesauge/piloto2009.html> accessed 14 
September 2013 
546 Chile, Ministerio de Salud, APRUEBA FORMULARIO NACIONAL DE MEDICAMENTOS, 
Decreto Núm. 194, Santiago, 26 de agosto de 2005 <www.leychile.cl/Navegar?idNorma=247938> 
accessed 14 September 2013 
547 Article 100, Código Sanitario de Chile, Decree Nº 725/67 later on modifie by Ley Nº 20.308 
published in Oficial Diary 27.12.2008 
548 See further, Article 46 of Decree Law 2.763 creating The Central Procurement Office of the 
National Health Service System (SNSS) 
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price of medicines, will win the bid.549  By using this method, the government also 
increases transparency in its purchasing programmes, since all the information is 
public. 
National data reveals that by 2005, the health care expenditure in medicines in 
Chile represents about 25% from the total sales within the country. CENABAST in 
2005 estimated that 85% from the pharmaceuticals purchased for Plan AUGE 
were of local generic production and only 15% of the pharmaceuticals used were 
imported.550 
At this point the question about if the patent system as a whole deters the access 
to medicines must be raised, as along the study it is intended to analyse whether 
there are other options to keep on protecting pharmaceutical inventions in 
developing nations while at the same time granting access to affordable 
medicines.  
4.5.1. National Drug Policy and the Chart of Essential Medicines 
Due to the Health Care Reform initiated in Chile in the late 80s, it is possible 
nowadays to talk about a national drug policy and seeking to complement the 
AUGE- GES plan the government has been developing new health care strategies 
and actively taking part in international forums.   
One of the Chilean Health Care Reform goals was to bring universal access to 
health care for its citizens. The health care objectives for 2010 were given in a 
report by the Ministry of Health where the need to reduce out of-pocket 
expenditure on medicines and health care in general was stated. Thereafter, 
financial protection is provided with the intention to limit this kind of 
expenditure, making health affordable instead of a luxury. The same report 
highlighted that the access to health care is deterred in many cases due to a lack 
of financial sources when seeking health care attention, meaning that in many 
poor countries with a weak public health care system its citizens are deemed to 
pay out of their own pockets for health care expenses, which may be very costly in 
many cases.551 This situation may be one of the reasons for why restraining access 
to medicines and not only to pharmaceutical patents is highly contended.  
A National Drug Policy has been carefully implemented in Chile, since public 
health and access to proper health care is a matter of the State. During the Lagos 
government(2000 -2004) a national drug reform was necessary since the one 
dating from 1996 was not fair enough;; inequalities within the health care system 
did not grant access to health care or medicines for the whole Chilean population. 
On 4 April 2004 the Resolution Nº 515 abrogated the 1996 National Drug Policy. 
                                                        
549 See further, commercial processes <www.cenabast.cl/ingles/proveedores/chilecompra.html> 
accessed 14 September 2013 
550 Meriches R, J., ‘AUGE el Nuevo Botín de las Farmaceuticas’ El Mercurio (Julio de 2005) 
<diario.elmercurio.cl/detalle/index.asp?id={2506c1e6-69b2-4c21-85e0-faa8c79372b3}> accessed 
14 September 2013 
551 Ministerio de Salud de Chile, División de Rectoria y Regulación Sanitaria, Departamento de 
Epidemiología  Los Objetivos Sanitarios para la Década 2000 – 2010, Primera Edición, Octubre 
2002, at 257<www.redsalud.gov.cl/portal/url/item/6bdb73323d19be93e04001011f013325.pdf> 
accessed 14 September 2013 
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This reform includes a 31 page document that is an explanatory tool that analyses 
the situation in Chile during that time and gives suggestions on areas that needed 
special attention. In that same year, the Chilean Senate was working to comply 
with the minimum intellectual property standards settled by the TRIPS 
Agreement. Furthermore, the tool highlights the importance in having generic 
pharmaceutical versions that will ensure access to medicines available and it also 
points out the need to include free medication within those clinical guides and 
protocols designed to provide attention in the AUGE-GES guaranties.  The Doha 
declaration on the TRIPS and Public Health were also taken into consideration by 
this Resolution, especially when the data concerning the price difference between 
a generic product and a brand name drug is assessed. Among the 
recommendations made, the National Chart of Essential Drugs should be updated 
on average every two years, and mechanisms to ensure access to affordable 
medicines should be reinforced or redesigned together with the role of 
CENABAST.552 
The report highlighted certain concerns regarding the use and prescription of 
generics, which basically is the fear by users of using a less effective and poor 
quality product due to cheap prices. Therefore, the National Drug Policy 
emphasises developing mechanisms destined to ensure quality, efficiency and 
good manufacturing processes. Brand loyalty and misinformation on the use of 
generics could be another reason restraining access to affordable medicines and a 
barrier for the entry onto the market of those products. Therefore, the 
government must provide enough information about the substitutability and 
security of the suggested generics through its national bodies. The issue on a lack 
of information on behalf of the responsible governmental bodies was raised at the 
Chilean Senate in its 10° Special Session on the 15 April 2009 by Senator Evelyn 
Matthei, who assured that due studies on bioequivalence that should have been 
provided by the National Health Institute – ISP were not available for the public 
or practitioners.553 This issue will be tackled later on in the study. 
The Office of Procurement- CENABAST - adopted a different business model 
during 2004, as mentioned above. The new model consisted of scale purchase 
programmes or bulk procurement, enabling it to provide the public health care 
sector with affordable medicines. This is also a strategy recommended by the 
World Health Organization (WHO) in its guide on “How to Develop and 
Implement a NDP-National Drug Policy,” and therefore when reading the Chilean 
National Drug Policy it is very easy to come across the terminology, concepts, 
definitions and guidelines provided by this Organization in its attempt to 
harmonise health care policies.  
This WHO guide suggests the use of price control policy, reduction of import 
duties on essential drugs, generating competition on basis of generic policies 
prompting generic substitution and good procurement practices among many 
                                                        
552 Politica Nacional de Medicamentos en la Reforma de Salud, aprobada por Resolución Exenta Nº 
515 de 2 de Abril de 2004, Ministerio de Salud, at 1 – 31 
553 Sesión 10, Especial del Senado de Chile, Análisis de la Situación Farmacéutica en Chile, from the 
15April, 2009.Audiovisual Senate session 
<www.senado.cl/prontus_audiovisual/site/artic/20090415/pags/20090415090512.html>accessed 
14 September 2013. The ISP shall require bioequivalence studies of those generic products applying 
for a marketing approval. 
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other strategies to increase the affordability of medicines.554 Moreover, bulk 
procurement seems to be one of the most efficient methods, or at least seems to 
be, working for Chile, since on average this country has the lowest medicine 
prices Latin America. In 2008, the average was $4, 73 in Chile, whereas the 
average in Latin America was $8, 50 according to the Cámara de la Industria 
Farmacéutica de Chile – The Chilean Pharmaceutical Chamber (hereinafter CIF 
Chile) and FIFARMA.555 In the same press article, CIF-Chile highlights that the 
low prices are due to the free market policies being followed in the country and 
that there is practically no intermediary between the producers and the 
pharmacy.  
One could think that a price control policy is used in Chile to regulate the 
pharmaceutical market, but it was not until 2009 that the Chilean Senate started 
suggesting that there should be some kind of price control policy for certain 
medicines.556  A project was submitted to the Senate to consider further 
regulation for the pharmaceutical industry, but at the 14° Ordinary Session from 
the 5 May 2009, the Senate rejected the agreement project. Hence, no price 
control policy was or is enforced so far in Chile.  
Following the recommendation made by WHO, the Chilean National Chart of 
Medicines contains a wide variety of essential medicines that must be available 
within the Chilean territory, but all of these are listed under their active 
component or generic name and not under any brand name product or patented 
drug. The Supreme Decree N° 466 in its Article 92 used to establish that those 
medicines included within the National Chart were to be available in their generic 
version or its brand name version; and the Supreme Decree N° 264/2003 Article 
4, establishes the duties of the Health care authorities’ in enforcing every legal 
mechanism available to ensure the availability of those essential medicines in 
Chile.557 By interpreting those articles, and in connection with the Doha 
Declaration on Public Health, that allows countries to make use of those 
flexibilities available in the TRIPS Agreement to deal with national emergencies, 
it could be assumed that if an innovative medicine is needed to provide treatment 
for any of the GES diseases that become a national emergency, then a compulsory 
                                                        
554 World Health Organization, How to Develop and Implement a national drug policy (Second 
Edition, 2001) 1-83 
555 El Mercurio, ‘Carta: Precios de Medicamentos’ (27 July 2008) 
<www.cifchile.cl/detalle_not.php?id=37> 
556 Press release, Colusión de Farmacias: Comisión de Salud le propondrá al Senado trabajar en 
conjunto con el Ministerio sobre la material, in Senado de Chile, Departamento de Prensa, 
Valparaíso, 14th April, 2009 
557 Decreto Supremo N° 466 de 31 de Diciembre de 1984, Articulo 92:  “… Drug stores shall keep in 
stock at list those pharmaceutical products listed within the National Chart of Medicines … those 
pharmaceuticals might be generics or its similar in the brand name version…” This article was 
eliminated in 2010 by Decreto 22 de 19 de Febrero de 2010, the new Decree in its Article 93 
highlights that drug stores shall have in stock those pharmaceutical products within the National 
Chart and the same article provides a list of the active components/generic medicines  
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licence could be sought by the Chilean Government if the medicine were to be 
patented within the country.558 
On the one hand, nothing specific is highlighted within the Chilean legislation 
regarding the patentability or non-patentability of those medicines included in 
the National Chart, but on the other hand there seems to be various ways to reach 
the exception to avoid the patentability of a needed pharmaceutical; either by 
making use of the TRIPS flexibilities or by enforcing the national legislation or 
public health care policy. According to the articles quoted above and Article 51 
part 2, from the Ley N° 19.996, national emergencies, public health crises and 
public non-commercial use among other situations are ground enough to pursue 
a compulsory license in Chile.559 WHO in its attempt to harmonise health care 
policies and to help improve health care –access to medicines for all has 
developed guidelines regarding the implementation and use of traditional 
medicines within the national drug policies in many countries. 
The Chilean Ministry of Health published a book containing 103 herbal medicines 
or plants used for biopharmaceuticals in its attempt to provide access to 
alternative ways for health care. Nowadays homeopathy is recognised in Chile as 
a form of alternative or complementary therapeutic treatment.  According to the 
WHO, in its Publication on the Legal Status of Herbal Medicines, in 1992 Chile 
provided protection or regulation for traditional medicines within Law N° 19.253, 
but when searching for that legislation at the Library of Congress database the 
only legislative piece that pops up is the one creating the commission for the 
protection of indigenous communities. Furthermore, the WHO Medicine Strategy 
2004-2007 proposes the use of traditional medicines (TM) and complementary 
and alternative medicines (CAM) as an integral part of the health care system. 
Therefore, it is suggested to create and implement a legislation regulating the use 
and protection for traditional plants.560 Chile became a signatory of the UPOV 
convention in 1995; therefore, new plant varieties have been protected in Chile 
since that time.  
4.5.2. Should Essential Drugs be Patented? 
The access to essential medicines is a highly controversial issue, as explained and 
defined within the Introductory Chapter. The Doha declaration on the TRIPS and 
Public Health states and highlights the need to recognise the gravity of public 
health matter within a globalised world many times, and therefore, flexibilities 
for those least developed and developing nations were drawn in the agreement.  
Flexibilities such as the use of compulsory licences, parallel imports for countries 
with no manufacturing capabilities, non-commercial use, subject patentability 
exemptions and patent exemptions are among the choices in addressing the 
                                                        
558 See further, The Doha Declaration on the TRIPS Agreement and Public Health, 
WT/MIN(01)/DEC/W/2, 14 of November 2001 
559 Ley N° 19.996, Enacted on 05 February, 2005; Article 51.- the decision on a compulsory licence 
will proceed within the following cases: … 2) When public health, national security, public non 
commercial use, or national emergency and other extreme emergency situations, ruled by the 
competent authorities justifying the use of such licences 
560 WHOM Strategy, WHO Medicines Strategy 2004–2007: Countries at the Core, World Health 
Organization, WHO/EDM/2004.2 
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solutions for a health care crisis. Nonetheless, the use of e.g. compulsory licencing 
under the TRIPS Agreement provisions and Paragraph 6 from the Doha 
Declaration could be proven costly and unviable as suggested by some scholars.561 
Therefore, further incentives need to be developed to address health care crises in 
least developed countries.  
Prior to the TRIPS Agreement, countries had the liberty on deciding whether or 
not to protect pharmaceutical products and processes, which could be considered 
as a shield to protect essential medicines. However, later TRIPS Article 27.1 
established that patents shall be available for any inventions, whether products or 
processes,562 and pharmaceuticals could no longer be excluded from patent 
protection except if they fall within the scope of the 2ndpart of the article. This 
states not granting a patent to an invention in such circumstances so as to protect 
public order and health among other things is justifiable; moreover, therapeutic 
and surgical methods to treat humans and animals are also to be excluded from 
patentability if it is required.563 
Arguably, free trade agreements constitute a barrier for access to medicines due 
to higher levels of intellectual property protection, but objectively the TRIPS 
agreement brought to the spotlight this difficulty on its own by allowing 
pharmaceuticals to be patented. 
When discussing access to essential medicines, should this be understood in the 
light of the TRIPS Agreement definition or should it instead be interpreted in 
light of the Model List of Essential Medicines given by WHO? Or is there a 
difference between interpretations? The questions arise from the fact that the 
medicines listed within the list of essential medicines are all done so according to 
their active ingredients and not by any brand name. So, if the lists are generic 
versions and active ingredients, should not the issue of essential medication be 
addressed towards creating new incentives to guarantee access to innovative 
patented drugs?  
Chile is characterised as a progressive state along with other nations moving 
towards development. Before becoming part of WTO, Chile had already by 1991 
reformed its industrial property legislation, and in that reform patents for 
pharmaceutical products were included. The situation then was quite delicate as 
the country was overcoming a period of military dictatorship, but this period was 
also characterised by having progressive views.  
4.6. Summarising the Chilean context 
Both intellectual property rights and public health (access to medicines) are 
priorities for the Chilean Government. Adapting its IP law to comply with 
international commitments, while at the same time strengthening the public 
health policies, are significant improvements within the geographical areas.  
                                                        
561 Lucyk, S., ‘Patents, Politics and Public Health: Access to Essential Medicines Under the TRIPS 
Agreement’ (2006-2007) 38 Ottawa Law Review, at 191 
562 Article 27(1) from TRIPS Agreement 
563 Article 27(2) and (3) from the TRIPS Agreement 
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The process is not free of controversy, and some challenges were identified in the 
analysis. For instance, Chile remains on the Priority Watch List of the Office of 
Trade Representatives in the 301 Report due to inconsistencies when enforcing 
intellectual property rights, among other reasons. This could eventually lead to 
sanctions from its trading partner. 
Regarding public health and access to medicines FIFARMA highlighted that the 
responsibility of providing adequate health care cannot rely solely on the 
affordability of medicines due to low prices. There are many issues concerning 
health care, and many actors working together to achieve a highly efficient 
system. This view is complemented in the case of Chile, with the report by the 
Ministry of Health on the expected goals for 2010, when describing a health care 
system that relies on a financial system based on good taxation policies and 
where social insurance becomes mandatory for its nationals. Another contended 
issue in Chile regards the possibility of having substitutes for the current 
pharmaceutical products, since this could increase competition between different 
producers to reduce the prices of the medicines.  
‘Free competition’ among the pharmaceutical industry in Chile did not seem to 
have worked out as originally envisaged, given than small chains where not able 
to compete with the prices provided by larger drug store chains. So far, Chile 
relies on bulk procurement to obtain reduced prices for the needed medicines, in 
Plan AUGE, and close cooperation with the WHO to maintain high standards of 
health coverage.  
In terms of intellectual property rights, Chile’s negotiating the FTA with United 
States does not come either as a surprise or coincidence.  This trend was initiated 
as early as 1996 when a Free Trade Agreement with Canada was signed and a 
provision on IPR’s’ were included.564 Along with the development of the Chilean 
economic and political growth several trade agreements have been signed with 
different countries, and within those negotiations different IPR provisions were 
included. Thus far, the national IP law has been modified to comply with the 
provisions settled within the U.S.-Chile FTA amid reluctance because specifically 
test data protection and extending the term of protection were perceived as 
potentially disruptive for access to medicines in Chile.  
 
 
 
 
 
 
 
 
 
 
 
                                                        
564 See Roffe, P., ‘Bilateral agreements and a TRIPS-plus world: The Chile-USA Free Trade 
Agreement’ (October 2004) Quaker International Affairs Programme - TRIPS Issue Paper 4 
  
115 
5 INTELLECTUAL PROPERTY RIGHTS AND ACCESS TO 
MEDICINES IN VENEZUELA 
  
Political views highly influence the way a society behaves. Moreover, legislative 
policymaking often revolves around a single idea or a single scenario. This is the 
case of countries like Venezuela, where pharmaceutical patents and IPRs in 
general are deemed capitalist interests that are by all means against social 
interests and needs. The economical rationale behind protecting IPRs has not 
been denied; nonetheless, the fact that these rights are foreseen within the 
human or fundamental rights chapter within the political constitutions of several 
developing countries has contributed to creating a balance of rights dilemma 
between intellectual property rights and public health.  
Venezuela has a long democratic tradition with an economy based mainly in oil. 
The country has ratified several bilateral and multilateral agreements with 
different trading partners. Among the most important agreements are the ones 
with the Andean Community of Nations, MERCOSUR and WTO since by ratifying 
the agreements with theses Organisations Venezuela also became a Member 
Country.  
After overthrowing, in 1958, the dictator Marcos Pérez Jiménez Venezuela began 
enjoying, in 1959, freedom of speech together with other prerogatives 
characteristic of a democratic regime. Later on, in 1999, President Hugo Chávez 
was elected, and even when his policies intended to fix the prevalent economic 
problems, Chávez ended up implementing similar policies to those despised by 
him only to accentuate social warfare, inflation, corruption and impunity among 
others. Accordingly, the oil production in Venezuela has significantly decreased 
within the past 14 years, thereafter, giving an advantage to the other OPEC 
Member Countries to increase their levels of productivity. 
Intellectual property rights have been safeguarded in Venezuela since as early as 
1842, when the specific legislative framework sought to protect inventions in 
general. Already at that time, patents were available not for pharmaceutical 
patents per se, but also for industrial purposes. In 1955, patents, trademarks and 
other rights were regrouped in a single IPR legislation that later on, in 1992, 
became unified through the Andean Community Sub regional Organisation. It is 
important to highlight that Venezuelan IP Law distinguishes between intellectual 
property rights and industrial property rights; the first ones are mainly related to 
copyright, and the second ones refer to patents, trademarks, utility models and 
geographical indications. 
No one could have had forecasted how well this Regional Integration was going to 
work, if at all. Scholars have pointed out the relevance of the Andean Justice 
Tribunal for the region's intellectual property law development. Between 1987 
and 2007 the Court gave 1303 preliminary court rulings related to intellectual 
property law from a total of 1338 cases; hence all of these rulings were binding 
decisions for all the Member States. Unfortunately, Venezuela withdrew from the 
Andean Community in 2006 and from then the national intellectual property 
legislation should have been modified in accord to the minimum standards of 
protection settled within the TRIPS Agreement. 
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At the beginning of the research a couple of challenges were identified leading to 
question whether or not the pharmaceutical patents granted in Venezuela have 
had a significant impact on the access to medicines, and whether or not the 
country would be in breach of the obligations undertaken as a WTO Member 
State if it re-enacted the IP legislation from 1955. 
This chapter will be structured in a manner so that even when the main focus is 
intellectual property rights and public health, the chapter still reflects the 
legislative changes from the pre-constitutional reform era to the era post- 
constitutional reform from 1999. For clarity within the analysis the reader will be 
presented with three sections: the first analyses the intellectual property rights 
legislation and related institutions; the second provides a public health care 
system overview; and the third addresses the link between pharmaceutical 
patents and universal coverage (access to medicines) as envisaged within the 
Constitutional framework from 1999, and other regulatory provisions related to 
medicines per se. The findings of the analysis will be preliminarily assessed 
within the remarks and the dissertation’s general summary. 
For the purpose of the study, the term intellectual property rights have been used 
as a synonym from industrial property rights. Within the Venezuelan IP law, 
there is a theoretical distinction between intellectual property rights and 
industrial property rights. The first ones mainly refer to copyright law, whereas 
the second one refers to patent, trademarks and industrial drawings, meaning 
those creations with industrial and/or commercial applicability.BB Both fields are 
constitutionally protected, but Ley para la Propiedad Industrial (hereinafter IP 
Law from 1955) only regulates the aforementioned rights; and a special law is 
meant to regulate copyright and author’s rights. Hence, differentiating between 
intellectual property rights and industrial property rights. 
5.1. Intellectual Property Rights in Venezuela 
The IPR system in Venezuela has been inspired or influenced by foreign systems, 
and in particular the American and French systems worked as a referential 
framework to shape the first intellectual property law, in 1878, in Venezuela. This 
legislation underwent several reforms during 1882, 1927 and 1955.566 
Given that Venezuela is a Member Country of both WTO and the Andean 
Community, the country was also required to reform the IP law from 1955 to 
comply with the new international and minimum standards of protection. Thus, 
patents for medicines, chemical formulas and compounds and alike were not 
possible.567 
                                                        
565 Rondón de Sansó, H., ‘El Concepto de la Propiedad Intelectual en el Régimen de la Constitución 
de 1999’(2005) 153 Boletín de la Academia de Ciencias Políticas y Sociales, at 396 
566 Morles Hernández, A., (ed.) ‘Las Patentes de Invención’ in Curso de Derecho Mercantil: 
Introducción, La Empresa, El Empresario (Tomo I, Universidad Católica Andrés Bello, 
Caracas:Venezuela -2004)at 311 
567 Ley de Propiedad Industrial, Publicada en la Gaceta Oficial Nº 24873 del 14 de Octubre de 1955. 
Artículo 15. “Patents are not available for: 1.- … the medicines of every kind, pharmaceutical 
compounds and their preparation processes, chemical combinations and reactions” Original  text in 
Spanish, translation provided by the author. 
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Some years later the Andean Community568 enacted a binding decision reshaping 
the IP system, Decision 344, that allowed Venezuela to comply with the 
aforementioned standards by implementing the Andean decision into their 
internal legislation. Decision 344 was later on substituted by Decision No. 486, 
which settled IPRs’ standards accordingly. In 2006, Venezuela withdrew from the 
Andean Community, and thereafter concerns encompassing the legal framework 
to protect intellectual property rights arose. Venezuela, as a former Andean 
Community Member, kept on applying the Decision 486 as a referential 
framework to revise patent applications and other intellectual property right 
claims. The country should have reformed its internal legislation so as to comply 
with the TRIPS agreement, but instead re-enacted the IP Law from 1955. The 
decision to re-enact the IP law from 1955 by the Servicio Autónomo de la 
Propiedad Intellectual –SAPI (Patent Office) in a notice dated 12 September 
2008 has been a controverted issue. This controversy will be analysed within the 
title assessing the implications for Venezuela from its membership in the Andean 
Community of Nations.  
In Venezuela, the Servicio Autónomo de la Priopiedad Intellectual (herein SAPI) 
– Venezuela’s Patent Office- is a body ascribed to the Ministerio del Poder 
Popular para el Comercio – Ministry of Commerce-, and therefore this is the 
entity responsible for the protection and registration of intellectual property 
rights.  
SAPI was created by the Presidential Decree number 1768 on 25 March 1997 and 
published in Gaceta Oficial No. 36.192 on24 April 1997. At that time the Ministry 
of Commerce was the Ministry of Commerce and Production, but later on was 
renamed to Ministry of Commerce. SAPI began to operate on 1s May 1998in 
accord with Resolución Ministerial Nº 054 del 07 de abril de 1998, published in 
Gaceta Oficial Nº 36.433 del 15 de abril de 1998.569 
Scholars have highlighted that only with a new IP Law would it be possible to 
derogate a transitional regime. Thus a new doubt emerges precisely with the 
Parliament approval of a Law for Science, Technology and Innovation (Ley 
Orgánica de Ciencia, Tecnología e Innovación - LOCTI), because of the conflict of 
competences brought into the spotlight. It has been seriously questioned whether 
or not the new legislation derogates the previous one. In the first instance, this 
law finds its basis in Article 98 of the Constitution of the Bolivarian Republic of 
Venezuela,570 where not only IPRs constitutionally protected, but also in the light 
                                                        
568 CAN see: Who are we? Andean Community - Brief history, is a sub regional integration 
community of countries (Bolivia, Chile, Colombia, Ecuador and Peru), created in 1969 through the 
Cartagena’s Agreement <www.comunidadandina.org/ingles/quienes/brief.htm> accessed 14 
September 2013 
569 SAPI “ Breve reseña histórica” <www.sapi.gov.ve> accessed 15 November 2011 
570 Constitución de la República Bolivariana de Venezuela de 1999. Publicada en Gaceta Oficial 
Extraordinaria N° 5.453 de la República Bolivariana de Venezuela. Caracas, viernes 24 de marzo de 
2000 “Article 98° Cultural creation is free. Including the right to invest in, produce and disseminate 
literary, scientific, technologic and humanistic work, as well as legal protection for the authors’ 
rights in their works. The State recognises and protects intellectual property rights in scientific, 
literary and artistic works, innovations, indications, trade names, patents, trade marks, slogans 
according with the conditions and exceptions established by law and in International treaties 
executed and ratified by the Republic in this field.” 
<www.unhcr.org/refworld/category,LEGAL,,,VEN,4c45ad8b2,0.html>accessed 20 January 2012 
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of the same Article the State has the responsibility of promoting innovation of 
technology.571 Articles 27 and 28 of the LOCTI with great vagueness rule over 
“previous conditions of ownership and IP protection”, and therefore by virtue of 
those articles this new entity created to promote technological innovation could 
be overlapping the competences of the Popular Ministry of Light Industries and 
Commerce, which initially managed these issues through SAPI.   
This first part analyses Venezuela’s intellectual property legislative framework, 
starting with an assessment of the Constitutional approach towards IP rights, 
followed by an overview to the IP Law from 1955. The analysis will continue with 
an overview of the Andean Community system, implications for the country, the 
legislative challenge as a consequence from Venezuela’s withdrawal from the 
Andean Community and the new challenges derived from the membership into 
MERCOSUR. The present structure aims to allow better understanding over the 
differences between the IP regime while Venezuela was an Andean Community 
member and the current system. 
5.2. Constitutional Approach to Intellectual Property Rights: In 
Accordance with 1999’s Constitutional Reform 
Before analysing in depth the constitutional provisions granting protection for 
intellectual property rights in Venezuela, it is important to dedicate a few lines to 
the legal sources governing these rights. 
The legal hierarchy starts with the political constitution at the top of the pyramid, 
followed by norms with legal rank –those implemented in a direct and immediate 
manner, such as formal laws and government acts – and at the bottom of the 
pyramid are those laws with a sub-legal character.572Within the Constitution 
currently in force, in Venezuela, there are four particular articles to take into 
consideration to understand the status of both IP rights and standards settled in 
international and integration treaties.  
Intellectual Property rights are constitutionally protected in Article 23 and 98 
under Title II - Chapter I is devoted to duties, human rights and guarantees,, and 
Chapter VI to establishing cultural and educational rights. The Constitution, as 
the primary source of law, grants supra constitutional573 rank to those 
international treaties, conventions and agreements ratified by Venezuela within 
the field of human rights.574 This implies direct and immediate application as 
highlighted in Article 153. Furthermore, the State recognises and protects 
                                                        
571Ley Organica de Ciencia, Tecnología e Innovación (LOCTI) still to be announced in the Oficial 
Gazette 
572 Rondón de Sansó, H., ‘El concepto de la Propiedad Intelectual’ at 399 
573 Supra National within the Venezuelan context means that an international regulation has a 
higher rank than the consitution itself, namely the Declaration on Human Rights 
574  Constitución de la República Bolivariana de Venezuela de 1999. Article 23 “Treaties, pacts and 
conventions relating to human rights which have been executed and ratified by Venezuela, have 
constitutional rank and prevail over national legislation as long as they contain provisions 
concerning the enjoyment and exercise of such rights that are more favorable than those established 
by this Constitution and the laws from the Republic, and are of immediate and direct application by 
Courts and other organs from the Public Power.” 
<www.unhcr.org/refworld/category,LEGAL,,,VEN,4c45ad8b2,0.html>accessed 20 January 2012 
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intellectual property rights –such as inventions- accordingly with the conditions 
and exceptions established by law and in International Treaties executed and 
ratified by Venezuela.575 Also falling within the human rights category, is the 
property right provided in Article 115. Given that, patent rights grant exclusive 
rights to right holders, withholding property rights over their inventions. Despite 
finding a general definition of property in the constitution, the exclusivity right is 
not stressed.576 One of the linking factors between the property right per se and 
intellectual property rights are the limitations foreseen by the IP Law from 1955, 
i.e. expropriation due public interest. This theory will be assessed in the heading 
analysing the aforementioned limitation. 
Even though intellectual property rights are included within the human rights 
chapter in the Constitution, due to the parameters settled in both Article 27 from 
the Universal Declaration of Human Rights and Article 15 from the International 
Covenant on Economic, Social and Cultural rights, highlight the scope of the 
freedom to create. This extends to the right to “invest financially” as stated in 
Article 98. Venezuelan scholars have suggested misplacement in the use of that 
terminology, stressing the fact that these are generally economical activities and 
therefore the word “invention” should have been placed instead.577 
Moreover, if Article 98 is analysed in detail, two parts can be identified. The first 
one regards cultural creations as free and immediately the elements of that 
freedom to create are described, namely the rights to invest, the right to produce 
and the right to disseminate creations. In the second part, intellectual property 
rights are recognised and protected by the State, namely scientific, literary and 
artistic works, inventions, innovations, denominations, indications, patents, trade 
marks and slogans.  Another interesting fact is that despite the Venezuelan law 
differentiating intellectual property rights from industrial property rights, Article 
98 from the Constitution conglomerates all immaterial rights under the scope of 
intellectual property rights.578 
The constitutional scope of protection in Venezuela is extended to indigenous 
collective intellectual property rights foreseen in Article 124. by safeguarding 
traditional knowledge by constitutionally prohibiting others from obtaining 
patent rights. In the light of this provision, traditional knowledge, indigenous 
technologies and inventions are regarded as property, specifically collective 
property that possibly grants collective benefits to the community. Hence, the 
main characteristics embedded in property rights -namely the right to use, enjoy 
and dispose of – are expressly laid out when establishing indigenous IP rights, 
whereas this is left to assumption within the context of Article 98.  
Even though the property right per se will be addressed later on, it is important to 
stress that Article 115 does not follow the general structure in all constitutional 
provisions, which is first stating and then settling the definition. In this case it is 
                                                        
575 Article 98, Constitución de la República Bolivariana de Venezuela de 1999 
576 Rondón de Sansó, H., ‘El Concepto de la Propiedad Intelectual’ at 390 
577 Fariñas Díaz, J., ‘La Protección Constitucional de la Propiedad Intelectual en Venezuela’ (2009) 
12 Revista de Propiedad Intelectual, 10-33 at 18. See also, Brewer Carías, Allan R. La Constitución 
de 1999, con el texto official de la Constitución Gaceta Oficial Nº 5453 Extraordinaria del 24-3-
2000 (Editorial Jurídica Venezolana, Edidorial Arte, 3rd Edition, Caracas, 2001) at 47 
578 Fariñas Díaz, J., ‘La Protección Constitucional’ at 18 
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only mentioned property, but its meaning is not described,579 leaving aside the 
fact that there three types of property in Venezuela –private, public and 
collective. 
Furthermore, Article 153 establishes the position from the Government in 
relations to international treaties and conventions;; in general terms those in 
virtue of integration organisation will have direct and preferred implementation 
within national law. This is especially relevant, given that Venezuela denounced 
the Cartagena Agreement in 2006, hence, controversies on the validity of the IP 
Andean Community framework governing until that date emerged.  This will be 
analysed within the Andean Community context further below.  
5.3. Current Intellectual Property Legal Framework 
Within the legal hierarchy, as a formal law, the IP Law from 1955 should be 
analysed next. In Venezuela, Ley de Propiedad Industrialof2 September 1955, 
published in Gaceta Oficial Nº 24.873 from 14 De Octubre de 1955, currently 
regulates the intellectual property system.  It comprises 15 chapters, general, 
transitional and final provisions. Given the focus of this study, only the chapter 
and provisions relevant to patents will be taken into consideration.  
This law has some characteristic features to look at, of which among them are the 
topics related to patentable subject matters –inventions, discoveries, 
improvements and introduction of inventions - property rights and the right to 
claim inventions. In other words, who is to be recognised as the patent holder, the 
inventor or the one filing the patent application.  According to Article 3º from the 
Patent Law from 1955 the property of the invention belongs to the one to whom 
the patent certificate has been issued.580 In this respect, the administration 
forgoes the right to verify who the real inventor is; most likely the only way for 
him/her to claim ownership will be through a judicial action,581 even though the 
Law specifically requests that the “real inventor “claim the patent protection.  
It has been suggested that Venezuela’s law differentiated between the patent right 
to exclude others and the rights emerged from the invention per se given that a 
patent could not be granted unless this invention met the legal requirements. 
However, the absolute right came after the right was granted.582 
In a sense, the IP law in Articles 5 and 59 (1) establishes as the original/real 
inventor the person entitled to patent ownership. Hence, the inventor’s name, 
domicile and nationality are to be specified within the application claiming patent 
rights.583 In other words, the inventor carries the burden of prove given that the 
                                                        
579 See Fariñas Díaz, “ La Protección Constitucional” and See also Rondón de Sansó, “El Concepto 
de la Propiedad Intelectual” 
580 Ley de Propiedad Industrial, Gaceta Oficial Nº 24.873, Article 3º “The Law presumes as the 
invention owner, …, the person to whon the patent certificate has been registered for” Original text 
in Spanish, translation provided by the author. Articulo 3º “Se presume que es propietario de in 
invento, …, la persona a cuyo favor se haya hecho el correspondiente registro” 
581 Sansó, B., and Rondon de Sansó, H., Estudios de Derecho Industrial (Universidad Central de 
Venezuela, Facultad de Derecho, Caracas: Venezuela - 1965) Vol. XXXV, at 7 
582 Ibid at 9 
583 See further Article 58 and 59(1) IP Law 1955 
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law in part (C) requires certification attesting that the applicant is the real 
inventor of the invention. Contradictorily, it has been argued that the 
administration is careless in either verifying or elaborating further over this 
matter.584 
Another interesting feature regards patentability requirements that can be 
summarised as new, defined and useful.585 This, read in conjunction with Article 
15 (9º) from the Law, could be interpreted as meaning that “new” refers to 
“novelty”, which is required and defined in modern legislation within the scope of 
the state of the art.  
This system is regarded as a declarative system, given that rights are born in the 
same moment as the inventive idea, and thus it becomes the State’s duty to grant 
protection to the inventor by issuing the patent certificate.586 
5.3.1. The Patent Office (SAPI) Competences 
Everything related to intellectual property rights are to be taken before the 
Registro de la Propiedad Industrial, nowadays Servicio Autónomo para la 
Propiedad Industrial (Hereinafter SAPI). This entity is responsible for the 
registration and grant procedure of IP rights.587 Therefore, IP law Chapter V 
contains all the relevant provisions defining this entity’s competences, 
qualifications to become Registrar, publicity, Registrars attributions and 
administrative remedy against this entity’s decisions.  
From the ten (10) articles contained in this chapter, four (4) of them are of 
particular interest. Article 38 establishes the conditions to become the Registrar, 
which are basically summed up as being a lawyer and that this position is of free 
removal by the president.588 
Within the many attributions given by law to the registrar, two are worth 
mentioning. Article 40 highlights the duty in providing information of public 
character to anyone who requests them, expect those patent files requested to be 
kept confidential in accord with legislative provisions.589 Secondly, the Registrar 
                                                        
584 See further Article 59 (c) from Ley de Propiedad Industrial, See also Sansó, B. at 9 
585 Article 14 from Ley de Propiedad Industrial, Patentable subject matters (1º) “products that are 
new, defined and usefull” Original in Spanish, translation provided by the author Atriculo 14 
Pueden ser patentados: (1º) “todo producto Nuevo, definido y útil”   
586 Uzcátegui Urdaneta, M., Invención y Patente de Invención en el Derecho Venezolano (Ed. 
Cazus, Caracas-Venezuela, 1965) at 97 
587Artículo 37 from Ley de Propiedad Industrial, “Everything related to industrial rights will be 
governed by an office named Registro de la Propiedad Industrial” Original text in Spanish 
translation provided by the author. Artículo 17 “Todo lo relativo a la Propiedad Industrial estará a 
cargo de una ofineca que se denonimará Registro fe la Propiedad Industrial” 
588 Article 38 from Ley de Propiedad Industrial, “Patent Office Registrar shall be a lawyer who will 
be freele elected and romoved by the President through Ministry of Commerce” Original text 
provided in Spanish translation provided by the author. Artículo 38 “ El Registrador de la ropiedad 
Industrial deberá ser abogado y de la libre eleción y remoción del Ejecutivo Nacional, por órgano 
del Ministro de Fomento” 
589 Article 40 rom Ley de Propiedad Industrial, “Is the Registrar’s duty to show all interest parties 
all patent files, office books, resolutions, etc, available within the Office free of charge … Public 
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also becomes an administrative judge, in the sense that he is designated to 
acknowledge and decide over oppositions presented before SAPI.590 Thirdly, the 
Patent Office archives shall remain open to the public for a period of four (4) 
hours per working day.591 
And fourthly, in light of Article 43 resolutions from the Registrar about 
registrations, oppositions or objections can be appealed before the Ministry of 
Commerce within five (5) working days from the notification date to the 
interested party.592 
The legislation also regulates in its chapter VI everything related to registration 
certificates, patent fees and claim taxes. All of these have been adapted to the 
current credit unit value in Aviso Oficial Nº 17, published within Boletín 
Nº512.593 
Moreover, IP agents are also regulated. This figure allows interested parties to do 
all necessary formalities before SAPI to request patent protection for an invention 
without having to do it him/herself exclusively. Therefore, certain requirements 
are to be taken into consideration before qualifying as an IP agent. Basically, a 
person must either be an economist or a lawyer and he/she shall be registered 
within the Registration Book for IP Agents.594 Further provisions suspending IP 
agents are also stated, and perhaps the most important one related to the 
Registrar’s competence to sanction agents de oficio.595 
                                                                                                                                                        
disclosure is limited to patent files requested to remain confidential accordingly with legislative 
provisions”Original text in Sapnish.Translation, modifications and highlights provided by the 
author. Articulo 40 “ El Registrados tiene el deber de hacer mostrar dentro de la Oficina, a todo 
aque que lo pida, libros, indices, documentos, expedients, actas y planos que existen en la Oficina, 
sin poder cobrar ningún emolumento por este trabajo nip or permitir que los solicitantes saquen las 
compias simples que deseen. Se Exceptúan de esta disposición los expedients de patentes de 
invención que se hubieren mandado a reservar conforme a la Ley.” 
590 Sansó, B., Las Patentes de Invención, at 27 
591 Article 41 from Ley de Propiedad Industrial, “ SAPI’s archives shall remain open to the public for 
a period of four (4) hours per working day”Original text in Spanish, translation provided by the 
author. Artículo 41 from Ley de Propiedad Industrial “El Archivo de Registro de la Propiedad 
Industrial estará abierto y a la disposición del público durante cuatro (4) horas por lo menos de 
cada día hábil” 
592 Article 43 from Ley de Propiedad Industrial, “All resolutions from the Registrar regarding 
registration, objections or oppositions, shall be appealed before the Ministry of Commerce, within 
five (5) working days from the notification date to the interested party” Original text in Spanish, 
translation provided by the author. Artículo 43 “De toda resolución del Registrador sobre 
registros, objeción u oposición, se oirá apelación por ante el Ministerio de Fomento, dentro de los 
cinco (5) días hábiles contados a partir de la fecha de la notificación al interesado.” 
593 SAPI, Aviso Oficial Nº 17 “Tasas, Marcas y Patents”  
<www.sapi.gob.ve/images/stories/AvisosOficiales/serviciosmarcaspatentes.pdf>accessed 21 
November 2011 
594 Article 52 from Ley de Propiedad Industrial To become an IP agent is necessary to: 1º Be an 
economist, or a lawyer…; 2º Shall be properly registered within IP Agents Book” Original text in 
Spanish, transpation provided by the author. Articulo 52. Para ser Agente de la Propiedad 
Industrial se requiere: 1º Ser abogado o economista …; y 2º Estar debidamente inscrito en el Libro 
de Registro de Agentes de la Propiedad Industrial que a tal efecto lleve la Oficina.” 
595 See further Parágrafo Primero – Artículo 53, Ley de Propiedad Industrial  
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As previously mentioned, an official notice (Aviso Oficial) informed the public 
about patent and trademark fees. Therewith, Chapter VIII regulates and gives 
public instrument character to those Avisos Oficiales and Boletínes de la 
Propiedad Industrial – Official notices and IP Journals - from the patent office.596 
In light of these provisions, two functions are embedded within the IP Journal. 
On the one hand, that of informing third parties over relevant matters dealing 
with the Patent Office per se, granting or patent denial and claims ultimately 
allowing interested parties to formulate opposition when his/her rights could be 
infringed. And on the other, the main function from this IP Journal is to give 
authenticity to those acts and resolutions contained in it, while at the same time 
informing the public about deadlines to comply with certain acts and 
procedures.597 
5.3.2. Types of Patents 
The Venezuelan patent law distinguishes among product patents, “introduction of 
invention or improvement patent”, and revalidation patents. The first ones, as 
described above, comprised products (others); within the second ones the 
legislative text seems to differentiate between an improvement and introducing 
an invention, but is not clearly defined; and, the third one regards those 
inventions already protected abroad. However, in practice it is not certain 
whether or not all of these are granted. 
Chapter II dedicated to “Patents” in Article 5 does not only set forth the types of 
patents and content, but also highlights rights conferred by each kind. In this 
respect, Patents for inventions, improvements, model or industrial drawings 
and those introducing an invention or improvement grant to patent holders 
exclusive rights to make use, produce or industrially process the patented subject 
matter within the terms and conditions given by Law. However, the same article 
provides that invention or improvements introductory rights are not exclusive per 
se since these cannot prevent third parties from importing the product or 
improvement introduced by them into the country.  
Given that introductory patents do not grant exclusive rights,598 these have been 
approached as inventions that required patent protection in Venezuela before 
commercialisation despite being protected abroad.599 
                                                        
596Article 54 from Ley de Propiedad Industrial “All publications envisaged within this law, shall be 
done through IP Journal as body from the Patent Office. All samples are binding public 
instruments.” Original text in Spanish, translation provided by the author. Artículo 54 “Todas las 
oublicaciones previstas en la presente Lay, deberán hacerse en el Boletín de la Propieda Industrial 
que es el órgano de la Oficina de Registro. Los ejemplares de este Boletín tendrán fuersa de 
instrumento público” 
597 Sansó, B., ‘Las Patentes de Invención’ at 29 
598 Article 5, Ley de Propiedad Industrial 
599 Sansó, B., ‘Las Patentes de Invensión’ in Sansó, B., and Rondon de Sansó, H., (eds), Estudios de 
Derecho Industrial (Universidad Central de Venezuela, Facultad de Derecho, Caracas, 1965) 
Volumen XXXV, 1-264 at 16. 
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In light of Article 5º the main difference between introductory patents and 
patents for inventions per se seems to be the scope of protection. One grants 
exclusive rights and the other one does not.  
Revalidation patents are those for which patent protection is granted on the basis 
of its previous approval abroad provided the term of protection has not expired 
yet.600 
Improvement patents are those concerning an invention perfecting the previous 
invention.601 
Given that there is almost no distinction between revalidation patents or patents 
introducing an improvement or invention, it has been suggested that the 
Venezuelan law seemed to create an additional patent category besides the classic 
ones -patents for inventions and industrial drawings- by introducing within the 
same enumeration “patent for improvements.”602 
Even though a distinction by means of definition is not feasible, it is possible to 
assume certain characteristics on the basis of the terms of protection and 
possibilities to have priority in obtaining the patent certificate. Article 9 foresees 
protection for inventions, improvements, models and industrial drawings for a 
period between five (5) to ten (10) years according to the inventors wishes; 
whereas only five (5) years is the term of protection granted to patents for 
introduction of inventions. 
Regarding the term or protection and possibility in obtaining it for revalidation 
patents, Article 10 is very clear in stating preconditions and terms of protection. 
In other words, on the one hand patent protection will be granted for those 
inventions already protected abroad “as long as these meet national legal 
requirements and that these are not part of the public knowledge” – which leads 
to another contradiction within the law – and on the other, the term of protection 
will be for the remaining period of validity on basis of the patent already granted.  
Priority rights or to obtain the patent certificate in Venezuela when this has 
already been granted abroad is given in Article 11. It stresses a timeframe of 
12months counted from the date the patent certificate was issued abroad to when 
it was petitioned before SAPI.603 But what happens if the patent application was 
submitted after this period? Would the patent then have to wait in the pipeline to 
be processed? The legislation is not clear on this matter. 
Among the patent requirements, even for those products already protected 
abroad, is the fact that any invention seeking protection cannot belong to the 
public domain. Furthermore, the IP law from 1955 seems to be vague when 
dealing with revalidation patents that became part of the public domain. In other 
words, it is not clear whether or not it is enough for a product to be known in a 
foreign territory as for the Venezuelan Registrar to denote this fact as also being 
                                                        
600 Rondón de Sandó, H., La Decisión 313 de la Comisión del Acuerdo de Cartagena y el Régimen de 
Propiedad Industrial (Caracas:Venezuela -1993) at 19 
601 Sansó, B., ‘Las Patentes de Inveción’ at 15 
602 Idem, at 16 
603 Articulo 11 from Ley de Propiedad Industrial 
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part of the national public domain;604 hence, not granting patent protection on 
the basis of public knowledge.  
Two interesting scenarios are presented in Article 12. First, the original or foreign 
patent holder is entitled by Law to oppose any patent claims made in Venezuela 
to introduce its invention or improvement within the following 12months after 
the patent has been granted abroad; and if during this time there is such a claim 
before SAPI. Secondly, if the foreign patent holder submits a patent application to 
protect its invention or improvement in Venezuela 12 months after this has been 
granted abroad, and at the same time this one has already been granted to a third 
party in Venezuela as a “patent for introducing an invention or improvement”, 
then the original patent holder is entitled to request the certificate’s abrogation.  
And thirdly, the patent’s office Registrar could give the patent nullity without a 
separate procedure other than the patent owner petition. Summing up, this 
article not only gives priority to a certain extent to those inventions or 
improvements already patented abroad, but also recognises inventors’ legitimate 
claim over their work by allowing them to request the abrogation of patent 
certificates without having to start a judicial procedure.  
5.3.3. Inventions and Discoveries 
Thus far, Venezuela’s IP Law from 1955 does not foresee a definition for either 
patent or invention, but instead aims to enumerate what does and what does not 
constitute patentable and non-patentable subject matter throughout Articles 14 
and 15. 
Despite Article 14 enunciating all patentable subject matters, as suggested above, 
it in section one also introduces patentability requirements. Hence, every product 
new, defined and useful could be worthy of patent protection.605 Therewith, 
“new” understood as “novelty” allows any product or industrial drawings not 
listed within non-patentable subject matters to receive patent protection, as 
clearly stated in the provision’s last paragraph.606 
No product meeting the novelty requirement -objective patentability 
precondition- would be entitled for such protection, meaning that the invention 
cannot be of either public knowledge or belong to the public domain.607 Initially, 
everything listed within Article 14 shall be patentable as long as it is new, defined 
and useful. Even when this provision does not assess how the novelty 
requirement is measured, Article 15(9º) moves forward in stating that inventions 
known by the public due to publications or disclosure in printed works or any 
other form, and those belonging to the public domain due to materialising, 
distribution and/or displaying it locally or abroad before the patent claim has 
been submitted, are not patentable.608 
                                                        
604 Sansó, B., ‘Las Patentes de Invención’, at 16 -18 
605 Article 14 (1) from Ley de Propiedad Industrial from 1955 
606 Article 14 in its Only Paragraph emphasises its enunciative character, hence, not restrictive. 
Given that in general terms anything resulting from human inventive efforts, with the exceptions 
given by law, can and would be patentable 
607 Sansó, B., ‘Las Patentes de Invención’, at 16 -18 
608 Article 15 (9) from Ley de Propiedad Industrial 
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Following the discussion on patentability, Uzcategui Urdaneta suggests that 
inventions are organised according to the objects’ nature, procedures and type of 
invention.609 Given the objects’ nature, patents are for machines,610 instruments 
and appliances.611In accord with the procedures612 and defining the kind of 
inventions this includes improvements,613 modifications,614 new industrial models 
and design.615 Another approach suggests Venezuela’s IP law categorises 
inventions according to the products’ invention object, procedure, machineries – 
instruments and spare parts; and discoveries with industrial applicability.616 
Moving on to non-patentable subject matter, Article 15 presents a list of 
inventions that are not protected despite meeting patentability criteria: 
1º drinks and foods, destined for human or animal consumption; all kinds of medicines, 
medicines pharmaceutical preparations and preparations, reactions and chemical 
combinations;617 
2º systems, combinations or business plans, speculative, commercial, marketing or of 
simple fiscal control;618 
3º use or simple use of substances or natural forces even when just discovered;619 
4º products, objects, substances or elements previously known or used for determined 
purposes, new uses or those simple changes or variations in shape, dimensions or 
materials originating from those;620 
5º know-how or industrial secrets;621 
6º strictly theoretical or speculative inventions unable to prove defined utility, practicality 
and industrial application;622 
7º inventions contrary to national law, health or public order, moral and good customs 
and States security;623 
8º Juxtaposition of already patented elements or that these belong to the public domain, 
unless these cannot operate independently without using their functionality.624 
9º Inventions known in the country due to their publication or that belong to a printed 
publication or in any other form, or those belonging to the public domain as a result of 
                                                        
609 Uzcátegui Urdaneta, M.,Invención y Patente de Invención en el Derecho Venezonalo (Ediciones 
Casuz, Caracas, 1965) at 29. 
610 Article 14(2) from Ley de Propiedad Industrial  
611 Article 14 (3) from Ley de Propiedad Industrial 
612 Article 14 (4) and (5) from Ley de Propiedad Industrial  
613 Article 14 (6) from Ley de Propiedad Industrial 
614 Article 14 (7) from Ley de Propiedad Industrial  
615 Article 14 (8) from Ley de Propiedad Industrial 
616 Sansó, B., ‘Las Patentes de Invención’ at 12 
617 Article 15 (1) from Ley de Propiedad Industrial de 1955 
618 Article 15 (2) from Ley de Propiedad Industrial de 1955 
619 Article 15 (3) from Ley de Propiedad Industrial de 1955 
620 Article (4) from Ley de Propiedad Industrial de 1955 
621 Article 15 (5) from Ley de Propiedad Industrial de 1955 
622 Article 15 (6) from Ley de Propiedad Industrial from 1955 
623 Article 15(7) from Ley de Propiedad Industrial from 1955  
624 Article 15 (8) from Ley de Propiedad Industrial from 1955 
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their use, sell or publicity inside or outside the country prior to filing the patent 
application.625 
In light of the aforementioned articles, patents for pharmaceutical products are 
not possible due to public interest, but a patent to manufacture them seems 
possible. The same is applicable for chemical products –non-patentable- but the 
industrial process to produce them is patentable.626 
Other scholar suggests the rationale behind these prohibitions was strictly 
considered to avoid abuses on behalf of patent owners i.e. restricting access to 
medicines.  But the prohibition, in his view, turned out to be detrimental because 
patents are an incentive to promote the country’s industrial development. The 
pharmaceutical industry relies on patents of R&D products destined to improve 
people’s health and lives; and, because there are enough legal means to stop or 
avoid abuses on behalf of patent owners.627 
5.3.4. Public Interest and Patents 
Venezuela’s IP Law from 1955 addresses two cases where public interest affects 
patents, but there is no provision dedicated to deal with compulsory or voluntary 
licences. In the worse case scenario, patent rights will be expropriated by the 
State when the invention is considered to be of fundamental public interest.628 
Analysing the content of Article 4- indirectly leaves open the door for patent 
holders to grant voluntary licences. This one regards the effects on third parties 
before rights were registered within the patent office’s books.629 
The law does not provide further provisions addressing either cases of public 
interest or public use. Article 20 refers to cases of lapsed patent registration 
rights, in which inventions will belong to the public domain, and hence, have 
public use.630 
There are certain important issues that need to be analysed in conjunction with 
Ley de Expropiación por Causa de Utilización Pública o Interés Social (Law for 
the Expropriation due Public Use or Public Interest  - herein LEXP) without 
falling into a pure administrative law discussion. What is of interest here is to 
assess, namely, who can expropriate goods, what is to be considered public 
interest, how are goods affected with public interest, which is the procedure 
followed and which are the provisions dealing with this matter. 
In Venezuela, in accordance with Article 2 LEXP, expropriation is an institution 
of Public Law that belongs to the National Government, therefore the State uses it 
                                                        
625 Article 15 (9) from Ley de Propiedad Industrial from 1955  
626 Sansó, B., ‘Las Patentes de Invención’ at 13 
627 Uzcátegui Urdaneta, M., Invención y Patente de Invención en el Derecho Venezolano at 100 -101 
628 Article 16 from Ley de Propiedad Industrial from 1955 
629 Sansó, B., ‘Las Patentes de Invención’ at 22 
630 Article 20 from Ley de Propiedad Industrial from 1955 
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to benefit society by taking goods that represent social or public interest.631 This 
action can only be achieved via court ruling and fair compensation.632 
Moreover, goods of public interest have to be defined or highlighted what is to be 
understood for these. In this respect, Article 3 points out that all kinds of goods 
destined to provide the Republic with uses or improvements for the general good 
are to be considered goods of public interest.633 Although the distinction between 
immaterial and material goods susceptible to expropriation is given within the 
legislation, there is no strict mention of intellectual property rights per se. This is 
why it is believed that expropriation of intellectual property rights can only be 
achieved via analogy, and the use of Article 62 foreseeing “goods with some 
artistic value”.634 Moreover, “goods of any kind” could fall within the public 
interest accordingly to the Constitution’s Article 115.635 
Property rights are also governed by the Código Civil (Civil Code – herein CC) 
Articles’ 545, 546 and public utility in Article 547 CC. Article 545 comprises both 
                                                        
631 Ley de Expropiación por Causa de Utilización Pública o Interés Social, Gaceta Oficial Nº 37.475, 
(hereinafter Ley de Expropiación) Article 2 “Expropiation is an institution of Public Law, the State 
acts in benefit of public use and social interest with the goal of forcing a transfer of goods property 
or individuals rights into the States patrimony through noneappealable judgement and fair 
compensation” Original text in Spanish, translation provided by the Author. Articulo 2 “La 
expropiación es una institución de Derecho Público, mediante la cual el Estado actúa en beneficio 
de una causa de utilidad pública o de interés social, con la finalidad de obtener la transferencia 
forzosa del derecho de propiedad o algún otro derecho de los particulares, a su patrimonio, 
mediante sentencia firme y pago oportuno de justa indemnización” 
632 Idem 
633 Article 3 from Ley de Expropiación “Goods providing the Republic in general, one or more of its 
States or territories, one or more municipalities all of those uses and improvements destined for 
general benefit, and shall be excecuted by the Republic, the States, the Capital District, 
municipalities, autonomous institutes, individuals or companies properly authorised” Original text 
in Spanish, translation provided by the Author. Articulo 3 “Se considerarán como obras de utilidad 
pública, las que tengan por objeto directo proporcionar a la República en general, a uno o más 
estados o territorios, a uno o más municipios cualesquiera usos o mejoras que procuren el beneficio 
común, bien sean ejecutadas por cuenta de la República, de los estados, del Distrito Capital, de los 
municipios, institutos autónomos, particulares o empresas debidamente autorizadas” 
634 Article 60 from Ley de Expropiación, “Expropiation of goods with artistic, historical, 
architectonical or archeological value will be done according to the present legislation”. Original 
text in Sapnish, translation provided by the Author. Articulo 60 “La expropiación de bienes con 
valor artístico, histórico, arquitectónico o arqueológico se efectuará de conformidad con lo 
dispuesto en esta Ley.” 
635 Article 115 from Constitución de la República Bolivariana de Venezuela, “Property rights are 
guaranteed. Everyone has the right to use, enjoyment, possession and disposition of its goods. The 
law for public utility or public interest will be subject to such contributions, restrictions and 
obligations imposed on the property. Only for reasons of public utility or social interest by final 
decision and prompt payment of fair compensation, may the expropriation of any class of goods be 
declared. Original version in Spanish translation provided by the Author. Artículo 115. ° “Se 
garantiza el derecho de propiedad. Toda persona tiene derecho al uso, goce, disfrute y disposición 
de sus bienes. La propiedad estará sometida a las contribuciones, restricciones y obligaciones que 
establezca la ley con fines de utilidad pública o de interés general. Sólo por causa de utilidad pública 
o interés social, mediante sentencia firme y pago oportuno de justa indemnización, podrá ser 
declarada la expropiación de cualquier clase de bienes.” 
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exclusivity rights and the benefits given by ownership rights.636 In light of Article 
546, inventions and patentable subject matters fit within the group of goods 
susceptible to ownership and property rights. This article specifically mentions 
products of human ingenuity or derived from a person’s talent are of their 
property and are to be governed by property rights’ laws in general, and those 
especially designed to rule those fields.637 Finally, Article 547CC entails the 
exception in giving away property rights due public utility or social interest, 
which shall be carried out through contradicting trial and previous or fair 
compensation.638 
 
Coming back to the expropriation procedure and its concept, it is important to 
bring to the spotlight the coercive character embedded in an expropriation. Even 
thought property rights are constitutionally protected, these rights are also 
limited to the exception of public or social interest. In this respect Venezuela’s 
jurisprudence acknowledged the Governmental need -under certain 
circumstances - to acquire goods in a coercive manner so as to meet public 
goals.639  Within the discourse, García de Enterría differentiates between public 
utility and social interest; arguing that the first one refers to the Administration’s 
need to use particular goods, whereas the second one refers to any interest 
overlapping the interest of the owner.640 In both scenarios, goods are taken over 
from the owner by the Government to satisfy public interest. 
It has been stressed that the severity of expropriating private rights or goods, 
given that this is a limitation to property rights, and therefore this must be a last 
resort to satisfy public interest.641 The same author addresses that expropriation 
shall not be confused with a sale by means of fair payment; three conditions shall 
be met before actually expropriating. This is a coercive measure taken to solve a 
conflict of interest, thereafter, concurrent elements –public utility, final judgment 
and fair compensation- need to be present prior to public utility or social interest 
declaration.642 
                                                        
636 Article 545 from Código Civil de Venezuela, Gaceta Nº 2.990 Extraordinaria del 26 de Julio de 
1982 (hereinafter Código Civil) “Property is the right to use, enjoy and dipose of something in an 
exclusive manner, with the restrictions and obligations given by Law” Original text in Spanish, 
translation provided by the Author. Articulo 545 “ La propiedad es el derecho de usar, gozar y 
disponer de una cosa de manera exclusiva, con las restricciones y obligaciones establecidad por la 
Ley” 
637 Article 546 from Código Civil 
638 Article 547 from Código Civil 
639 Brewer-Carías, Allan., La Expropiación por Causa de UtilidadPública o Interés Social: 
Jurisprudencia, Doctrina Administrativa, Legislación (Editorial Jurídica Mohigo, Facultad de 
Derecho, Universidad Central de Venezuela, Caracas, 1966) Colección de Publicaciones del Instituto 
de Derecho Público, Vol. 2, 1-416 at 27 
640 García de Enterría, E., and Fernández, T.,Curso de Derecho Administrativo (Segunda Edición, 
Civitas, Madrid, 1988) Vol II, 1-627 at 214 
641 Badell Madrid, R., ‘Limitaciones al Derecho de Propiedad’ in (Artículo publicado en libro 
homenaje a Gonzalo Pérez Luciani "Temas de Derecho Administrativo", 2002) vol. I 
<badellgrau.com/?page=render&params=id%3D11544487022776&menu_id=m-115133237542#> 
accessed 31 October 2011 
642 Ibid 
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Satisfying public interest is the main aim. Therewith, a national health emergency 
would be the sensitive ground to expropriate a pharmaceutical patent or enact a 
compulsory licence if the Venezuelan IP law foresaw this mechanism. 
5.4. Venezuelan Expropriation Procedure and Patent Rights 
Without entering into depth about the expropriation procedure, basic steps643 
must be highlighted. It is important to assess the expropriation procedure not 
only because the current IP Law envisages this procedure as a corrective 
measurement, but also given the current administration’s trend in making use or 
taking over industry and property regardless of the filed as long as its operation is 
deemed necessary for the government.644 
This procedure starts with the public utility declaration, which according to 
Article 13 LEXP is the Assembly or collegiate bodies that are the ones legally 
enabled to do so.645 Generally, the legislation identifies and defines public utility, 
however the pre-requisite of declaring public utility over a good/right is not 
completely necessary when these are defined within LEXP and other special laws’ 
context. Scholars have highlighted that a declaration prior expropriation Decree 
is not completely necessary, provided that both LEXP and Special law –Ley de 
Propiedad Industrial- already foresee goods and rights object to expropriation 
without fulfilling the formal legislative declaration.646 
Continuing with the administrative procedure is the “expropriation decree” per 
se. This step cannot be reached unless there is a legislative declaration of public 
utility as provided by Article 5 LEXP. The expropriation decree is also known as 
the enforcement decree, initiating the administrative procedure by virtue and 
determination of those expropriation goods.647 This formal act brings along three 
denotable effects, which are expropriation procedure concrete start up, 
individualisation and specification of the expropriating goods creating the 
obligation for the owner to transfer property rights to the beneficiary prior to fair 
compensation.648 
On the other hand, Article 5 defines the expropriation decree as the declaration 
stating the execution of works requiring compulsory acquisition of all property or 
several properties.649 
                                                        
643 Article 7 Requisitos de expropiación from Ley de Expropiación 
644 América Económica, ‘Expropiaciones siguen en la Agenda de Venezuela. 
<www.americaeconomia.com/economia-mercados/finanzas/expropiaciones-siguen-en-agenda-de-
venezuela> accessed 10 March 2013 
645 Article 13 from Ley de Expropiación 
646 Larez Martinez, E., Manual de Derecho Administrativo (22th Edition, Venezuela: Exlibirs, 
2001) 478-621 
647 Badell Madrid, R., ‘Limitaciones al Derecho de Propiedad’, 2002 
648 Ibid 
649 Article 5 Ley de Expropiación “E1 Decreto de Expropiación consiste en la declaración de que la 
ejecución de una obra requiere la adquisición forzosa de la totalidad de un bien o varios bienes, o de 
parte de los mismos. Dicha declaración le corresponderá en el orden nacional, al Presidente de la 
República, en el orden estadal al Gobernador, y en los municipios a los Alcaldes.  
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Amicable settlement is also part of the expropriation procedure administrative 
phase. This settlement deems to negotiate the value of the goods to be 
expropriated aiming to reach an agreement between the parties. Given the 
coercive and restrictive character from this procedure, owners have relative 
freedom to settle the price. If a price is not agreed upon, this will be determined 
via judicial ruling.650 
Article 22 LEXP grants thirty -30- continuous days following publication of the 
Decree for the parties involved to come before the expropriating entity. This 
publication will be done only one time in the newspaper of major national 
circulation, and one in the place where the good is located. In this phase, the 
opportunity is given for the parties to agree upon the value via appraisal 
commission that shall also be constituted according to legislative provisions.651 It 
is not clear whether or not the value provided by the appraisal commission will 
also be published within the expropriation decree. What is clear is that the owner 
by accepting a fair compensation amount in this phase relinquishes opposition 
rights to this offer.652 It is important to stress that expropriating goods or 
determined goods does not involve or imply a direct purchase, since these are 
completely different procedures.  
According to the same provision, owners have five working days following the 
notification procedure to either accept or reject the fair compensation offered by 
the expropriating entity. If no agreement is reached over fair compensation, the 
expropriating party is enabled to reach an agreement over the fair compensation 
via the judicial system.653 Fair compensation is an appraisal commission that can 
settle the amount after following strict parameters, which also differentiates this 
procedure from a simple sale.654 
There are two ways to conclude an expropriation procedure, either via amicable 
settlement or pertaining to administrative litigation.655 Either way, property 
valuation by the appraisal commission is necessary. Article 36 LEXP provides 
obligatory elements to take into consideration when valuating the property.656 
Furthermore, Articles 38657 and 39658 foresee brief valuation guidelines for 
                                                                                                                                                        
El Decreto de Expropiación requerirá la previa declaratoria de utilidad pública de conformidad con 
lo establecido en los artículos 13 y 14 de esta Ley” 
650 Brewer Carías,A., La Expropiación por Causa de utilidad Pública, at 69 
651 Article 22, 19 and 20 de Expropiación 
652Badell Madrid, R., ‘Limitaciones al Derecho de Propidad’ at 5.2.3 
653 Article 22 Ley de Expropiación 
654 Badell Madrid ‘Limitaciones al Derecho de Propiedad’ at 4. Características del Instituto 
Expropiatorio.  
655 Brewer Carías, A., La Expropiación por Causa de Utilidad Pública, at 267 
656 Article 36 from Ley de Expropiación 
657 Article 38 from Ley de Expropiación – Valoración de Bienes Muebles (Tangible Assests 
Valuation) “En el justiprecio de bienes muebles que sean objeto de expropiación, se especificará su 
clase, calidad, dimensiones, marcas, tipo, modelo, vida útil, estado de conservación y demás 
características que contribuyan su plena identificación. Los peritos tomarán obligatoriamente en 
cuenta el volor de adquisición; el valor actualizado, atendiendo al valor de reposición y a la 
deprecación normalmente aplicable; los precios medios del mercado para bienes muebles similares, 
y cualesquiera otras circunstancias que influyan en los análisis y cálculos necesarios para realizar el 
avalúo” 
658 Article 39 from Ley de Expropiación 
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both personal property and industries, and goodwill. In cases of taking over 
goods with artistic, historical, architectural or archaeological value these will be 
valuated accordingly with Articles 60 onwards.659 
Legislation and different scholars merge at the point that the amicable settlement 
is exhausted once these 30 days have lapsed, and the acceptance or rejection of it 
was notified. Once amicable settlement has been exhausted the expropriating 
entity will require from the competent court to conclude this procedure, therefore 
transferring the property from the owner to the government. Hence, judicial 
procedure will only start in three given situations: when the party affected is not 
willing to reach any amicable settlement; when the property owners are not 
known; and in cases where taking over the property is of extreme urgency.660 
Three important phases within this judicial part have been identified. The initial 
phase starts by: submitting the expropriation petition before the competent court 
together with the request for those details referred to the property made before 
the Registrar Office where the property is located; a subpoena is given to all of 
those who might have an interest in the property; a written answer is given to the 
mentioned petition, opposition and evidence, relation, reports, rulings and 
appeals. The Intermediary phase is constituted of the agreement and property 
value determined by the appraisers designated by the Court. And the final phase 
is process where the indemnity amount is settled by the Court, effectively 
transferring the expropriated goods/rights or property by registering the 
respective the court ruling.661 
Decision INVERSIONES RIFEBA, S.R.L. contra auto del Juzgado Décimo de 
Primera Instancia en lo Civil, Mercantil y del Tránsito de la Circ. Jud. del Área 
Metropolitana de Caracas by the Sala Político Administrativa, Tribunal Supremo 
de Justicia in 2000, also highlighted the precise moment for the conclusion of the 
expropriation procedure, the one established in LEXP 2002 Article 46 and 
previously 41.662 In this respect the aforementioned provision states that once 
there is proof of indemnity payment to the expropriated owner, the court hearing 
the case will request to provide the interested entity with a copy of the decision 
declaring the expropriation for its formal registration before competent 
authorities, and thereafter requesting formal and effective property transfer from 
the expropriated to the requesting entity.663 
                                                        
659 Articl 60 from Ley de Expropiación 
660 Badell Madrid, R., ‘Limitaciones al Derecho de Propiedad’ at 5.3. El Procedimiento Judicial 
661 Idem Badell Madrid; and See Brewer Carías at 74; and, Seealso INVERSIONES RIFEBA, S.R.L. 
contra auto del Juzgado Décimo de Primera Instancia en lo Civil, Mercantil y del Tránsito de la Circ. 
Jud. del Área Metropolitana de Caracas, Sala Político Administrativa, Tribunal Supremo de Justicia, 
República Bolivariana de Venezuela, Expediente Número 12.699 de fecha 5 de Noviembre de 2000 
<www.tsj.gov.ve/decisiones/spa/Noviembre/02201-151100-12699%20.htm> accessed 14 
September 2013 
662 Idem INVERSIONES RIFEBA, S.R.L. contra auto del Juzgado Décimo de Primera Instancia en 
lo Civil, Mercantil y del Tránsito de la Circ. Jud. del Área Metropolitana de Caracas, Sala Político 
Administrativa, Tribunal Supremo de Justicia, República Bolivariana de Venezuela, Expediente 
Número 12.699 de fecha 5 de Noviembre de 2000 
663 Article 46from Ley de Expropiación“Once it has been provided proof of indemnity payment, the 
court hearing the case will order that a copy of its decision declaring the expropriation to be given 
for its formal registration before the competent office; consecuently it will also be ordered that the 
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Before moving on to the last part of the expropriation procedure, it is important 
to mention some relevant facts related to those three phases within the 
expropriation trial highlighted above. 
The trial will initiate with a petition made by the expropriating entity to the 
competent court.664 But which is the competent court and how shall the 
competence be determined? In this respect Article 23 deems competent for 
hearing the case the Judge in first instance within the Civil Court -Juez en 
Primera Instancia en lo Civil- at the jurisdiction where the good is located; and 
for appeals and remedies the competent court in the second instance is the 
Tribunal Supremo de Justicia -Supreme Court- en Sala Político Administrativa. 
In case of the República being the one requesting the expropriation of a good, the 
competent court in the first instance is the Corte Primera en lo Contencioso 
Administrativo – First Court for Administrative Litigation; and for appeals and 
remedies it is the Tribunal Supremo en la Sala Político Administrativa – Supreme 
Court in Political Administrative Chamber.665 
Once the competent court, depending on the case, acknowledges the case by 
receiving the petition to expropriate determined good/right or property, this 
court then, in accord with Article 26, will subpoena owners, holders, leased, 
creditors and in general everyone having rights over the property intended to be 
expropriated. In accord with the same article, the court shall subpoena within the 
three following working days after receiving the petition, and such notification 
shall be publish three times in one month within ten days in between publications 
in a journal of major national circulation and in one where the good is located. 
Following the subpoena, the parties shall present before the court, either in 
person or represented by proxy, within ten subsequent days to the last 
publication date. If the interest person or his/her proxy does not come before the 
Court, this shall designate a public defender to represent the party in the trial.666 
Anther relevant aspect in the first expropriation trial phase is the right to oppose 
the petition to take over good/right or property. Opposition to the expropriation 
petition shall be formulated by the party when presenting before the court in the 
timeframe given in Article 27. The grounds for opposition are established in 
Article 30 LEXP, that foresees violations to the legal text itself and in cases where 
expropriating part of the good or property will un-utilise it or damage it totally, 
hence expropriating part of it is not possible.667 The party is to provide the court 
with proof of ownership or the rights over the good, and proof that the good 
claimed in the expropriation decree is the same as the one owned by him/her.668 
                                                                                                                                                        
competent authority make effective and formal property transfer to the requesting entity” Original 
text in Spanish, translation provided by the author. Articulo 46 “Consignada la suma o constancia 
de haberse realizado el pago al expropiado, el tribunal de la causa ordenará expedir copia de la 
sentencia que declara la expropiación al que la ha promovido, para su registro en la oficina 
correspondiente y, además, ordenará a la respective autorida del lugar, haga formal entrega del bien 
al solicitante.” 
664 Article 24 from Ley de Expropiación 
665 Article 23 from Ley de Expropiación 
666 Article 27 from Ley de Expropiación 
667 Article 30 from Ley de Expropiación 
668 Badell Madrid, R., ‘Limited al Derecho de Propiedad’ at 5.3.3.1.d. Contestación y oposición 
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Right after the final judgment by the court in the first instance, the party can 
proceed to appeal the ruling and expropriation of the goods in questions before 
the court in the second instance.669 The second phase, as described above, entails 
agreement and the fair compensation. For the present study’s purpose only the 
appraisal will be made reference to due to the relevance in determining a price or 
evaluating patent rights.  
Fair compensation shall be calculated in a manner to compensate the owner for 
loosing the property, but not in a way to neither enrich nor deter his patrimony 
due fair compensation for the expropriated good. In this respect, the purpose of 
Article 36 and onwards has been quoted before, since those provide the appraisal 
commission with guidelines and mandatory elements to take into consideration 
when valuating and appraising the good/right or property. This denotes that 
these are given for real state, goods and personal property but it is not clear 
whether or not LEXP’s guidelines can also be followed for appraising the 
aforementioned patent rights. 
Finally, the third phase concludes the expropriation trial with the fair 
compensation payment. Accordingly, there are two moments when the 
transaction can be achieved, either at the agreement or after the final decision.670 
The appraisal’s commission duty is not limited to estimating the value of the 
good, but also calculating an indemnity amount to compensate the owner for 
further damages directly derived from expropriating his/her property or rights.671 
Article 37, 39 and 41 LEXP refer to cases where indemnity for damages is 
applicable. For all of the cases an indemnity is due for further damages foreseen; 
either permanent damage derived from the property loss or due to diminishing 
rights with the expropriation.672 
In the light of Article 40’s indemnity in cases of permanent loss caused to the 
right holder, it could be argued that patent right holders could get both a fair 
compensation and also indemnity due having their right taken over.  But it still 
remains to determine whether or not valuation guidelines provided by LEXP are 
sufficient to appraise patent or intellectual property rights in general.  
As denoted above, the expropriation procedure brings to the spotlight many 
questions that will be addressed within the summary at the end of this chapter. 
                                                        
669 See idem Badell Madrid, and Article 33 “The timeframe to appeal thos decision from the Court in 
First instance is of five (5) days”. Original text in Spanish, translation provided by the author 
Artículo 33 “ El Término para apelar de las decisions de Primera instancia srá de cinco (5) días” 
670 Idem. 
671 Lares Martínez, E., ‘Los Procecimientos de Expropiación’ in Manual de Derecho Administrativo, 
(12º Edición Actualizada a la Constitución de 1999, Facultad de Ciencias Jurídicas y Políticas de la 
Universidad Central de Venezuela:Caracas, 2001) 9-742, at 611 
672 See further Article 40 from Ley de Expropiación “Habrá lugar a la indmenización cuando a los 
propietarios … sufran un daño permanente que se derive de la pérdida o de la disminución de sus 
derechos.” Modification of the article and translation provided by the author, “In cases of … 
permanent damage cause to the owners or when their rights have been dimished an indemnity will 
proceed to compensate for these” 
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5.4.1. Grounds for Patent Extinction 
As mentioned before, the Venezuelan IP law foresees certain cases when patent 
rights may be recalled or extinguished, specifically in Article 17 a series of 
scenarios justify the extinction of the right. For instance, Patents are left without 
effects in cases of nullity, when voided, non-payment of annual fees, expiration of 
patent protection term and by express resignation of patent rights by the inventor 
or right holders. 
The first case for patent nullity is a due court ruling in favour of a better right.673 
Another case for nullity is due to the fact that patents do not meet essential 
patentability requirements, hence giving Courts enough grounds to rule against 
the right initially granted.674 Article 17(a) provision is also complemented by 
Articles 63 and 66, where both the period for opposing patent claims and the 
right to present a petition to void patent rights before competent courts are 
settled.  
When reading these articles in conjunction, a better right could not only be the 
inventor’s genuine right over the good but also public interest. However, the fact 
that the legislation foresees protection for third parties’ better rights does not 
seem to be either limited to only those cases stated above or clear to what extent 
third party rights could be deterred. In this respect, Article 66 from the IP Law 
from 1955 envisages a period of two years counted from the date the certificate 
was issued. This is perceived as extreme protection to third parties and also 
constituting a limit in itself for patent holders’ legitimacy to exploit their patent 
rights.  
Patent rights should meet a working requirement, which if breached will provide 
grounds to revoke the rights since they will be failing to comply with the non-
working clause within the law.675 
Other cases qualifying for patent nullity as stated in Article 17 are those provided 
in Articles 12 and 21, where the law acknowledges the original inventor’s rights. 
Therefore, any patent claim for improvements or introduction granted to another 
person shall be revoked or voided in the original inventor’s favour.676 And the 
                                                        
673 Article 17 from Ley de Propiedad Industrial “Patents are left without effect: a. nullity due court 
ruling by compente authorities when these are considered to go against the best right of third 
parties; d. nullity in light of articles 12 and 21 from the same law” 
674 Benito Sansó, at 23 
675 Article 17 (c) from Ley de Propiedad Industrial “When the patent holder let pass two (2) years 
from the grant date, without exploitation in Venezuela, or when the exploitation was interrupted for 
an equal period of time, expect in cases of force majour properly proven before the Patent Office, 
patents will be left without effects” Original text in Spanish, translation provided by the author. 
“Cuando el titular de un patente haya dejado transcurrir dos (2) años, contados a partir desde la 
fecha de su expedición, sin explotar en Venezuela el invento que las motivo, o cuando se interrumpa 
la explotaciñon por un tiempo igual, salvo caso fortuito o fuerza mayor, debidamente comprobado 
ante la Oficina de Registro de la Propiedad Industrial;” Aslo see further Benito Sansó “Las Patentes 
de Inveción” at 24 
676 Article 12 from Ley de Propiedad Industrial 
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Ministro de Fomento shall revoke patent rights granted in contravention with the 
law, after proper justification from the Registrar.677 
Venezuelan IP Law envisages local working requirement as grounds to void 
patent rights, as stated above. If a patent has been left without exploitation or 
work for a period equivalent to 2 years, unless force majeure can be proven, the 
Government is entitled not only to take back the patent rights granted but also 
make the information part of the public domain.678 
Loosing patent rights due to unpaid annual fees to SAPI is perhaps the only case 
within the legislation when these rights can be re-enacted or rehabilitated. Article 
19 entails the possibility of reinstating patent rights if the patent holder petitions 
before the Registrar, after payment of annual fees and the fine given by law.679 On 
the one hand, the article envisages suspension of patent rights, and on the other 
opens the possibility to lose permanently patent rights if neither the fine nor fees 
are paid within the period of time given by law. 
Patent rights are extinguished in two cases, either by expiration of patent term 
protection or by express resignation on the inventor’s behalf. Article 17 letters 
e)680 and f)681 foresee in a clear cut manner this extinction of rights, thereafter 
becoming part of the public domain in light of Article 20. 
                                                        
677 Article 21 from Ley de Propiedad Industrial “At all times the Ministro de Fomento, prior 
Registrar’s report, shall revoque patent rights over inventions, improvements, models or industrial 
drawings in a resolution explaining the reasons contraveining the law. Interested parties shall 
appeal before Federal Court within three (3) months from the date the resolution was published in 
Gaceta Oficia” Original text in Spanish, translation provided by the author. Articulo 21 “En todo 
tiempo podrá el Ministro de Fomento, previo informe del Registrador de la propiedad Industrial, 
anular, en Resolución razonada el regitro de los inventos, mejoras, o modelos o diseños industrials, 
obtenidos en contravención a esta Ley. La parte interesada podrá interponer recurso de apelación 
para ante la Corte Federal dentro del lapso de tres (3) meses, contados desde la fecha en que se 
publique la resolución en la Gaceta Oficial.” 
678 See Article 17(c) from Ley de Propiedad Industrial 
679 Article 19 from Ley de Propiedad Industrial “Patent rights left without effect due to unpaid 
annual fees, in light of Article 17 (d), can be reinstated only one time if the patent holder petitions 
its reinstatement before SAPI within a period of three (3) months from the expiration date to pay 
annual fees, and after payment of the debt plus double  the amount. The Registrar will provide the 
patent holder with a certificate reinstating patent rights, and this decision will be publish at the 
Boletín de la Propiedad Industrial” Original text in Spanish, translation provided by the author. 
Artículo 19” La patente que haya quedado sin efecto por falta de pado de una anualidad conforme 
a la letra d) del Artículo 17, podrá ser rehabilitada por una sola vez, si su titular lo solicita ante la 
Oficina de Registro de la Propiedad Industrial, dentro de los tres (3) meses siguientes al 
vencimiento de plazo establecido para el pago de la anualidad, previo pago al Fisco de la cantidad 
adeudada más el doble de la misma. El Registrador otrogará al interesado constancia de la 
rehabilitación y hará la correspondiente publicación en el Boletín de la Propiedad Industrial” 
680 Article 17 from Ley de Propiedad Industrial “Patents will be left without effects (e) when the time 
of protection expires” Original text in Spanish, translation provided by the author. Artículo 17 “Las 
patentes quedan sin efectos: (e) Por el vencimiento del término; y” 
681 Article 17 from Ley de Propiedad Industrial, “Patents will be left without effects (f) by express 
resignation on the inventor’s behalf” Original text in Spanish translation provided by the author. 
Artículo 17 “Las patentes quedan sin efectos: (f) Por renuncia expresa del inventor” 
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Scholars have also suggested as the first case for patent exhaustion, the limitation 
in time of patent rights or in other words once the patent expires the rights are 
exhausted.682 
5.4.2. Grant Procedure and Registration 
The grant procedure as foreseen in Chapter IX from the 1955 IP Law regulates 
everything related to the application, including cases that request patent nullity, 
and void by third parties. Firstly, it can be denoted that patent protection can 
only be applied for by the “real inventor” or those looking to either introduce and 
invention or improvements,683 in accord with Article 58.684 And secondly, Article 
59 begins summarising the requirements to present and to be annexed within the 
patent claim. Among these, special attention will be later on given to the patent 
disclosure.  
Besides presenting the patent claim form, a simple copy of the same form shall be 
presented before SAPI, in which, both basic inventors information such as name, 
address and nationality shall be given, together with a statement certifying that 
the inventor is the “real inventor”. Some other information is also required, but 
thus far the most important requirements deem the novelty of the invention, 
which seems to rely on the inventor.685 On the one hand, global novelty is 
required but on the other, novelty within the Venezuelan territory seems to be 
sufficient. However, this provision seems to contradict the cause for patent 
rejection based on public knowledge either in Venezuela or abroad provided in 
Article 15(9º).  
At a first glance, providing the Registrar with the number, date and place where 
this was granted, does not seem to be enough. The inventor shall also hand in 
legalised Spanish translation of the foreign patent certificate. There with proving, 
the patent is still valid and that protection can be granted for the time before this 
lapses in the foreign country.686 On a second glance, only providing the registrar 
                                                        
682Astudillo Gómez,F., La Protección Legal de las Invenciones: Especial referencia a la 
biotecnología (Colección Ciencias Sociales, Serie Jurídica, 1ra Edición, Universidad de los Andes, 
Mérida – 1995) 1-412, at 121 
683 Article 14 from Ley de Propiedad Industrial 
684 Article 58 Ley de Propiedad Industrial, “Patents for inventions and discoveries within parts 1, 2, 
3, 4, 5, 6, 7 and 8 from Article 14 can only be claimed by the inventor or the one looking to either 
introduce an improvement or a product envisaged in part 9 from the same article 14”. Original text 
in Spanish, translation provided by the author. Artículo 58 “Podrán solicitar patentes los 
inventores o descubridores de los objets a que se refieren los numerals 1, 2, 3, 4, 5, 6, 7 y 8, del 
Artículo 14, y los introductores de las invenciones o mejoras a que se refiere el ordinal 9º del mismo 
artículo citado” 
685 Article 59, 1º (d) Ley de Propiedad Industrial,  “That the object of the invention has never been 
used in Venezuela” Original text in Spanish, translation provided by the author. Artículo 59 (d) 
“Que el objeto de la patente no ha sido utilizado en ningún caso en Venezuela;”  
686 Article 59, 1º(g) Ley de Propiedad Industrial,  “Number, date and origin of the foreign patent or 
source of information necessary when this are not known, in cases of patents for introducing an 
invention” 2º (d) “Patent certificate in a certified copy, legalised and translated into Spanish, in 
case of patent claim for inventions, dicoveries, improvements or models or industrial drawings 
already patented abroad;” and 3º Proof that the foreign patent is still valid and how long before 
the expiration date remains in the country of origin, for those cases when the patent claim verses 
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with the information source in case of not knowing necessary details could687 
pose a problem in term of legal certainty. Perhaps this is the reason the law gives 
a period of two years to claim patent nullity for these kinds of patents. 
In light of those quoted articles within the footnotes, two questions arise from the 
fact that further or complete proof seems to be only necessary in cases of patents 
already granted abroad for inventions, discoveries, improvements, models or 
industrial drawings, but that is not deemed applicable for patents for introducing 
an invention. By this point the legislation once more makes clear the distinction 
between patent types and burden of proof. Hence, in light of these provisions 
further proof is to be provided only in those aforementioned cases; and given that 
the Registrars function is to study the files, this obligation might suffice for the 
verification of foreign information that might not even be in SAPI’s official 
language.  
The patent disclosure is foreseen as an invention’s descriptive memory, that shall 
clearly describe the patentable subject matter in a specific, complete and exact 
way as possible, particularly to manufacture, produce and for the procedure of 
manufacture or composition.688 Just to mention a few cases relevant for the 
pharmaceutical industry. 
Moreover, the Venezuelan grant procedure is without examination unless there is 
opposition. The Administration excludes itself from examining the invention’s 
novelty, utility and industrial applicability unless a third party opposes the patent 
claim. In which case, the Administration will examine the patent claim but only 
with regard to the opposition.689 Some scholars have suggested that Venezuela’s 
grant procedure as stated in the IP Law from 1955 is actually a system of 
attenuated previous examination with call to opposition from third parties.690 
                                                                                                                                                        
over inventions, discoveries, improvements, models or industrial drawings already patented 
abroad.” Original text in Spanish, translation and italics provided by the author. Artículo 59, 
1º(g) “El número, fecha y origen de la patente extranjera o la fuente de información necesaria en 
caso de que ignore esos datos, cuando se trate de patentes de introducción.” 2º (d) “Copia 
certificada, legalizada y traducida al castellano de las letras patentes del país de origen, en caso de 
solicitud de patente para una invención, descubrimientos, mejore o modelos o dibujos industrials, 
ya patentados en otro país;” and 3º “Comprobar que la patente extranjera está vigente y el tiempo 
que falte para vencerse en el país de origen, en caso de solicitud de patente para una invención, 
descubrimiento, mejora, modelo o dibujo industrial, ya patentados en otro país.”  
687 Idem Article 59 1º(g) 
688 Article 59, 2º (a) Ley de Propiedad Industrial, “two descriptive memory copies in Spanish, 
describing in a clear manner the object seeking patent protection, with complete and exact 
specifications from both the operating and methodology to build, make or combine the 
corresponding machinery, manuphacture, material composition, procedure, improvement o model 
or industrial drawingss;” Original text in Spanish, translation and remarks by the author. Artículo 
50, 2º (a) “Una memoria por duplicado y en idioma castellano, en la que describa con la mayor 
claridad, el objeto industrial sobre la cual ha de recaer la patente, con específicación completa y 
exacta de la operación y método de construir, hacer o combinar la correspondiente máquina, 
manufactura, composición de material, procedimiento, mejora o modelo o dibujo industriales;” 
689 Benito Sansó ‘Las Patentes de Invención’ at 31 
690 Uzcátegui Urdaneta, M., ‘El Orden Jurídico Industrial’ in Invención y Patentes de Invención en 
el Derecho Venezolano’ at 95 
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The burden of proof falls with the inventor and/or successors in a subjective 
manner. This happens, as highlighted above, by requiring the part to provide 
proof of being the “real inventor.” Also it denotes how SAPI limits to verify over 
documentation provided without further inquires, unless -as mentioned a few 
times before- this right were to be contested by third parties. 
Other scholars address the grant procedure in the light of the national law as a 
declarative act on behalf of the administration, since this one based on a iuris 
tantum presumption, only recognises or verifies the existing rights from the 
moment the invention was created. This enables the inventor to claim patent 
rights in his/her name, formulate opposition on the basis of his/her better right 
and request nullity action against patents granted to third parties.691 
To a certain extent, part of the aforementioned statement contradicts part of the 
doctrine. Despite being a declarative act on behalf of the administration the 
burden of proof relies on the inventor, since this is the one proving who he is and 
the administrations takes his word for it, as it does not thoroughly verify the 
veracity of these claims.  
The grant procedure involves publication of the decisions. This publication 
should be done via the newspapers of major circulation in the country and for 
three times. Once the three publications are fulfilled, then it will be published in 
the Boletín de Propiedad Industrial- Industrial Property Official Journal.692 The 
period to formulate opposition will begin on the same date as the decision 
publication within the official industrial property journal. The parties will initially 
have 60 days to oppose the patent claim, and then as mentioned before up to two 
years for requesting to null and void patent rights based on misappropriation or 
prior inventor. 
Recognising who the prior inventor or real inventor is, in case of a nullity trial, 
could be complicated especially in cases when the inventor has either transferred 
or forgone his rights to a company that is the one presenting the patent claim 
before SAPI. Even though the real inventor is not the company, by the Law 
foreseeing the possibility for an inventor to relinquish his rights to a company, 
this one is legally entitled to present opposition instead of the inventor.693 
If a patent claim fails to comply with those requirements settled in Articles 49 
and 59, the registrar will return the patent claim to the interested party. Granting 
a 30-day period to solve or comply with missing requirements, this period can be 
extended for up to three months if the Registrar, after petition on the interested 
party’s behalf, considers adequate such an extension.694 
                                                        
691 Astudillo Gómez, F., ‘La Protección legal de las invenciones: Especial referencia a la 
biotecnología’ (Colección: Ciencias Sociales, Serie: Jurídica, 1ra Edición, Universidad de los Andes, 
Mérida-1995) 1-412, at 88-89 
692 Article 60Ley de Propiedad Industrial 
693 Uzcátegui Urdaneta ‘Invención y Patentes de Invención’ at 97 
694 Article 61 Ley de Propiedad Industrial,  “The Registrar shall return patent claims when 
interested parties are not in compliance with Articles 49 and 59 from this Law, a rationale for such a 
rejection shall also be provided. Returning a patent claim accordingly with this Law does not 
extinguish priority rights if the patent claim fulfilling the requirements is presented before a period 
of thirty (30) days from the return date of the claim…. Is the Registrar’s faculty to extend the 
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Following with the legislative analysis, Article 62 points out the cases for denying 
a patent claim. Basically, patents falling out of Article’s 14 and within Article’s 15 
scopes will be denied by the Registrar.695As mentioned before, right after the 
publication and for a period of 60 days, all interested parties may oppose a patent 
claim but they are not restricted to present opposition to this period. Article 63 
read in conjunction with Article 60, gives 19 days in total to oppose a patent, and 
then up to two years as highlighted above for specific cases. In light of Article 63, 
a person may oppose in three cases: first, because he/she considers the invention 
to be non-patentable and not falling within Article’s 15 scope; secondly, because 
he/she was granted a patent abroad;696 and thirdly, because the one opposing the 
patent claim considers to have a better right or to have been the real inventor to 
the one presenting the claim.697 
Once someone has presented opposition, the patent claimant will be informed via 
Boletín de la Propiedad Industrial. This has a period of 15 working days from the 
publication date to come before SAPI and learn about the opposition made to the 
patent claim. Once these 15 working days have expired, another period of 15 
working days will start running for the claimant to respond to the opposition’s 
reasoning against it.698 
                                                                                                                                                        
compliance period for up to three (3) months, previous petition on the interested party’s behalf, 
when the Registrar consideres suitable on a case by case basis” Original text in Spanish, translation 
and modification by the author. Artículo 61 “Si el solicitante no cumpliere cin los requisitos 
establecidos en los artículos 49 y 59 de esta Ley, el Registrador devolverá al interesado la solicitud 
que hubiere presentado, con exposición de las razones en que funde la devolución. La devolución, 
de conformidad con este artículo, no extingue el derecho de prioridad de la presentación, si en el 
plazo de treinta (30) días contados desde la fecha de la devolución, fuere consignada nuevamente la 
solicitud con las correciones del caso … El registrador queda facultado para prorrogar este plazo 
hasta port el término de tres meses, previa solicitud del interesado, cuando a juicio de aquél la 
naturaleza del asunto así lo requiera.”  
695 Article 62Ley de Propiedad Industrial, “When a patent claim is not within Article 14 but within 
Article 15’s  scope it will be denyed by the Registrar, whom shall provide a resolution reasoning the 
basis for denying the patent claim” Original text in Spanish, translation by the author. Article 62 
“Cuando la solicitud no se encuentre comprendida en los casos del artículo 14 o se encuentre 
incursa en las prohibiciones contempladas en el artículo 15 de la esta Ley se negará su registro 
mediante resolución del Registrador en la cual indicará la causa de la negativa” 
696 See Article 11 Ley de Propiedad Industrial 
697Article 63 Ley de Propiedad Industrial, “During the publication period and sixty days after this 
one expires, any person shall object and oppose the patent grant: 1º to consider patent subject 
matter to fall outside of Article 14’s and within ArticleArticle 15’s scopes of patentability; 2º Because 
the patentable subject matter falls within the scope of Article 11; and, 3º Because he/she is the real 
inventor or believes to have a better right that the one who presented the patent claim” Original text 
in Spanish, translation provide by the author. Artículo 63 “Durante el lapso de publicaciones y 
sesenta días después de expirado éste, cualquiera persona podrá objetar la solicitud y oponerse a la 
concesión de la patente: 1º Por considerar que el objeto de la patente no se halla comprendido en 
los casos contemplados en el artículo 14 de esta Ley o que está incurso en las prohibiciones 
establecidas en el artículo 15 de la misma; 2º Por encontrarse en el caso previsto en el artículo 11 de 
la Ley; y 3º Por considerarse el opositor autor del invento o con major derecho que el solicitante.” 
698 See Article 63, second paragraph Ley de Propiedad Industrial, “Opposition will be notified to the 
patent claimant via notice within Boletín de la Propiedad Industrial, for him to come before SAPI to 
learn about the opposition made to the patent claim within fifteen working days from the 
publication date. Once these expires a new period of fifteen working days will start running for the 
claimant to response against the opposition made.” Original text in Spanish, translation provided by 
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In light of Articles 63 and 64, the Registrar is the one who solves the opposition, 
especially when analysing whether or not the inventions falls outside of the scope 
of a protection case, taking into consideration both proof and facts provided by 
the parties and the ones brought to his own attention.699 In this case, and in 
accord with Article 64, the Registrar has the possibility to consult technical 
official bodies and/or experts in the field to solve and determine whether or not 
the invention claiming patent protection really falls outside of the scope of 
protection as formulated within opposition procedure.700 To solve oppositions 
presented regarding better right or infringement of priority rights, the file needs 
to be passed on to the Civil Court in the First Instance who will decide whether or 
not the patent shall be granted or voided.701 
Besides express mention of the Registrar’s limitation to solve opposition for those 
aforementioned cases, there are no further provisions on this procedure. 
Thereafter, those principles embedded in the Venezuelan Civil Procedure are 
applicable to determine available judicial remedies when pursuing a solution. In 
this respect, Article 16 Código de Procedimiento Civil – Civil Procedure Code, 
herein CPC- highlights that civil action can be pursued as long as the interest 
justifies it; and the interest can be limited to determine whether or not certain 
rights or juridical relations exist.702 
Therewith, civil procedure entitles protection of the patent holder’s moral right 
over the invention as follows: it recognises him/her as the inventor; protects 
his/her right to exclude others from freely using the invention by pursuing civil 
actions addressed to void and extinguish patent rights granted wrongfully; and 
allows the inventor to pursue actions strictly linked to the exclusivity of the right, 
or in other words the exclusive right entitles the patent holder to seek remedies 
for the defence of this right.703 Civil sanctions include, monetary compensation 
for patrimonial damages caused to the patent holder,704 moral right indemnity705 
                                                                                                                                                        
the author. Artículo 63, parágrafo Segundo “La oposición se notificará al solicitante por medio 
de aviso en el Boletín de la Propiedad Industrial, para que comparezca a informarse de auélla en el 
plazo de quince días hábiles a contra a partr de la publicación. Vencido dicho plazo comenzará a 
correr un plazo de quince días hábiles para que el solicitante aduzca lo que estime conveniente a sus 
derechos.” 
699 Benito Sansó “ Las Patentes de Invención”, at 31 
700 See Uzcátegui Urdaneta “Sistemas de Concesión” in Patentes y Patentes de Invención en el 
Derecho Venezolano, at 118; and see Article 64 Ley de Propiedad Industrial 
701 Article 63 third paragraph Ley de Propiedad Industrial, “… For the second and third case, the 
Registrar will pass on the file to Civil Court in First Instance to solve the opposition with the proves 
presented before him according to ordinary trial proceedings, while at the same time suspending 
the administrative procedure to grant the patent until the Court reaches a decision and the 
interested party re starts the grant procedure” Original text in Spanish, translation provided by the 
author. Artículo 63, tercer párrafo “ … en el Segundo y tercer caso, el Registrador pasará el 
expediente al Tribunal de Primera Instancia en lo Civil para que éste resuelva la oposición con las 
pruebas que ante él se presentan según los trámites del juicio ordinario, y suspenderá el 
procedimiento administrativo de conseción de la patente hasta que el Tribunal decida y la parte 
interesada gestione nuevamente el asunto.”  
702 Article 16 Código de Procedimiento Civil, Gaceta Oficial N° 4. 209Extraordinaria de fecha 18 de 
Septiembre de 1990 (hereinafter Código de Procedimiento Civil) 
703 Benito Sansó “ Las Patentes de Invención” at 32 
704 Article 1185 from Código Civil 
705 Article 1196 from Código Civil 
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and seizure and destruction706 of those products infringing the patent holder’s 
rights. 
Article 66 LPI reinforce the possibility of a civil trial for up to two years if there 
was no opposition during the time foreseen to do that and if patent rights were 
granted in detriment of third parties rights, as mentioned several times before. 
Once the opposition has passed or met all patentability requirements, a patent 
certificate will be granted and issued in accord with Article 68. This certificate 
shall indicate basic information, most importantly expiration date. Registration 
procedure is dealt with in Chapter XI, Article 92 to 96 where fees owed to SAPI 
are established. All of these need to be read according to newer provisions given 
the change in fiscal unit value. 
Besides having the possibility to solve oppositions via civil courts, the 1955 IP 
Law envisages criminal remedies as well. Chapter XII begins with Article 97 
where reference is made to the penal code’s typified crimes against intellectual 
property. This law also describes and typifies infringements and penalties for 
each of them.  
For patent infringements, according to this IP Law, an infringer faces jail from 
one to twelve months. Expressly manufacture, reproduction, transferring or using 
patented inventions without the patent holders consent will be considered as an 
infringement punishable by law. Hence, introducing criminal sanction 
possibilities as corrective measures. 
Article 104 of IP Law brings to the spotlight the fact that criminal actions can only 
start by petition on the aggravated party’s behalf. Thus, a criminal proceeding will 
rule over the matter, not only establishing the sum due compensation for 
damages but also seizing and destroying illegal goods together with everything 
used to manufacture or to produce them.707 
Scholars have highlighted the importance in determining if the illegal patent 
appropriation by making use of the invention without authorisation was done in a 
manner so as to commercially benefit from it or not. Without having determined 
illegal commercial exploitation, typifying the crime seems difficult; hence, no 
criminal sanction could be applicable. Criminal intent needs to be evident to 
determine the crime. In other words, the will to misappropriate the patented 
good, and have the knowledge about the existence of patent protection are 
needed. This knowledge is assumable by the fact that this protection is of public 
knowledge once it has been published in Boletín de Propiedad Industrial. Thus, 
criminal intent is embedded within the action of the infringer.708 
                                                        
706 Article 1268 from Código Civil 
707Article 105 from Ley de Propiedad Industrial “In every crime ruling establishing intellectual 
property infringments will contain an order to seize and destroy illegal goods and instruments used 
to produce or manufacture them.” Original text in Spanish, translation provided by the author. 
Artículo 105 “En toda sentencia condenatoria por delito contra la Propiedad Industrial se 
ordenará la destrucción de los instrumentos que hayan servido o estuvieren preparados para la 
comisión del delito, asó como los objetos que provengan de los mismos.” See also, Benito Sansó “ 
Las Patentes de Invención en Venezuela” at 34-35 
708 Idem Benito Sansó. 
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Accordingly, patent infringers will either face criminal penalties, or civil sanctions 
shall also be applicable, to compensate for patent holders’ loses. Chapter XIV 
contains transitional provisions addressed to solve questions emerging from 
patent claims caught in the pipeline; in other words, patent applications not 
published or in first and second publication at the time this 1955 IP Law came in 
force.   
 
Articles 108 to 110 established that these patents will be decided on the basis of 
this Law despite the fact that claimants might have had formulated their claims 
having a wider or completely different regime in force at that moment. By 1955, 
this legislation might have had benefited claimants, but if followed for claims 
structured under the umbrella of Andean Community IP Regime the current 
framework might prove challenging. 
5.5. Intellectual Property Regime in Venezuela Prior to the 
Withdrawal from the Andean Community 
Within the National legislation hierarchy there is an important aspect to be taken 
into consideration. That is, the legal framework given by the Andean Community 
(hereinafter ACN) for intellectual property rights and related rights. Before 
moving on to describe the legislation and the challenges brought to Venezuela 
due to its membership of the Andean Pact as it is also known, perhaps it is better 
to start analysing the implications, nature and functions of this organisation. 
The Andean Pact, as originally named, is a sub regional integration organisation 
created in 1969 and its aim was to harmonise policies, define a common external 
tariff, liberalise integration trade, regulate foreign direct investment and organise 
production across member Andean countries.709 Five countries came together 
under the integration organisation aiming to improve its people’s living 
conditions.  
Facing almost a full failure, by 1985 the Andean pact needed to revise its policies 
and readdress strategies to consolidate later on in 1987 as a trade area. The 
Trujillo Protocol of 1996 reshaped the organisation into what it is known today as 
the Andean Community of Nations. This time the emphasis was on open 
regionalism, establishing the Andean Free Trade Zone and the Andean Customs 
Union. During the 90s the organisation’s governance changed, shifting from 
merely trade-oriented policies into a political, social and economic integration 
agreement aiming to achieve similar goals as those from the European Union, but 
on a smaller scale. The country members and initial founders were Bolivia, 
Colombia, Chile, Ecuador and Peru, with Venezuela becoming a member state in 
1973.710 
In accord with the Cartagena Agreement, each country had to sign the agreement 
in full, with no reservations allowed and once deposited in each of the member 
                                                        
709 Creamer, G., ‘Andean Community’Andean Community Journal at 61 
710 Andean Community, Who are we, brief history, <www.comunidadandina.org> 
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states for ratification then it was understood that the Agreement was in force in 
that country.711 
5.5.1. Bodies, Institutions and Jurisdiction 
Another interesting feature of this sub-regional integration organization isthe14 
bodies and institutions constituting it, given that it also entails a division of 
powers.  
The Andean legal order is structured in six bodies and eight institutions. The 
executive, legislative and judicial bodies comprise of the following: the Andean 
Council of Presidents, Andean Council of Foreign Affairs, Andean Community 
Commission, Andean Community Secretariat, Andean Community Court of 
Justice and the Andean Parliament. The financial, integration and educative 
institutions are as follows: the Andean Development Corporation, Latin American 
Reserve Fund, Andean Business Advisory Council, Consultative Council of the 
Indigenous Peoples – it is a consultative body-, Andean Health Body, Simón 
Rodríguez Convention and Simón Bolivar’s Andean University. 
Each of these has delimited functions and competences, but the Andean 
Community Commission and the Andean Community Court of Justice are the 
most important bodies within the organisation. The Andean Community 
Commission is the main policy making body and the Andean Community Court of 
Justice is the judicial body, which has territorial jurisdiction in the four countries 
as well as being the only body that actually can interpret community law and 
settle disputes among member states or derived from community law.712 
5.5.2. Principles of the Andean Community 
The Andean Community’s characteristic principles are to be found within the 
Treaty Creating the Andean Community Court of Justice created in Cartagena on 
28 May1979. Venezuela ratified the agreement in 1983, thereafter coming into 
force 2 January 1984.713 A later Treaty amendment in 1996 named the Protocol of 
Modification of the Treaty Establishing the Court of Justice of the Andean 
Community brought significant changes to the principles, since the member 
states now agree on giving direct implementation to Court Decisions and also 
broader jurisdiction.714 
                                                        
711 Cartagena Agreement final provision 
712Andean Community, Andean Court of justice, comunidad andina.org.  
713 Sáchica, L., Derecho Comunitario Andino, (Segunda Edición, 1990) at 100 
714 Id ut Supra Sáchica, at 98. Previous the amendment Community Law was considered to be 
secondary law in each national framwork, given that decision and resolutions came into force when 
each member found suitable instead of when it was required; there was no uniformity in 
interpreting community law neigther real possibilities to harmonise the system 
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With the amendment to the first treaty, the rules became somewhat clearer 
having as principles direct implementation,715 preferred implementation716 and 
immediate application. 
Direct implementation and direct effect principles, in the words of the Court of 
Justice, are correlated. Thus, community law that has direct implementation 
within member Countries has direct effects on its nationals. This means, that 
once rights and duties are created they enable nationals to claim and feel 
protected by them.717 As a concluding remark, in a different procedure where the 
above was quoted by the Court, it is emphasised that those legal norms becoming 
part of internal legislation are directly applicable with direct effects, given that 
from the moment those are published in the Official Gazette means they are 
binding and immediately implemented by Country Members.718 Moreover, in 
1999 the Court ratified its position regarding the direct implementation principle 
where it is suggested that the sole idea of discussing or analysing community law 
within the context of each national legislation denies the possibility of having 
community law at all.719 Hence, is it inadmissible that Country Members use an 
internal legal framework as an excuse for breaching and not implementing 
Community Law.720 
Preferred implementation is to be found in the Treaty’s Article 4° when it is 
stated that, “Member Countries are under the obligation to take such measures as 
may be necessary to ensure compliance with the provisions comprising the legal 
system of the Andean Community. They further agree to refrain from adopting or 
employing any such measure as may be contrary to those provisions or that may 
in any way restrict their application”721 According to Fabián Novak Talavera, this 
means that a Member Country cannot base its non-compliance with community 
law on having a contrary national framework, because the Member’s duty is to 
                                                        
715 Article 3 from Treaty creating the Court of Justice of the Cartagena Agreement (hereinafter 
Andean Court of Justice Treaty) “Decisions of the Andean Council of Foreign Ministers or of the 
Commission and Resolutions of the General Secretariat shall be directly applicable in Member 
Countries as of the date they are published in the Official Gazette of the Agreement, unless they 
indicate a later date.” 
<www.comunidadandina.org/ingles/normativa/ande_trie2.htm> accessed 14 September 2013 
716 Article 4 from the Andean Court of Justice Treaty,“Member Countries are under the obligation to 
take such measures as may be necessary to ensure compliance with the provisions comprising the 
legal system of the Andean Community.They further agree to refrain from adopting or employing 
any such measure as may be contrary to those provisions or that may in any way restrict their 
application”  
717 Tribunal De Justicia de la Comunidad Andina, proceso N° 03-AI-96 del 24 de Marzo de 
1997<intranet.comunidadandina.org/Documentos/Gacetas/Gace261.pdf> accessed 14 September 
2013 
718 Tribunal De Justicia De la Comunidad Andina, Proceso N° 07-AI-99 del 12 de Noviembre de 
1999. Original text in Spanish “En conclusión, las normas que conforman el ordenamiento jurídico 
andino, cualquiera que sea su forma (Tratados, Protocolos, Acuerdos, Convenios o Resoluciones) 
son, por regla, de efecto y aplicación directa en todos los Países Miembros desde su publicación en 
la Gaceta Oficial del Acuerdo de Cartagena, lo que significa que son de obligatorio e inmediato 
cumplimiento por los Países Miembros, los órganos del Acuerdo y los particulares.” 
719 Id ut Supra, Proceso N° 07-AI-99 quoting Proceso N° 03-AI-96, at 10-11 
720 Novak Talavera, F., ‘La Comunidd Andina y Su Ordenamiento Jurídico’ in Derecho Comunitario 
Andino(1ra Edición, Pontificia Universidad Católica del Perú:Lima, 2003) 57-100, at 72 
721 Id ut Supra Article 4° from Andean Court of Justice Treaty 
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adapt the internal legislation as to allow community law’s governing principles to 
function as established within the agreement.722 
Immediate application principle within the context of the Andean Community 
refers to the instant entry into force of those resolutions creating rights and 
duties, and rulings from the Court, by mere publication in the Official Gazette 
from the Cartagena Agreement.723 
5.5.3. Challenges and Implications for Venezuela as an Andean 
Community Member 
The aforementioned principles brings to the spotlight the supra-national 
character of the Andean Community, which has also been contested by 
Venezuela, as will be described below. Given the nature of the principles 
described above, it is only natural to assume that the Andean Community is a 
supra national organisation. This can also be inferred due to the transfer and 
giving up - to a certain extent - of some State competences to the Andean Judicial 
Body. Furthermore, the concept of sovereignty had to evolve at least in theory as 
to allow the survival of these sub-regional integration organisations.724 
To assess the impact and inconsistencies when joining the Andean Community, 
the Venezuelan Constitution from 1961 needs to be taken into consideration since 
this was the version in force at that time. In this respect, Article 128725 stipulated 
that before any international treaty could become part of the national legal 
framework, it had to be either sanctioned by the Parliament or approved via 
Presidential Decree, depending on whether or not this dealt with areas reserved 
to the Constitution. In other words, if the foreign framework modifies the 
national legislation then Parliamentary approval followed by its publication 
within the Official Journal was required, as happened with the Cartagena 
Agreement.  This Agreement was approved and published in Gaceta Oficial No: 
1620 01-11-1973. Moreover, the approbatory law within its only paragraph stated 
precisely this: 
Those decisions made by the Cartagena Agreement Commission that modify Venezuela’s 
legislation, or deal with areas assigned to the legislative power, shall be approved by law 
sanctioned by the Venezuelan Congress726 
                                                        
722 Novak Talavera., F.,‘La Comunidd Andina y Su Ordenamiento Jurídico’, at pp 76 
723 Idem Novak Talavera, F., at 78 
724 Pérez Navarro, L., ‘Los Principio Básicos del Derecho Comunitario en la Consitutiones 
Venezolanas de 1961 y 1999’(2000) 5 Aldea Mundo 9, 33- 37 
725 Constitución de la República de Venezuela, enmienda publicadas en Gaceta Oficial Nº 3.357 
Extraordinario publicado el 2 de Marzo de 1984. Articulo 128 “Los tratados o convenios 
internacionales que celebre el Ejecutivo Nacional deberán ser aprobados mediante ley especial para 
que tengan validez, salvo que … la ley atribuya expresamente al Ejecutivo Nacional…” Modification 
and translation by the author. Article 128 “International Treaties and Agreements subscribed by the 
President shall be approve via especial law as for them to have validity, except the cases where the 
area agreed upon belongs to a field reserved by the Consitution” 
726 Gaceta Oficial Nro: 1620 01-11-1973, República de Venezuela, Párrafo Primero del Artículo 
único: “Las decisions de la Comisión del Acuerdo de Cartagena que modifican la legislación 
Venezolana, o sean sobre material de la competencia del Poder Legislatico, requeren la aprobación 
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It is somewhat clear that Venezuela’s Legislative Power was not interested in 
loosing or giving up its competences, which are reserved areas by law of this 
power. Even though the 1961 Constitution within Article 108727 favoured the Latin 
American integration process, committing its recourses in achieving common 
goals, any Treaty or community law required parliamentary approval before full 
implementation.  
Thus, Hildegard Rondón de Sansó develops this theory when highlighting one 
important appeal on the ground of unconstitutionality presented before 
Venezuela’s Supreme Court in 1982.728 This appeal demonstrated both the 
legislator’s discomfort in transferring competences and jurisdiction from the 
national judge to the Andean Court of Justice, and also with community 
legislation to have direct implementation.729 In this respect, Marianela Zubillaba 
de Mejía, highlights that the Venezuelan Corte Suprema de Justicia, with this 
ruling gives evidence to the lack of constitutional framework to guarantee the 
integration process: there is no real competence attribution to communitarian 
bodies or institutions, there is no such thing as communitarian supremacy 
overriding national controls to approve community law and there is no direct 
implementation principle established within the constitutional framework.730 
Following the discussion about impossibilities for community law to have direct 
implementation in Venezuela, Brewer Carías highlights that after the Supreme 
Court’s aforementioned ruling all decisions related with the Cartagena’s 
Agreement Commission having an impact on inland legislative areas needed 
approval via formal law by the Congress. Also he points out that those which were 
not approved did not have any validity in the country, in accordance with national 
law, in practice until 1992,731 such as Decisions 85 and 311 related to community 
IP regime. 
A shift in favour of the integration process became noticeable from 1992 onwards, 
when as it will mentioned below, the President began approving community law 
by ordering its immediate publication in Gaceta Oficial without the need for 
                                                                                                                                                        
mediante Ley del Congreso de la República” Original text in Spanish, translation above by the 
author 
727 Constitución de la República de Venezuela, enmienda publicadas en Gaceta Oficial Nº 3.357 
Extraordinario publicado el 2 de Marzo de 1984. Articulo 108 “La Republica favorecera la 
integracion economica latinoamericana. A este fin se procurara coordinar recursos y esfuerzos para 
fomentar el desarrollo economico y aumentar el bienestar y seguridad communes.” Translation by 
the Author. Article 108 “The Government will give prority to the Latinametican economical 
integration. Therefore, efforts and coordination of resources will be assigned as to promoto 
economic development,  and increase both well-being and common safety” 
728 Rondon de Sansó, H., El Régimen de la Propiedad Industrial (Editorial Arte, Caracas: 
Venezuela– 1995) at 24 
729 Pérez Navarro, L., ‘Los Principios Básicos del Derecho Comunitario’ at 33-37 
730 Zubillaga de Mejía, M., ‘Sentencia del Caso José Andueza vs. Ley Aprobatoria del Acuerdo de 
Cartagena’ in 61 Revista de Derecho Público62(Editorial Jurídica Venezolana –Caracas:Venezuela, 
1995) 519-522 
<www.ulpiano.org.ve/revistas/bases/artic/texto/RDPUB/61-62/rdpub_1995_61-62_519-522.pdf> 
accessed 14 September 2013 
731 Brewer Carías, A., ‘Implicaciones Constitucionales del Proceso de Integración en la Comunidad 
Andina’ Estudio para el Proyecto del Instituto de Estudios Internacionales (IDEI) de la Pontificia 
Universidad Católica del Perú, Perú, 2002. 
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Congress approval; i.e. Decisión 313 - Régimen Común sobre la Propiedad 
Industrial.732 
Furthermore, in 1997 within Proceso N° 03-AI-96 that dealt with import barriers 
on coffee from Colombia, it addressed the breach of the Cartagena agreement by 
Venezuela.  In this case the Andean Community Court highlighted that Article 27 
from the Agreement creating the Court recognised the supremacy of community 
law over any national law, since otherwise the idea of having a “Community” is 
just inadmissible and continued defining the transfer of powers from the national 
judge to community judge for all matters related to community interests.733 Thus, 
amending the national constitution was deemed necessary as highlighted by some 
scholars.734Finally, in 1999 Venezuela’s Constitutional framework was amended 
in favour of the integration agreement. Article 153 specifically grants direct 
implementation of community law within the national framework.735 
5.6. Andean Intellectual Property Regime 
Intellectual property rights, as for any other integration agreement, played an 
important role within the life of the Andean Pact. Thus, as early as 1971, the first 
community IPR regime came in force, specifically “Régimen Comunitario de 
Tratamiento a los Capitales Extranjeros y sobre Marcas, Patentes, Licencia y 
Regalías.”736 Accordingly, the Cartagena Agreement aimed to achieve in specific 
periods of time diverse agreements, but these goals were not met, except in the 
case related to IPR where article 27 from the agreement specifically draws a 
deadline for such a regime to be published and implemented by its member 
states.737 This regime is deemed emblematic, given that regulated specific areas 
                                                        
732 Idem, and Seealso Gaceta Ofical N°4.284 from 28 June 1992 
733 Pocreso N° 03-AI-97, original text in Spanish “a propósito de la interpretación del artículo 27 del 
Tratado del Tribunal, al considerar que para la existencia del derecho de la integración es 
indispensable el reconocimiento del principio de supremacía o prevalencia sobre el derecho interno 
de los países miembros; la misma sentencia define el tránsito de la competencia reguladora 
nacional hacia la comunitaria en los asuntos cuya decisión corresponde a esta última, como el 
desplazamiento automático de competencias, que pasan del legislador nacional al comunitario.” 
734 Zubillaga de Mejía, M., ‘Sentencia del Caso José Andueza’, at 520 
735 Constitución de la República Bolivariana de Venezuela, Gaceta Oficial del 30 de Diciembre de 
1999, Nº 36.860. Article 153 “those legal norms adopted within the frame of international 
agreements will be considered as integral part of the national legal system, having direct and 
preferred implementation into national legislation” Original version in Spanish, translation 
provided by the author. Articulo 153: “…Las normas que se adopten en el marco de los acuerdos de 
integración serán consideradas parte integrante del ordenamiento legal vigente y de aplicación 
directa y preferente a la legislación interna.” 
736This was the first community IPR regime for the Andean Pact and besides IPRs also dealt with 
foreign investments as derived from its name in Spanish. “Foreign Capitals and trademarks, 
Patents, Licenses and Royalties Common Regime” also known as Decision 24. 
737Articulo 27 Cartagena Agreement “Before 31 December 1970 the Commission, by the Board’s 
mandate, shall approve and consult with member states a community regime for Foreign Capitals, 
trademarks, Patents, Licenses and Royalties. Each Member State commits in implementing and 
amending its internal legislation within a six months from the approval of such regime, as for this to 
become in practice” … “Antes del 31 de diciembre de 1971 la Comisión, a propuesta de la Junta, 
aprobará y someterá a la consideración de los Países Mienbros un regimen común sobre el 
tratamiento a los capitals extranjeros y entre otros, sobre marcas, patentes, licensia y regalías. Los 
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are based on international criteria for transfer technology contracts and licences. 
Thus, the use of foreign brands and technology transfer sought to develop the 
national manufacture industry that represented national capitals, instead of 
foreign capital developing other industries such as oil and mining.738 
Following Andean Community Decisions, they aimed to harmonise the standards 
of protection while at the same time complying with international ones. Several 
decisions have been enacted since the birth of this organisation, but for the 
purpose of this work, only those relevant during Venezuela’s membership will be 
taken into consideration. Focus in particular will be on Decision 486, which was 
in force at the time of the withdrawal, and the current applicable IP Law from 
1955. 
The Rules for the implementation of the Norms of Intellectual Property  - 
Reglamento para la Aplicación de las Normas sobre Propiedad Industrial – also 
known as Decision 85 which were enacted by the Cartagena Agreement 
Commission in extraordinary sessions from 27 May – 5 June 1974, despite the 
fact that this had to come into fore within a period of six month in Venezuela, 
Decision 85 was never implemented.739 Accordingly, this decision modified 
substantially the internal IP regime and required changes to both legislative and 
administrative structures. Furthermore, economic sectors closely related to the IP 
sector seemed to have played an important role, since allegedly their patent rights 
were affected in a negative manner due to controls and limitations to work with 
them, and together with the crisis itself within the Andean Pact structure, they 
were determinant factors in Venezuela is regarding this Decision’s 
implementation.740 It must be remembered that the Andean Pact faced a period 
of uncertainty during the 70s, among many things, due to Chile’s withdrawal and 
the slowness in regulating the integration procedure itself.741 
In 1991 the Andean Commission reformulated the intellectual property regime 
first in Decision 311, which was never published in Venezuela even when 
elaborated in Caracas on 8 November 1991,742 and then in Decision 313.  
5.6.1. Andean Community Decisions 313 
The latest community regime settled in Decision 313, enacted by the Andean 
Commission on 12 December 1991 superseded Decision 85. Accordingly, this 
binding resolution should have been immediately implemented in each country 
                                                                                                                                                        
Paíces Mienbros se comprometen a adoptar las providencias que fueren necesarias para poner en 
práctica ester égimen dentro de los seis meses siguientes a su aprobación por la Comisión” (Datos 
del acuerdo agregar) 
738 Kresalja Rosselló, B., ‘La Política en Materia de Propiedad Industrial en la Comunidad Andina’ 
Separata del Libro Derecho Comunitario Andino (Lima: Perú – 2003) at 241 
739 Rondón de Sansó, H., ‘La Decisión 313 de la Comisión del Acuerdo de Cartagena y el Régimen de 
Propiedad Industrial’ (Caracas-1993) 13- 190, at 22 
740 For further insight about the rationale behind Decision 85 non-implementation in Venezuela, 
see Rondón de Sansó, H., La Situación Actual de la Propiedad Industrial: Venezuela-Noviembre 
2008 (Editorial Litoformas, Caracas-2008) 1-266, at 23-24 
741 Rondón de Sansó, H., La Situación Actual, at 24 
742 Hildegard Ronsón de Sansó, El Régimen de la Propiedad Industrial (Editorial Arte, Caracas – 
1995) 1-401, at 39 
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member once published within the Official Journal of the Agreement. However, 
the government did not acknowledge the Andean mandate and instead of 
approving it via formal law or approbatory decree, it was published in Gaceta 
Oficial N° 4.457 Ext. del 5 de Agosto de 1992.743 
This brings to the spotlight a disparity in the criteria used when implementing 
community law. On the one hand, parliamentary approval is required, but on the 
other this decision was approved de facto since its publication was ordered 
without following the normal approval procedure. Hence, giving legal effects 
inside the country. In other words, and following Hildegard Rondón de Sansó’s 
line of thinking, there was no clear understanding about the implications for the 
country in implementing community legislation even though some jurists moved 
forward petitioning for an unconstitutional action before the Supreme Court, as 
highlighted above. 
Andean Community Decision 313 is of particular interest for the pharmaceutical 
industry in Venezuela. Following the discussion on the supranational character of 
this organisation, the community regime supplemented the IP Law from 1955, 
which was restrictive in terms of patentable subject matters. Hence, the 
progressiveness embedded within the intellectual property regime recently 
established envisages in Article 7, part (d), the non-patentability of those 
pharmaceutical products included on the WHO list of essential medication.744 
A shift in policy criteria was evident between the IP Law from 1955 and the 
regime in Decision 313. Several aspects are worth mentioning: patentable subject 
matter; non-patentable subject matters; and patent ownership, term of protection 
and the compulsory licensing regime. Inventions, discoveries and improvements 
on those previously highlighted were worthy of a patent certificate in accord with 
Article 1° and 2°745 from the 1955 law. Thus, Decision 313 introduced 
patentability requirements746 - industrial applicability, novelty and innovative – 
needed for an invention to obtain patent protection, which were not present 
within the previous national system.  
                                                        
743 Rondón de Sansó, La Situación Actual, at 26 
744 Acuerdo de Cartagena, Decisión 313, Article 7 Non-patentable subject matters; (d) “…Inventions 
related to pharmaceutical products listed within the Essecial Medication List from the WHO…”, 
Original version in Spanish, translation provided by the author. “Articulo 7 No serán Petentables: 
(d) Las invenciones relativas a productos farmacéuticos que figuren en la lista de medicamentos 
esenciales de la Organización Mundial de la Salud;y,” 
745 Article 1 from Ley de Propiedad Industrial “This Law regulates inventors, discoverers and those 
introducing the creations, rights over creations, inventions or discoveries related to the industry; 
and producers, manufacturers or merchants rights over phrases or special sings used to distinguish 
their works from similar ones.” and Article 2: “The State will provide certificates of registration to 
trademark, slogan and commercial denomination owners, and patent certificates to owner for 
inventions, improvements, models and industrial drawings, and to those introducing inventions or 
improvements also registered.” 
746 Decision 313 – Regimen Común Sobre la Propiedad Industrial, Comisión del Acuerdo de 
Cartajena, Articulo 1° Member Countries will grant invention/product patents for inventions with 
industrial applicability, novelty and innovatieve. Original version in Sapnish, translation provided 
by the author. Articulo 1° Los Países Miembros otrogarán patentes de invención a las creaciones 
susceptibles de aplicación industrial, que sean novedosas y tengan nivel inventivo”  
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The second aspect to be mention relates to non-patentable subject matters, which 
in light of the IP Law from 1955 extended to all kinds of medicines and 
formulations, reactions and chemical combinations.747 This is in contrast to 
Article 7 (d) from Decision 313 that limits the scope to solely the medicines listed 
within the List of Essential Medicines – WHO. This provision could be seen as a 
ground-braking one, given that developing countries could benefit from limiting 
the scope of protection for determined medicines without completely banning 
medicines’ patentability. The third shift related to patent ownership, which 
substantially varies from one framework to another. Within the IP Law from 
1955, ownership was given by assumption to the person in whose name the patent 
was registered.748 In contrast, Decision 313 in Article 8, establishes the possibility 
for legal or natural persons to claim ownership over an invention, but 
nevertheless patent rights belong to the inventor or its successor.749 
The term of protection is another aspect worth mentioning, since it varies from 
the national to the community one. In the light of Article 9 of the IP Law from 
1955, patent protection will be granted for a period of up to 10 years, whereas the 
term of protection in Decision 313 is extended to 15 years with the possibility to 
prolong  it for another 5 years. 
Another interesting feature brought by Decision 313 was the possibility to grant 
compulsory licences in determined cases, whereas the IP Law from 1955 omits 
this legal mechanism to correct competitive practices or solve national crises.750 
In the light of the national law, not working a patent for a period of two years 
following patent grant will give enough grounds for the revocation of patent 
rights, but in Decision 313 a compulsory licence not only corrects the situation 
but also has a wider window of opportunity to work the patent in terms of time – 
3 to 4 years depending on the case.  
One particular point of interest in this Decision is the protection for 
pharmaceutical products. In an attempt to reach a resolution that would please 
both the pharmaceutical industry and the national pharmaceutical industry,751 
Decision 313 included two provisions destined to protect patent rights and access 
to medicines. Article 7 (b) excluded from patentability those inventions related to 
pharmaceutical products listed within the WHO charter of essential medicines, 
and the third transitional provision leaves to the discretion of each country 
member whether or not to exclude pharmaceutical products from patentability, 
even when these are not listed.. Accordingly, the patent will be prohibited for a 
                                                        
747 Article 15, ord 1° from Ley de Propiedad Industrial 
748 Article 3º from Ley de Propiedad Industrial 
749 Dec. 313, Article 8º “Either legal or natural persons are entitle to patent ownership. However, 
patent rights belong to the inventor or its successor” Original text in Spanish, translation provided 
by the author. Articulo 8º “ Los titulares de las patentes podrán ser personas naturales or jurídicas. 
El derecho a la patente pertenece al inventor o a su causahabiente” 
750 See Article 42 from Decision 313 
751 Rondón de Sansó, H., highlights the efforts from the “Junta de la Comisión del Acuerdo de 
Cartagena” in providing an obscure an complicated Decision that pleases both the pharmaceutical 
industry and the national pharmaceutical industry. Each side of the industry lobbied in its 
favour::the generic did not agree with the protection of pharmaceuticals since it did not have to pay 
for royalties, and the pharmaceutical industry stressed the need to protect their inventions. For a 
better insight, see Rondón de Sansó, Hildegard, “La Decisión 313 de la Comisión del Acuerdo de 
Cartagena y el Régimen de la Propiedad Industrial” (Caracas-1993) 1-190, at 51-52, 97 
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maximum period of 10years after the Decision came into force, or the time 
established in the national law, not later than the 15 February 2002.752 
From the aforementioned transitional provision it is important to highlight the 
complementary character given to national law, in this case, to Venezuela’s IP 
Law from 1955. On the one hand this law is considered as complementary to the 
rules settled in Decision 313. But on the other, and given the nature of Decision 
313, scholars have suggested that this abrogates national law since it establishes 
lower standards of protection than those provided in the Andean framework. In 
this respect, Rondón de Sansó, stresses that even though the national law coexists 
with community law, if there are provisions colliding with one  another then 
community law prevails over national law, therefore abrogating it.753 
Decision 313 contradicts the national patentability threshold, particularly in the 
field of pharmaceutical patents. The IP Law from 1955 specifically prohibits 
patents for these kind of inventions, hence, the contradiction and the 
supplementary character of community norm suggests that the standards of 
protection were those of Decision 313 and not the national law. Given this issue’s 
complexity, the then President by virtue of Article 190 part 10 from the 
Constitution regulated in Decreto N° 2.887 the Decision itself.754 However, this 
legal framework swiftly changed into Decision 344, reforming the IP system. 
5.6.2. Andean Community Decision 344 
After regulating on 15 April 1993 the Decision 313, later that year on 20 October a 
new reformulation on the community intellectual property regime was 
announced and published in the Official Journal of the Cartagena Agreement. 
Decision 344 only regulates the IP system in general; specific provisions, namely 
the Common Provisions on the Protection of the Rights of Breeders of New Plant 
Varieties, were given in a separate framework, Decision 345 that will not be 
analysed within the present work.   
As with the previous decision, this one is part of a particular kind of law that 
implies direct and immediate application under a Constitutional framework that 
requires parliamentary approval.755 So far there are no clear answer on this 
matter; it has been argued that the important thing is to determine whether or 
not the law approving the Cartagena Agreement per se continues in force in 
Venezuela –at that time, 1995- or if the reform and posterior approval of the 
Agreement Protocol abrogated the last one.756 
Despite the constitutional discussion, as established before, community law 
should be of preferential application in all country members. In this respect, 
Rondón de Sansó, stresses the importance of those “complementary provisions” 
contained within the Decision 344 itself. These, in Article 144, refer to national 
                                                        
752See Disposición Transitoria “Tercera,” Decisión 313, 6 February 1992, published in Gaceta Oficial 
de la República de Venezuela N° 4.457, Extraordinario del 5 de Agosto de 1992.  
753 Rondón de Sansó, Hildegard, ‘La Decisión 313 de la Comisión del Acuerdo’,at 37-40 
754 See Rondón de Sansó, H., El Régimen de la Propiedad Industrial: Con especial referencia a la 
Decisión 344 de la Comisión del Acuerdo de Cartagena (Caracas-1995) 1-401, at 50-52 
755 See Article 139 from Constitución de Venezuela from 1961 
756 Rondón de Sansó, H., El Régimen de la Propiedad Industrial, at 88 
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law for those cases not regulated in the community framework, such as 
determining which is the competent office to deal with intellectual property 
rights. “National Competent Office” and “National Competent Authority” are 
defined, even though the previous provision is not to be found in the 
complementary provisions, but only on the final provision from the Decision.757 
This new reform began aligning with the minimum standards of protection that 
were later on settled in TRIPS. Thereafter, it is important to briefly assess the 
main differences between Decisions 313, 344 and IP Law from 1955 so as to 
provide a broader picture on the improvements or this ’framework’s evolution 
under the Andean Community umbrella. 
Both Decision 313 and 344 fail to provide a concrete definition for the term 
“invention;” in other words, there is neither a specific glossary of terms nor an 
article defining what constitutes invention per se. In this respect, scholars suggest 
as inventions those human creations that develop new products or processes 
destined to operate in the state of the art.758 
The IP Law from 1955 also fails to provide such a definition, and instead a list of 
patentable and non-patentable subject matters is provided. Within the three 
legislations analysed so far, there are important differences. In Article 1 from 
Decision 344 it is expressly stated that member countries shall grant patents for 
inventions, both products and processes, in all fields of technology as long as 
these are new, involve an inventive step and are industrially applicable. Whereas 
Decision 313, Article 1 limits member countries to granting patents for “creations” 
industrially applicable, that is novel and involves an inventive step. Moreover, 
Article 2 specifically foresees patent protection for inventions, improvements, 
models or industrial drawings and introduction of improvements and inventions.  
However, it has been argued the fact that discoveries are also patentable in the 
light of the IP law from 1955, which contradicts in the first instance Article 6 from 
Decision 344, where these are expressly non-patentable subject matters. Astudillo 
Gómez suggests the use of the word discovery as a synonym for inventions within 
the Venezuelan law. In this regard, the scholar proposes to accept that inventions 
withhold discoveries of not known scientific facts, which are or not transformed 
into an invention due to human intervention. Therefore, both concepts 
complement each other and could have the same conceptual value if industrial 
applicability is proven.759 
                                                        
757 This is an express case of community law referring to national law, as perhaps to avoid 
overlapping national competences. Therefore, determining national competences, entities and 
bodies relies solely in national law, in this case the IP Law from 1955. Accordingly the national 
competent office is SAPI or the National Registration Office, as known in the past, and the national 
competent authority is the Ministry of Development – Ministerio de Fomento- nowadays Ministry 
of Commerce – Ministerio del Poder Popular para el Comercio. See Decision 344, Dispocision Final, 
Unica.  
758 Rondón de Sansó, H., El regimen de la Propiedad Industrial, at 125. According to the scholar, 
the aforementioned concept can be deducted from the Decision itself and the articles listing 
patentable and non-patentable subject matters 
759Astudillo Gómez, F., La Protección Legal de las Invenciones: Especial referencia a la 
biotecnología (Colección Ciencias Sociales, Serie Jurídica, 1ra Edición, Universidad de los Andes, 
Mérida:Venezuela, 1995) 1-412, at 43-48 
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Another important difference between the Decisions and the national law relates 
to the term of protection, which significantly varies from one to the other. The 
Venezuelan law grants from 5 to 10 years of protection depending on the 
inventions and the owners request, Decision 313 granted 15 years of protection, 
and Decision 344 in Article 30 now grants 20 years of protection following the 
filing date.760 
The starting point for the term of protection established in the Andean 
community framework differs from the one settled in the IP Law from 1955. Both 
Decision 313 and 344 start counting the term of protection following the filing 
date, but the national law starts computing it from the moment the patent 
certificate has been granted. 
In relation to the compulsory licensing regime, both Decisions provide somewhat 
clear terms for sanctioning patents. Ultimately, in cases of national emergency, 
member countries shall grant via patent offices compulsory licences for the 
necessary period of time. Perhaps Decision 344 in Article 46761 is more precise in 
delimiting terms and conditions for such a licence than Decision 313 Article 42. 
Nevertheless, the Andean framework envisaged a compulsory licensing regime to 
solve both anti-competitive practices and national emergencies, whereas the 
national regime entails expropriation of patents to correct these issues. 
5.6.3. Andean Community Decision 486 and the TRIPS Agreement 
As is widely known, in 1994 Uruguay achieved the Agreement on Trade Related 
Aspects of Intellectual Property, ratification and implementation that became 
compulsory for all those member countries wishing to accede the World Trade 
Organization.  
The Andean Community of Nations, following the minimum standards of 
protection settled within the TRIPS Agreement, reformulated its common 
intellectual property regime, providing member countries with Decision 486 
published in the Official Journal of the Cartagena Agreement in 19 September 
2000.  
Accordingly, Decision 486 came into force on the 1 December 2000.Thereafter, 
member countries came into compliance with the TRIPS Agreements in the same 
year. Scholars have denoted as an interesting fact the prompt compliance on 
behalf of this organisation integrating five developing countries.762 Initially, least 
– developed countries had 10years to come into compliance, and developing 
                                                        
760 Decision 344, Article 30: The patent shall have a term of 20 years following the filing date of the 
corresponding application. 
761 See Decision 344, Section VII – Licensing Regime,  
<www.sice.oas.org/trade/junac/decisiones/Dec344e.asp> accessed 20 February 2012 
762 Even when the scholar makes reference to the transitional period given to least-developed 
countries, according to the United Nations countries classification, no Andean Country member is 
listed within the least-developed nations at the U.N. Therefore, the applicable transitional period 
allowed was of 4 years instead of 10 years, unless as a developing country complied with Article 65 
part 4 extending the transitional period for an extra 5years. See, Mogollón-Rojas, I., ‘The New 
Andean Pact Decision No. 486 on the Common Industrial Rights Regime’ (2001) 4 The Journal of 
World Intellectual Property, 549-555 at 550 
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nations had one year to comply after the WTO Agreement came into force,763 
unless the member country was “in the process of transformation from a 
centrally-planned into a market, free-enterprise economy and which is 
undertaking structural reform of its intellectual property system and facing 
special problems in the preparation and implementation of intellectual property 
laws and regulations” in which case Members could benefit from a transitional 
period of 4years.764 Extensions to this initial transitional period could be taken on 
the basis of Article 65 (4), therefore allowing another 5 years to come into 
compliance with the aforementioned legislation. Whether or not member 
countries made use of this advantage to extend the transitional period, Andean 
Community Decision 486 ratified the possibility in claiming patents for products 
and processes in all fields of technology, as Decision 344 previously did. 
Neither IP Law from 1955 nor community Decisions define inventions or patents 
for inventions. In all cases an enumeration on patentable subject matters and 
types of patents provide users, in between lines, with the concept for patent for 
inventions. In this respect, Astudillo Gómez suggests the former are certificates 
expedited by the Estate granting exclusive rights for a determined period of time 
to its inventors or right holders.765 The term of protection between this Decision 
and superseding one remains 20 years from the application date. Important 
differences are found within the national and the community framework, with the 
local one as also denoted above, granting 5 to 10 years of protection following the 
patent certificate and not from the filing date as granted in Decision 486. 
The Common IP Regime follows the International Patent Classification 
established in 1971 by the Strasbourg Agreement Concerning the International 
Patent Classification, together with its effective amendments.766 Perhaps another 
important difference, given the consequences derived from it, refers to both the 
timeframe to work a patent and cases where failing to do so will not cease patent 
rights. Accordingly, the national law in Article 17 (c) foresees as justifiable cases 
where the patent holder effectively proves force majeure as the rationale behind 
not working the patent in those 2years from the time the certificate was granted. 
Instead, Decision 486 defines in Article 60 what is to be understood as the 
working requirement, which can also be fulfilled by importing, distributing and 
commercialising the product in a sufficient manner to satisfy national market.767 
The local working requirement is directly intertwined with the compulsory 
licensing regime established within Chapter VII contained in Decision 486.  For 
instance, if the local market has not been supplied with the patented product in 
accord with Articles 59 and 60, any interested third party is entitled to work the 
patent. This prerogative is not de facto; on the contrary, the interested party 
needs to petition the competent authority –patent office- to enact such a licence, 
and the former needs to verify that the patent has not been exploited in a period 
of 3years from the time it was granted or 4years since the application date. On the 
                                                        
763 Article 65 and 66 from TRIPS Agreement, Initially least-developed countries had until February 
2005 to comply with Trips, but later on this transition period was extended until 2016 
764 Article 65(1) and (2) from TRIPS Agreement 
765 Astudillo Gómez, F., La Protección Legal de las Invenciones: Especial referencia a la 
Biotecnología (Universidad de Los Andes – Universidad Gran Mariscal de Ayacucho, 2da. Edición, 
Mérida – 2004) 1-498, at 84 
766 Decision 486, Article 49 
767 See Decision 486 Article 59 and 60 
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other side, the third party needs to prove the efforts in obtaining a contractual 
licence from the patent holder to work the patent.768 
In this respect, the national law is more restrictive given the local working 
requirement must be fulfilled within a period of 2 years, and this needs to take 
place in a determined geographical area, whereas community law allows to take 
into consideration the patent exploitation in not only one of the member 
countries but in all of them. In other words, if the patent product has been 
produced, commercialised or distributed in only one of the Andean countries it 
seems to be enough so as to fulfil the working requirement despite the 
insufficiency in satisfying another Andean country member’s market.  
A striking difference between national and community law refers to the grant 
procedure, in which the national law –as stated above- consists of claims without 
formal examination with call to formulate oppositions; whereas community law 
foresees formal examination769 with preliminary examination770 and call to 
formulate oppositions.771 
The opposition period in both frameworks grants60days following the 
publication within the IP Official Journal, with the only divergence relating to 
those enabled to contest patent claims. Decision 486, Article 42 provides that 
only those with a legitimate interest may contest the application, whereas in IP 
Law from 1955, Article 63 this “privilege” is extended to anyone wishing to 
contest it.  Furthermore, as highlighted within the IP law from 1955 analysis, the 
opposition procedure as provided by that framework is decided either by 
administrative or judicial authorities depending on the nature of the opposition, 
whereas Decision 486 provides administrative authorities, specifically 
“competent authorities within the patent office”, to solve oppositions.772 The 
timeframe when filing for opposition may be extended to 2 years right after the 
patent has been issued. If a third party wishes to oppose such a patent, it can do 
so before a court, possibly leading to invalidating the patent.773 
Patent nullity or invalidating a patent in accord with Decision 486 can be 
declared ex oficio by the national patent office or by third party petition. In either 
of the cases, the motivation behind patent nullity or invalidation can be 
summarised in the cases where patentability requirements are not either met or 
fulfilled, or because these are breached, or because this grant is against public 
                                                        
768 Decision 486, Article 61 
769 Decision 486, Article 38 refers to the time given to the competent authority to examine the 
application, and Article 39 refers to the examination of form or formal examination 
770 Decision 486, Article 44 established that an applicant should request the examination on the 
patentability 6 months after the first publication regardless of any opposition formulated to the 
patent claim 
771 Decision 486, Article 42 allows a period of 60 days following publication for anyone with a valid 
interest to contest (oppose) the patent claim, of course, the rationale for such opposition shall be 
provided. 
772 Rondón de Sansó, La Actual Situación de la Propiedad, at 164 
773 Bazzani, H., and Pacheco, Carlos., ‘Venezuela: What next for industrial property as Venezuela 
leaves the Andean Community’Building and Enforcing Intellectual Property Value 2010 (IP Value 
– An International Guide for the Boardroom, 2010) 105-108 
<www.iam-magazine.com>accessed 2 April 2012 
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order or interest.774 Patent and patent application lapses within this legal 
framework when annual fees are not paid for in the timeframe given in Article 
80.775 In contrast, the national law provides patent invalidation and/or nullity not 
only for unpaid administrative fees, but also when this was granted against a 
better right, which needs to be ruled by a court. 
Besides those aforementioned differences between legal frameworks, the 
compulsory licensing regimes significantly differs from each other, given that 
these are not foreseen within the national framework.  
Accordingly, compulsory licences are not only to correct anti-competitive 
practices. Another important use is to address health emergency crises and/or 
national emergencies. Hence, Article 65 from Decision 486 settles the conditions 
for these to be enacted. Within the Andean regime, a compulsory licence, due to 
public interest –e.g. national emergencies-, will last for as long as the rationale to 
enact it exists, and this provision also stresses the patent holder’s right to keep on 
making use of his/her patent rights while third parties make use of the 
originators right to solve a specific situation.776 
When analysing the national IP law from 1955, it was stated the fact that once 
patent rights are affected with public interest these will be expropriated, and 
passed into the public domain. Under this legal framework, patent holders lose 
patent rights given that once patent rights have been expropriated by the State 
patent owners will no longer be able to produce, distribute or commercialise their 
product regardless of the duration of the national emergency. 
Whereas the Andean Community regime foresees the use of compulsory licences 
for four different scenarios,777 which are not limited to national emergencies, 
namely for breaching the local working requirement, previous declaration of 
national emergency on behalf of a member country, to correct anti-competitive 
practices, and as a necessary element to work a posterior patent. 
5.6.4. Venezuela’s withdrawal from the Andean Community: Legal 
Consequences778 
The Venezuelan Government, on the 22 April 2006, denounced the Andean 
Integration Sub-regional Agreement before the President of the Andean 
Community Commission. Venezuela’s withdrawal from the Andean Community 
was founded on the ratification of the U.S-FTA with Colombia and Peru who are 
still CAN member States. Even though all other Andean Community Members 
did not oppose Colombia and Peru from negotiating such an agreement, 
Venezuela did express its concerns in terms of the impact that this FTA with the 
U.S. would have on the remaining trading partners despite them not having 
                                                        
774 Decision 486, Articles 14,15 and 20 
775 Decision 486, Article 75 – 80 
776 Decision 486, Article 65 
777See further Rondón de Sansó, ‘La Situación Actual de la Propiedad’, at 134-135 
778 Parts of this analysis were also mentioned by Cadillo Chandler, Dhanay; and González Otero, 
Begoña, "Legal Certaity, TRIPS and Venezuela on the matter of patents and trade marks: What has 
happened?” submitted for publication at IIC Journal in February 2012. (Pending acceptance) 
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subscribed to such FTA. In other words, Venezuela feared imposition of higher 
standards of protection by CAN.779 
With the withdrawal, Venezuela aimed at protecting national interests. However, 
this decision brought along a set of challenges that needed to be addressed so as 
to ensure the normal development of subsequent trading operation among the 
former trading partners. Namely, determining the precise time when the link 
between CAN and Venezuela ceased to exist, and if and for how long ACN’s 
framework and binding decisions were applicable in Venezuela once the 
withdrawal was formalised.780 To solve the first question, scholars suggested the 
need to consult, or even apply if possible, the principles set forth within the 
Vienna Convention on the Law of Treaties from 1969. They did, however, stress 
the fact that rules are only applicable as general principles of public international 
law since Venezuela has not ratified its adherence to the Convention.781 
To address the validity timeframe for Venezuela to keep on applying or be subject 
to both ACN framework and binding decisions, it is then necessary to consult the 
Cartagena Agreement (as modified in Decision 406). In this respect Article 153 
provides:  
Any Member Country wishing to denounce this Treaty shall so inform the Commission. 
From that moment on it shall cease to enjoy the rights and have the obligations deriving 
from its status as Member, with the exception of the benefits received and granted in 
accordance with the Sub-regional Liberalisation Programme, which shall remain effective 
for a period of 5 years after the date of the denouncement. 
The time period stipulated in the paragraph above may be shortened in duly 
substantiated cases by decision of the Commission and at the request of the interested 
Member Country. 
Insofar as the Industrial Integration Programmes are concerned, Article 62 paragraph I) 
shall be applied.782 
In light of the Cartagena Agreement, Venezuela was to continue applying Andean 
regulations for a period of 5 years. In accord with the Vienna Convention’s Article 
70.2, applicable to this case because Venezuela was denouncing a multilateral 
treaty and because the Cartagena Agreement did not foresee otherwise, the 
former Andean Community member’s duties and obligations ceased to exist once 
formalising the denouncement procedure. Nevertheless, the rights, obligations or 
legal situation of the parties created through the execution of the treaty prior to 
its termination continue to exist783 for a period of 5 years after formalising the 
                                                        
779 Prensa Vicepresidencia “Texto de la carta donde Venezuela denuncia acuerdo de Cartagena y se 
retira de la CAN” Newspaper <www.aporrea.org/tecno/n76531.html>accessed 9 January 2012 
780 Rondón de Sansó, La Situación de la Propiedad Industrial (Lito-Formas, Caracas 2009) at 78 
 781Ibid Rondón de Sansó at 79 
782 Art. 153 of de Cartagena Agreement: “Any Member Country wishing to denounce this Treaty 
shall so inform the Commission. From that moment on it shall cease to enjoy the rights and have 
the obligations deriving from its status as Member, with the exception of the benefits received and 
granted in accordance with the Sub regional Tariff Reduction Programme, which will remain 
effective for a period of 5 years after the date of the denouncement.” 
783 Vienna Convention on the Law of Treaties from 1969. Article 70: Consequences of the 
termination of a treaty: 1.Unless the treaty otherwise provides or the parties otherwise agree, the 
termination of a treaty under its provisions or in accordance with the present Convention: (a) 
releases the parties from any obligation further to perform the treaty; (b) does not affect any right, 
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withdrawal when taking into consideration the aforementioned Article 153 from 
the Cartagena Agreement. 
The intellectual property rights framework settled within Decision 486 was also 
believed to enjoy those 5 years of validity posterior to the withdrawal. With the 
Memorandum of Understanding (hereinafter M.O.U.)784signed and published in 
Decision 641, the parties committed in applying the Andean regulatory 
framework during the 5 years agreed upon a transitional period in order to 
safeguard trading activities.785 In this respect, the Andean Court of Justice in 
proceeding N° 2-AI-2006 ratified the 5 years period of time given to any country 
member to enjoy and maintain the right to import and export duty and restriction 
free, all those products originated in any of the other members.786 
Decision 486 continued ruling up to 2008, until SAPI published in an Official 
Note, dated 12 September 2008, that Decision 486 was no longer applicable, thus 
re-enacting Venezuela’s IP Law from 1955. The patent office, in principle, has no 
legislative faculties to abrogate and re-enact laws. This de facto shift of regulatory 
frameworks preoccupied Venezuelan scholars and practitioners, since the validity 
of the IP Law from 1955 was questionable. On 5 November 2008, SAPI in Bulletin 
Nº 497 dismissed a petition to suspend the legal effects of the Official Note from 
12 September 2008.787 Before re-enacting the aforementioned law, it was 
important to determine whether or not this IP Law from 1955 had actually been 
abrogated or partially abrogated by Decision 344 and previous ones, since these 
became part of the internal legislation. 
SAPI’s rationale for not overturning its Official Note was relayed in an Andean 
proceeding from 25 May 1988 (Proceso N° 2-IP-88). It argued against the validity 
of Decisions 344 and 486 since the patent office considered that the 
aforementioned framework only temporarily suspended the IP Law from 1955 by 
virtue of the direct and preferment treatment given to the community. 
Furthermore, SAPI also suggested that the implementation of those Decisions 
issued by the Andean Commission788 only derived from an international 
                                                                                                                                                        
obligation or legal situation of the parties created through the execution of the treaty prior to its 
termination. 2. 
784 Memorandum of Understanding – also known as M.O.U.- often sets out operational 
arrangements under a framework international agreement and it can also be used to regulate 
technical or detailed matters. See United Nations, “Treaty Handbook” 55 (United Nations 
Publication, 2006) 
785 SainzBorgo, J., in his article ‘La Salida de Venezuela del CAN’ 30Politeia28, 127-150 seems to 
suggest that this M.O.U subscribed new international obligations for the parties, which in first place 
was not the rationale motivating Venezuela’s withdrawal from the Organisation.  
786 Tribunal de Justicia de la Comunidad Andina, Proceso CAN N° 2-AI-2006 de 13 de Julio de 
2006, Secretaria General de la Comunidad Andina vs. República Bolivariana de Venezuela: Accion 
of  assumpsit (accordingly with common law or civil enforcement action in civil law) for breaching 
the principle of national treatment in terms of import tariffs. 
787 SAPI – Boletín Nº497 
<www.sapi.gob.ve/images/stories/contenido/boletines/Boletin_597.pdf>accessed 9 January 2012 
788 The Andean Community Commission is the main policy making body and the Andean 
Community Court of Justice is the judicial body, which has territorial jurisdiction in the four 
countries as well as being the only body that actually can interpret community law and settle 
disputes among member states or derived from community law. Hence, the binding character 
embedded in all of its Decisions and rulings. See Andean Community, Andean Court of justice 
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obligation which ceased to exist once the Agreement was denounced, thus, could 
not be considered as real law or part of internal law and could even abrogate 
national laws.789 
Even though SAPI quotes a proceeding from 1988 to interpret the principle of 
preferred treatment in community law, this interpretation seems to be erroneous 
for two reasons. Firstly, SAPI lacks the competence to fulfil interpretation tasks, 
and secondly the only authority competent to interpret the principles within the 
Cartagena Agreement is the Andean Court of Justice. However, following 
Venezuela’s withdrawal, SAPI prior to its Official Note continued applying the 
Andean regulation as a referential framework.  
Another interesting fact from SAPI’s interpretation is that the Constitution from 
1999, which was in force at the time of the withdrawal, enshrined direct and 
preferred treatment in an attempt to favour integration processes.790 To 
implement community law it is necessary to have a real transfer of both power 
and jurisdiction to community bodies. Nevertheless, Venezuelan authorities 
seemed reluctant to give up competences, as several court rulings from the 
Supreme Court portrayed previous years.791 
In terms of the Andean Community norm implementation tradition in Venezuela, 
scholars have highlighted a few disparities that could influence one way or the 
other how SAPI interpreted the applicability of Decision 486 after the 
withdrawal. The first resolutions harmonising intellectual property rights were 
Decision 84 and 313, which received presidential approval in 1992 when their 
publication was ordered by the President so as to have immediate effect in 
national law. Nonetheless, Decision 84 was never implemented in Venezuela 
because it was neither sanctioned by the Congress nor approved by the President.  
The challenging issue when SAPI disregarded Decision 486 relates to the legal 
hierarchy involved as it deals with Human Rights. In accord with the Venezuelan 
Constitution’s Article 23, treaties, pacts and conventions on human rights ratified 
by the country receive constitutional status. Intellectual property rights,792 as 
pointed out a few headings above, are enshrined within the Constitution’s human 
                                                        
789 SAPI – Boletín N° 497 
790 Constitución de la República Bolivariana de Venezuela, Gaceta Oficial del 30 de Diciembre de 
1999, Nº 36.860. Article 153 “those legal norms adopted within the frame of integration agreements 
will be considered as integral part of the national legal system, having direct and preferred 
implementation into national legislation” Original version in Spanish, translation provided by the 
author. Articulo 153: “…Las normas que se adopten en el marco de los acuerdos de integración 
serán consideradas parte integrante del ordenamiento legal vigente y de aplicación directa y 
preferente a la legislación interna.” 
791 See, Tribunal De Justicia de la Comunidad Andina, proceso N° 03-AI-96 del 24 de Marzo de 
1997, and also See, Ventata, V., ‘Estudio de la Sentencia Galleries Lafayette’(1993)90 Revista de la 
Faculta de Ciencias Jurídicas y Políticas, 226 – 255 
792 Constitución de la República Bolivariana de Venezuela de 1999. “Article 98° cultural creation is 
free. This liberty foresees the right to invest, produce and divulge a literary creation, a scientific, 
technological and human one, including legal protection for authors over their works. The State 
shall recognise and protect intellectual property rights for scientific, literary and artistic inventions, 
innovations, indications, patents, trademarks, slogans according with the conditions and exceptions 
established by law given by International treaties, related to the topic, ratified and subscribed by the 
Republic.” Translation by the Author. Original text in Spanish. 
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rights chapter, and hence they have a supra-national rank that allows them to 
enjoy direct and immediate implementation.793 
SAPI’s official notice re-instating the IP Law from 1955 contributed to the already 
existing legal uncertainty. Moreover, scholars have not only questioned the patent 
office’s competence to re-instate legislation, but also which is right procedure to 
re-enact the aforementioned IP Law. Two suggestions have been widely 
discussed: on the one hand, it has been argued that only the National Assembly 
should have abrogated Decision 486 by enacting a law reinstating the IP Law 
from 1955.794 Thus, drafting a law that copes with minimum standards of 
protection. And, on the other hand, it has also been argued that regardless of how 
the Andean IP framework was abrogated and the old one reinstated, the new 
legislation should have been drawn up to comply with the minimum standards of 
protection.795  Both suggestions address the issue of compliance with TRIPS since 
Venezuela belongs to the World Trade Organization. The Supreme Court’s 
Appellate Chamber formally dismissed the applicability of Decision 486,796 
portraying the existent division between scholars and the judicial system. This 
court ruling contradicts the transitional period set forth within the M.O.U.; the 
Court highlights that Decision 486 was only applicable for a period of 180 days 
after the withdrawal. Practitioners have emphasised the legal limbo that 
Venezuela’s intellectual property regime has been placed in with this court ruling 
and also by the fact that SAPI continued applying Decision 486 well past the 
aforementioned 180 days.797 
5.7. Can MERCOSUR improve Venezuela’s current Intellectual 
Property system? 
Besides its membership within the Andean Community of Nations, Venezuela 
pursues full membership of MERCOSUR (Mercado Común del Sur – Southern 
Common Market). The Treaty of Asunción, signed on 26 March1991, created this 
integration organisation that was inspired by similar principles settled within the 
European Community. 
                                                        
793 Idem, Article 23: Treaties, pacts and conventions relating to human rights which have been 
executed and ratified by Venezuela, have constitutional rank and prevail over national legislation as 
long as they contain provisions concerning the enjoyment and exercise of such rights that are more 
favourable than those established by this Constitution and the laws from the Republic, and are of 
immediate and direct application by Courts and other organs from the Public Power.  
<www.unhcr.org/refworld/category,LEGAL,,,VEN,4c45ad8b2,0.html>accessed 20 January 2012 
794 Carrascosa de Mena, J.M., ‘Notas sobre la involución en el derecho de marcas venezolano’ El 
Universal 25 August 
2009<www.marcasur.com/es/opinion_resultado.asp?NoNoId=1245>accessed 4 January 2012 
795 Rondón de Sanso, H., ‘Ex magistrada propuso la redacción de ley de propiedad industrial para 
desplazar a Eduardo Samán del Gobierno’ Observatorio Sudamérica de Patentes, 6 September 2011, 
available at: <www.aporrea.org/tecno/n188101.html> accessed 4 January 2012 
796 See Anchor Fasteners, C.A. contra Anclajes Powers, C.A. in Sala de Casación Civil, Tribunal 
Supremo de Justicia, República Bolivariana de Venezuela, Expediente N° 2010-000465 
797see Antequera Parilli, R., ‘Tribunal Supremo de Justicia de Venezuela declara la inaplicaci’on de 
la norma andina en propiedad industrial’ (13 April 2011) Articulos de Estudio Antequera Parilli & 
Rodríguez <www.antequera.com.ve/index.php?mod=articles&exec=detail&id=227> accessed 10 
April 2014 
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Argentina, Brazil, Paraguay and Uruguay founded the organisation based on 
reciprocity, respect for each other’s sovereignty and free market.798 Later on in 
2006 Venezuela signed the Protocol of Adhesion to Mercosur, which comes into 
force in accord with the ratification rules settled in the aforementioned Treaty, 
and Venezuela’s Adhesion Protocol.799 To this date, Paraguay is still pending 
Venezuela’s ratification within the organisation, despite the fact that this country 
has the right to take part in all negotiations and meetings concerning 
MERCOSUR. In accord with the Consejo de Mercado Común (Council of the 
Common Market – CMC), Venezuela was not a full member country until 
recently; therefore it only has the right to be heard, but not to vote.800 
This organisation will not be analysed in depth given that it is not as relevant as 
the Andean Community’s framework, when assessing access to medicines. 
However, it is important to highlight certain aspects related to intellectual 
property rights, specifically patent rights within Mercosur. 
Despite the fact that trade is regulated, and to a certain extent harmonised, 
within the organisation there is not an intellectual property regime conceived as 
in the Andean Community.  In this respect, there are only two Protocols signed, 
but not yet in force, to regulate trade names, appellations of origin and 
denomination of source, and another one regulating industrial drawings.801 
Therefore, patents are left to be regulated by each country’s own legislation, as 
long as the territoriality principle is followed.802 Article 2 in both Protocols 
elaborates on the validity of member countries’ international commitments, 
demanding compliance with the norms and principles settled in both the Vienna 
Convention and the TRIPS Agreement.  Furthermore, MECOSUR Decisions could 
be regarded as Directives from the European Community,803 and provide within 
the first article the commitment on behalf of the member countries to effectively 
protect those intellectual property rights regulated within the protocol, allowing 
at the same time higher standards of protection as long as these do not collide 
with the ones settled in the Protocol. Hence, like TRIPS, they settle minimum 
standards of protection.804 
                                                        
798 Article 1 and 2 Tratado para la Constitución de un Mercado Común entre la República Argentina, 
República Federativa de Brasil, República de Paraguay y la República Oriental de Paraguay 
799 Accordingly, prospective member countries wishing to become full members will do so thirty 
days after the fifth ratification instrument has been deposited. Article 12 Protocolo de Adhesión de 
la Reública Bolivariana de Venezuela al Mercosur, and Article 20 from the Treaty of Asunción 
800See further Reporte del Grupo de Trabajo Ad Hoc, MERCOSUR/V CMC EXT./DI N° 04/07  
<www.mercosur.int/msweb/SM/Actas%20TEMPORARIAS/CMC/V%20ext%20CMC%2001%20_
%2007/AnexoVI_InformeGT-VENE.pdf>accessed 20 December 2012.See also footnote 2 at the 
document XXXVI REUNIÓN DEL CONSEJO DEL MERCADO COMÚN DEL MERCOSUR 
<www.ciu.com.uy/innovaportal/file/752/1/cumbre_mercosur_xxxvi.pdf> accessed 20 December 
2012 
801 Protocol of Harmonisation Norms on Intellectual Property in Mercosur in matters of trade 
marks, indications of source and appellation of origin, Dec. No. 08/95, signed in Asunción, 5 
August 1995, and Harmonization Protocol of norms on Industrial Design, Dec. No.016/1998, signed 
in Rio de Janerio, 10 December 1998 
802 Rondon de Sansó, H., ‘La situación de Actual de la Propiedad’ at 177 
803 Ibid at 176 
804 See further, Art. 1 from Protocol of Harmonisation Norms on Intellectual Property in Mercosur 
in matters of trade marks, indications of source and appellation of origin, Dec. No. 08/95, signed in 
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Scholars have addressed the need for further norm harmonisation on matters 
related to patent rights. Specifically, the patent regime should clarify aspects such 
as: patentability, exhaustion of rights, compulsory licences, term of protection 
and renewal of it, scope of protection, exclusive rights exceptions, parallel 
imports and patent nullity among several other aspects. This scholar stressed that 
member countries are left with the option of legislating over these matters with 
certain freedom, taking into consideration that TRIPS only establishes minimum 
standards of protection. Therefore, it is fundamental in her view to harmonise 
patentability, exhaustion of rights, compulsory licences and term of protection.805 
In this respect, it is important to mention the fact that Venezuela is currently 
heavily dependent on imports from Mercosur member countries, while at the 
same time becoming a large energy and oil/derivate exporter. This energy 
cooperation belongs to the energy cooperation between Argentina, Brazil, 
Uruguay and Venezuela under the Petroamérica project, which includes a natural 
gas pipeline to supply the Brazilian market among other initiatives. 806 Medicines 
are among the goods imported by Venezuela, thus, considering the current 
applicable law in Venezuela that breaches TRIPS and other international 
agreements, it deems essential to harmonise the patent regime to contribute to 
the country’s legal certainty within the field of intellectual property rights.   
Despite de fact that patents are not regulated within MERCOSUR, trademarks 
are, thus parties are deemed to comply with the Nice International classification 
system if already not implemented.807 Therefore, the reinstatement in Venezuela 
of the IP Law from 1955 was thought to place Venezuela in a borderline situation 
when aspiring to become a full Mercosur member country,808 which in the end it 
did not.809 
Perhaps the linking point between the Andean Community legislation and 
MERCOSUR relates to the use of the Nice classification system, which was not in 
use in Venezuela for some time between 2008 and 2010. As mentioned above, 
when analysing the implications for Venezuela with regard the withdrawal from 
the Andean Community, the use of the national classifier became one of the 
challenges when applicants sought trademark registrations. Two years post- 
withdrawal, SAPI enacted an official notice informing the public on the change in 
classifiers, enforcing from that moment onwards the national one, which is not 
compatible with the Nice classification system. Venezuela in its attempts to adapt 
                                                                                                                                                        
Asunción, 5 August 1995, and HarmonisationProtocol of norms on Industrial Design, Dec. 
No.016/1998, signed in Rio de Janerio, 10 December 1998 
805 Rondón de Sansó, H.,  La Situación Actual de la Propiedad, at 180  
806 Romero Méndez, C., La Entrada de Venezuela en el Mercosur: Repercusiones Interna (Ildis ed.: 
Caracas, 2007) at 15<www.ildis.org.ve/website/p_index.php?ids=7&tipo=P&vermas=99> accessed 
4 March 2012 
807 See Harmonization Protocol of Norms on Intellecutal Property matters or trademark … find 
article 
808 Henriquez, L., ‘Venezuela al mager de las normas de Propiedad Intelectual del MERCOSUR’ 
(October 2008) 26 VenEconomía 1  
809 Venezuela became a full MERCOSUR member country on 31 July 2012. See Declaración sobre la 
Incorporación de la República Bolivariana de Venezuela al MERCOSUR,  (19 June 2012) 
<www.mercosur.int/innovaportal/file/4501/1/vzl.pdf> accessed 30 June 2012 
Also See Adhesión de la República Bolicariana de Venezuela, MERCOSUL/CMC/DEC. Nº 27/12 (30 
July 2012)  
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national legislation to MERCOSUR requirements in 2010 via another official 
notice, reinstated the use of the international classifier, and yet there are 
unsolved issues relating to trademark, denomination of source and appellations 
of origin protection under the current legal framework.810 
Without analysing in depth the Venezuelan trademark system, by pointing out 
some differences between the Andean Community regime and the one currently 
in force, it may perhaps be possible to show the challenges involved when seeking 
intellectual property protection under the regime settled by the national IP Law 
from 1955. On this note, in Articles 138 and 139 of Decision 486, among the 
requirements was the indication or statement of which category/class the product 
or service belonged to. Thereafter, the filing of a single application was to be 
made indicating to which class, under the international classification system, the 
trademark was to be registered while at the same time indicating the equivalents 
within the national classifier.811 
As indicated above, in practice, if an applicant’s claim sought protection for a 
trademark covering the products within class 5 (Pharmaceutical and veterinary 
preparations, etc.) of the Nice Classification system, but according to the 
Venezuelan Classifier fell under classes 6, 10 and 46, then these were to be only 
mentioned; therefore filing only a single claim independently of the amount of 
national classes covering the product. In contrast, IP Law from 1955 clearly states 
in Article 73 the need to file one claim per class covering the product. In other 
words, if a trademark that under the Nice Classification system is also covered by 
several classes within the national one, then a separate application should be filed 
per national classes affecting the product’s trademark.812 
Furthermore, SAPI’s official notice dated 1 October 2010 introduces a new set of 
requirements when claiming trademark protection. For instance, they reinstated   
international classification system while demanding the need to indicate its 
equivalent within the national one, which as highlighted by practitioners 
increases both the expense and time needed to register determined 
trademarks.813 Besides requiring this double classification, SAPI increases the 
requirements by demanding that the applicants enclose in the application 
phonetic, graphic or a search of figurative and phonetic elements depending on 
the trademark.814 The patent and trademark office based these new set of 
requirements on the national framework ruling over the matter, given that Article 
71 (g) from the IP law from 1955, somewhat prohibits similarities between 
registered and potential trademarks within the same or similar class of product(s) 
that possibly leads to public confusion.  
                                                        
810 Cadillo, et al ‘Legal Certaity, TRIPS and Venezuela’ unpublished 
811 See Article 151 from Decision 486 – Andean Community 
812 Article 73 from Ley de Propiedad Industrial de 1955, states that an application can only claim 
trademark registration for a determined group of products in accord with the official classification.  
813 Pérez-Irazáble, M., ‘Venezuela: Standing on its own: Venezuela re-establishes its national IP 
system in IP Value 2010 – Building and enforcing intellectual property value: An international 
guide for the Board room (10th, Edition) 76. 
814 SAPI, Aviso Oficial de fecha 10 de octubre de 2010. 6.- Indicar correctamente la clase 
international con su equivalente a la nacional 
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This duality in classifying trademarks under the current Venezuelan system, as 
highlighted above, came after committing to join MERCOSUR in an attempt to 
comply with the intellectual property regime.  
Regarding patents, the same official notice provides another set of requirements 
that should be enclosed with the application, but nothing within the notice 
extends patentability to those products or procedures previously protected under 
the Andean Community regime.  
On a positive note, it is believed that Mercosur could be a way to increase legal 
certainty in the region, but so far everything is dependent on each member 
country’s ability to adapt its legislation accordingly.815 
5.8. Public health and Patents 
This part of the analysis presents the reader with general features from the 
Venezuelan health care system and the link with medicines, and thereafter 
assesses the impact of pharmaceutical patents on access to medicines from a legal 
perspective. The first part briefly addresses past legislative reforms within the 
health system. The second part analyses the current health care system in accord 
with the legislative and constitutional reform from 1999. The third part assesses 
structural organisation and characteristics of the system, and the fourth part aims 
to highlight the correlation between the reforms and access to medicines;; 
therefore, price control policy and the list of essential medicines will be taken into 
consideration for the analysis.  
The Venezuelan health care system has gone through some reforms, which could 
be summarised for the purpose of this work as “pre- 1999 constitutional reform” 
and “post-1999 Constitutional reform.” The analysis aims to show the reader, in a 
general fashion, the most relevant changes, and whether or not the current 
structure provides access to affordable medicines that could be under patent 
protection. Hence, identifying the system, its coverage and the national list of 
essential medications, if any, is affected or deterred by patents and enforcement 
of intellectual property rights in Venezuela. 
By assessing the constitutional approach on public health and access to medicines 
in both stages, pre and post reform, while at the same time taking into 
consideration structural and legislative changes, will provide a further insight 
about the system. 
The Venezuelan health system falls under the MNHS category provided by 
Suarez, given that the three main characteristics of this system are met despite 
the universal coverage envisaged within the constitutional framework, as will be 
assessed. In Venezuela, the health system is a mixed system. Therefore, both 
public and private sectors provide health services. On the one hand, hospitals and 
outpatient clinics constitute the public sector, and private clinics the other. At a 
first glance, by just looking at the numbers, this should suffice the demand. 
However, fast infrastructural deterioration and slow problem solving capability 
within the system, especially as managing both human and economic resources, 
                                                        
815 See Rodríguez Yong, C., ‘Providing Legal Certainty in South America: Can MERCOSUR Help? 
(2010) Pace International Law Review Online Companion, at 1 
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lack of supplies and technology, are some of the issues that have been identified 
as detrimental for the system, and as such, making it inefficient and 
insufficient.816 
5.8.1. Public Health in Venezuela: Moving towards universal 
coverage 
As mentioned before, the health system underwent reforms from 1998 onwards, 
when the Political Constitution was reformed itself. This new approach settled in 
Article 83ofthe constitution and contains both citizens rights and the Estate’s 
obligation by providing health as a fundamental social right, while at the same 
time creating an obligation for the State to safeguard it as part of the right to 
life.817 The same constitutional provision goes beyond delimitating the concept of 
health into addressing the extent to which this is to be safeguarded, highlighting 
the need to prompt and develop policies addressed to giving quality of life, 
collective well-being and access to health services. 
One of the main challenges within the system derives from the high cost bared by 
the Government, given that many of the first aid health care centres are either not 
functional or perceived as reliable by patients. Thereafter, hospitals are used 
instead, for which costs are higher.818 In 2002 some structural changes were seen 
within the health system, as a popular health programme had been implemented. 
This was the “Barrio Adentro y Hospitales del Pueblo” (Inner Slums and Popular 
Hospitals) that was to cover and take care of those who could not afford private 
insurance and those not formally employed. The latter point has also been 
identified as a challenge for the current health system, since it portrays existing 
inequalities when accessing health care.819 
The aforementioned access inequalities contradict the universal coverage 
provided by the Constitution within Article 84. To a certain extent the 
government is creating further health benefits by ensuring that those who cannot 
afford the costs of illness also have the opportunity to receive treatment. Another 
thing to take into consideration under the new Constitutional health structure is 
the fact that free of charge services are to be provided, hence, ensuring the 
population with access to health care.820 This is particularly important when 
analysing the patent system and its relation to access to affordable medicines in 
all of the systems analysed. 
Universal Coverage as understood by WHO, aims to ensure everyone’s access to 
the needed health services and promotes preventive, curative and rehabilitative 
procedures that should also be of sufficient quality and effectiveness while at the 
                                                        
816 Jaén, M., ‘¿Por qué un estudio sobre el costo del sistema de sauld en Venezuela?’, in Jaén, M., 
Salvato, S., Daza, A.,and Rivas, J.,Costo de la Salud en Venezuela: Gasto y Sostenibilidad 
Financiera del Sistema de Salud (IEASA eds. Caracas, 2006) at 30-31 
817 Article 83 from the Constitución Bolivariana de la República de Venezuela, 1999 
818 Jaén, M., ‘¿Por qué un estudio sobre el costo del sistema de sauld en Venezuela?’ at 31 
819 Ibid at 35. 
820 Article 86 from the Constitución de la República Bolivariana de Venezuela, 1999. See Also Ibid at 
35. 
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same time safeguarding users from financial hardship.821 But to ensure universal 
coverage, a good or efficient financing system should also be implemented. In this 
regard, the Venezuelan Constitution within Article 86, not only self imposes the 
duty to create a Social Insurance health care system based on universal coverage, 
but also financial hardship should not be faced by individuals making use of the 
system given the solidarity principle embedded within it. In other words, 
allocating sufficient funding to the health system and administering it relies 
exclusively on the Government as provided by the Constitution and special 
laws.822 
Furthermore, the special law regulating Venezuela’s health system is Ley 
Orgánica de Salud (Health Organic Law – hereinafter LOS), that governs over 
every aspect related to health within the national territory extended, but not 
limited to, determining structure, function, financing and controlling health care 
service delivery.823 Nevertheless, it is important to highlight that LOS is from 
1998 and the universality principle found within the Constitution dates from 
1999. Although it is known that a legislative project is being discussed at the 
National Assembly, until this date (2012) this law has not been formally 
abrogated nor reformed.  
So far, Venezuela’s health challenge is actually providing everyone -independently 
of their level of contribution, if at all- with proper universal coverage, which shall 
be financed with Governmental funds, tax payers and citizens’ contributions.824 
5.8.2. General Structure 
The Venezuelan health system, as described above, has structurally changed 
about four times; the last reform’s implementation is still incomplete, as LOS 
continues to be discussed at the National Assembly.  
Accordingly, the national system can be, in a general fashion, structured into two 
subsystems: the public and the private mainly. This classification seems to 
correlate with each type of institution’s means of funding or financial sources. 
Public institutions are, mainly, those founded with taxpayers money and 
mandatory contributions; and the private ones, are the ones funded by private 
sources.825 
A few entities are part of this public sector: namely Ministerio del Poder Popular 
para la Salud (Ministry of Health –hereinafter MPPS) that was created or 
renamed in June 2009 via Decreto Nº 6.732, published in ?Gaceta Oficial de la 
                                                        
821 See further, The World Health Report: Health Financing Systems - The Path to Universal 
Coverage, WHO, (Geneva – 2010) at. ix. And Sustainable Health Financing -Universal Coverage-
Universal Coverage, and Social Health Insurance, WHO, Fifty Eight World Health Assembly 
Resolution WHA58. 33, (Geneva-16-25 May 2005) 
822 Article 86 from the Constitución de la República Bolivariana de Venezuela, 1999 
823 Article 1, Ley Orgánica de Salud, Gaceta Oficial Nº 5.263 Extraordinario del 17 de septiembre de 
1998, Re printed G/O Nº 36.579 de fecha 11/11/1998 
824  Jaén, M., ‘¿Por qué un estudio sobre el costo del sistema de sauld en Venezuela?’ at 40 
825  González R, M., ‘Reformas del sistema de salud en Venezuela (987-1999): balance y 
perspectivas’ in Serie 111 Financiamiento del desarrollo, Naciones Unidas – CEPAL (Santiago de 
Chile, 2001) at 9 
  
168 
República Bolivariana de Venezuela?N° 39.202 dated 17/JUN/09. This 
Presidential Decree reorganised the entire Public Administration’s functions and 
organisation, hence its name Decreto sobre la Organización y Funcionamiento de 
la Administración Pública Nacional - Decree about functions and organization of 
the National Public Administration. The same Decree in Article 17 settles MPPS’s 
competences, accordingly, to which this entity governs the national health system 
designing and delimitating national health programmes, surveying food and 
medicine production among other important competences.826 
Designing and implementing policies related to national production of medicines, 
supplies and biological products are one of MPPS’s competences that were 
established within Article 17(7) from this law. This is of particular importance 
given that the Ministry of Commerce should also take part when drawing up such 
policies. 
The Ministry of Health’s internal structure is provided, or was provided, by a 
prior Decree in 2006 when this was Ministerio de Salud instead of Ministerio del 
Poder Popular para la Salud. Decree Nº 5.077 of22 December 2006 and also 
published within Gaceta Oficial Nº 38.591 from 26 December 2006 contains the 
Ministry’s Organic Regulation. This Regulation establishes not only the internal 
structure but also delimits functions. On the one hand, the ministry is the main 
body governing the national health care system, but on the other it also has 
attached entities responsible for providing health services within the public 
sector.  
Among the most important entities are: the Instituto Venezolano de los Seguros 
Sociales – Social Insurances Venezuelan Institute (hereinafter IVSS); the 
Instituto Nacional de Higiene Rafael Rangel – Rafael Rangel National Health 
Institute (Hereinafter INH); Instituto de Previsión y Asistencia Social del 
Ministerio de Educación – Institute for Prevention and Social Assistance from de 
Ministry of Education (Hereinafter IPSAME), and the Instituto de Previsión 
Social de las Fuerzas Armadas – Armed Forces Social Prevention Institute 
(hereinafter IPSFA), among others.  
IVSS has particular importance, given its tripartite source of founding and the 
fact that pensions and other social security benefits from most workers in 
Venezuela are managed by this entity.827 
In relation to medicines, INH is rather important, since this is the Institute taking 
care of prevention, observance and health control, including pharmaceuticals 
produced and/or distributed within the country.828 Independent of the entity, if it 
is related to health it may be attached to both the Ministry of Health and/or 
another ministry such as i.e. the labour one. Therefore, it is possible to find 
employees covered by two different institutions, creating inequities when 
accessing health care.829 
                                                        
826  See Article 17 from Decreto Nº 6.732, published in Gaceta Oficial de la República Bolivariana de 
Venezuela Gaceta N° 39.202 dated 17/JUN/09 
<intranet.inapymi.gob.ve/Formatos/Gaceta_39202.pdf>accessed 10 June 2012 
827 <www.ivss.gov.ve> accessed 14 September 2013 
828 <www.inhrr.gob.ve/instituto/instituto.html> accessed 14 Septemer 2013 
829  Jaén, M., ‘¿Por qué un estudio sobre el costo del sistema de sauld en Venezuela?’ at 35 
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5.8.3. Main Characteristics 
Given the fragmented structure within the system, the main characteristics830 can 
be summarised as various sources of financing, such as: the State, insurances, 
employees and individuals. 
There are no homogenous provisions of services within the system. Some only 
provide ambulatory services, whereas others like the hospitals managed by the 
Ministry of Health and IVSS provide not only ambulatory services but also 
treatment and rehabilitation or follow up. The system per se is complex, and 
there is a lack of information for the users. There are visible inequities to access 
public health care, since not only does misinformation about the system exist, but 
also a person needs to be either employed or belong to the formal working 
market, or in the case of not being employed, working in determined professions 
so as to entitle them to a certain kind of coverage. 
The system’s fragmentation also deters real possibilities for bulk procurement 
that eventually challenges large-scale purchase of medicines. Bulk procurement 
and purchase on a large scale of medicines – essential medicines, is one of the 
suggestions given by WHO to tackle barriers to access and affordability. This 
issue will be developed further within the following heading. Real per capita 
expenditure on health details seems to be impossible to get, accordingly to 
scholars who attempted to analyse financial and health expenditure in Venezuela. 
In 2000, WHO highlighted Venezuela’s expenditure per capita as the lowest 
within the Latin-American region, expending an average of $ 298, whereas 
countries like Chile and Brazil spent $581 to $428 respectively.831 
5.8.4. Health Services and Coverage 
Health services and access to medicines are provided within LOS and the Ley 
Orgánica del Sistema de Seguridad Social – Social Security Organic Law 
(hereinafter LOSS); the latter one published and ultimately reformed in Gaceta 
Oficial No 39912 and dated 30 April 2012. Given the Constitutional mandate in 
safeguarding health through social health care, there are a few interesting things 
that arise.  
As described within the pre-Constitutional Reform in 1999 heading, the health 
system underwent four important reforms that regardless of purpose never 
became fully implemented. However, in the process of providing universal 
coverage, in all three legislative bodies(the 1999 Constitutional text, LOS from 
1998 and the latest LOSS reform from 2012) “catastrophic or high cost illnesses” 
                                                        
830  The characteristics of the system were mainly take from the readings: Jaén, M., et al., Costo de 
la Salud en Venezuela: Gasto y Sostenibilidad Financiera del Sistema de Salud (IEASA eds. 
Caracas, 2006) at 1-201; González R, M., ‘Reformas del sistema de salud en Venezuela (987-1999): 
balance y perspectivas’ in Serie 111 Financiamiento del desarrollo, Naciones Unidas – CEPAL 
(Santiago de Chile, 2001) 1-39; Organización Panamericana de la Salud, ‘Perfil del sistema de 
servicios de salud de la República Bolivariana de Venezuela’ Programa de Organización y Gestión de 
Sistemas y Servicios de Salud (2a. Ed. 14 de Mayo 2001) at i-20 
831 González R, M., ‘Reformas del sistema de salud en Venezuela (987-1999): balance y perspectivas’ 
in Serie 111 Financiamiento del desarrollo, Naciones Unidas – CEPAL (Santiago de Chile, 2001) at 
18 
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are brought to the spotlight as an especial category. On the one hand, the 
Constitution foresees protection from financial hardship through shaping social 
policies with the Government itself as the main guarantor,832 and on the other 
hand, the previous reform foresaw a public health subsystem that defined or 
delimited the extent of these catastrophic illnesses.  
Despite chronological issues, both LOS and new LOSS seem consistent. One in 
mandating to create clinical and epidemiological research, programmes for 
prevention and treatment of chronic illnesses, while at the same time allocating 
funding for prevention and treatment of catastrophic or high-cost illnesses for 
patients with low or no financial means.833 And the other one specifically 
provides integral attention for catastrophic illnesses.834 
When analysing the legislation and structure in light of these provisions, access to 
affordable medicines to treat catastrophic, chronic and/or high cost illnesses 
seem to be part of the Government’s duties within safeguarding and guaranteeing 
health care. Therefore, delimitating which are these illnesses, the medication in 
itself and where and how to find it are questions that should also be found within 
both legislative frameworks and health system provisions. Instead, the 
information regarding theses illnesses is briefly found on the IVSS website.835 
In light of LOSS Article 18, social benefits are delimitates, and among those 
treatment for catastrophic illnesses. Therefore, it is within this institution’s –
IVSS- functions or duties to provide medicines for patients afflicted by any of the 
13 illnesses enumerated by IVSS.836 Namely cancer, multiple sclerosis, hepatitis, 
                                                        
832 Article 86 from Constitución de la República Bolivariana de Venezuela. “Toda persona tiene 
derecho a la seguridad social como servicio público de carácter no lucrativo, que 
garantice la salud y asegure protección en contingencias de maternidad, paternidad, 
enfermedades, invalidez, enfermedades catastróficas, discapacidad, necesidades especiales, 
riesgos laborales, pérdida de empleo, desempleo, vejez, viudedad, orfandad, vivienda, cargas 
derivadas de la vida familiar y cualquier otra circunstancia de previsión social. El Estado tiene la 
obligación de asegurar la efectividad de este derecho, creando un sistema de seguridad social 
universal, integral, de financiamiento solidario, unitario, eficiente y participativo, de contribuciones 
directas o indirectas.” 
833 Article 56(3) and (4) Ley Orgánica de Salud, Gaceta official Nº 5.263 Extraordinario del 17 de 
septiembre de 1998, Re impresa en Gaceta Oficial Nº 36.579 dated 11 de noviembre de 1998 
(hereinafter LOSS) 
834 Article 18 from LOSS 
835 See Ley que Regula el Subsistema de Salud, Gaceta Oficial Nº 5.568 Extraordinario de fecha 21 
de Diciembre de 2001. This law highlighted the former Labour and Health Ministry’s competences, 
among which Article 9 (4) and (15) points out both the need to write medical protocols defining 
which illnesses are to be protected/covered, and the need for the President to delimitate the budget 
and allocation of funding to finance the Fondo Especial a la Atención de Enfermedades de Alto 
Costo, Riesgo y Largo Plazo – Especial Fund for High-Cost, Risk and long term illnesses. This 
legislation became abrogated via legislative reform in Gaceta Oficial Nº 37600 dated 30 December 
2002 
836 Idid. Thus far, finding any official regulation/statement or presidencial Decree or even medical 
guides other than those briefly estated at IVSS website, establishing what is considered a 
catastrophic illness or high cost within the Venezuelan context has not been possible. Therefore, 
and after a phone consultation with the Centro Venezolano para la Clasificación de Enfermedades – 
CEVEDE, it can be assumed that Venezuela follows suggestions and guidelines by both WHO and 
PAHO 
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rheumatoid arthritis, hematologic, transplants, attention deficit hyperactivity 
disorder, osteoporosis, schizophrenia, pulmonary hypertension and chronic 
kidney disease in the terminal phase are the assumed to be high cost illnesses 
covered by Venezuelan social security system. The website highlights that other 
diseases are also considered as catastrophic, but no information whatsoever is 
found within the aforementioned legal framework or website.  
Previously in Venezuela a Health Subsystem used to define via Protocols those 
illnesses covered by social security, whereas nowadays besides the enumeration 
available on the IVSS website and the seven health programmes (Tuberculosis, 
Immunisations, Cardiovascular diseases, Diabetes, HIV/AIDS, PNANNA –
National Programme for Children’s’ Medical Attention, and Breastfeeding) 
conducted by the Health Ministry –MPPS, there is no further information on 
these medical guides for the rest of the diseases highlighted above. Strikingly, 
only the Tuberculosis programme contains or publicly displays a medical 
protocol837 to treat the illness. 
Despite enumerating those illnesses, the Asosiación Venezolana de Alegría, Asma 
e Inmunología seems to be lobbying for inclusion of other respiratory illnesses, 
such as asthma, which reportedly afflicts twenty per cent (20%) of Venezuelan 
children between the ages 6-7 years old and sixteen per cent (16%) between the 
ages 13-14 years old. More or less one in five children is afflicted by this chronic 
respiratory illness.838 WHO recognised asthma as a chronic respiratory 
disease,839hence, should not this be also considered and treated by IVSS? After 
all, Venezuela follows both WHO and PAHO suggestions as mentioned earlier. 
Nevertheless, before understanding the connection between the Venezuelan 
health system and access to medicines, essential medicines and patents within 
the IVSS and MPPS context, it is important to remember that IVSS does not only 
provide health care services, but also takes care of peoples’ pensions.  
The mixed management sought reforms for both fields simultaneously, which has 
been criticised as one rationale behind failing to successfully either reform or 
implement the system’s reforms in the past.840 One of the lessons from past 
reforms is the fact that health reforms should and could be different from the 
ones attempted in the pension system, and given the structural challenges 
realistic and feasible policy definition is needed.841 The same scholar in his report 
for CEPAL suggested a couple of interesting points - in case of future reforms - of 
which some seem to have been taken into consideration by the legislator in 2008 
and 2012. 
                                                        
837 See Directrices para el Despistaje, Diagnóstico y Tratamiento de la Tuberculosis en Pacientes con 
Indicación de Terapias Biológicas, MPPS, 
<www.mpps.gob.ve/index.php?option=com_content&view=article&id=915&Itemid=946>accessed 
15 June 2012 
838 Sociedad Venezolana de Alergía, Asma e Inmunología, ‘En Venezuela: uno de cada cinco niños 
sufre de asma’, <www.svaai.org.ve/noticias/informacion-para-pacientes/35-noticias/95-en-
venezuela-uno-de-cada-cinco-ninos-sufre-de-asma.html>accessed 15 June 2012 
839Asthma, World Health Organization, Fact Sheet Nº 307 (May 2011) 
<www.who.int/mediacentre/factsheets/fs307/en/index.html>accessed 15 June 2012 
840 González R, M., ‘Reformas del sistema de salud en Venezuela (987-1999)’ at 29 
841 Ibid González at 31 
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In this regard, the modifications in 2008, besides practically rewriting the law, 
whilst health benefits were delimited, brought about some inconsistencies. Given 
this doctoral thesis focuses on patents and access to medicines, only those 
suggestions – reform related to medicines and health care provisions  –will be 
taken into consideration, despite the fact that further financial and organisational 
reforms are deemed relevant for a health system’s effective performance. 
Reforming the whole health system, in accord with Gonzalez, goes beyond health 
per se, as the system’s sustainability is fundamental for a full and successful 
implementation. 
Given the existing and diverse health care needs, Gonzalez considers it rather 
important to combine actions addressed to tackle both infectious and nutritional 
illnesses, and chronic or catastrophic illnesses, since in Venezuela both 
epidemiologic patterns coexist and demand innovative and efficient health care 
attention. One priority sector relates to children’s nutrition, immunisation and 
attention in general for pregnant women; the second health priority regards the 
treatment and prevention of both cancer and cardiovascular illnesses; and the 
third aspect concerns HIV/AIDS.842 
As highlighted above, Venezuela is epidemiologically diverse and therefore 
medical attention within the health care system has been divided into three levels 
within LOS. This legislation in Article 28 addresses the need to delimitate each 
medical centre’s capabilities according to the patient treatment needs.843 
Thereafter, the first two levels of medical attention are given in out-patient clinics 
where promoting health, preventing illnesses, diagnosing and treating these 
differs as the first level takes everyone without discrimination, whilst the second 
has criteria to take in patients based on age, sex, illness and requirements.844 The 
third level of medical attention handles specialised cases, or in other words, only 
patients with determined needs –chronic illnesses- with/without 
hospitalisation.845 
LOS as it is today does not provide further information, but a report in 2001 by 
PAHO indicates a deeper classification within the levels of attention than 
originally established by law. In this regard, there is a division between out-
patient clinics for rural and urban areas; the first ones provide medical attention 
in places with a population lower than 10,000 habitants and these are destined to 
give primary health care without hospitalisation, whereas in the second ones, 
even when hospitalisation is not provided, specialized medical care is.846 
Furthermore, the second level of medical attention is only provided in 
establishment for hospitalisation where the three levels of medical attention can 
be given.847 This report follows the classification given by the health subsystem 
found in Gaceta Oficial Nº 32.650 from January 1983 that became abrogated by 
the legislative reform in 2002.  
                                                        
842 Ibid González at 33 
843 See Article 28 Ley Orgánica de Salud, Gaceta official Nº 5.263 Extraordinario del 17 de 
septiembre de 1998, Re impresa en Gaceta Oficial Nº 36.579 dated 11 de noviembre de 1998 
844 Ibid Articles 29 and 30 from LOSS 
845 Ibid Article 31 from LOSS 
846 Organización Panamericana de la Salud, ‘Perfil del sistema de servicios de salud de la República 
Bolivariana de Venezuela’ Resumen Ejécutivo, Programa de Organización y Gestión de Sistemas y 
Servicios de Salud (2a. Edition, 14 de Mayo 2001) at 11 
847 Ibid at 12 
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Having in mind the classification in LOS, and the fact that the subsystem was 
abrogated, finding an up-to-date health care structure seems rather challenging. 
It has been highlighted, that the latest LOSS reform does not address the issue 
and the LOS enforced today is from 1998 and thus portrays significant delays that 
at the same time may contradict constitutional principles.848 Assuming the 
validity of LOS, health care attention is provided on three levels; mainly hospitals 
and outpatient clinics within the public sector. However, in 2002 with the Inside 
Neighbourhood Programme, a set of popular clinics began operating providing 
specialised and good quality medical attention mainly destined to take patients 
from marginalised rural areas of the country.849Summing up, this programme 
represents the first level of attention, and according to reports, solves up to 80% 
of health problems, followed by popular medical practices, popular clinics and the 
people’s hospitals.850 
5.8.5. Access to Medicines 
The former health subsystem law in Article 9 (4) and (15) pointed out both the 
need to write medical protocols defining which illnesses are to be 
protected/covered, and the need for the President to delimitate the budget and 
allocation of funding to finance the Fondo Especial a la Atención de 
Enfermedades de Alto Costa, Rison y Largo Plaza – Especial Fund for High-Cost, 
Risk and Long Term Illnesses. But since this legislation became abrogated via 
legislative reform in Gaceta Oficial Nº 37600 dated 30 December 2002, it is not 
clear whether these protocols are written or not and if so where they can be 
found.  
Thus far, the only protocol available as such on MPPS’s page is the one to treat 
Tuberculosis, which includes the medicines or active compounds used.851 Two 
things are to be highlighted from the protocol: one, the active compounds listed 
on there are also to be found on the Venezuelan List of Essential Medicines, and 
secondly it is not clear whether or not tuberculosis is considered either a high cost 
or a chronic illness.  
MPPS bylaw structures the Ministry in Article 2, assigning functions and 
competences to Ministers and Vice Ministers offices. Among those, the Vice 
Ministry Office for Collective Health, and the Vice Ministry Office for Health 
Recourses are identified as the ones in charge of both creating health 
programmes and coordinating the purchase and distribution of medical supplies. 
At the same time, each Vice Minister’s office is structured into several Divisions. 
Among these, the Health Programme Division has the duty to coordinate with the 
Supply Division from the Vice Ministers Office for Health Resources to define 
                                                        
848 González, M., ‘Políticas de Salud en Venezuela: Ni lo urgente, ni lo importante’ (2005) 18 Anales  
Venezolanos de Nutrición, at 39-44 
849 Jaén, M., ‘¿Por qué un estudio sobre el costo del sistema de sauld en Venezuela?’ at 31 
850 Ojeda Liendo, J., ‘Barrio Adentro, una Política Pública de Salud Emergente de Atención’ Revista 
FACES (Universidad de Carabobo, 2007) <servicio.bc.uc.edu.ve/faces/revista/a15n26/15-26-
7.pdf>accessed 10 May 2012 
851 See Directrices para el Despistaje, Diagnóstico y Tratamiento de la Tuberculosis en Pacientes con 
Indicación de Terapias Biológicas, MPPS, 
<www.mpps.gob.ve/index.php?option=com_content&view=article&id=915&Itemid=946>accessed 
15 June 2012 
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medical supply policies to ensure people’s access to health.852Anther important 
Division to take into consideration is the General Division for Medical Supply 
Production; this one should encourage both the public and private sectors to 
produce medical supplies –medicines- in accordance with the Public National 
Health System’s priorities.853 The General Division for Medical Supply 
Distribution is also rather important for access to essential medicines; therefore, 
its functions will be described within the heading below that analyses access to 
essential medicines. 
The legislation’s wording suggests a division between chronic854 and high-cost 
illnesses,855 but reference is only made to treatment of catastrophic diseases. 
Although none of these are defined within the current legislation, WHO through 
its regional office –PAHO- comes close to a definition by pointing out the 
seriousness of the medical conditions associated with the high costs in terms of 
both drug therapies and health care services necessary to treat the patient, 
demanding significant financial resources on behalf of those affected.856 If high 
costs are associated with catastrophic illnesses due to their consequences on 
those affected, then a chronic illness can also entail fatal consequences not only 
associated with the disease per se, but also expenses incurred by the affected 
ones.857 
Given the new principles –free access, quality, universality, and solidarity- 
embedded within the new health reform had made the Government readdress 
health policies towards pharmaceutical availability, rational use and accessibility 
by drawing up the national health policy.858 Part of this, are the new missions or 
social initiatives859 to solve or pay social debts,860as highlighted by scholars, 
including free access to pharmaceuticals and/or reduced price.  
                                                        
852 See Article 29(9) from Reglamento Orgánica del Ministerio de Salud, published in Gaceta Oficial 
Nº 38.591 del 26 de diciembre de 2006 (hereinafter Reglamento MINSALUD) 
853 See Article 33(2) from Reglamento MINSALUD 
854 According to the WHO, chronic diseases are those of long duration and generally slow 
progression, such as cardiovascular diseases, cancer, diabetis and respiratory illnesses among 
others. See WHO, Health Topics, Chronic Diseases 
<www.who.int/topics/chronic_diseases/en/>accessed 20 June 2012 
855 Chronic diseases are generally treated with high cost medicines, therefore, a chronic disease 
could also be understood as a high cost illness derived from overwhelming expenditure on 
healthcare and medicines. See ‘Access to High-Cost Medinices’ infra note 313. See also, Preventing 
chronic diseases: a vital investment, WHO global report, World Health Organization (Geneva, 
2005) at 66 
856Access to High-Cost Medicines in the Americas: Situation Challenges and Perspectives, 
Technical Series Nº 1 Essencial Medicines, Access, and Innovation, Panamerican Health 
Organisation (September 2010) at 10 
857 This can be inferred from various readings on the WHO and PAHO site addressing the severity 
of these illnesses. See Ibid at 34 
858 Organización Panamericana de la Salud, ‘Perfil del sistema de servicios de salud de la República 
Bolivariana de Venezuela’ Resumen Ejécutivo, Programa de Organización y Gestión de Sistemas y 
Servicios de Salud (2nd. Ed, 14 May 2001.) at 7 
859 Definition given by the Ministerio Popular para la Cultura – Ministry of Culture – in its own 
website 
<www.misioncultura.gob.ve/index.php?option=com_weblinks&view=category&id=5&Itemid=4>a
ccessed 10 June 2012 
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5.8.6. The Essential List of Medicines in Venezuela 
Previous to the aforementioned health reform, the national list of essential 
medicines or Formulario Therapeutic Nacional – National Therapeutic 
Formulary- was and is put together by the Ministry of Health in cooperation with 
national universities,861 despite the changing name of this Ministry. In this 
respect, Ley de Medicamentos –Medicines Law (hereinafter LAMED)- contains 
certain aspects that shall be taken into consideration to elaborate the National 
Therapeutic Formulary. 
In the light of LAMED, essential medicines are those destined to satisfy   
Venezuelans’ population health care needs862 that may vary from country to 
country. Therefore, the same legislative framework provides that WHO and 
PAHO guidelines are to be taken into consideration when classifying medicines as 
essential, and therefore, includes them within the National Therapeutic 
Formulary.863 Furthermore, access to medicines in Venezuela seems to be 
safeguarded and provided by several stakeholders within the public and some 
times even by the private sector. In this regard, the creation of Comate Nacional 
Therapeutic – National Therapeutic Committee- is foreseen in the legislation with 
the purpose to revise the aforementioned list, among other functions.864 Another 
important body seems to be the Consejo Nacional del Medicamento - National 
Medicines Council- created to advice the president on related matters.865 
Among the Ministry of Health’s competences, are creation and implementation of 
pharmaceutical policies to ensure safety, availability and access to essential 
medicines found on the National Therapeutic Formulary. In addition, others are 
ensuring that medicines are safe, efficient, of good quality and affordable.866 
Hence, the Ministry of Health bylaws in Article 38 recognises Servicio Autónomo 
de Elaboraciones Farmacéuticas –Autonomous Service of Pharmaceutical 
Elaborations (hereinafter SEFAR) as part of its own structure.867SEFAR is an 
important entity attached to MPPS, since this one ensures accessibility, 
availability and rational use of essential medicines via policies addressed to 
incentivise national production of medicines.868 Besides producing this entity, it 
                                                                                                                                                        
860 Alvarado, C.,et al. ‘Cambio Social y Política de Salud en Venezuela’ Sección Especial: Reformas 
Progresistas en Salud (Mayo, 2008) 3 Medicina Social 2, 113-129, at 119-120 
861 Previously known as Ministerio de Salud y Desarrollo Social and currently known as the 
Ministerio del Poder Popular para la Salud. See also ‘Perfil del sistema de servicios de salud de la 
República Bolivariana de Venezuela’  
862 Article 7 Ley del Medicamento, published in Gaceta Oficial Nº 37.006 dated 3 agosto 2000 
863 Ibid 
864 Article 11 from Ley de Medicamentos, Gaceta Oficial Nº 37.006, and Resolución Nº 247 
published in Gaceta Oficia Nº 37.453 dated 29 May 2002 
865 Ibid Article 16 and 17 
866 Article 17 (25) from Decreto Nº 6.732, sobre Organización y Funcionamiento de Administración 
Pública Nacional, publicado en Gaceta Oficial de la Republica Bolivariana de Venezuela?N° 39.202 
de dated 17 June 2009 
867Article 38 from Decreto Nº 5.077 dated 22 December 2006, published in Gaceta Oficial Nº 
38.591 del 26 de diciembre de 2006 
868 SEFAR was created by Decreto N° 3.061 dated 8 July 1993, published in Gaceta Oficial N° 
35.263 dated 29 July 1993, Reformado Parcialmente y publicado en Gaceta Oficial N° 4.949 
Extraordinario de fecha 10 de agosto de 1995. See, SEFAR, ‘Objectives’ 
<www.sefar.gob.ve/index.php/sefar/quienes-somos> accessed 10 June 2012 
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aims also to strengthen the observance of pharmaceuticals, which is mainly 
carried out by the INHRR’s authorisation to commercialise.  
Studies have shown that up to 2001, only 2% of the population had access to 
essential medicines, therefore, a programme named SUMED subsidises up to 
80% of the price of medicines included on the list and those prescribed by public 
health care providers.869 Further reports suggest as an achievement of the current 
health system the fact that an average of 106 different medicines had been 
provided for free to Barrio Adentro users.870 Allegedly, this year alone, SEFAR-
SUMED donated around 175,000 pharmaceutical products,871 and SEFAR gave to 
a single Estate – Bolivar Estate- more than 400,000 products between 
pharmaceutical and medical supplies for Estado Bolivar to use in its missions’.872 
In 2000, the national list of essential medicines contained around 280 active 
ingredients, and in 2003, given money control policies, a list of medicines 
receiving preferential currency was published via Gaceta Oficial.873 Despite 
having foreign and national pharmaceutical companies in Venezuela with 
manufacturing capabilities, most raw materials are imported into the country, 
and therefore, these companies need to apply for foreign currency purchase 
authorisations from CADIVI.874 
Currently around 1,200 active compounds are part of this national list of essential 
medicines, and in accord with IVSS high functionaries, 119 pathologies are 
protected in Venezuela for which free access to medicines is guaranteed by this 
institution’s “high cost pharmacies.”875 Reportedly, free medicines are given at 
IVSS pharmacies to patients afflicted with illnesses such as cancer, diabetes 
among other high cost-chronic diseases, as a result from billions of bolivars 
(national currency) invested by the current government into these health 
programmes.876 However, an extract number of treated illnesses, and medicines 
                                                        
869 Organización Panamericana de la Salud, ‘Perfil del sistema de servicios de salud de la República 
Bolivariana de Venezuela’ Resumen Ejécutivo, Programa de Organización y Gestión de Sistemas y 
Servicios de Salud (2nd. Ed, 14 May 2001.) at 7 
870 Alvarado, C.,et al. ‘Cambio Social y Política de Salud en Venezuela’ at 120 
871 See, Ministerio del Poder Polular para la Cultura, ‘Sefar Sumed donó alrededor de 175.000 
unidades en medicamentos e insumos’ (Caracas, 4 April 2012) 
<www.casadelartista.gob.ve/index.php?option=com_content&view=article&id=90:sefar-sumed-
dono-alrededor-de-175000-unidades-en-medicamentos-e-insumos&catid=4:noticias-
fca&Itemid=1> accessed 10 June 2012 
872 See, Ministerio del Poder Popular para la Salud, ‘Más de 400 mil rubros médicos entregó Sefar 
en Bolívar’, (Caracas, 22 May 2012) 
<www.mpps.gob.ve/index.php?option=com_content&view=article&id=1459:mas-de-400-mil-
rubros-medicos-entrego-sefar-en-bolivar&catid=1:ultimas-noticas&Itemid=18>accessed 10 June 
2012 
873 See Resolución 283, publicada en Gaceta Oficial Nº 328.307 dated 14 April 2003 
874 Explicar CADIVI, see Also, Nicole Yaupur, ‘La falta de divisas enferma a la industria 
farmacéutica, el universal (2 de Mayo de 2012) 
875 IVSS blog de Administración, ‘Más de 885 millones de BSF invirtió el IVSS en enfermedades de 
Alto Costo’  
<www.ivss.gob.ve/MÁS%20DE%20885%20MILLONES%20DE%20BSF%20INVIRTIÓ%20IVSS%
20EN%20ENFERMEDADES%20DE%20ALTO%20COSTO> accessed 15 June 2012 
876 Oswaldo González Moreno, ‘Garantizados medicamentos para enfermedades de “alto-costo”’ 
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provided for free at these pharmacies are not available. It must be remembered 
that IVSS provides health care services to those affiliated, one way or another, to 
this institution via employment of some sort. Therefore, it is interesting to spot 
an initial inequality when accessing medicines in Venezuela. As suggested within 
the introductory chapter, pharmaceutical patents are considered by one side of 
the literature as detrimental to the access of medicines, however, by analysing 
public health care policies other factors seem to play an important role in both 
ensuring and denying access to medicines. 
5.9. Access to Affordable Medicines in Venezuela: Price Control 
Policy 
Within the previous paragraph a brief assessment was made of the existence in 
Venezuela of a ‘national list of essential medicines’ and that some of these are 
provided for free at determined pharmacies. Given the disparities within 
Venezuelans’ purchasing capabilities, due to a fragmented social system, Ley de 
Medicamentos foresees in Article 12 the State’s possibility in regulating medicine 
prices as to ensure fair access to those with low economic resources.877 
This regulation is know as price control policy, and the Venezuelan Government 
has made use of it throughout the years to ensure peoples’ access to most needed 
medication, or at least tried to do so. Official statements in 2005 regulated 
approximately 135 active ingredients found in nearly 1,142 essential medicines, 
therefore, providing more affordable medicines to an estimated 75% of the 
illnesses protected in Venezuela.878 The same press release indicated the 
availability of a list containing medicines and its prices; however, the prices 
indicated in such a report are “referential prices” and not “maximum prices”. This 
led the government to emphasise during 2012 the need to use the “maximum 
price for customer purchase – precio máximo de venta al público” instead of the 
referential price, so as to ensure the affordability of medicines.879 The latest press 
release came after the Ley de Costos y Precios Justos – Fair Costs and Prices Law, 
hereinafter LCPJ- was enacted in July 2011 after creating Superintendencia de 
Costos y Precios Justos – Fair Costs and Prices Superintendence, hereinafter 
SUNDECOP - . 
However, in 2003 via Gaceta Oficial N° 5.684, around 1105 medicines were price 
regulated by the Government, and the list also indicated the maximum sales price 
for consumers.880  The use of this “maximum sales price” is later on foreseen by 
LCPJ in Article 31(7) that describes SUNDECOP´s attributions. Interestingly, on 
                                                                                                                                                        
<www.asambleanacional.gob.ve/index.php?option=com_content&view=article&id=35792%3Agara
ntizados-medicamentos-para-enfermedades-de-alto-costo&catid=1%3Alatest-
news&Itemid=246&lang=es> accessed 15 June 2012 
877 Article 12, Párrafo único from Ley de Medicamentos, Gaceta Oficial Nº 37.006, dated 3 August 
2000. 
878 Prensa MSDS y Prensa RNV, ‘Regulado precios de 1.142 medicamentos esenciales’ 
<www.rnv.gov.ve/noticias/?act=ST&f=&t=24517>accessed 15 June 2012 
879 Últimas Noticias, ‘Fijación de Precios Justos a Medicamentos refuerzan su carácter social’, 3 July 
2012 <www.sundecop.gob.ve/index.php?option=com_content&view=article&id=300:fijacion-de-
precios-justos-a-medicamentos-refuerzan-su-caracter-social&catid=49:ultimas-
noticias&Itemid=18>accessed 5 July 2012 
880 See Gaceta Oficial N° 5.684 date December 2003 
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the list regulating medicines’ prices, not only active ingredients are found, but 
brand medicines as well.881 
On the one hand, prices are regulated, but on the other regulated medicines 
seemed to have disappeared from pharmacies’ shelves, and even brand name 
medications are reportedly hard to find nationwide.882 Other sets of challenges 
are also taking a toll on the availability of medicines in Venezuela. Allegedly, by 
increasing the tax unit, administrative proceedings relating to imports, 
registrations and authorisations to commercialise also became more expensive 
for pharmaceutical companies to supply the Venezuelan market.883 Price control 
policies seem to influence market entry of new or products already available 
elsewhere.884 This, together with the identified challenges above, could be the 
reason behind pharmacies’ shelves being empty. Regarding active ingredients and 
generic versions of patented medicines, both SEFAR and Ley de Medicamentos 
settle promotion, prescription, and production of generics found on the national 
list of essential medicines by public health care providers so as to ensure peoples’ 
access to medicines.  
In previous years, Venezuela took part in joint negotiations with four other 
Andean countries to purchase antimalarics, managing to reduce medicine prices 
by between 36% and 90% of the estimated average price within the Andean sub-
region.885 Accordingly, several Latin American countries also participated in 
other joint purchases ventures, and therefore, ensuring access to medicines. 
There is not only a national health policy, but also a medicine policy for the 
Andean sub region that includes joint purchases as part of the initiatives that deal 
with access to affordable and good quality essential medicines.886 
5.9.1. Medicine Policy for the Andean Sub region: Further Efforts to 
Achieve Access to Medicines regardless of Patents 
The above mentioned health policy’s achievements are handled under the Andean 
Health Organization which is at the same time part of the Andean Integration 
System. Even though confusing, Venezuela still belongs to this organisation 
                                                        
881 See Annex continting the list and own highlights denoting regulation of both brand medicines, 
and active ingredients 
882 Casanova, R., ‘Medicinas en Crisis’, El Universal, 12 May 2012 
<www.eluniversal.com/opinion/120511/medicamentos-en-crisis> accessed 15 June 2012 
See also Primera, M., ‘Venezuela extiende el control Estatal de precios’, El País, 23 November 2011 
<internacional.elpais.com/internacional/2011/11/23/actualidad/1322083666_953043.html>acces
sed 17 June 2012 
883 Códio Venezuela, ‘Escazes de medicamentos por control de precios’, Últimas Noticias, 29 
February 2012 
<www.codigovenezuela.com/2012/02/noticias/pais/escasez-de-medicamentos-por-control-de-
precios>accessed 17 June 2012 
884 Lanjouw, J., ‘Patents, Price Controls and Access to New Drugs: How Policy Affects Global 
Market Entry’, NBER Working Paper Series, Working Paper 11321 (2005) at 22 
885 Los Medicamentos Esenciales en la Región de las Américas: logros, dicultades y retos, 
Organización Panamericana de la Salud, Centro de Documentación OPS/OMS en el Perú  – 
Catalogación en la fuente (2007) at 16 
886 See, Politica de Medicamentos de la Subregión Andina, Organización Mundial de la Salud, 
WHO/DAP/97.3 (1993). 
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despite having withdrawn from CAN. In 1970, under the auspice of the 
Government of Peru and its Ministry of Health, the Andean Health Organization 
was created with the aim of tackling health needs within the region.887 Later on in 
1971, the Hipólito Unanue Cooperation Agreement was subscribed to by all six 
original Andean Community member states (Bolivia, Colombia, Chile, Ecuador, 
Peru and Venezuela). This Agreement foresaw a series of measures or actions as 
highlighted by the legal instrument, designed to solve health challenges and also 
to reach a certain level of norm harmonisation.888 Despite having subscribed to 
the aforementioned agreement, this organisation did not become an integral part 
of the Andean Liberalisation Programme until 1998 when Decision 528 formally 
gave it a higher status within the organisation.889 As highlighted previously, 
Venezuela has taken part in several initiatives to address purchasing drugs for 
malaria and AIDS/HIV.890 Allegedly, countries located within the Andean Sub-
region continued working together towards the same goal – to improve peoples’ 
health conditions.891 
However, it is not clear what the terms are for Venezuela’s membership once 
withdrawing from the Andean Community; other than Venezuela remaining part 
of the Liberalisation Programmes, such as the Hipólito Unanue. On the one hand, 
with regard to the Agreement and the following Agreement on Attachment Terms 
from the Hipólito Unanue Agreement, Venezuela takes the Andean Community 
framework as the one governing this Organisation, but on the other hand nothing 
is clearly stated in case of a member State withdrawing from the Andean 
Community. Admittedly, this agreement also needs to be denounced, as for 
withdrawal purposes, but what happens once this becomes an integral part of the 
AC. Countries like Chile, in dispute settlement cases, agree to taking the Andean 
Court of Justice as the jurisdictional body to solve conflicts arising with other 
member states. However, this is something that needs to be agreed upon well 
beforehand.892 So the question is, whether Venezuela needs to renegotiate its 
membership terms now that it no longer belongs to the Andean Community. 
This Andean body is of a certain importance for Venezuela given the initiatives on 
tackling the needs regarding medicines within the country, especially for the 
public sector’s distribution of free medicines. In 2008, a report named 
                                                        
887 Organizmo de Salud Andino Convenio Hipólito Unanue, Historia,  
<www.orasconhu.org/quienes-somos/historia>accessed 20 July 2012 
888 Article 3 from Convenio “Hipólito Unanue” sobre Cooperación en Salud de los Países del Área 
Andina. 
889 See Decisión 528 Designación del Convenio Hipólito Unanue sobre Cooperación en Salud de los 
Países del Area Andina como “Organismo Andino de Salud - Convenio Hipólito Unanue”, and 
Decisión 445 del Consejo de Ministros de Relaciones Exteriores, se aprobó la adscripción del 
Convenio Hipólito Unanue al Sistema Andino de Integración 
<www.comunidadandina.org/Documentos.aspx#>accessed 20 August 2012 
890 Organizmo Andino de Salud Convenio Hipólito Unanue, “Un ejemplo de Integración Exitosa: 
Diez Países Latinoamericanos y un Propósito en Común por las Personas que Viven con Sida/VIH” 
(Lima – Perú, 2003) 1-47 
891 This remark relates to Chile working closely in this cooperation regardless of its associate 
member state status in the Andean Community. Other coutries, such as Brasil, Argentinal, Paraguay 
and Uruguay have also taken part in some of the iniciative to buy massive amounts of medicines to 
supply AIDS/HIV patients’ needs.  
892 Article 3, Proyecto de Decisión “Términos de la Adscripción al Sistema Andino de Integración y 
Reglamento de Organización y Funciones del convenio Hipólito Unanue” (1998) 
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Observatorio de Precios de Medicamentos Escenciales de la Subregión Andina, 
prepared for the Andean Health Organization, highlighted that the Venezuelan 
private health sector did not actually implement or take into consideration public 
health policies to purchase or acquire medicines, as this sector has its own 
information system.893 As highlighted above, relevant reduction of prices was 
achieved in the past, benefiting the public health care sector that delivers free 
medication in accord with national regulation. Despite the Government having 
identified illnesses afflicting the Venezuelan population, ensuring universal 
access to medicines is another topic.  
5.9.2. Venezuela and the Doha Declaration on Public Health 
When addressing public health, reference to the Doha Declaration and TRIPS 
needs to be made. Venezuela, as a WTO Member, supported several 
communications and motions before the Council for Trade-Related Aspects of 
Intellectual Property aiming to raise awareness over public health issues, and 
implications on pharmaceutical patent protection.894 An active roll seemed to 
have taken place as to have a Doha Declaration better suited with the needs of 
developing and least-developed nations.  
In this respect, Venezuela, jointly with a number of WTO Members, in 2001 
lobbied for public health emergencies to be defined by each country member 
instead of having a universal definition. In addition, it lobbied for the Declaration 
to include a clause stating that nothing in the TRIPS Agreement should prevent 
Members from taking measures to protect public health.895 Both suggestions are 
found within the Doha Declaration adopted on 14 November 2001.896 
Similar efforts were drawn following the aforementioned Declaration, by another 
group lobbying -Venezuela included- for the solutions envisaged in Paragraph 6 
of the Doha Declaration not to be limited exclusively to determined categories of 
countries, given that any Member could face difficulties in making use of 
compulsory licences.897 
Later on, the General Council in Decision WT/L/540 from 1 September 2003 
complemented the previous Declaration by amending Paragraph 6 according to 
the suggestions made by all the countries lobbying for them.  Interestingly 
                                                        
893 Villacorta Santamato, J.. ‘Observatorio de Precios de Medicamentos Escenciales para la 
Subregión Andina’ Organizmo Andino de Salud – Convenio Hipólito Unanue (May, 2008) at 21 
894 Seethe list of documents involving Venezuela before the DOHA Declaration from September 
2003. <commerce.nic.in/wto_sub/trips/trips_index.htm> accessed 10 August 2012 
895  Communication from the African Group, Barbados, Bolivia, Brazil, Cuba, Dominican Republic, 
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896 Declaration on the TRIPS Agreement and Public Health, World Trade Organization, 
WTO/MIN(01)/DEC/2 (20 November 2001) 
897 Communication from Bolivia, Brazil, Cuba, China, Dominican Republic, Ecuador, india, 
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enough, the deadline to accept the TRIPS amendment has been extended,898 but 
Venezuela is yet to accept the amendment before the WTO.  
As a WTO Member, Venezuela has at its disposal the use of flexibilities found in 
the TRIPS Agreement, but to make use of them most likely this needs to be re –
implemented given its current legislative jump in the past with the IP Law from 
1955. On the one hand, every country is entitled to take measurements to protect 
public health, but on the other hand, by just making use of bulk procurement and 
initiatives like the ones from the Hipólito Unanue Agreement might not suffice 
the country’s needs, and international commitments. In this regard, the Andean 
Sub-region has recognised the value embedded in protecting intellectual property 
rights as a way to promote innovation within the pharmaceutical field, while at 
the same time a balance must be found between public health and IPRs to ensure 
people’s access to medicines.899 
Thus, representative’s from the Cámara Venezolana del Medicamento – 
Venezuelan Medicines Chamber (Hereinafter CAVEME), has pointed out that 
legally protecting inventions is also part of public policies addressed to promote 
scientific development and also economical growth, benefiting general or specific 
sectors such as public health.900 
Nevertheless, a few years after, Venezuela took part in these negotiations at the 
WTO to achieve better understating about the flexibilities and also lobbied to 
reach TRIPS amendments, and in 2007 the Government considered patents for 
pharmaceutical products as being restrictive for access to medicines since this 
protection raises the price of medicine.901 Even though 6-10%902 of medicines 
available in the market are patented, thus proving difficult to assert in a general 
fashion that patents deter access to medicines or essential medicines, the 
government still deems patents as one of the main factors strengthening the 
pharmaceutical industry’s monopoly.  
Public declarations from high ranking officials against the patent system also 
seem to be contradictory. On the one hand, patent protection is pointed put as 
some kind of failed system in promoting innovation and R&D of medicines 
mainly because patents create monopolies, but on the other hand, and in the 
                                                        
898 WTO Members will have until 31 December 2013 to accept the TRIPS Amendment. See World 
Trade Organization, ‘Amendment of the TRIPS agreement – third extension of the period for the 
acceptance by Members of the protocol amending the trips agreement’, WT/L/829 (5 December 
2011) 
899 Política Andina de Medicamentos. ‘Comisión Técnica Subregional para la Poítica de Acceso a 
Medicaments’, Organizmo Andino para la Salud – Convenio Hipólito Unanue (Lima –Perú, 2009) 
1-36 at 21 
900 Allende, F., ‘Las Patentes de Invención y la Salud Pública’, in Antequera Parilli, R., and Andrade, 
R., (eds.) Congreso Internatcional de Propiedad Intelectual: Derecho de Autor y Propiedad 
Industrial – Homenaje al Dr. Ricardo Antequera Parilli, (Universidad de Margarita, 2004) Tomo 1, 
5-463, at 182 
901 Sáman, E., ‘Patentes y Salud Pública’, Aporrea, 30 September 
2007<www.aporrea.org/tecno/a41884.html>accessed 25 August 2012 
902 Allende, F., ‘Las Patentes de Invención y la Salud Pública’, at 186 
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same report, high costs derived from obtaining patent protection make it difficult 
for small pharmaceutical companies to sell their products at a lower cost.903 
Later on in 2008, another statement was made public in relation to SAPI’s 
Official Notice disregarding the Andean IPR framework, but this time even when 
it was not directly due to minimum standards of protection that Venezuela 
withdrew, indirectly patent protection for pharmaceuticals is blamed for a lack of 
R&D on diseases afflicting poor countries, such as Dengue.904 
Interestingly enough, in the Andean Medicines Policy from 2009 that prioritises 
the diseases in need for effective medication, each country is highlighted among 
the strategies to promote R&D in a specific place. Therefore, this also makes use 
of those suggestions given in the Strategy and Plan of Action for Public Health, 
Innovation and Intellectual Property.905 Evidently, this also requires a certain 
solidarity on behalf of the pharmaceutical industry, but ultimately, creating 
incentives to promote R&D on the most needed medication in a determined 
country is left to the Governments to delimitate. 
5.9.3. Marketing approvals 
Before a pharmaceutical product reaches either hospitals or pharmacies there are 
a few necessary steps to follow, which can differ from country to country. Within 
the Venezuelan context, pharmaceutical products need to obtain mandatory 
authorisation to commercialise from the national health institute Instituto de 
Higiene Rafael Rangel, as national laws and international treaties regulate these. 
The national laws are Ley de Medicamentos - Medicines Law (L Med), 
Reglamento de la Ley del Ejercicio de la Farmacia - Regulation of the Law of 
Pharmacy Practice (hereinafter Pharmacy bylaw), and Normas de la Junta 
Revisora de Productos Farmaceuticos del Instituto de Higiene Rafael Rangel - 
Standards from the Rafael Rangel Hygiene Institute’s Pharmaceutical Products 
Review Board (hereinafter Review Board Standards). The only international 
treaty or agreement ruling over the matter is the TRIPS Agreement, given that 
Venezuela withdrew from both the Andean Community of Nations (Decision 
486), and also denounced in 2006 the Free Trade Agreement between Colombia, 
Mexico and Venezuela known as the 3G Agreement.906 Therefore, the former two 
treaties are no longer applicable to Venezuela. 
Despite intellectual property rights being of a private nature, given their social 
purpose and specifically pharmaceutical products, they require Governmental 
                                                        
903 Samán, E., ‘Patentes y Salud Pública’ 
904 Frente de Trabajadores Socialistas MPPILCO-SAPI, ‘Venezuela: Revolución Bolivariana, 
Patentes y Acceso a Medicamentos’, Aporrea, 26 September 2008. 
<www.aporrea.org/tecno/a64530.html>accessed 20 August 2012 
905 Política Andina de Medicamentos. ‘Comisión Técnica Subregional para la Poítica de Acceso a 
Medicaments’, at 29-31 
906 See Status of the Free Trade Agreement Colombia, Mexico, and Venezuela  
<www.sice.oas.org/trade/go3/g3indice.asp#PropInt> accessed 20 August 2012 
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approval which is not limited to patent rights, but also extends to the quality and 
safety verification procedure.907 
So as to comply with safety and quality procedures, a product must obtain 
marketing approval from the National Health Institute.908 This was created in 
1938, initially, to backup the Health Ministry’s projects, but later on became the 
place of reference on Venezuelans’ health by surveying and controlling the safety 
and quality of those products and services related to health.909 
Both L Med and the Pharmaceutical Practice bylaws require pharmaceutical 
products to be registered and approved by the National Health Institute. Article 
18 from L Med not only defines the Sanitary Permit as the procedure followed by 
a pharmaceutical product to obtain marketing approval, but also states that every 
medicine, regardless of the place where it was produced, needs to obtain such a 
certificate before it can even be produced or distributed within the national 
territory.910 
The national law provides a broad definition for medicines and also one for 
generics,911 but does not give the same treatment to pharmaceutical products, 
since it only states what is considered as a pharmaceutical product.912In contrast, 
the Pharmacy bylaw provides a concrete definition for “pharmaceutical 
products.”913 Other important issues addressed within the national law are: which 
are products requiring registration, which is the authority providing registration 
certificates,914 delimits the scope of clinical trials necessary to obtain registration 
certificate,915 and requests the creation of a special body within the National 
Health Institute to draft a set of internal rules with the criteria to follow when 
examining an application to obtain marketing approval.916The Pharmaceutical 
bylaw provides specific set of rules delimitating the issues defined by L Med. For 
instance, Article 53 divides pharmaceutical products into two classes.917 First, 
into known products –productos conocidos- which are those containing one or 
many active ingredients previously registered in Venezuela, and second, into new 
products –productos nuevos- defined as those constituted by one or many active 
                                                        
907 Astudillo Gómez, F., La Protección Legal de las Invenciones: Especial referencia a la 
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ingredients that have not been registered previously in Venezuela. This 
classification is important at the moment when applying for the marketing 
approval, since a set of different requirements applies to each class. 
Among the main functions of the Board of Review, the most important ones are 
evaluating scientific and analytic documents supporting the approval of 
pharmaceutical products, and also surveying and controlling those products 
commercialised in the national territory.918 Both competences constitute 
administrative procedures that will lead to either approving or rejecting an 
application for the interested party. Scholar Francisco Astudillo raises an 
important question regarding legitimacy to claim marketing approvals, since the 
public administration cannot grant such a certificate to an illegitimate third 
party, and within the legal framework there is nothing linking the Patent Office 
with the National Health Institute: so how can the Board of Review know who is 
and who is not a legitimate third party?919 In his opinion, this could only happen 
if there is a certain collaboration between the stakeholders involved, but thus far 
no linkage provisions are available within the national framework.  
Even when L Med rules over everything related to medicines, and also provides 
the general framework, the Pharmacy bylaw is the one giving more precise 
information on the requirements and definitions. In this respect, Article 55 from 
the bylaw needs to be read in conjunction with Capítulo II, Grupo E and Grupo G 
–Chapter II, Group E and Group G- in order to submit all the legal requirements 
to obtain a marketing approval.  As of 2006, bioequivalence and biodisponibility 
studies are mandatory in accord with the Norma Venezolana de Bio Equivalencies 
y Bio disponibilidad. In previous years, these studies were not required since the 
National Health Institute had pending the approval of these guidelines.920 
Following the aforementioned provision, pre-clinical and clinical trials are 
required for new products, but known products are not required to submit full 
pre-clinical and clinical trials.921 The legislation, as Valentín points out, not only 
contains a typing error but also waives these trials for known products since a 
summary with the most relevant data will suffice and substitute a full pre and 
clinical trial.922 The problem with this, is that the data to be provided can only be 
obtained if the file is consulted by a third party, which technically leads to 
disclosing information that is to be protected against unfair competition.923 
Previously, when the Free Trade Agreement between Colombia, Mexico and 
Venezuela was in force, Venezuela had the obligation to protect undisclosed 
information for 5years, unless the third party interested in obtaining approval to 
commercialise similar products had express authorisation from the original 
party.924 
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In the Andean Community context, Decision 632 from 7 April 2006, left it to each 
country to regulate the length of the exclusivity period for the protection of 
undisclosed information.925 This Decision came after a polemic court ruling from 
the Andean Court of Justice ordered Colombia to modify its internal law on the 
basis of the Andean IP framework which did not foresee the protection of 
undisclosed information for any specific length of time, therefore giving the court 
90 days to void the national Decree protection of this kind of information for 5 
years (as required by the FTA Colombia-United States).926 
Initially, Decision 486 did not foresee anything different than TRIPS.927 In other 
words, no exclusive or specific period of time was required to protect undisclosed 
information, but later on with Colombia and Peru signing FTA with the United 
States of America, these were deemed to protect undisclosed information for a 
period of between 5 to 10 years, depending on the product.928 Venezuela argued 
the validity and sustainability of the Andean Community after it legislated in 
‘favour’ of member countries implementing higher standards of protection, 
allegedly the pharmaceutical linkage generally foreseen within the FTA’s 
frameworks was another reason behind Venezuela’s rationale to withdraw from 
the ACN. 
5.10. Competition Law and Pharmaceutical Patents in Venezuela 
In general terms, patents are seen as a natural monopoly granted by the State to 
reward the inventor for his contribution to society. Some may not agree 
completely with this position The right to exclude an other for a determined 
period of time is nothing else but a competition law exception, and therefore, it is 
not right to conceive patent rights as monopolies in the strict sense of the 
word.929 Other scholars suggest that given the nature of patents, there is a tension 
between the rights granted under intellectual property law and the rights 
protected under competition law. Thus, creating economical barriers for 
products’ market entry is a challenging topic, since excluding others from 
competing with similar products –in the case of medicines- at the same time 
seems highly difficult. 930 
Before addressing some common factors between competition law and IP in 
Venezuela, and trends when dealing with patent infringements within the 
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pharmaceutical field, it is important to establish Venezuela’s competition law 
regulatory framework. 
In 1992, via Official Gazette Nº 34.880 dated 13 January 1992, was enacted Ley 
para Promover y Proteger el Ejercicio de la Libre Competencia – 
PROCOMPETENCIA Law. And it was this legislation that also created the official 
body responsible for surveying, controlling, regulating and solving any issue 
related to competition law. Article 19 creates the Superintendencia para la 
Promoción y Protección de la Libre Competencia - Superintendence for Free 
Competition also known as PROCOMPETENCIA, which is a body attached to the 
Ministry of Commerce.931 
Despite looking after ensuring free competition, there are certain practices that 
are illegal in the first place; there are few exceptions or legitimate economic 
restrictive practices, such as patents, where infringement would actually be 
considered unfair competition.932 Nevertheless, PROCOMPETENCIA Law is also 
intended to protect these rights from unfair competition. The legislation starts 
with general prohibitions, followed by especial ones (Articles 6-16), and continues 
with unfair competition practices as the accessory part of the legislation.933 
Thereafter, a precise definition of what is to be understood for these practices is 
not obtained via legislation. 
Thus, the ‘unfair competition’ concept is an interesting link between competition 
law and IP. On the one hand, the legislation in Article 17 provides the intention to 
eliminate the competitor as a key element embedded within unfair competition. 
Therefore, the following are the main ways portraying unfair competition:  false 
or deceiving publicity to prevent or limit free competition;934 promoting goods 
and services based on false advantages; disadvantages and/or risks derived from 
the competitor’s product;935 and commercial bribery, infringing industrial secrets 
and simulating products936 . But on the other hand, in general terms, the doctrine 
and jurisprudence understand a third party’s dishonest and reprehensible 
behaviour towards another merchant as unfair competition.937 
Precisely this general behaviour has been also interpreted within Venezuelan 
doctrine ‘as making use of other’s effort to obtain certain benefits’. This is an 
argument frequently seen in unfair competition claims related to marketing 
approvals obtained by third parties.  
 
Accordingly, marketing approvals are obtained from the National Health 
Institute, whose Board of Review analyses every certificate’s application before 
the product itself can be commercialised nationally. However, as described above, 
known products only forego a summarised procedure which excludes clinical 
trial. Allegedly, undisclosed information is used by third parties submitting 
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marketing approval application for generic versions, hence, making use of the 
originator’s efforts by supporting their product with data that was already given 
to the Board of Review. 
 The aforementioned assumption leads the discussion to the relation between 
undisclosed information and trade or industrial secrets in Venezuela. As argued 
before, both Decision 486 and Article 39 (1) from TRIPS deemed every member 
country responsible for ensuring protection of undisclosed information against 
unfair practices. But Article 260 – Decision 486 also regards industrial secrets as 
undisclosed information within the control of an individual or legal person that 
may be used for productive, industrial or commercial activities and that is capable 
of being transmitted to a third party as long as it has commercial value because 
the information may be related to the nature, purpose and characteristics of the 
product938 – pharmaceutical products and undisclosed information. 
Infringing on the protection of industrial secrets– as undisclosed information- is 
precisely the closest link between competition law and intellectual property law, 
given that not only are individual rights protected, but also the unfair practice can 
be sanctioned if in the light of competition law both reprehensible behaviour is 
proven and the relevant market is affected.939 
Some scholars have also briefly pointed out the link between intellectual property 
and competition law in Venezuela, by asserting that a third party seeking to 
obtain marketing approvals for known products is partaking in the reprehensible 
behaviour of abusing the efforts of others, which is considered unfair competition 
as described by both doctrine and jurisprudence.940 
PROCOMPETENCIA has been very clear in verifying the concurrence of elements 
when ruling over third parties’ marketing approvals as unfair competition. In 
Resolution No SPPLC/0016-2003 the court considered the intention to eliminate 
a competitor via unfair competition practices as a key factor. The case related to 
infringements over industrial secrets, since allegedly the third party used 
undisclosed information to apply for marketing approval without informing the 
originator about it. There are two important things settled by the court in that 
decision: firstly, it highlights that the abbreviated procedure for known products 
does not necessarily imply infringements over industrial secrets since a third 
party only needs to choose on the application form whether the application is for 
new products or known products, and by choosing the second option the 
company is neither accessing a private file nor making use of the efforts of others. 
Secondly, the court addresses the elements necessary to fulfil Article 17 from Ley 
PROCOMPETENCIA, indicating the bad faith is also embedded within unfair 
competition practices.941 
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During 2003, four resolutions dealt with unfair competition due to alleged 
infringements over industrial secrets. One way or another the court kept on 
ratifying the need to verify bad faith as an element incurred in commercial 
practices, and by complying with legislative requirements a company or third 
party cannot be deemed as an infringer.942 Therefore, proving unfair competition 
due to misappropriation of undisclosed information, seems rather challenging. 
Another interesting fact related to competition law, is that patent infringement 
cases seem to be solved as competition law cases instead. In 2008,Resolution N° 
SPPLC/ 0018- 2008 dealt with a couple of interesting issues, patent procedure 
infringement, applicability of Andean Decision 486 and anti-competitive 
practices. This court case was between Meyer Productos Terapéuticos, S.A. vs 
Sanofi-Aventis,943 where the latter had obtained in 1998 patent protection for the 
procedure to manufacture “Procedimiento para la preparación de Enantiomeros 
Dextrogiros de Alfa-(Tetrahidro-4,5,6,7-Tien (3,2-C) Piridil-5) (Cloro-2-Fenil) 
Acetado de Metil”944 as published in Official Journal Nº 377 dated 6 December 
1993. Sanofi-Aventis had exclusive rights until 5 February 2008. However, Meyer 
in 2006 obtained authorisation to commercialise the generic version with the 
same active ingredient (Clopidogrel Bisulfato). 
Meyer sought to compete in the market with two generic versions based on the 
same active ingredients as the patented version owned by Sanofi-Aventis. 
Thereafter, when the right holder tried to stop the generic producer, this one 
argued before PROCOMPETENCIA anti-competitive practices; namely abuse of 
dominant position, restrictive practices and obstructing market access. With 
regard to patent rights, the court did not dismiss Sanofi’s legitimate right, but it 
did not disregard the generic producer’s right to obtain marketing approval for 
the generic product, since in the court’s view, the procedures to manufacture 
either of the versions were different. Therefore, no patent infringement could be 
alleged.  
Regarding abuse of dominant position, the Court found Sanofi-Aventis as 
incurring in anticompetitive practices as framed by Articles 5, 6, 8 and 13 from 
PROCOMPETENCIA law. And the last issues dealt with by this Court related to 
Decision 486 to determine patent rights, highlighting its applicability despite 
Venezuela having withdrawn from the Andean Community. 
Competition courts have been used to determine whether obtaining marketing 
approval for known products can or cannot be considered as infringement over 
industrial secrets due to unfair competition. As analysed within the 
aforementioned case law, and in accord with national regulations, the fact that a 
third party uses the abbreviated procedure does not necessarily imply that this 
had access to administrative files that seem to be for the exclusive access of the 
National Health Institute’s Board of Review.  
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944 Sanofi-Synthelabo, Patent Nº R050740, Filing date 5 February 1988, Expiration date 5 February 
2008, Official Journal Nº 377 
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5.11. Summarising the Venezuelan context 
Prior to addressing the factors or elements deterring access to medicines in 
Venezuela, it is important to summarise some final remarks within the current 
legal framework, Andean community framework and the Venezuelan public 
health care model to thereafter convey with the Venezuela strategy of protection 
for intellectual property rights while balancing access to medicines. 
Venezuela’s intellectual property regime is based on the IP Law from 1955 as re-
implemented following the withdrawal from the Andean Community of Nations. 
The current legislation is not in compliance with the TRIPS Agreement, therefore, 
pharmaceutical patents are no longer protected in Venezuela. This argument has 
availed patent application rejections since 2008. Within the Official Journal of 
the Patent Office, in 2009 a total of 200 patents were returned on basis of 
administrative requirements; of these 65 related to pharmaceutical products and 
processes, and all of them were later on rejected on legislative grounds.  
The Andean Community IP regime did comply with TRIPS and also harmonised 
the system among the countries belonging to the Agreement. As part of the 
Andean Community, Venezuela also retained certain privileges and duties, among 
these applying the legislation enforce for a period of 5 years so as to allow an 
adequate legislative reform. Venezuela, right after the transitional period expired, 
re-implemented the old legislation bringing the IP system into chaos. 
In terms of public health, admittedly, within the last 14 years significant 
investments within the health care sector have been registered. However, by the 
country implementing a new system instead of boosting the existing one, more 
challenges arose and the situation within the sector also deteriorated. 
Misinformation and inequalities characterise public health care in Venezuela. 
Access to medicines is provided for a limited number of diseases; despite this the 
Government has taken part in the Andean Sub-regional Group to purchase 
medicines.  
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6 IDENTIFYING STRATEGIES 
Intellectual property rights and access to medicines have been in the spotlight for 
some time now; even prior to the TRIPS Agreement the pharmaceutical industry 
lobbied against the generic industry or at least asserted that generics were of 
inferior quality to branded name ones.945 Nevertheless, the debate intensified 
after ratifying the TRIPS Agreement given that its implementation seemed to 
compromise public health policies around the world due to a fear raised in 
medicines prices. Moreover, all signatory nations were not at the same or even on 
a similar level of development that would ensure, in principle, an “impact-free” 
implementation. Significant legal reforms were and still are needed to come into 
compliance with TRIPS. 
Whether patents are granted for pharmaceuticals, or certain medicines are given 
at low or no cost in determined geographical areas, the problem of balancing 
these rights –patents and access to medicines- worldwide is far from being 
achieved. The challenge remains, and both developing and least developed 
countries struggle to provide patent protection while allowing generic production 
without infringing patent rights or even providing citizens with top of the line 
medicines at affordable prices.946 Given the extent and the diversity within the 
discourse, both analysis and discussion have been limited in time and 
geographical extension. This project is limited to Brazil, Chile and Venezuela by 
mainly focusing on gathering further understanding upon their view and 
strategies to address patent legislation and access to medicines in each country. 
Even after the background of each country had been looked at, the real analysis 
began within the implementation of TRIPS and onwards.  
In this respect, the analysis begins with the overall description of the project, its 
methodology and research questions. The purpose of the research was to identify 
the strategies used by Brazil and Chile to balance patents and access to medicines, 
while assessing whether or not Venezuela could benefit from implementing either 
of the strategies analysed. To provide the reader with some basic knowledge, 
several aspect were taken into consideration, thus, the general context introduced 
the concepts of public health, access to medicines, universal coverage, intellectual 
property rights and patents. This chapter aims to summarise, on the one hand, 
the aspects that shaped and emerged while setting the international framework 
relevant to the analysis, i.e. TRIPS Agreement and the access to medicines 
discourse. And on the other hand, it aims at presenting the “strategies” or 
“models of protection” identified following the general framework discussed 
within the background of the study. 
As depicted within the introductory chapter, intellectual property rights and 
access to medicines had been clashing even before the TRIPS Agreement. In an 
                                                        
945 See t’ Hoen, E. The Gobal Politics of Pharmaceutical Monopoly Power (the Netherlands, AMB 
Publishers, 2009)15-16 
946 Refer to the Supreme Court if India, Novartis vs. Union of India & Other CIVIL APPEAL Nos. 
2706-2716 OF 2013. The Supreme Court of India prevented patent evergreening due to a clause 
within the Indian Patent Act. Although this case was not analysed within the research, it is 
important to mention its relevance within the international framework as it setss an example for 
countries aiming to balance patent rights while putting their health needs first.  
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attempt to balance rights, access to essential medicines is considered to be part of 
the human right to health. But the analysis of this concept brought to the 
spotlight interesting points denoting further challenges when balancing rights. 
For instance, the ‘right to health’ has different interpretations, globalisation does 
not always have a positive impact, socioeconomic theories and the definition of 
‘health’ per se pose challenges in themselves for achieving adequate access to 
health care from the theoretical point of view. Then, from a practical point of 
view, the need for further funding and commitment on behalf of the States as to 
adequately implement health care policies that assure access to essential 
medicines has been highlighted. 
Within the diverse human rights, international agreements and conventions, 
access to medicines per se is not expressly protected, however, the ‘human right 
to the highest attainable standard of health’ is.947 Allegedly, the several 
interpretations of this right contributed with the creation of derivate rights 
according to its scope. Nonetheless, today access to essential medicines is as 
much part of the human right to the highest attainable standard of health, as is 
access to health care providers. Having said this, it is important to highlight the 
fact that all three political constitutions –Brazil, Chile and Venezuela- enshrine 
protection for fundamental rights and among these is access to health.  
The current discourse generally refers to the right of access to medicines, but 
note, that this does not necessarily imply access to ‘essential medicines’ or the 
other factors involved in providing it. Some scholars have challenged the use of 
the definition of ‘health’ provided by WHO as the basis for the human right to 
health since this might “outlaw diseases, the infirmities brought on by aging and 
even mortality.”948 In practice, diverse epidemiological scenarios, despite having 
a globalised world949 challenge the possibilities in tackling health care needs. 
When discussing access to medicines, the concept and goal of providing citizens 
with universal coverage also comes to the spotlight raising the question on 
whether or not it is feasible for developing and least-developed countries that are 
lacking resources to implement adequate health care reforms to achieve this goal.  
Whether concepts are not sufficiently defined or countries need to comply with 
international commitments, the challenge in providing adequate health care 
seems to be dependent from several aspects that go beyond providing patent 
protection or not. Namely, public health policies consistent with the country’s 
needs, significant investments in infrastructure and human resources, 
governmental commitment and continuity, decreasing poverty and improving 
sanitation and prioritising the attention of specific illnesses among several other 
factors.950 Thus far, the study shows the feasibility in implementing public health 
                                                        
947 Schroeder, D., ‘Does the Pharmaceutical Sector have a Corresponsability for the human Right to 
Health?’ (2011), 20 Cambridge Quarterly of Healthcare, 298-308, at 298 
948 Evans, T., ‘A Human Right to Health?’, 198 
949 Informe de epidemeologia de WHO 
950 UN Millennium Project, Prescription for Healthy Development: Increasing Access to 
Medicines, Report of the Task Force on HIV/AIDS, Malaria, TB, and Access to Essential Medicines, 
Work- ing Group on Access to Essential Medicines. (Sterling, Va.: Earthcscan, 2005) 29-30. Also 
see World Bank Group, Improving Effectiveness and Outcomes for the Poor in Health, Nutrition, 
and Population: An Evaluation of the World Bank Group Support since 1997, The World Bank 
(Washington, D.C. - 2009) 5 
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policies addressed to tackle health needs while at the same time implementing 
the TRIPS Agreement in at least two of the countries object to the research. 
WHO has not only provided countries with general guidelines about public health 
and access to essential medicines, but it has also harmonised to a certain extent 
the most important aspects related to the ‘highest attainable standard of 
health.’951 Within this referential framework the need to implement an adequate 
health care system together with solving other needs that directly or indirectly 
affect health, such as poverty, sanitation, housing, education and financial 
resources are stressed. Ideally, countries’ health care systems would cover all of 
the diseases while providing access to medication. But if this is not feasible due to 
each country’s particular situation, it may be more efficient to begin by moving 
forward to achieve access to adequate health care and essential medicines instead 
of not providing anything at all or even perhaps prioritising the illness or illnesses 
afflicting the most in the national context. Admittedly, this has been part of the 
success in Brazil’s battle against HIV/AIDS; even though there are several other 
illnesses afflicting an important sum of the population, the focus on and 
commitment to developing and implementing health care policies consistent with 
the aforementioned situation has also been highlighted as being influential to the 
global development of HIV/AIDS health care provisions elsewhere.952 
Common health goals, social conscience and political will953 have proven to be 
key factors in the fight against epidemics, i.e. HIV/AIDS. Also demonstrating that 
a clear, straightforward and precise discourse is fundamental for people to 
understand their rights and governmental duties towards them since the topic in 
itself is broad enough. As for access to medicines, despite the State being the 
main actor responsible for ensuring adequate implementation of health policies, 
both the international community and the pharmaceutical industry play an 
important role in the realisation of health rights.  
The pharmaceutical industry develops and produces drugs and services destined 
to improve people’s quality of life. Given this role, it has been questioned whether 
the industry has a co-responsibility with the human right to health.954 When 
discussing access to medicines, affordability and availability are fundamental, 
and as it will be discussed below, high prices are generally associated with 
pharmaceutical patents and the industry per se. Nevertheless, a certain level of 
co-responsibility has been determined in terms of costs and innovation. 
The pharmaceutical industry heavily relies on patent protection. At least three 
theories argue in favour of the patent system as a tool to create innovation.955 
However, the efficacy of the system as an engine to incentivise innovation is 
under public scrutiny since the pharmaceutical industry has allegedly failed to 
                                                        
951 World Health Organization, ‘How to Develop and Implement a national drug policy’1-83 
952 Nunn, A. et al. ‘AIDS Treatment in Brazil’ 1112,  
953Homedes, N. Et al, ‘Improving access to pharmaceuticals in Brazil’ 129 Points out how 
remarkable is the fact that Brazil, despite all of the political changes, has manage to mantian in time 
the programme to treat HIV/AIDS and that the only changes made where addressed to improve the 
quality in response to the disease.  
954 Schroeder, D., ‘Does the Pharmaceutical Industry have corresponsability’at 299 
955 Boulet, P., Garrison, C., and t’ Hoen, E., 'Drug Patents Under the Sport Light: Sharing practical 
knowledge about pharmaceutical patents', Médecins Sans Frontières (May 2003) at 8 
<apps.who.int/medicinedocs/pdf/s4913e/s4913e.pdf> accessed 20 June 2013 
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engage in R&D in order to address solving priorities related to health needs in 
developing and least developed nations. Affordable and top of the line vaccines or 
medicines destined to cure illnesses afflicting the poor are not widely available, 
which also challenges the patent system’s efficiency.956 
Admittedly, new products bear the investment costs and the rationale behind 
pharmaceutical products is to allow the companies to both recoup the investment 
and to obtain revenues for their invention. The cost of developing a new medicine 
varies  largely; during 2012 the cost is estimated to have ranged from $1.2billion 
to as much as $12 billion, which also seems to take into consideration the cost of 
failure for the industry since it has been said that for every 10 medicines tested in 
human trials only one may succeed.957 
On the one hand, patent protection grants to the inventor -pharmaceutical 
industry- a period of 20 years to recoup their investment. But on the other hand, 
these 20 years restrict competition in terms of allowing third parties to freely 
produce the same medicine without the owner’s consent. Therefore, the current 
R&D model has been analysed by scholars whom asserted that a collaborative 
open innovation model would allow the pharmaceutical industry to come up with 
breakthrough medicines, while at the same time lowering costs of R&D.958 
Within the background of the study, several points were brought into the 
spotlight in terms of definitions and understanding of the system per se. In this 
respect it was established that regardless of having a unanimous definition as to 
what a patent is, it is widely accepted that patents are immaterial rights granted 
by the State to an inventor to reward him for his invention; that is, as long as the 
invention complies with patentability requirements, the inventor has a period of 
20 years to exclude others from using the invention. Inventions are generally not 
defined either. Nevertheless, the doctrine has come to understand inventions as 
solutions to a technical problem that satisfy patentability requirements while at 
the same time are not excluded by virtue of non-patentable subject matters.959 
Treaties and Conventions shaping the international legal framework, as we know 
it today, were also addressed. The Paris Convention and the TRIPS Agreement 
mark the before and after of the protections of intellectual property rights. The 
Paris Convention, initially, provided the international framework for the 
protection of intellectual property rights. However, its mandates are not as 
detailed and extensive as those found within the TRIPS Agreement. Under the 
Paris Convention, patents were to be granted to inventions that met patentability 
requirements, however each country had the prerogative to extend patent 
protection to pharmaceutical or agricultural products.960  Later on, the TRIPS 
                                                        
956 Ibid 
957 Herper, M., ‘The Truly Staggering Cost of Inventing New Drugs’, Forbes, 12 October 2012, 
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958 Munos, B., ‘Using Open Innovation to Tackle the Dearth of Antibiotics’presentation made at the 
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959 Thorley, Q.C., S., Miller, R., Q.C. Burkill, G.,et al. (eds.) Terrel on the Law of Patents (London, 
Sweet & Maxwell, 2006) at 20-21 
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Agreement broadened the scope of protection to all fields of technology, whether 
product or process, as long as the patentability requirements were also met.961 In 
this respect, pharmaceutical patents were no longer a prerogative of the State, but 
instead a mandate imposed on all member States if these were to integrate into 
the World Trade Organization in 1994. 
Despite having a new set of rules, each country implemented TRIPS according to 
their own needs, or at least attempted to do so. As has been established before, 
the approach towards the Agreement has not been all that positive among least-
developed and developing countries due to public health concerns. In this 
respect, Brazil implemented TRIPS in a manner consistent with their needs, 
thereafter enacting the prior consent requirements for pharmaceutical patent 
applications. Chile engaged in trade negotiations with developed countries, which 
required it to implement even higher standards of protection, but at the same 
time achieving further national growth. Venezuela initially implemented the 
Agreement via the Andean Community, only to later on withdraw from this 
organisation and re-implement the old IP Law.  
6.1. Identifying strategies or models of protection on a case-by-case 
basis 
The comparative law method can be used in academia to pursue legal reform, 
analyse different systems and transplant solutions into another system.962 
Venezuela, like many other countries, followed this tradition in transplanting 
legislation and institutions, hence, amid legal uncertainty, analysing the 
intellectual property regime only seems convenient and fruitful. Having said this, 
the purpose of this analysis is not to transplant institutions, legislation or 
solutions, but more to tailor a system to fulfil both IP and public health needs in 
Venezuela. Therefore, the following lines will provide in a nutshell the strategy or 
model used in each country to protect both IP rights and access to medicines. 
Detailed descriptions and country profiles have already been carried out within 
the substantive chapters. 
Given the extent of the research and the changing variables, the comparison will 
be divided into two parts. Firstly, within this section’s description of each 
country’s strategy, both IP institutions and legal framework and public health 
context and legal framework will be assessed. Secondly, the strategy aims at 
answering the question of how these countries tackled the challenges derived 
from the Agreement. The following chapter, Conclusions and Suggestions, will 
present the lessons from Brazil and Chile in terms of IP and Public health. When 
assessing whether or not Venezuela could learn from Brazil and Chile, both 
advantages and disadvantages will be discussed with the aim of shedding light on 
the Venezuelan intellectual property doctrine. 
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6.1.1. Brazilian Strategy or model of protection 
The historical and political context in Brazil suggests a long battle against 
oppression and political abuse. Nevertheless, several elements came together to 
achieve remarkable progress in terms of public health, specifically the battle 
against HIV/AIDS. The civil society and activists played an important role in both 
raising awareness over certain health issues and reaching a political change from 
dictatorship to democracy. 
Both intellectual property rights and access to health (extended to medicines and 
treatment) find protection within the political constitution. IP provisions, 
specifically pharmaceutical patents seem to be tightly intertwined with public 
health concerns. Brazil, a founding member of the Paris Convention, has followed 
a respectable tradition towards protecting IP rights and also is a key player in 
terms of public health and the fight against HIV/AIDS. Interestingly, 
pharmaceutical patents where available in Brazil long before TRIPS, but after 
1945 the legislation was amended in a way that these kinds of inventions were no 
longer protected.963 
Brazil was among the first South-American countries to implement TRIPS, and 
also the one which tailored such an implementation by making use of the 
flexibilities available within the Agreement, and as such this argument partially 
frames the Brazilian Strategy or model of protection, as will be explained below. 
By the time TRIPS became a mandatory adherence, Brazil had been struggling for 
some time to tackle the HIV/AIDS epidemic.964  Allegedly, the programme 
destined to provide free access to ARV to treat patients living with the illness was 
in jeopardy between 1990 and 1995 since there was an insufficient supply of 
medicines.965  Later on in 1996, guidelines to supply medicines to treat the 
disease were created by the Ministry of Health,966 which also implemented the 
public procurement system to purchase and distribute medicines ensuring an 
increased level of supply that was not existent in the past.967 
The timeframe for both increasing internal supply of ARVs, and the coming into 
force of the IP Code implementing TRIPS –compulsory licensing regime- does 
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not seem to be a mere coincidence. The challenge, in a nutshell, was/is how to 
solve the HIV/AIDS health care crisis while at the same time complying with 
international commitments. On the one hand, the whole IP framework had to be 
amended in views of both constitutional provisions and the minimum standards 
of protection. INPI –the patent office- would now have to accept patent claims for 
pharmaceutical products and processes, examine claims caught up within the 
pipeline and also observe whether or not these claims met with the social function 
requirement. On the other hand, the public health care sector was also developing 
a purchase and distribution system aiming to ensure constant supply of ARVs.  
How could the Brazilian government deal with all of these interests and needs at 
once without perishing on its way? As a country with one of the largest economies 
in the region, determined bargaining power was also embedded. Therefore, the 
country moved forward in using this power to not only intimidate other trading 
partners seeking market entry into the Brazilian market, but also allowed them to 
have wider decision making powers in terms of policymaking. In other words, 
policy makers seemed to have had in mind a clear goal, which was to balance 
rights and to gain something from implementing TRIPS. 
IP reforms came in two or three stages, indicating that the government was to a 
certain extent learning from its weaknesses. The first stage of reforms (during 
1996) only included some of the flexibilities and safeguards within the 
Agreement, namely compulsory licensing, experimental use and limited use of 
parallel imports.968 The second stage of reforms coincides with the time when the 
government was negotiating with a set of pharmaceutical industries to reduce 
ARVs prices (during 2001); the negotiating team noticed weaknesses within the 
current patent system in terms of public health concerns.969 Prior to these 
negotiations, the prior consent mechanism was created (1999), thus involving 
INAPI to evaluate the impact derived from said pharmaceutical patent claims. 
Within the current IP Code (or Patent Act) two important mechanisms exist, 
namely the prior consent mechanism and the local working requirement, which 
have been rather controverted issues. For the first one, neither jurisprudence nor 
literature agree on its legality and if it really breaches the TRIPS Agreement. For 
instance, several attempts have been made for the courts and comptrollers’ office 
to delimit the attributions of the National Health Institute in examining 
pharmaceutical patents. Several patents have been denied from patent protection 
given ANVISA’s veto over these patent applications submitted before the Patent 
Office INPI. Even when the prior consent mechanism was set out so ANVISA 
would assess the impact that such a claim would have over public health 
concerns, the scope and limits of this analysis were initially not clear. On the one 
hand, patent applications where to be examined by INPI (patentability 
requirements), but on the other, ANVISA also understood or misunderstood the 
scope of its attributions by examining the same patentability requirements as 
INPI but in light of public health instead. 
Prior Consent is a convoluted topic in Brazil, as it was described within the 
substantive chapter. A series of case law demonstrated that ANVISA was actually 
misinterpreting Article 18 from the IP Code, which basically establishes that 
inventions, contrary to health, shall not receive patent protection. However, this 
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provision is said to have been set out in the context of forbidden substances by 
the law, and not with the interpretation given by ANVISA. To complicate things 
further, ANVISA never issued or made public for that matter the criteria used to 
examine the patent applications sent by INPI. It was not until 2013 that finally 
this agency published RDC n° 21, which addressed the scope of its analysis. 
Nonetheless, this resolution does not seem to completely clear out the context of 
the examination in terms of patentability requirements.  
Art. 4° Após recebimento dos pedidos de patente encaminhados pelo INPI, a Anvisa 
analisará tais pedidos à luz da saúde pública, mediante decisão consubstanciada em 
parecer técnico emitido pela unidade organizacional competente no âmbito da 
Agência. ??????Considera-se que o pedido de patente será contrário à saúde 
pública quando:?? - O produto ou o processo farmacêutico contido no pedido de 
patente apresentar risco à saúde; ou ?II - O pedido de patente de produto ou de 
processo farmacêutico for de interesse para as políticas de medicamentos ou 
de assistência farmacêutica no âmbito do SUS e não atender aos requisitos 
de patenteabilidade e demais critérios estabelecidos pela Lei no. 9.279, de 
1996.970 
Article 4 points out that after ANVISA receives the patent applications sent by the 
patent office, the agency will assess them in light of the public health context in a 
binding decision given by the competent department of the agency to carry out 
the examination. Until this point, the issue seems to be rather clear, but the 
article goes further in establishing the cases that ought to be considered as 
contrary to public health. Part II begins by narrowing the rejection to claims that 
portray an interest to public health policies in the context of the universal 
coverage granted by SUS –until here it also seemed rather clear- but then appears 
the phrase “e não atender aos requisitos de patenteabilidade e demais 
critérios estabelecidos pela Lei no. 9.279, de 1996”.This last part could be 
translated as: “and that do not fulfil or comply with the patentability 
requirements established by the IP Code”. Thus, two possibilities emerge when 
interpreting or attempting to translate this past part of the provision. Either 
ANVISA will continue to examine patent claims in light of patentability 
requirements, or this is definitely a personal limitation given by the fact that the 
doctoral student’s mother tong is not Portuguese. Unfortunately, only time will 
clarify the issue.  
The compulsory licensing regime was also modified in 2003 under the umbrella 
of de Decree n° 4.830/203, which specifically settles the frame for compulsory 
licences in cases of national emergency and public interest. Initially, products 
imported into Brazil to supply the internal market had to be patented elsewhere 
or even in Brazil, but the new reform included a provision allowing Brazil to 
import from other countries the same product even if this had not received patent 
protection in that country.971 Compulsory licences can also be issued due to 
unfulfilment of the local working requirement, which already had been settled 
within the IP Code (1996), but nevertheless challenged in light of the Paris 
Convention. Many considered as illegal the provision and duty to fulfil a local 
working requirement in a period of 3years from the date the patent was granted. 
At this point, it seems necessary to remember that Brazil justified the provision 
with the need to boost their national industry, and also to prevent import 
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monopolies from pharmaceutical companies and all of these in light of the 
HIV/AIDS crisis. 
Regarding public health policies, Brazil’s government and society have advocated 
for equal access and specially to provide affordable medication. Solving the 
HIV/AIDS crisis in Brazil has been a central issue when developing both the 
patent regime and public health policies. In the past compulsory licences have 
been used as a bargaining or pressure mechanism in negotiations with the 
pharmaceutical industry to obtain lower prices for medicines. When this failed, 
Brazil issued a compulsory licence by dropping royalties by about 20% from the 
price already suggested in negotiations. This compulsory licence was extended 
until 2015, as highlighted within the substantive Brazilian chapter. 
Admittedly, implementing the TRIPS flexibilities requires each country to 
integrate them into their national system. This is said to portray ‘changes in the 
balance of power amongst the parties involved in the bargaining process.’972This 
has precisely been one of the strengths of Brazil during the negotiation processes. 
However, since this implementation carries the threat of using a compulsory 
licence, Brazil faced strong opposition from trading partners. 
In May 2000, the American government complained before WTO demanding to 
call Brazil for consultation over the provisions contained in their IP Law. In their 
view, the Brazilian government was in breach of TRIPS Articles 27-28 since 
Article 68 from the IP Code required patent holders to comply with the local 
working requirement. Reportedly, the pharmaceutical industry lobbied efficiently 
enough as for the WTO to establish a panel before the Dispute Settlement Body 
from the organisation in 2001. Notwithstanding, the Brazilian government found 
their share of support from other large emerging economies to backup their 
intention of both implementing and using the provision to ensure universal 
access to essential medicines. After finding consistent support from different 
international organisations, and given that further American commercial 
interests where also at stake, the United States of America withdrew the case 
before the DSB in July 2001.973 
The Brazilian model resembles that the government is proactively and willing to 
protect internal concerns - both IP and public health related. Initially, IP reforms 
did not include all TRIPS flexibilities. However, during negotiations with the 
industry to obtain cheaper prices for the antiretroviral the government noticed its 
weaknesses and corrected them in a decent period of time. Given its condition as 
an emerging economy with high bargaining power, Brazil has managed to stay 
focused in tackling the HIV/AIDS epidemic, and hence access to essential 
medicines. Resisting immense pressure from trading partners like the United 
States of America has been a keynote in their success towards IP policies that are 
consistent with internal health concerns. Some have regarded the system as a 
system with no formal patent protection. However, if the patent system is to work 
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in a way to boost national economies, inventive activities and transfer of 
technology, by Brazil protecting its national industry, it could be said that to a 
certain extent the goal of the patent system is not far from being reached within 
the Brazilian context. 
Advancements within the public health care sector seemed to focus primarily on 
access to essential and HIV/Aids medication. Perhaps this shows that a clear 
focus, and policymaking continuity, are better than resetting the health care 
system and policies every time there is a governmental elect. 
Thus, the Brazilian model or strategy of protection is based on high levels of 
bargaining power, local manufacturing capability and incorporation of TRIPS 
flexibilities, and safeguards within the national law may suggest that Brazil is a 
bargaining rebel. 
6.1.2. Chilean Strategy 
As an open market economy, Chile has signed FTA with around 50 countries, 
among them  the United States of America. Thus, Chile not only ratified a TRIPS 
Plus Agreement but also implemented public health policies consistent with 
Chile’s requirements to provide universal coverage. 
The intellectual property legislation has been reformed so as to comply with its 
international commitments. However, TRIPS flexibilities had not been 
incorporated in full into their national system. Compulsory licences are foreseen 
to correct anti-competitive behaviour and also to address national emergencies. 
Thus far, Chile has never threatened to use a compulsory licence. 
In terms of the IP Legislation per se, policy makers defined patents, patentability 
requirements that are generally not defined within other IP laws analysed.974 The 
Chilean legislation differs from the Brazilian most noticeably by the fact that no 
local working requirement is either envisaged to sanction a compulsory licence or 
conceived as a possible anti-competitive behaviour. In the case of unfair 
competition, “the competition court [is] the competent authority to determine 
whether or not certain practices are contrary to fair competition.”975 
Despite some authors considering that countries whom have signed TRIPS plus 
agreements tend to loose their bargaining power,976 the commercial exchange 
between Chile and other trading partners does not seem to be affected or to affect 
the health care quality. From a legislative standpoint, the correlation between the 
patent system and health care policies run in parallel without strictu sensu 
interfering with each other.  
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Admittedly, the US-Chile FTA brought certain concerns related to pharmaceutical 
patents. In principle, protection of undisclosed information and the use of the 
bolar exemption could have affected or impacted access to medicines in Chile. 
However, as the lessons from the Chilean health care system will portray, access 
to medicines in Chile is safeguarded and ensured by the State via other 
mechanisms that are not as aggressive as perhaps the ones used by Brazil. 
Other issues brought by the FTA regard the pharmaceutical linkage imposed by 
this and the protection of test data information against unfair commercial use.977 
Since the agreement was ratified in 2003, Chile has been constantly placed on 
both the Priority Watch List and Watch List in the yearly 301 Report from the 
Office of Trade Representatives from the United States. Thus, pharma related 
concerns are not the only ones mentioned or causing Chile to be placed in such a 
position before the US. In terms of the pharmaceutical linkage, it has taken 
several years for the Courts to acknowledge that sanitary permits are marketing 
approvals. Despite the fact, the Chilean legislation before ratifying the FTA 
foresaw the duty to inform right holders about applications from third parties, 
and also requested patent certificates.  
As discussed within the substantive chapter, the consequences from the 301 
Special Report from the Office of the United States Trade Representatives, could 
translate into commercial sanctions imposed on Chile. In the past, two tariff 
sanctions have been imposed to two other trading partners, whom ironically had 
not signed a FTA with the US. Any sanction to be imposed on Chile would require 
the trading partner to initiate the proceeding before the Dispute Settlement Body 
from WTO. If such a proceeding would take place, then the US would also have to 
evaluate the impact of this for its own commercial interests.978 
Chilean politicians have been working, since the Chicago boys, to achieve greater 
national development through an open market economy. Therefore, Chile 
currently enjoys a rather stable economy gaining access to foreign markets, 
forming alliances to achieve greater public health awareness, and to boost their 
national pharmaceutical industry. 
The current health care model has required many years of work to shape it into 
what it is today. Creating uniformity within the system, to make it available to all 
without discrimination, is what really ensures both universal access and 
coverage.979 Evidently, the system depends on high levels of funding to keep it 
running; it is primarily funded by taxpayers’ contributions and other taxes 
imposed on determined items.980Chile has also had its fair battle against 
HIV/AIDS, thus, this country has partnered up with Brazil to achieve greater 
                                                        
977 Marantis, D., The Office of the United States Trade Representative, 2013 Special Report 301 
(May 2013) at 22,31 
978 Keller, N., and Zanette, R., ‘Los posibles castigos que enfrenta Chile’ El Mercurio, 10 de Enero de 
2007, at Negocios y Economía. Argentina was sanctioned by reducing in 50% the products within 
the Sistema Generalizado de Preferencia in 1997. Earlier on, Brazil had also been sanctioned with a 
tariff raise of 100% for several products, which could not be imported into the US between 1989 and 
the 90s 
979 Borzutzky Yozmot, S., ‘Social Security and Health Policies in Latin America’ at 246-256 
980 Borzutzky Yozmot, S., ‘Health in Chile’ at 645 
  
201 
international support from diverse organisations. By 2006, Chile was able to 
provide 100% coverage to treat the illness.981 
The Chilean model is based on commercial exchanges that allow them to allocate 
further funds into the development of the country. The liberal and market-
oriented Chile has also seen how continuity and solidarity principles from all 
administrations benefit the overall development of the nation. 
6.1.3. Venezuelan Strategy 
In general terms, as the analysis of the 1955 IP Law shows, a significant setback 
for Venezuela’s protection of both intellectual property rights and also access to 
medicines might have taken place by re-enacting this legislation. 
As described above, the current IPR legislation foresees patents for inventions, 
discoveries and creations with the limitations denoted.982 Thus, unlike Decision 
486, the current Venezuelan IPR legislation fails to provide a definition as to 
what it is considered to be an “invention”, however it tries to define it by 
providing a structure with four elements. This legislation grants and regulates 
patent rights from the inventor, the one who made the discovery and those who 
introduced the creations, inventions and discoveries relevant to the industry. 
Article 14 enumerates patentable matters and also states that generally 
everything resulting from someone’s inventive effort taking into consideration 
legal exceptions shall be protected. Furthermore, it also enumerates the things 
that cannot be patentable.983 
Following the discussion on whether or not discoveries are patentable, Decision 
486 came to solve this issue to a certain extent. Given that patents where foreseen 
for inventions materialised in a product or a process including pharmaceutical 
products. This decision, as stated many times before, complied with the 
standards settled in the TRIPS Agreements.  
Currently, as 1955´s legislation is enforced in Venezuela, in theory patents for 
discoveries are allowed, whilst patents for pharmaceutical products are denied. 
Hence, defining what is considered to be an invention within the legal framework 
becomes, once again, a crucial issue. Beyond the legal uncertainty related to the 
applicable law, there is an important backlog of applications within the Patent 
Office to examine. Unclear rules may enable right holders to either receive 
protection or enforce their rights, and therefore under the Andean community 
umbrella there are a few legal remedies against SAPI that could and should be 
taken into consideration. 
To start with, the legislation provides the possibility of taking over goods and 
rights, specifically patent rights, but when analysed in conjunction with LEXP 
there is not a single provision clarifying or guiding the procedure affecting patent 
rights. Several challenges are found, namely establishing the place for the 
expropriation decree publication affecting patent holder and third parties’ rights. 
The legislation shows a weakness in determining valuation guidelines aimed to 
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settle fair compensation of those rights or goods to be expropriated. The only 
guidelines or mandatory aspects to take into consideration by the appraisal 
commission are addressed to real state, personal property and goods with artistic, 
historic, architectural and archaeological value, but nothing within this 2002 
LEXP addresses valuation of intellectual property rights, hence patents, to be 
expropriated by the National Government. 
Furthermore, as early as 1965, Mariano Uzcátegui Urdaneta already advised the 
need to delimit in a clear manner, which is the procedure to follow in Venezuela 
regarding patent grant procedure. Given that, as highlighted above, there is no 
certainty on the timeframe to examine the novelty aspect beyond the opposition 
period that could happen either before or after publication. The same author 
brings to the spotlight disorganisation inside SAPI that already by 1965 made the 
grant procedure difficult and unclear. This specifically suggests, that previous 
examination could be performed before publications if SAPI organised itself for 
this matter and previous examination could also be performed after publications 
due to oppositions by designation of experts to carry on examination.984 
At this point it is important to mention that utility models are protected within 
the scope of the Andean Community IP regime. Although these are not relevant 
for the protection of pharmaceutical products, it constitutes an important 
difference between the regime settled in Decision 486 and superseding, and the 
IP Law from 1955 that only protects models and industrial drawings.  
Given the Andean Community’s nature as an integration organisation, there are 
important inconsistencies between what should have been and what was done 
back then. To start with, the mere fact that Venezuela’s Constitution was not at 
the same level as the integration process already poses an obstacle to reach 
common goals. Furthermore, important scholars suggest that becoming part of 
any integration agreement limits national powers and competences of 
constitutional courts and the “supra-national” character that these organisations 
portray.985 
As highlighted within the discussion, in Proceso No. 03-AI-96 the Andean Court 
of Justice does actually assert that Venezuela was breaching the agreement and 
therefore was to be sanctioned. The threat was to raise export tariffs for 
Venezuelan products to any other country member, as inferred by the Summary 
Process following this decision. Within the same document it is found how the 
Venezuelan Government started taking measures to come into compliance by 
substituting an internal Regulation from the Agriculture Ministry in order to 
allow products in the conditions settled by the Agreement initially. 
The IPR situation in Venezuela by no means seems to be an easy topic to address. 
Only a few authors have written about the national legal framework and its 
disparities. Use and misuses of IPRs are to be found, and the whole system seems 
to be at the edge of a cliff still debating on whether or not patents are detrimental 
for the access to medicines in Venezuela.  
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The current legal framework does not provide patent protection for 
pharmaceutical products. It has been argued by highly ranked officials how 
patents are a big detriment both to access to medicines and universal coverage 
granted by the Constitution986, hence justifying to a certain extent the rejection 
and silence in granting pharmaceutical patents since 2002.  
Coming back to the legislative findings, it could be argued that Venezuela came 
into compliance with its international duties by implementing Decision 313, and 
later on 344 that adequate IPR standards to those settled in at the TRIPS 
Agreement. However, it can also be seen how the legislator’s will collided with the 
President’s in 2000 when direct implementation was achieved by publishing the 
aforementioned Decision within the country’s Official Journal without formal 
parliamentary approval. At that time, the Venezuelan Constitution did not foresee 
direct and preferred implementation, as did the following amendment in 1999. 
The differences between the scheme under Andean Community Law and the 
current national legal framework are evident; portraying the country’s distance 
from complying with its international duties, for instance with the TRIPS 
Agreement. As widely discussed within the heading dedicated to Venezuela’s 
withdrawal from CAN, until 2008 when SAPI enacted in its Official Journal an 
official communication disregarding Decision 486, the public in general 
understood as an integral part of the national system those provisions settled in 
the aforementioned framework. Furthermore, it is rather interesting that there 
are just a few Supreme Court rulings addressing the issue, but there is no formal 
ruling solving the constitutionality of SAPI’s decision in 2008. 
Going beyond the legal body per se, it is an interesting fact that after almost 
6years from the date when Venezuela withdrew from the Andean Community, 
there is not a single “proyecto de ley” (legislative project) presented for discussion 
before the National Assembly. One important difference between frameworks is 
the compulsory licensing regime, which to a certain extent may leave the country 
in a delicate position when facing national health emergencies.  
Admittedly, compulsory licences are not the only legal mechanisms to protect 
public health, and in Venezuela “price control policies” as analysed above, 
become one of the preferred mechanisms to guarantee access to affordable 
medicines, which in reality might prove challenging considering the inexistence 
of a comprehensive list of illnesses covered in the country.  Some illnesses are 
protected in Venezuela, and medication and treatment may be provided at 
affordable prices or even for free but there is general misinformation about the 
issue. It is important to mention that Venezuelans are heavily dependent on 
private insurance to cover their health care needs due to overload and inefficiency 
of public health care providers regardless of statistics showing significant 
governmental investment in the public health care sector. 
Thus far the Venezuelan health system has been reshaped into a “mission” based 
one addressing primary, secondary and specialised attention. As highlighted 
above, inside the neighbourhood mission it is said to provide attention in rural 
areas, but further solving capabilities lead to create Barrio Adentro II –Inside the 
neighbourhood II- through the newly named Integral Diagnostics Centres –CDI-, 
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and Centres with High Technology – CAT. All of these aim to accelerate social 
integration while safeguarding universal human rights contained within 1999’s 
Venezuelan political constitution –health, education, and place to live and 
work.987 These missions originated out of cooperation between the Cuban and 
Venezuelan Governments, and began operating at first as a pilot programme in a 
few barrios from the Metropolitan District where Cuban health practitioners 
treated those in need.988 
On the one hand, health services are perhaps more accessible in rural areas, but 
on the other hand, rampant inequalities keep on emerging within the health 
sector. The fact that access to health care provided by Barrio Adentro is highly 
politicised, together with neglecting the existent public health care infrastructure 
are factors taking a toll on the private health care sector. Private health care 
providers are reported to be over crowded. Two of the reasons for this area lack of 
faith in the public sector and reluctance in receiving medical care from foreign 
doctors .989 Allegedly, private health care is only in reach of 3% to 4% of the total 
population who can afford to pay it. The rest of the cases or people seeking 
attention from them do it through private insurance policies, either individual or 
employment related, which is a clear indication of access inequalities.  
Parliamentary Ismael García became very critical of the government policies in 
general, but regarding health care, he finds no reason for such a poor 
performance within the sector when considerable investments have been made to 
raise the level. He is also of the opinion that running a parallel system (Barrio 
Adentro), importing foreign doctors, discriminating national doctors and 
institutions are just some of the hypotheses leading the current system to fail.990 
Rapid price increase in private health services due to high demand, lead to price 
regulations on behalf of the Government so as to ensure access. Accordingly, this 
measurement, where both the private health sector and Government agreed upon 
evaluating and determining singular fees for services and attention provided in 
clinics and hospitals, came after social pressure in recent months.991 
Another relevant challenge, relates to lack of resources to ensure quality, as both 
financial and human resources are needed to boost the public and private health 
sector. In the Wiki Leaks scandal a few years ago, something regarding the 
national health care system was also leaked. An important international journal 
pointed out the most important information contained in a cable sent from the 
Embassy of the United States of America in 2008, which addressed the exodus of 
                                                        
987 Alvarado, C.,et al. ‘Cambio Social y Política de Salud en Venezuela’ Sección Especial: Reformas 
Progresistas en Salud, 3 Medicina Social 2, (Mayo, 2008) at 121 
988 Ibid at 120 
989Dávila, E., ‘Medicina Privada ¿Un negocio poco lucrativo?’, 25 VenEconomía Mensual: Insutria y 
Comercio (2008) at 1 
990 Méndez Cegarra, A., ‘El Sector Salud en Venezuela, tanto público como privado, anda de mal en 
peor’ <ismaelgarcia.net/home/index.php/el-sector-salud-en-venezuela-tanto-publico-como-
privado-anda-de-mal-en-peor/>accessed 15 June 2012 
991 Efe Agencia, ‘Acuerdo del Gobierno y La Patronal Médica: Venezuela: Congelan las tarifas en 
salud privada’, Los Tiempos, 17 August 2011 
  
205 
Venezuelan doctors to foreign countries offering better labour conditions than the 
ones found at home among other things.992 
The lack of financial resources within the public health care sector has never been 
a secret either; the Bermudez vs. Ministerio de Sanidad y Asistencia Social 
(Ministry of Health) case is a vivid example of how priorities are managed in 
Venezuela. This case highlighted not only the incompetence of the Government to 
offer decent health care, but also demonstrated that pharmaceutical patents did 
not have anything to do when denying access to health care. In this case the 
Supreme Court failed in favour of an HIV patient who did not receive adequate 
treatment even though he had the right to access public health care.993 It was the 
first time that a Court recognised a lack of budget to provide proper public health 
in the country. The Courts’ ruling was deemed to create social concern towards 
health care needs.994 
Besides the current legal uncertainty surrounding the country in general, other 
issues collide with constitutional rights like access to proper health care and the 
emerging “right to health”.995 
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7 CONCLUSIONS AND SUGGESTIONS: WHERE DO WE 
GO FROM HERE ONWARDS? 
Disease is largely a consequence of poverty and of governments being unable or unwilling 
to undertake the public health measures to eradicate them.996 
This doctoral dissertation’s main focus was to analyse the relationship and 
conflict between pharmaceutical patents and access to medicines within a specific 
geographical context, namely Brazil, Chile and Venezuela. Thereafter, it asked 
what strategies are used to balance patents and public health concerns, as it was 
largely established within the previous chapters.  
Having defined the focus, the dissertation was structured in a manner that 
allowed the doctoral student to address three main objectives: (a) to understand 
the patent and health care systems at a national level in each context; (b) to 
review the challenges related to access to medicines to see if any derived from the 
implementation of the TRIPS Agreement; and (c) to learn how countries balance 
these rights, if at all, and what strategies are used (Rebel Brazil, “Liberal” Chile 
and In Limbo Venezuela). 
The findings have been presented within the descriptive chapters where each 
country is analysed on a case-by-case basis. However, given the comparative 
nature of the current dissertation these findings are discussed in two stages: 
within the general summary, which provided the general framework and also 
identified the strategies or models of protection; and in this chapter, which aims 
to discuss and present the reader with the conclusion on the dissertation’s main 
goal - to determine whether or not Venezuela can benefit from implementing a 
similar strategy to the one used in either Brazil or Chile. This was done keeping in 
mind its purposes in creating knowledge, demystifying the patent system, and 
raising awareness on the need for major governmental involvement to balance 
rights while at the same time ensuring people’s access to medicines.  
By delimitating the context of the discussion about access to medicines, it is 
possible to both find plausible solutions addressing patents and access to 
medicines, and to demystify the patent system that has proven to be relevant for 
some developing countries’ economies e.g. Chile.  
Given the difference in the strategies used by Brazil and Chile, the lessons are 
intended to portray the strength of each strategy. In other words, the Brazilian 
strategy heavily relies on the use and implementation of TRIPS flexibilities while 
at the same time strengthening its public health policies. In contrast, the Chilean 
strategy seems to rely on health care policy implementation, therefore the lessons 
will focus on this development since there are only a few controversies relating to 
pharmaceutical patents. 
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7.1.1. Lessons from Brazil and Chile in Terms of Patent Protections 
From an institutional standpoint, both Chile and Brazil provide a comprehensive 
legal framework for intellectual property rights protection. However, each of the 
countries implemented the Agreement in a different manner and time. Brazil did 
not make use of the transitional period given to developing and least developed 
countries to implement the Agreement, whereas Chile did make use of it and 
actually ended up implementing the TRIPS Agreement and TRIPS plus 
provisions within the national legislation almost at the same time. 
Each country had a different set of challenges, and a different strategy or model of 
protection. Both Brazil and Chile have opened their markets to foreign 
investments and competition aiming to become part of the globalised prosperity 
envisaged with the creation of the WTO. 
The impact of TRIPS in Brazil does not seem to be clear. On the one hand, INPI 
reported an increase in patent applications for pharmaceutical products mostly 
from foreign companies.997 But on the other, given the sharp decline in the 
national pharmaceutical industry’ productivity, Brazilian also saw a rise in its 
own generic industry.998 The rise of this industry in particular is also intertwined 
with public health policies, i.e. the Generics Drug Law. Data collected by the 
Brazilian government shows an increase of nearly 224% in Brazilian imports in 
total in the period 1982-2002, and imports of pharmaceutical products grew by 
6,112%FFF
It is important to remember that to this date Brazil has no FTA with any other 
major industrialised country, thus higher standards of protection have not been 
implemented in Brazil via FTAs. Admittedly, the caveat in implementing TRIPS 
relies on the import data indicating that the national industry might not –after 
all- benefit from pharmaceutical technology transfer if limited manufacturing 
capabilities prevail in the country. Nevertheless, Agreement, Lei n° 9.279 (IP 
Code) and the following amendment in Lei n° 10.196 seem to have been 
implemented in a manner consistent with national needs, perhaps mainly health 
related. Implementing the TRIPS Agreement in Brazil happened at the same time 
that the country was implementing health reforms, restructuring the health care 
system amid HIV/AIDS crises. The research brought to the spotlight several 
important reforms that were addressed to both lowering drug prices and 
increasing affordability and availability of ARVs. Increasing availability also 
implied increasing the national generic industry’s manufacturing capability that 
was to be in jeopardy due to the implementation of TRIPS since patented drugs 
could no longer be copied.1000 Thus, the amendment to the IP Code set forth the 
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compulsory licence regime, and also the prior consent mechanism to ensure –to a 
large part- its governmental commitment in fighting HIV/AIDS. 
Two other controverted issues within the IP Code are the local working 
requirement, and parallel imports; both “mechanisms” seem to have been 
envisaged following the need to ensure the country’s availability and affordability 
of medicines. Even when the legislation, as it is, portrayed strong commitment 
and awareness of national interests in 2013, the Bill no. 5402/2013 (hereinafter 
the Bill) was introduced before the congress for consideration to reform the 
current IP Code. This Bill aims at providing Brazil with an IP framework more 
suitable to its current challenges, and also to take further advantage of TRIPS’ 
flexibilities. The analysis introducing the Bill highlights that if patent law is duly 
balanced with other fundamental rights, as provided by the Constitution, then the 
patent system will promote technological development while striking a balance 
between exclusivity and competition.1001 Fulfilling Article 5 of the Brazilian 
Constitution –social function- seems to inspire in substantive parts this proposal 
for reform, the goal of which is to foster an environment for innovation in the 
country that will translate into both productivity and the foundations for the 
Brazilian society’s sustainable development. 
Within the previous chapter, depicting the strategy of model of protection, 
particular attention was given to Article 4 from ANVISA’s Resolution RDC n° 21 
due to the fact that patentability requirements still seemed to be under the 
agency’s scrutiny despite controversy related to misunderstanding its attributions 
or limitations to examine patent claims. Furthermore, the Newton Lima Bill –as 
it is also known- confirms the interpretation of the Article 4 y by not only making 
reference to the newly reformed Resolution, but also by providing ANVISA with a 
series of recommendations on how to verify that patent applications fulfil 
patentability requirements in light of the public health context; ones that do not 
necessarily differ from the suggestions given to the patent office on the same 
issue.1002 The proposal to reform the current intellectual property regime will be 
discussed during 2014.1003 
The lesson from the Brazilian IP law regime in terms of patents and access to 
medicines relies on the way policy makers have tailored and are still tailoring the 
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TRIPS implementation within the country. Even though the Agreement settles 
minimum standards of protection, this also provides a set of flexibilities that can 
be used in favour of the country implementing the Agreement. 
The minimum standards of patent rights are established by the WTO TRIPs Agreement, 
that leaves considerable room to adapt each country’s patent laws to their own reality and 
current stage of technological development, and social and economic needs.1004 
It has been suggested that Chile only implemented higher standards of protection 
since ratifying the US-Chile FTA, as this was the legal framework actually 
compelling Chile to reform their national IP law.1005  Admittedly, the Chilean IP 
law may be among the most sophisticated laws drafted in the region, since this 
even provides definitions for inventions and patentability requirements, which 
generally are not defined, but enunciated, within the legislation.  
Moreover, the legislation includes a provision granting protection to undisclosed 
information within the context of supplementary terms of protection as provided 
by the FTA. This provision aims at not only preventing the National Health 
Institute or third parties from making use of sensitive information to grant 
marketing approvals, or sanitary authorisation as regarded by the law, for similar 
products without the originator’s consent, but also at delimitating the scope of the 
supplementary term of protection that ought to be granted due to unreasonable 
curtailments of time in granting patent protection1006 
 
Artículo 53 Bis 2.- Dentro de los seis meses de otorgado un registro sanitario de un 
producto farmacéutico protegido por una patente, el titular tendrá derecho a requerir un 
término de Protección Suplementaria para aquella parte de la patente que contiene el 
producto farmacéutico, siempre que haya existido demora injustificada en el 
otorgamiento del sen alado registro. Podrán requerir esta protección suplementaria, 
aquellos titulares cuya autorización o registro sanitario haya sido otorgado después de un 
ano contado desde la fecha de presentación de la solicitud. La protección suplementaria 
se extenderá sólo por el período acreditado como demora injustificada por parte del 
órgano administrativo encargado de resolver dicho registro.1007 
The legislation, by implementing the provisions within the FTA, sets forth the 
linkage between the patent office and the national health institute. Initially this 
was only between the need to communicate third parties about prior and existing 
patents rights. However, with the test data protection provision the legislation 
now foresees the possibility in granting a supplementary term of protection due 
to administrative curtailments of time in granting marketing approvals. In other 
words, a right holder may be entitled to receive a supplementary time of 
protection if either the patent offices takes longer than envisaged by law to grant 
the patent and/or if the national health agency takes more than a year to grant 
the marketing approval. In this respect, the legislation also clarifies the 
circumstances that cannot be understood as unreasonable curtailments of time; 
namely, oppositions presented before the Agency, waiting for reports from 
competent authorities that are also relevant for the process and actions and 
                                                        
1004 Lima, N. ‘Brazil’s patent reform’, 16 
1005 Salama, B. and Benoliel, D., ‘Pharmaceutical Patents Bargains: The Brazilian Experience’ at 9 
1006 Ley N° 20.160. 3. Revised, Coordinated and Sistematized Text of the Industrial Property Law. 
Ministerio de Economía, Fomento y Reconstrucción, Santiago, Chile, marzo de 2006. Article 53 
bis(2) <www.wipo.int/wipolex/es/text.jsp?file_id=270135> accessed 15 September 2013 
1007 Ibid Article 53 bis 2 from the Ley N° 20.160 
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omission on behalf of the right holder.1008 In light of this provision it may be 
feasible to assert that a linkage has been set out in both directions. On the one 
hand, the INPI is to grant a supplementary term of protection due to unjustified 
delays in marketing approvals, and on the other hand, the national health agency 
is to acknowledge the existence of patent right and also to inform the right holder 
if third parties are intending to commercialise a similar product to the one 
patented and commercialised by the originator. 
Chile, in the first instance, denies patents for second uses, but then presents the 
exception within the same article by establishing that patents for second medical 
uses can be granted if patentability requirements are met.1009 Admittedly, this 
article, at first glance, seems rather confusing, and in this context it has also been 
argued that patents could be extended if a second use is considered to meet 
patentability requirements.1010 
Non-voluntary licences are also foreseen within the context of the Chilean IP law.  
However, the local working requirement set out in the Brazilian IP law is not. 
Article 51 envisages the use of non-voluntary licences to correct anti- competitive 
practices, which need to be determined by the Competition Court; to address 
national emergencies, public health, national security or any other situation of 
extreme urgency that will also need to be declared by the competent authority. 
The last provision allowing the use of compulsory licences seems to be more of an 
exception among the exceptions that a compulsory licence per se is allowed to be 
used. In this respect, Article 51 (3) allows a non-voluntary licence when the third 
party needs to make use of a posterior patent, and this one cannot be used 
without infringing the previous patent.1011 Thus far, Chile has not made use of 
either the threat to use or actually issued a non-voluntary licence to address any 
of the cases provided within the framework. 
Thus far, the Chilean IP lesson portrays how the country has aligned national 
interests within the sphere of international commercial exchanges. In terms of 
policy-making, all provisions prompted within the FTA, although reluctant to 
admit linkage, were actually implemented in the national IP law. The fact that no 
sanction has been imposed on Chile for those ‘IP concerns’ may reflect that 
                                                        
1008 Article 53 bis 3 from Ley N° 20.160. 3. Revised, Coordinated and Sistematized Text of the 
Industrial Property Law. 
1009 Article 37 (e) from Ley N° 20.160. 3. Revised, Coordinated and Sistematized Text of the 
Industrial Property Law. “e) new uses, the shape change, size change, changing proportions or 
changing the material of articles, objects or elements known and used for certain purposes. Without 
prejudice of the aforementioned, it may also constitute an invention new use of articles, objects or 
elements known, provided that the new use solves a technical problem without previous equivalent 
solution, meets the requirements settled in Article 32 and requires a change in the dimensions in 
the proportions or durable materials or known object to obtaina solution to the aforementioned 
problem. The claimed new use shall be justified by experimental evidence in the patent 
application.” (original text in Spanish, translation provided by the author) 
1010 Rodriguez Spinelli, F., ‘El Sistema de Patentes y el Desarrollo Tecnológico: algunas 
Consideraciones en el Marco de la Libre Competencia’ 11 Revista Propiedad Intelectual (2008) 87-
109, at 101 
1011 These kind of patents have been defined or reffered to within the legislation as ‘dependent 
patents’. Article 51 (3)  ”Cuando la licencia no voluntaria tenga por objeto la explotación de una 
patente posterior que no pudiera ser explotada sin infringir una patente anterior. La concesión de 
licencias no voluntarias por patentes dependientes quedará sometida a las siguientes normas:” 
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commercial interests of both parties are a heavier burden than lobbying for a 
‘perfect IP system’. 
7.1.2. Lessons from Brazil and Chile in Terms of Access to Medicines 
and other Public Health Issues 
Providing access to affordable essential medicines is one of the goals pursued by 
developing countries. However, as it has been argued, this access seems to be in 
jeopardy due to intellectual property protection. Before reaching a conclusion on 
whether patents are deterring access to medicines in Brazil, Chile and Venezuela, 
it is important to address the lessons from Brazil and Chile in terms of public 
health policies and structure. Given that the substantive chapters analyse the 
current health care system and policies within the aforementioned context, this 
section will be limited to addressing the main characteristics of each system. 
Structural, practical and theoretical differences are observed. Both Brazil and 
Venezuela have Mixed National Health Systems (MNHS), which are characterised 
by having different funding sources within the public sector. In contrast, the 
Chilean health care system is based on the National Social Health Insurance 
System (NHIS) and has an important distributive impact on the government’s 
health expenditure: about 31% of the expenditure is accrued from the population 
within the poorest sector,1012 thus the political Constitution provides universal 
coverage, financed via taxpayers’ money and mandatory contributions to fund the 
health care system.  
The Chilean health care system is based on four guarantees or principles: access, 
quality, opportunity and financial protection.1013 In  contrast, the Brazilian system 
does not specifically mention either quality or financial protection, but this does 
not mean that universal coverage is not given. As the analysis shows, both 
countries provide universal coverage, and both countries have strong public 
health policies addressing availability and affordability of medicines. 
International experience has proven that countries with a “strong State” are the 
only ones able to provide efficient, effective and equitable health care for 
everyone. This is so because strong states are capable of regulating, taxing and 
making proper disposition and administration of governmental funds.1014 
Both countries have comprehensive National Charts of Essential Medicines. The 
difference is in the fact that the Chilean one includes medicines to treat either 
high-cost or catastrophic and common illnesses, whereas the Brazilian one covers 
most of the common diseases (HIV/AIDS among them), with the so-called high-
cost medicines being envisaged within a separate framework.  
In 2006 at the UN General Assembly an organisation named UNTAID was 
launched under the auspice of several developing and least developed countries, 
                                                        
1012 Rubén Suárez – Berenguela, ‘Health system inequalities in Latin America and the Caribbean: 
Findings and policy implications’ Working paper prepared for the Health and Human Development 
Division of the Pan American Health Organization-World Health Organization (January, 2000) at 
27 
1013 Biblioteca Nacional del Congreso de Chile, “Guía Legal sobre Plan GES” in Ley Fácil, available 
only in Spanish at :  <http://www.bcn.cl/guias/plan-ges-ex-auge> 
1014 Jaén, M., ‘¿Por qué un estudio sobre el costo del sistema de sauld en Venezuela?’ at 40. 
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among them Brazil and Chile. UNTAID is dedicated to “provide regular, 
sustainable, predictable, additional, long-term financing for drugs and diagnosis 
for AIDS, tuberculosis and malaria for use in developing countries.”1015 
The Brazilian model is widely praised for the undeniable success in battling 
HIV/AIDS. It is said to be an important key player in changing or influencing 
global health care policies in terms of the illness. At the same time, also key to 
their success are the following factors: developing their national generic industry, 
fearless use of compulsory licences to reduce ARVs prices and using the human 
rights doctrine to shape their internal essential medicines policies.1016 In the fight 
against HIV/AIDS, Brazil has implemented a series of measures addressing 
access to affordable medicines if they cannot be provided for free. The Popular 
Pharmacy Programme intended to reach rural areas while ensuring affordability 
and availability of medicines. This programme allows patients to cover only 10% 
of the full cost of the medicine since the government subsidises 90% of the 
price.1017 
Brazil relies on public procurement practices to purchase the essential medicines 
that are distributed within the health programmes in the country. Procurement 
was initially centralised under CEME, but later on amid corruption issues the 
system was decentralised allowing every state to purchase their own medicines. 
Even though procurement is decentralised, the country still reserves the right to 
centralise the procurement of medicines addressed to tackle an illness of such 
magnitude that at the same time poses a severe risk to public health, i.e. 
HIV/AIDS crisis.1018 Despite the analysis focusing primarily on the 
aforementioned illness, it is important to highlight that other medicines are also 
purchased by the Federal Government to thereafter provide them at affordable 
prices. Medicines for malaria, Hansen’s disease, cholera, haemophilia, diabetes, 
                                                        
1015 Bermudez, J. and ‘t Hoen, E., ‘The UNITAID Patent Pool Initiative: Bringing Patents Together 
for the Common Good’ in The Open AIDS Journal, 2010, 4, pp 37-40 at 37 
1016  Nuun, A., et al. ‘Changing Global Essencial Medicines Norms to Improve Access to AIDS 
treatment’ at 134-138 
1017 See further, Du Borcage Santos Pinto, C., et al. ‘Medicines prices and availability in the Brazilian 
Popular Pharmacy Program’ 44 Revista de Sáude Pública 4 (2010) 1-8 
1018 Nuun, A. ‘The Politics and History of AIDS’ at 108; also see Brasília, Ministerio da Saúde – 
Secretaria de Políticas de Saúde, Departamento de Formulação de Políticas de Saúde, Portaria n° 
3.916/GM em 30 de outubro de 1998, Política Nacional de Medicamentos. Artigo 3.3 ” A assistência 
farmacêutica no SUS, por outro lado, englobará as atividades de selec a o, programaca o, aquisica o, 
armazenamento e distribuic a o, controle da qualidade e utilizac a o - nesta compreendida a prescrica o 
e a dispensac a o - , o que deverá favorecer a permanente disponibilidade dos produtos segundo as 
necessidades da populac a o, identificadas com base em critérios epidemiológicos.  
No tocante aos agravos e doenc as cuja transcendência, magnitude e ou vulnerabilidade tenham 
repercussa o na saúde pública, buscar-se-á a contínua atualizaca o e padronizac a o de protocolos de 
intervenca o terapêutica e dos respectivos esquemas de tratamento.  
Assim, o processo de descentralizaca o em curso contemplará a padronizac a o dos produtos, o 
planejamento adequado e oportuno e a redefinic a o das atribuic oes das três instâncias de gesta o. 
Essas responsabilidades ficam, dessa forma, inseridas na aca o governamental, o que deverá 
assegurar o acesso da populaca o a esses produtos. Para o Ministério da Saúde, a premissa básica 
será a descentralizac a o da aquisic a o e distribuic a o de medicamentos essenciais” 
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schistosomiasis, trachoma, leishmaniasis and filariasis are also among the 
medicines provided by the Ministry of Health.1019 
Scholars have also attributed the success of the Brazilian health care system to 
both linking prevention and treatment and to the intertwined development of 
public health policies with intellectual property legislation.1020 Admittedly, the 
development and sustainability of the AIDS treatment programme became 
challenged when Brazil became a WTO member country. Nonetheless, and even 
when the country did not make use of the ‘period of grace’ to implement the 
Agreement, Brazil instead used innovative strategies to promote access to 
medicines for the treatment of HIV/AIDS,1021 and also found away to implement 
the flexibilities within TRIPS to ensure the programme’s sustainability. 
The lesson to learn from Brazil in terms of public health development is also 
based on the continuity and solidarity with the Brazilians on behalf of their policy 
makers. Changing the strategy as soon as a new administration is elected would 
not have led to the system that they have today. Politicians remain aware of the 
challenges, thus the changes made in the context of health care policies have only 
improved the system. 
Chile on the other hand, developed one of the most complete health care systems 
in the region. Allegedly, this is the only system that grants real universal access to 
both health care and medicines. Chile has also been prized for their efforts in 
battling HIV/AIDS within the country.1022 Health care reforms have taken several 
years to build the system into the current one, and perhaps their strategies have 
not been as aggressive as in Brazil. Investing in infrastructure, human resources 
and implementing adequate health care policies are key factors determining the 
country’s success. Close cooperation with the Pan-American World Health 
Organization, World Health Organization and working with diverse groups 
lobbying for affordable medicines have also played an important role. 
Accordingly, Chile has implemented and follows the guidelines given by WHO for 
the mass scale purchase of medicines. The Central Procurement Office 
(CENABAST) is in charge of standardising acquisition processes to ensure 
availability and affordability of essential medicines.1023 CENABAST is functionally 
decentralised, which differs from the Brazilian procurement system because this 
one allows every county to purchase its own medicines, but independently of the 
prevalent system in each country, with each of them being able to provide citizens 
with essential medicines at affordable prices if not for free.   
At some point in Chile, competition within the pharmaceutical sector was 
encouraged to decrease medicines prices. However, pharmacy chains 
demonstrated aggressive practices that were a detriment to smaller pharmacies. 
The government had to both subsidise medicines and also negotiate directly with 
the industry (in the case of ARVs) to obtain reduced prices. Chile is one of the 
                                                        
1019 Galvão, J., ‘Brazil and Access to HIV/AIDS Drugs: A Question of Human Rights and Public 
Health’  (July 2005) 95 American Journal of Public Health 7, 1110-1116 
1020 Idem 
1021 Nuun, A. et al., ‘AIDS Treatment in Brazil’ 1107 
1022 Editorial E.M, ‘Medicamentos y Auge’ (2006) 
1023 Decreto Ley N° 2.763, Creating the Central Procurement Office of the National Health Service 
System (SNSS) Article 46 
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South American countries with the lowest average price for medicines. Reducing 
out of pocket expenditure was also important to ensure people’s access to 
medicines. The use of traditional medicines is also encouraged by the Ministry of 
Health who has provided guidelines for the use of herbal medicines in certain 
cases. Rational use of medicines has also been encouraged both by Chile and 
Brazil and international organisations. 
Chilean health care is another example of having a common goal embedded in the 
society, since every administration has worked towards achieving higher 
standards of health care. Relying on national GPD, taxpayers’ contributions and 
other taxes seems to have sufficed to cover the costs derived from the health care 
system. 
7.1.3. Could Venezuela Learn from either Brazil and/or Chile: How 
could these Lessons be implemented? 
The initial goal of this research was to define the role of pharmaceutical patents 
within the Latin American development and to find whether or not patents play 
an important role when delimitating public health policies. Due to the 
geographical extent, the research focused on three relevant but distant countries: 
Brazil, Chile and Venezuela. 
Understanding how the health care system works in each country was of vital 
importance before analysing the role of patents. The importance of this 
assessment relies on the fact that the author needed to address the governmental 
commitment of those countries surveyed before reaching the simplistic 
conclusion that patents are the main reason hampering access to medicines in 
developing nations. Patents may contribute to raise the prices of medicines, but 
as the study shows, there are countries with a more or less balanced health care 
system where not only are pharmaceutical patents protected but also health care 
and access to medicines is provided. 
The research began with the idea of comparing three different patent systems, 
which were initially thought to be at a comparable level. All three (Brazil, Chile, 
and Venezuela) had effectively implemented TRIPS’ minimum standards of 
protection. In the following years, Venezuela withdrew from the Andean 
Community and re-implemented its IP Law from 1955, which is not in line with 
TRIPS. 
Pharmaceutical patents may influence people’s ability to access affordable 
medication, but there were also indications of other factors taking prevalence 
over patent issues when ensuring access to medicines. Therefore, this dissertation 
analysed both intellectual property rights and public health frameworks at a 
national level, taking into consideration legal, social and political aspects present 
in the discourse. The aim was to identify not only the strategies or models of 
protection, but also the relevance of the patent system within the development of 
health care policies. The international debate and developments were also 
important in order to understand the rationale for determined measures in 
determined contexts, such as prior consent mechanism in Brazil.  
Within the early stages of the research certain developments brought to the 
spotlight the lines of thinking followed by each country, hence framing the 
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strategies or models of protection. For instance, Brazil (The Bargaining Rebel), 
strongly protects public health but also implemented the TRIPS Agreement into 
its national law attempting to bypass the negative repercussions that could have 
been brought upon their fight against HIV/AIDS. Chile (The Commercial 
Liberal), did not only implement TRIPS, but also higher standards of protection 
with the US-Chile FTA while at the same time taking care of public health 
concerns. And Venezuela (In Legal Limbo), which is politically active and strongly 
oriented towards ‘socialism’ and going through a transitional period, 
implemented TRIPS but rapidly went back to the previous legislation thus placing 
the country in legislative uncertainty. 
Despite having different strategies of protection, the interesting part of the 
research was determining if and how Venezuela could benefit from implementing 
either a similar strategy to the ones used in either Brazil or Chile or simply by 
reforming its national patent law in a manner consistent with Venezuela’s needs. 
Before stating the conclusion and the rationale behind it, it is also important to 
mention the limitations encountered while carrying out the research that 
constrained the analysis to a review and interpretation of national literature, 
legislation and case law. Although case law was not constantly available in its 
digital form, and in certain contexts there was limited literature written from the 
national perspective, this research intended to portray interpretation and 
implementation issues in each country from their very own perspective. The aim 
was to provide the reader with the specific context in each country, thus avoiding 
or reducing the risk of transplanting foreign institutions. Among the limitations, 
language issues are also to be mentioned particularly because there is always a 
risk in misguiding the interpretation of national precepts when translated into 
foreign languages. However, the conversations and guidance provided by experts 
in the field in each country aimed at both reducing such a risk and also at gaining 
further insight about the situation in each context. 
After carrying out the analysis in the substantive chapters and also referring to 
part of the comparative discussion it can be concluded that Venezuela could not 
only learn from the strategies used in Brazil and Chile, but that it is also in a 
‘privileged position’ in terms of implementation and balancing rights.  By no 
means does this statement agree with voiding the patent system or unfulfilling 
international commitments, such as implementing TRIPS since Venezuela is also 
a WTO Member.  
The rationale behind stating that Venezuela seems to be in a ‘privileged position’ 
– in terms of the TRIPS implementation- is because tailoring the implementation 
of TRIPS in Venezuela in a manner consistent with national health policies, 
would seem to be a natural step for Venezuela so as to balance rights, boost 
national growth, foreign investments and contribute to legal certainty. Such 
implementation could help ensure for citizens the enjoyment of their human right 
for the highest attainable standard of health, but only if public health policies are 
also implemented in parallel. I will elaborate further about this argument when 
addressing the Brazilian compulsory licence regime.  
Admittedly, intellectual property rights are not a priority within the Venezuelan 
context. However its membership in WTO and MERCOSUR call for the country 
to engage in legal reforms to implement minimum standards of protection if 
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Venezuela in the long run is to continue enjoying the prerogatives derived from 
trade agreements and the organisational integration.1024 
The current IP law in Venezuela differs from TRIPS in several aspects: patentable 
subject matter, term of protection, patent grant procedure, disclosure and 
compulsory licence regime. Thus, two of the aspects where Venezuela could 
benefit greatly from tailoring IP law implementation relate to disclosure, and 
compulsory licence regime. In terms of disclosure, Article 59(2) from the IP law 
of 1955 required patent applications to attach a comprehensive description of the 
inventions. The provision requests for “clear description of the patentable subject 
matter, with complete and exact directions on how operates, and what was the 
method used to build it, create it or mix the invention.” And the TRIPS 
Agreement in Article 29 requires for applicants to “disclose the invention in a 
manner sufficiently clear and complete for the invention to be carried out by a 
person skilled in the art.” At first glance, it seems that the disclosure required 
within the current Venezuelan law may be slightly higher than the one settled in 
TRIPS, and perhaps even resembles the requirement to disclose the best 
mode.1025 
In terms of the compulsory licence regime, the Venezuelan law is at disadvantage 
in comparison to other countries that have implemented the Agreement. Thus 
far, compulsory licences are not foreseen within the current legislation, and the 
only legal mechanism to address public interest (as public health in this case) is 
via expropriation procedures. This has proven to be the latest Venezuelan trend 
to “solve” “public interest” concerns, such as those a significant part of the 
agricultural industry has experienced over the last 14 years. The challenges 
related to intellectual property expropriation have already been described within 
the substantive chapter. 
The Brazilian strategy, in terms of TRIPS implementation, maybe suitable for 
Venezuela, since the Venezuelan discourse portrays a strong inclination towards 
the protection of public interests, and therefore public health aiming to provide 
universal coverage. Moreover, if Venezuela would implement a compulsory 
licence regime similar to the Brazilian one, perhaps the country will be able to 
promote the development of the national generic industry by setting out the local 
working requirement to avoid patents being granted without actually making use 
of patent rights in the country. If a compulsory licence regime would be in place 
to tackle national health crises, perhaps Venezuela could even threat to use or 
even issue a compulsory licence to obtain better medicine prices thus allowing 
Venezuelans to have access to both affordable and availability of medicines. The 
system in Brazil has proven advantageous in achieving lower medicine prices to 
address the HIV/AIDS epidemic. Thus, this could be a means for Venezuela to 
                                                        
1024 Protocol of Harmonization Norms on Intellectual Property in Mercosur in matters of trade 
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incorporate one of the TRIPS flexibilities into the national framework and to also 
increase bargaining power to achieve affordable access to determined medicines.  
Nonetheless, there is a caveat to this suggestion, if the legislation is not drafted in 
a clear manner setting forth the limits of the flexibilities incorporated - how and 
when is to be used - the legislation would not serve with the purpose of clarity and 
predictability required to both define and typify an act before the law.  Reforming 
the national health policies and extending public procurement practices to lower 
medicine prices would also need to be established for the compulsory licence 
regime to serve its purpose. 
The Brazilian IP Code in Article 68, establishes the use of compulsory licences to: 
(a) correct anti-competitive practices, abusive behaviours; (b) satisfy the local 
market when either there is no sufficient supply, or because the patent holder has 
not worked the patent within a period of 3 years from the date this was granted –
unless economical unfeasibility can be proven or force majeure; and (c) deal with 
cases of national emergency or public interest.  But the current Venezuelan IP 
Law in terms of anti-competitive practices also foresees the expropriation 
procedure to correct them. As highlighted within the substantive chapter, the 
terms and conditions to carry out such a procedure in the case of pharmaceutical 
patents or even intellectual property rights is not clear.  
‘Nulla poena, sine lege’ traditionally allows the imposition of sanctions on 
determined behaviour that has been previously typified within a law. But how can 
or could Venezuela correct an-anti competitive behaviour with a compulsory 
licence if this provision has not been implemented within the internal legislation.  
Price control, money control policies, and an out-dated IP legal system are just 
three of the factors from a legal and economical point of view impeding access to 
affordable medication in Venezuela. On the one hand, prices are controlled, but 
on the other, foreign currency is exchanged at staggering prices in the parallel 
market since currency at the official rate is not awarded or available with the 
speed and efficiency that the industry requires.1026 
The other provision that could be implemented into the Venezuelan system is the 
Prior Consent mechanism. This mechanism was implemented in Brazil after 
negotiations in 2001 with the pharmaceutical industry brought to the spotlight 
certain weaknesses in the patent system when taking into consideration the 
impact of pharmaceutical patents over public health needs. If Venezuela were to 
implement a similar mechanism that would assess the impact derived from 
granting a pharmaceutical patent, perhaps even the local industry and 
universities carrying out R&D could actually benefit from patent protection. 
Nevertheless, the attributions from the National Health Institute in this case El 
Instituto de Higiene Rafaél Rangel, would have to be delimited and specific since 
the very beginning in order to avoid overlaps of competences between the SAPI 
and IHRR, or the veto power from one institution to the other. 
The Chilean strategy of protection for intellectual property rights, given the 
current political trends in the country, will not be accepted or even applicable. If 
the country is struggling to implement minimum standards of protection, then 
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$1,00 = Bs. 78,00.  
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implementing higher levels that in principle were to benefit foreign companies 
would definitely not be aligned with the actual governmental line.  
To be fair, intellectual property rights seemed to have been forgotten in 
Venezuela. The country withdrew from the Andean Community in 2006, and the 
Andean community framework was in force until 2010. Since then, almost 4years 
have past and the patent system is still out-dated. The sanctions imposed on 
Brazil in 1989, and the posterior consultations before the DSB on behalf of the 
United States for the implementation of Prior Consent, give weight to the belief 
that Venezuela should have been brought before WTO for breaching TRIPS. The 
fact that nothing has happened since the legislative debacle with the Andean 
Community suggests that commercial interest may also play an important role in 
the relations between Venezuela and other trading partners. Regardless of 
political and commercial interest, Venezuela could benefit greatly from 
implementing a health care system similar to the one available in Chile, or even 
the Brazilian strategy as long as consistence and continuity are achieved. 
Currently, three health care systems are ‘running’ in parallel: the public, the 
private and the Bolivarian system Barrio Adentro. 
The government is trying to control prices via all possible legislative solutions, as 
if this is the main factor challenging access to affordable medicines in Venezuela. 
However, the system is running out of funding and several clinics have 
threatened to close their doors since they are not able to provide health care 
services.1027 Laboratories are also in trouble, since the government has also 
regulated their prices; lab supplies are imported and not produced nationally. 
Therefore, clinical labs are also struggling to have access to preferential currency 
to purchase supplies.1028 
The term access to medicines encompasses the array of problems faced by the world’s 
lowest-income habitants, who often cannot afford, or do not have access to, medications 
that could greatly reduce the disease burden under which they suffer. The problems 
include deficient medical infrastructure, imbalances between prices and 
ability to pay, and the lack of incentive to develop medicines that would treat 
diseases endemic to low-income nations1029 
High levels of bureaucracy, corruption and even over legislation contribute to the 
economical chaos prevalent in Venezuela. Despite the country’s investments in 
the public health care sector, the facts that there are three systems running in 
parallel, that there is unequal distribution of resources and that there is no 
intention in unifying the systems to achieve a better performance, all seem to 
dilute any efforts in providing universal coverage. For instance, there is a health 
programme within both IVSS and the Barrio Adentro health centres that provide 
free or affordable medication for those diseases identified in the country as costly 
and catastrophic. However, lack of information and impartiality challenges 
citizens’ access to affordable, essential medication. 
                                                        
1027 ‘Sociedades Médicas en emergengia por regulación de precios de en clínicas’ El Carabobeño, 14 
de Julio de 2013 
1028 Moreno Sucre, J., ‘Advierten del cierre de 70% de los laboratorios clínicos’ El Universal, 9 de 
Julio de 2013 
1029 Scherer, F.M., ‘Essential Drugs’ (February 2007) KSG Working Paper No. RWP07-003, 1-11, 
2<ssrn.com/abstract=939659 or http://dx.doi.org/10.2139/ssrn.939659> accessed 4th April 2014 
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In the Venezuelan context it is not possible to infer that either pharmaceutical 
patents or patents in general have had a negative impact on the economic or 
national development. On the contrary, development began deterring about the 
same time the IP Law from 1955 was re-implemented. Reportedly, no 
pharmaceutical patent has been granted since 2008, and during 2009 the Patent 
Office began rejecting patent applications. The Patent Office Journal from 
November 2009 states that from 200 patent applications in total, 65 were related 
to pharmaceuticals and all of them were returned due to administrative 
requirements, only to later on be rejected again. 
The situation in Venezuela is far from easy; several other challenges need to be 
addressed soon, among them staggering inflation rates.1030 Money control policy 
is an interesting and complicated component of the Venezuelan strategy.  
Asserting that in Venezuela pharmaceutical patents pose an obstacle for people’s 
access to medicines only seems to be out of context and misleading. Recent 
trends, or those followed in the last 14 years, indicate otherwise. With no concise 
health care provisions, no continuity within the goals settled by each elected 
administration with regard to regulation of prices and services, poor 
infrastructure, lack of human recourses, bureaucratic procedures slowing down 
administrative processes and consultation in my opinion would pose a heavier 
burden policies related to access to medicines in Venezuela than protecting 
pharmaceutical patents per se.  
Both health care and intellectual property provisions need to be developed in 
synchrony and harmony –implementing TRIPS flexibilities and efficient public 
procurement practices - if the country really aims at having a patent system that 
in the long run will favour both the national industry and that will ensure people’s 
access to affordable and top of the line medicines. Solidarity, continuity and 
accountability seem to be the elements conveying governmental success in 
implementing health care policies addressed to achieve access, affordability and 
availability of essential medicines while at the same time implementing IP 
policies addressed to foster innovation. 
7.1.4. Other General Suggestions: Developing a Side System to Create 
Incentives for R&D on Neglected Diseases 
 
Despite the conclusions and suggestions presented above within a specific 
context, there is another set of suggestions that could be applicable in the general 
context of patents and access to medicines and the access to the discourse on 
medicines. Thus, the present discussion aims at addressing the solutions within 
the context of neglected medicines. The little amount of R&D on neglected 
diseases might also be linked to the market size for which the pharmaceutical 
product is intended. Michael Kremer in 2002 analysed how companies are driven 
by the market size to develop and commercialise a specific product.1031 
                                                        
1030 ‘BCV reporta una inflación acumulada de 42,6% en los últimos 12 meses’, El Nacional Web, 6 
August 2013 
1031 Kremer, M., ‘Pharmaceuticals and the Developing World’(Autumn, 2002) 16 The Journal of 
Economic Perspectives4, at 67 – 90 
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Developing a new drug has also proven costly: approximately $800 million was 
spent by the pharmaceutical industry in 2006 when carrying out this task,1032 and 
it is also estimated that “less than 1 per cent of the new chemical compounds 
examined are used in human testing”1033 which is part of the factors increasing 
R&D costs. 
Given the crisis in supplying certain markets with affordable medications or 
effective medicines post TRIPS Agreement, scholars have argued the inefficiency 
portrayed by the patent system in solving or addressing a solution to lower the 
price of essential medicines.  
A couple of suggestions or solutions outside of the legal framework (compulsory 
licences) have been presented, such as out-licensing or prize founded research in 
an attempt to find a balance between private and public interests. 
It is commonly found that perhaps the best solution to lower pharmaceutical 
prices, hence, increasing access to essential medicines, would be to leave the 
pharmaceutical industry and the generic industry to compete in the market.1034 
Free competition could be a good way to lower the price of medicine, except in 
those countries i.e. Chile where free competition has proven to worsen the 
situation for the small size pharmaceutical industry and pharmacies trying to 
survive in the market.1035 However, more likely than not, only a few would debate 
on patents being the successful mechanism to recoup R&D investment. 
7.1.5. Suggestions for a Side or Parallel System 
A possible solution to prompt innovation and R&D in the field of neglected 
diseases, is a prize award model. This model is suggested by Joseph E. Stiglitz, 
who believes that a medical prize fund would function as a better incentive than 
the patent system itself, in order to reward the discovery of a cure or treatment 
                                                        
1032 Civan, A., et al. ‘The Determinants of Pharmaceutical Research and Development Investment’ 
(2006) 5 Contributions to Economic Analysis & Policy 1, Article 28 
1033 Idem 
1034 This could only happen once the patent has expired. Another way to guarantee lower prices for 
certain medicines is generally achieved though prices control policy, although this might deter 
innovation. For a further insight see, WHO- Commission on Intellectual Property Rights, 
Innovation an Public Health  “Public Health, Innovation and Intellectual Property Rights”, in 
Report of the Commission on Intellectual Property Rights, Innovation and Public Health, at 116 
1035 Between 2007 and 2009 two of the most renowned pharmacy branches in Chile started a so-
called “price war” by reducing prices of certain pharmaceutical products. This business decision 
allowed them to compete for a better positioning within the Chilean Market, but it lead to many 
small and medium sizedsize pharmacies to almost go out of business, because it was not possible for 
them to keep up with the bigger franchises. Later on this case reached the Competition Court, due 
to collision agreements with producers. The case is still in Court and further information about this 
will be available at the Chilean chapter of my thesis. But you can also see El Mercurio, “La Pelea de 
Cruz Verde y FASA por adueñarse del concepto de bajos precios” from October 9th, 2007. Also 
available at <www.economiaynegocios.cl/noticias/noticias.asp?id=34637>. Also see El Mercurio, “ 
Grandes Farmacias Registran hasta una diferencia de precio del 78% por un mismo remedio” from 
May, 21st, 2009, < diario.elmercurio.cl/detalle/index.asp?id=%7Bb3991d5b-ce65-43f4-8101-
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for a neglected disease. A prize fund could allocate enough resources for the R&D 
of those diseases that the current patent system has not been able to 
incentivise.1036 
The aforementioned model comes as a parallel solution to the patent system. The 
prize fund system focuses on promoting research on neglected diseases, and 
ideally once the discovery1037 is made this would be licensed.1038 It is no secret 
that pharmaceutical industries do not only spend considerable amounts of money 
on R&D, but also on marketing campaigns. It is precisely the resources spent on 
marketing and the invention of lifestyle drugs1039 that forms Stiglitz’s main 
arguments against the pharmaceutical industry’s current behaviour: the 
pharmaceutical industry focuses on recouping R&D through commercialisation of 
lifestyle drugs which generally are in fashion.  
A couple of challenges have been identified in relation to this method. First, prize 
issues: how much would the prize be worth? Would the sum settled be enough to 
actually be duly noted by the pharmaceutical industry? How much will be 
enough?  Up to 2001, the pharmaceutical industry spent about half a billion 
dollars on developing a new drug; from 5,000 compounds used, maybe only one 
would be successful.1040 
Secondly, it is suggested to have a skilled body (Scientific panel) evaluating the 
claims. But who will be part of this skilled body? Besides settling a prize fund, 
what are the conditions applicable for wining and claiming the award? Is it 
enough to just raise the awareness of the Scientific panel about the invention? 
Who would be part of this scientific panel? How would it be structured?  
Third, commercialisation and marketing approval issues that will be necessary to 
fulfil if a product reaches the market. For instance, if the pharmaceutical industry 
finds a prize fund as an incentive to engage in R&D of a needed drug, then 
pharmaceutical company in any case will also have to go through the national 
mechanisms before supplying the market with the affordable drugs. This means 
that in complying with quality, clinical trials and all the safety requirements will 
be necessary before either applying or receiving the marketing approval for a new 
drug.  
                                                        
1036 Stiglitz, J.,‘Prizes, Not Patents’ in Project Syndicate, 2007<www.project-
syndicate.org/commentary/stiglitz81/English> accessed 21 June 2010 
1037An important remark shall be made regarding Stiglitz’s assumption on the patentability of a 
discovery. Discoveries are not patentable, but inventions are. Although there is no reference made 
by the author as to whether or not the invention adjudicated with the award will claim patent 
protection, the author mentions the possibility of licensing such an invention. Hence, it could be 
assumed that the author refers to a discovery as a synonym of an invention that in law is not 
correct. Nevertheless, Stiglitz offers a possible side solution to promote innovation of R&D of 
certain diseases, but this method needs further development, as there are many things unaddressed 
1038 Is ut Supra Stiglitz at 9 
1039 Lifestyle drugs are considered to be those to treat none life threatening conditions. Definition 
taken from Stiglitz quoted above 
1040 Love, J., ‘How Much Does it Cost to Develop a New Drug’ in Draft on consumer Project on 
Technology, 2000 <www.cptech.org/ip/health/econ/howmuh.html>accessed 23 June 2010 
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Scholars have also assessed alternative incentives, other than patents. Therefore, 
several models have been analysed and among them are the pull and push 
models, which seek to reform or replace TRIPS. 
The push model seeks to encourage R&D by using public funds to invest in 
research either by public or private institutions; and the pull model seeks to 
encourage innovation by offering prize or some other financial incentive.1041 
Whilst taking into consideration these two models, Odermatt assesses the 
bureaucracy and financial burden brought about by the patent system, which in 
his opinion is a pull model in itself. The scholar also highlights that the push 
model seems to encourage R&D on finding a cure for certain diseases which will 
be better than leaving to the market the possibility of coming up with a solution at 
some point. This model portrays a compatibility problem with the patent system 
since the structure of the pull model seems to convey more. In other words, the 
risks undertaken by either of the models vary and so does the burden undertaken 
by the parties involved. In one case the higher investment risk is for the fund and 
or the financers of the Research, and in the other the risk is for the different 
companies racing to find a cure. Since one of the parties will bare higher risks and 
costs than the other one will.  
One of the suggestions is to create alternative incentives for R&D of new drugs for 
neglected diseases is the creation of a pull prize system. This indicates, that if the 
prize system is based on the therapeutic benefits portrayed by the drug, this alone 
will provide enough economic incentive for the pharmaceutical companies to 
invest in the creation of drugs for neglected diseases, and most likely it will allow 
the generic industry to sell the drugs at more affordable prices.1042 
The other solution presented at the beginning of this heading was the out-
licensing option, which consists of giving a voluntary licence to generic 
manufacturers who would agree in only manufacturing and supplying medicines 
to the least developed and developing countries.1043 These legally binding 
agreements will allow generic manufacturers to compete with each other in the 
least developed and developing countries, but they will not allow them to compete 
with the original patent holder in richer countries. Hence, prices will be lowered 
considerably due to competition and the incentive to keep R&D of new drugs will 
not be deterred. This approach has a couple of drawbacks, since there is the need 
to have nonexclusive licence rights to really promote “free competition”; most 
likely companies will reduce their presence in the markets of the developing 
countries. Secondly, the success of this mechanism will depend on economic 
conditions determined by the market itself and not the company out-licensing, 
which in other words could deter interest in out-licensing agreements if there are 
not many buyers for the product due to massive amounts of money provided by 
foreign aid to treat a specific disease. This will probably deter generic 
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1042 Ibid 
1043 Friedman, M., den Besten, H., and Attara, A.,  ‘Out-licensing: a practical approach for 
improvement of access to medicines in poor countries’ (January, 2003) 361 The Lancet, at 341 -344 
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manufacturers’ interest in reaching out-licensing agreements with 
pharmaceutical products to supply needed markets.1044 
These out-licensing agreements shall take into consideration specifically the 
definition of which medicine, country, enforcement measures and legal rights are 
to be granted and the royalties.  
Having said this, it is necessary to define how this mechanism would work, if it 
has been used, who has used it and which medicines could actually be out-
licensed. 
Pharmaceutical companies such as Glaxo Smith Kline, Boehringer Ingelheim and 
Bristol-Myers Squibb have used this mechanism in the past to help supply the 
market of South Africa. Accordingly, this mechanism is a more encouraging 
option than compulsory licences. So far, some possibilities to create other 
incentives and the patent system to foster further R&D on neglected diseases 
have been assessed. Every suggestion discussed above brings a set of questions 
and perhaps challenges that need to be solved before having something more 
serious to present to the pharmaceutical industry. 
Given that the situation in every developing nation may differ from that of 
another, and that access to essential medicines it is not solely dependent on 
patents, further incentives may need to be considered. However, when assessing 
the public health discourse, there are a couple of issues that need to be analysed 
separately. If it is widely accepted that access to medicines is part of the human 
right to health, then it is also very important to stress the duty of governments to 
protect public health needs, which most likely vary from country to country. 
Therefore, the duty in guaranteeing access and affordability does not rest alone 
on the pharmaceutical industry’s decision-making power. The pharmaceutical 
industry must guarantee availability in the sense of production, but the 
governments must negotiate if necessary to guarantee affordable prices for 
essential medicines.  
For some tropical countries, that also happen to be developing nations, dengue 
medication belongs to the chart of their essential medication. However, since this 
one also falls within the neglected disease category, it is the author’s opinion that 
perhaps these nations should provide wider incentives for R&D at universities. 
Perhaps a way to create further incentives would be to allocate more resources to 
local talent that would possibly lead to a manufacturing capability to supply the 
internal market without depending exclusively on private interests.  
Striking a balance between patents and access to medicines has proven 
controversial. Neither compulsory licences or parallel imports seem to be widely 
accepted mechanisms providing a solution to the problem, and perhaps there will 
not be a single solution along the lines of “one size fits all”. Perhaps the issue is to 
assess and tackle the crises individually within the globalised and standardised 
system. Therefore, it seems only appropriate to stress the need to tailor the TRIPS 
Agreement implementation within the national contexts. 
Price competition is not possible until immediately after the patent has expired. 
So how can prices be driven down without affecting the pharmaceutical industry’s 
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interests (profitability and recouping the investment)? Could this be achieved via 
direct negotiations between the governments and the industry? What about 
public – private partnerships? Currently there are a couple of NGOs allied with 
the pharmaceutical industry which follow WHO’s recommendations in fighting 
and providing treatment for neglected diseases.1045 So far the Partnership for 
Diseases Control initiatives and the Task Force for Global Health seem to be 
having great success in fighting some of the tropical and neglected diseases 
afflicting the Developing world. However, it is also known that further donations 
will be required in the future to keep on going with these programmes. The 
question remains as to which is the adequate system to foster R&D for neglected 
diseases? 
Within the idea of creating a side system of incentives, the possibility of creating 
different sources of funding for either R&D or raising money to purchase cheaper 
medication on amass scale or in bulk procurement also comes into the spotlight. 
The model followed by UNITAID country members is actually very interesting, 
since the funding for the organisation comes from levying taxes on flights. A short 
flight in economy class is deemed to give up to 1€ and a long-haul flight departing 
from any of the countries in business class can raise up to 40€; hence, a full flight 
between London and New York is said to raise enough money to cover a years 
treatment of 60 HIV-positive children. Other countries, part of the organisation, 
are committing multi-year budgetary contributions.1046 
Despite the model chosen to create further incentives to foster R&D, it is 
important to remember that a reward system for the inventors’ efforts in giving 
society a solution to a problem should exist. The cases of Brazil and Chile show 
the importance in both guaranteeing access to medicines while at the same time 
protecting intellectual property rights. Moreover, both systems also demonstrate 
the efficacy of setting long-term goals within the government and policymaking 
mind-set. In other words, independent of a determined administrations’ ideology, 
if a system is not set forth to be on-going and in solidarity with the country's 
needs, then most likely any legal reform will not solve the public health care 
challenges or private interests (patents) prevalent in that country. 
Admittedly, the issue at stake is complex and providing a single applicable 
solution is not possible since every country has a different set of needs. Therefore, 
it is important to reiterate that in the case of Venezuela, the possible solution is to 
reform both the patent and the health care system in a manner consistent with 
the country's needs. For instance, if we start from the assumption that the current 
issues related to the access to foreign currency do not exist, and that the economy 
in the country allows the normal development of the industry in general, then 
hypothetically the only issue at stake in terms of access to medicines is to balance 
the patent system. So, a possible solution could be presented as follows: 
- Two legislative reforms would be necessary. On the one hand, bring the 
current IP system into compliance with the TRIPS Agreement, but do so 
in a manner similar to the Brazilian system: curve the negative effects by 
taking into consideration the country’s needs and make use of the 
flexibilities provided within the Agreement i.e. compulsory licences and 
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parallel imports. On the other hand, a reform within the public health 
sector deems it necessary to unify the current systems running in parallel 
–for organisation and clarity’s sake. In doing so, the priority health 
concerns within the country may be identified to thereafter actually make 
use of the flexibilities to guarantee access to affordable medicines. 
However, it is important to stress the fact that the health reforms, as 
stated, may be simplistic. Thus, it is my belief that such a reform will need 
to be carried out in at least three to four stages. The utmost priority is to 
identify health needs requiring pressing attention due to the severe 
consequences for the society; regardless of whether these are related to 
epidemics, catastrophic diseases or high cost medicines. In doing so the 
government will be able to implement public procurement practices to 
obtain better prices, and if necessary increase bargaining power by 
threating to use compulsory licences. Once the priorities have been 
identified it will be also necessary to implement protocols and guidelines 
for treatment and diagnosis to be followed by practitioners, together with 
massive education and media campaigns to reach out to the public about 
the illnesses and also to inform them about the existence of such 
programmes. Admittedly, some of these exist in Venezuela, however, the 
analysis showed how critical the lack of information is for patients to 
either access the programmes or even know about their existence. Even 
though practitioners are nowadays compelled to use the generic versions 
or even prescribe medicines by their active ingredient, it is important to 
educate patients and demystify the use of generic medicines. Within the 
stages of reform it will be also suggested to increase the levels of efficiency 
and effectiveness of the health agencies granting marketing approvals.  
The Brazilian analysis showed that the implemented health policies where drafted 
in a manner that patent rights would not prevent the country from providing 
access to affordable medication, and in the cases where patents would seem to 
interfere or become an obstacle it was the IP Code providing the exception to 
grant patents. Whether or not the prior consent mechanism is compatible with 
the Brazilian Constitution, its implementation seems to address fulfilling the 
social function enshrined within the constitutional text. Acknowledging the 
disparities would only serve as an example for other countries trying to 
implement a similar system in terms of solving or making it work within a 
determined context. Beyond implementing a solution similar to that in Brazil or 
Chile, it is important to stress the common factors between these two countries in 
terms of patent protection and access to medicines i.e. investment, consistency, 
solidarity, political will and civil society’s activism. Another aspect of utmost 
importance is to create a mechanism ensuring transparency and fairness when 
using procurement practices, designing distribution and the logistics when 
bringing affordable medicines to both patients and the market. Without rational 
use of the resources, at all level involved, the health care system would most 
definitely destine to fail. Intellectual property rights hand in hand with public 
health reforms could contribute with the country’s development. 
Given that the author is of the opinion that pharmaceutical patents have not 
influenced or directly deterred access to medicines within the Venezuelan 
context, the author has given as a possible solution the reforming of the IP Law 
from 1955 according to the minimum standards of protection settled within 
TRIPS.  Thus, this reform and implementation should take advantage of the 
provisions allowing the country to address the access, innovation and 
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affordability of medicines given that the current model is not working. In doing 
so, Venezuela would ensure that both IP rights and access to medicines are 
somewhat balanced within the country. 
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Access to medicines, pharmaceutical patents, and 
public health are topics often addressed in the news. 
On the one hand, there is an imperative need to tackle 
pressing health concerns, and on the other hand, it is 
also important to provide adequate incentives to carry 
out research and development. Even though common 
health concerns exist within the developing world, each 
country has a different set of needs. The approach to solve 
or the strategies to balance intellectual property rights 
and access to medicines vary at large. Latin American 
countries i.e. Brazil, Chile and Venezuela, even though 
geographically located in the same continent, deal with 
the challenges in a different and unique manner.
Before the TRIPS Agreement countries had the freedom 
to decide on whether or not to grant patent protection 
for medicines. Thus, most of the developing and least 
developed countries, now WTO member countries, did 
not provide patent protection for pharmaceuticals because 
they feared that patent protection would increase the price 
of pharmaceuticals, and hence, become an obstacle for 
the access to medicines.
On the one hand, patent protection represents an 
incentive for the pharmaceutical industry to carry out R&D 
for new and needed drugs. But on the other hand, patents, 
as the system of ﬁnancing R&D, has been regarded 
as a ﬂawed system due to the high costs transferred to 
the ﬁnalised product (medicine) thus deterring access to 
medicines. Patent protection allows the inventor to prevent 
others from making use, selling, producing or distributing 
the invention without his consent for a period of no less 
than 20 years. Moreover, these rights conferred by 
the patent grant seem to constitute the pharmaceutical 
industry’s incentive to recoup the high costs associated 
with the R&D of a new drug. 
This book reviews the strategies or models of protection 
used in Brazil, Chile and Venezuela to balance both 
intellectual property rights (pharmaceutical patents) 
and access to medicines. Each country seems to have 
shaped their policies in accordance with their national 
priorities, whether these are motivated by health, political 
or commercial issues. This study portrays the different 
approaches followed in different national contexts 
despite all three having to implement the minimum 
standards of intellectual property protection according 
to the Agreement on Trade Related Aspects of Intellectual 
Property Rights (TRIPS Agreement). The outcome of the 
comparison of the policy implementations and the patterns 
followed by each of the analysed countries is without a 
doubt the main contribution of this academic study.
